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ABSTRACT 
 
The rapid advancement of drug delivery systems (DDS) has raised the possibility of 
using functional engineered nano/micro-particles as drug carriers for the 
administration of active pharmaceutical ingredients (APIs) to the affected area. The 
major goals in designing these functional particles are to control the particle size, the 
surface properties and the pharmacologically active agents release in order to achieve 
the site-specification of the drug at the therapeutically optimal rate and dose regimen. 
Two different equipment (i.e. glass capillary microfluidic device and micro-
engineered membrane dispersion cell) were utilised in this study for the formation of 
functional nano/micro-particles by antisolvent precipitation method. This method is 
based on micromixing/direct precipitation of two miscible liquids, which appear as a 
straightforward method, rapid and easy to perform, does not require high stirring rates, 
sonication, elevated temperatures, surfactants and Class 1 solvents can be avoided.  
 
Theoretical selection of a “good solvent” and physicochemical interaction between 
solvent-water-polymer with the aid of Bagley’s two-dimensional graph were 
successfully elucidated the nature of anti-solvent precipitation method for the 
formation of desired properties of functional pharmaceutical nano/micro-engineered 
particles. For the glass capillary microfluidic experiment, the organic phase (a mixture 
of polymer and tetrahydrofuran/acetone) was injected through the inner glass capillary 
with a tapered cross section culminated in a narrow orifice. The size of nanoparticles 
was precisely controlled by controlling phase flow rates, orifice size and flow 
configuration (two- phase co-flow or counter-current flow focusing). The locations at 
which the nanoparticles would form were determined by using the solubility criteria 
of the polymer and the concentration profiles found by numerical modelling. This 
valuable results appeared as the first computational and experimental study dealing 
with the formation of polylactide (PLA) and poly(ε-caprolactone) (PCL) 
nanoparticles by nanoprecipitation in a co-flow glass capillary device.  
 
The optimum formulations and parameters interactions involved in the preparation of 
paracetamol encapsulated nanoparticles (PCM-PCL NPs) using a co-flow 
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microfluidic device was successfully simulated using a 25-full factorial design for five 
different parameters (i.e. PCL concentration, orifice size, flow rate ratios, surfactant 
concentration and paracetamol amount) with encapsulation efficiency and drug 
loading percentage as the responses. PCM-loaded composite NPs composed of a 
biodegradable poly(ᴅ,ʟ-lactide) (PLA) polymer matrix filled with organically 
modified montmorillonite (MMT) nanoparticles were also successfully formulated by 
antisolvent nanoprecipitation in a microfluidic co-flow glass capillary device. The 
incorporation of MMT in the polymer matrix improved the drug encapsulation 
efficiency and drug loading, and extended the rate of drug release in simulated 
intestinal fluid (pH 7.4). The encapsulation of MMT and PCM in the NPs were well 
verified using transmission electron microscopy (TEM), energy dispersive x-ray 
spectroscopy (EDS), x-ray diffraction (XRD), differential scanning calorimetry 
(DSC), thermogravimetric analysis (TGA) and attenuated total reflection-Fourier 
transform infrared spectroscopy (ATR-FTIR). 
 
PCL drug-carrier nanoparticles were also produced by rapid membrane micromixing 
combined with nanoprecipitation in a stirred cell employing novel membrane 
dispersion. The size of the NPs was precisely controlled by changing the aqueous-to-
organic volumetric ratio, stirring rate, transmembrane flux, the polymer content in the 
organic phase, membrane type and pore morphologies. The particle size decreased by 
increasing the stirring rate and the aqueous-to-organic volumetric ratio, and by 
decreasing the polymer concentration in the aqueous phase and the transmembrane 
flux. The existence of the shear stress peak within a transitional radius and a rapid 
decline of the shear stress away from the membrane surface were revealed by 
numerical modelling. Further investigation on the PCL nanoparticles loaded 
immunosuppressive rapamycin (RAPA) drug were successfully synthesised by anti-
solvent nanoprecipitation method using stainless steel (SS) ringed micro-engineered 
membrane. Less than 10 µm size of monohydrate piroxicam (PRX) micro-crystals 
also was successfully formed with the application of anti-solvent precipitation method 
combined with membrane dispersion cell that has been utilised in the formation of 
functional engineered nanoparticles. This study is believed to be a new insight into 
the development of integrated membrane crystallisation system. 
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CHAPTER 1  
 
INTRODUCTION 
1.1 Background 
Engineered functional pharmaceutical particles have attracted intriguing attention of 
the scientific community due to their significant therapeutic potential for site specific 
delivery in their applications for drug targeting to particular organs/tissues, as carriers 
of active pharmaceutical ingredients (API), DNA in gene therapy, and in their ability 
to deliver proteins, peptides and genes through a per oral route of administration. 
Great attention has been given to this drug delivery strategy owing to its numerous 
advantages and rapid resolution: 
 
“The late 1960s and early 1970s saw the advent of polymer microparticles (MPs) 
based on acrylamide micelle polymerization (Crommelin & Florence, 2013). Since 
then, along with different polymerization methods, preformed polymers also have 
been developed and studied. The majority of studies on nanoparticles (NPs) reported 
to date have dealt with microparticles created from poly(ᴅ,ʟ-lactide), polylactide 
(PLA), poly(ᴅ,ʟ-glycolide) (PLG), poly(lactide-co-glycolide) (PLGA), and poly-
cyanoacrylate (PCA) (Barratt, 2000; Crommelin & Florence, 2013)”.  
 
Various pharmaceutical carriers, including nano/micro-carriers, such as nano/micro-
spheres, nano/micro-capsules, liposomes, micelles, cell ghosts, lipoproteins, 
nano/micro-crystals and many others, are widely used for the experimental and 
clinical delivery of therapeutic and diagnostic agents in order to enhance the in vivo 
efficiency of many drugs and drug administration protocols (Kreuter, 1996; Lee, 
2003). Modifications of these carriers are often used to control their in vivo properties 
in a desirable fashion, for example: (i) stay (circulate) long in the body; (ii) 
specifically target the site of the disease; (iii) respond to local stimuli characteristic of 
the pathological site, such as intrinsically abnormal pH values or temperature, or 
externally applied or changing properties, (iv) provide an enhanced intracellular 
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delivery of drugs and genes as required, and (v) carry a reporter (contingrivast) 
component supplying real time information about the drug delivery systems (DDS)  
biodistribution and target accumulation (Torchilin, 2009).  
 
Various methods for the manufacture of polymer nano/micro-particles have been 
described (De Jaeghere et al., 1999; Delair, 2004), such as solvent evaporation, 
salting-out, dialysis and supercritical fluid technology. They can be also directly 
synthesized by the polymerization of monomers using various polymerization 
techniques such as micro-emulsion, mini-emulsion, surfactant-free emulsion and 
interfacial polymerization (Legrand et al., 2007; Rao & Geckeler, 2011). The choice 
of production method is practically crucial depending on their physiological, 
anatomical, clinical behaviour and potential application (Otto et al., 2014). Among 
the different methods, precipitation, which is simple, fast and economic, has the 
advantage of using preformed polymers as starting materials rather than monomers, 
as well as employing non-toxic solvents (Fessi et al., 1989). Nanoprecipitation often 
enables the production of small nanoparticles (100–300 nm) with a narrow 
monomodal distribution and a wide range of preformed polymers can be used (Bilati 
et al., 2005; Nagavarma et al., 2012). A study by Legrand et al. (2007) showed 
promising results related to the influence of polymer behaviour in organic solution on 
the production of PLA nanoparticles by the nanoprecipitation process. Most of the 
previous studies have reported concerns about the mixing process enhancement with 
serious consideration given to polymer-solvent solubility, polymer-water and 
polymer-solvent interaction (Galindo-rodriguez et al., 2004; Legrand et al., 2007). All 
of these physico-chemical parameters are predominantly important for the 
precipitation process that is associated with nano/micro-particles formation. 
 
In recent years, technologies for particle preparation using microfluidics have been 
developing very fast, because of their many advantages in material preparation, such 
as uniform flow and mixing, easy control, high efficiency, continuous operation and 
low cost.  Requirements for particle monodispersity, chemistry, porosity, shape and 
size are becoming increasingly stringent (Dendukuri & Doyle, 2009), thus calling for 
controllable technologies and equipment for particle preparation. Novel morphologies 
and special properties particles can be synthesised with the use of controlled 
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microfluidics devices (Luo et al., 2011; Xu et al., 2005). Recently, a new micro-
engineered nickel/stainless steel membrane has become available, consisting of an 
array of regularly spaced, rectilinear pores, which is analogous to an array of parallel 
microfluidic channels through with one fluid phase can be introduced into another 
fluid at an overall flow rate much higher than is possible in microfluidic devices 
(Laouini et al., 2013a; 2013b). Microporous membranes are increasingly used for the 
preparation of nano/micro-particles and emulsions, such as polymeric nanoparticles 
(Charcosset & Fessi, 2005a; Du et al., 2011), lipid nanoparticles (Charcosset et al., 
2005b), nanocapsules (Charcosset & Fessi, 2005c), gel microbeads (Zhou et al., 
2007), microcapsules (Wagdare et al., 2011) and liposomes (Jaafar-Maalej et al., 
2011).  
 
Membrane processes have recently been considered as being amongst the most 
promising of strategies to improvise on the existing crystallisation techniques with the 
main feature of a porous or a dense material acting as a physical semi-permeable 
barrier between the two phases (Chabanon et al., 2016). Thus, the integrated 
membrane crystallisation/precipitation process is seemingly possible; (i) to control 
and limit the maximum level of supersaturations due to the defined mass transfer 
across the membrane; (ii) to act as heterogeneous nucleation-inducing substrates; (iii) 
to control solid features such as crystals size distribution (CSD), polymorphic form, 
shape, and purity; and (iv) to reduce energy consumption compared to cooling or 
evaporative crystallisation. To achieve these goals, several membrane techniques 
have been reported: the membrane contactor, membrane templates, reverse osmosis 
and membrane distillation (Charcosset et al., 2010; Charpentier, 2002). In this study, 
a micro-engineered membrane dispersion cell was used to produce monodispersed 
micro-crystals as seeds for crystallisation process. Hence, it is often desirable to 
design a crystallisation process to avoid excessive fine generation, which help to 
minimise downstream processing problems, with its uniform and narrow CSD. The 
product quality and efficacy of the system are often contingent on adequate control of 
particle size and shape in the crystalliser, which may have a detrimental impact on 
downstream unit operations such as the filtration rate, drying and formulation 
operations (Aamir et al., 2010; Barrett et al., 2005; Nagy & Braatz, 2012).  
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Many researchers have tried to couple computational and experimental results in an 
effort to unveil the mechanism through which micro-confinement affects 
nanomaterial characteristics. Thus, computational fluid dynamic (CFD) models 
appeared as favourable computational tools to investigate how various system 
parameters (such as device geometry, flow rate ratio, total flow rate and etc.) affect 
the mixing dynamics with the ultimate goal of correlating device/system operational 
conditions to nano/micro-material output (Capretto et al., 2011). For example, 
Capretto et al. (2011) used a CFD model by considering the variation of the diffusion 
coefficient of the species according to the Stokes–Einstein equation, which 
pronounces the relation between the viscosity of the medium and the diffusion 
coefficient of the species; they investigated its effect on the microfluidic mixing 
process and the polymeric micelles size. To the best of our knowledge, this study 
proposed the first computational and experimental study dealing with the formation 
of nanoparticles by nanoprecipitation in a co-flow glass capillary device which 
indicated a good agreement with experimental results. This numerical simulation has 
also been applied in order to investigate velocity and shear profiles in the vicinity of 
the micro-engineered membrane surface associated with an effective inter-diffusion 
(between aqueous-to-organic phases) mixing area during the formation of 
nanoparticles. This then successfully revealed a better performance for the stainless 
steel ringed membrane compared to a whole nickel membrane.  
1.2 Problem statements 
The major goals in designing nano/micro-particles as a delivery system are to control 
the particle size, the surface properties and the release of pharmacologically active 
agents in order to achieve the site-specific action of the drug at the therapeutically 
optimal rate and dose regimen. A few problems or pitfalls have been identified in this 
study, so that vital concerns should be focused on three major issues as follows: (i) 
the synthesis of nano/micro-particles by the precipitation method, (ii) micro-
engineered dispersion devices applied in the formation of nano/micro-particles, and 
(iii) the development of a membrane crystallisation system by combining the 
nanoprecipitation-membrane technique for the formation of micro-crystals as seeds 
for the crystallisation process.       
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The original precipitation method suffers from some drawbacks. This technique is 
mostly suitable for compounds having a hydrophobic nature, such as indomethacin 
which is soluble in ethanol or acetone, but display very limited solubility in water. 
Thus, reduced or even zero drug leakage towards the outer medium leads to 
nanoparticles with entrapment efficiency values reaching 100 % (Barichello et al., 
1999; Fessi et al., 1989). When nano/micro-particles are produced by a method which 
involves the solvation of the polymer and the drug and, further, evaporation of the 
solvent leading to precipitation, the state of the drug and the polymer may vary from 
crystalline to amorphous. The drug can be present as a solid solution (dissolved) or it 
may form either a molecular or a crystalline dispersion among the polymeric matrix 
(Dubernet, 1995). Besides this, the state of the drug can be a combination of different 
possibilities, such that it can be partly solubilised in the polymer and partly deposited 
in the matrix as both amorphous and crystalline domains (Hung & Lee, 2007; 
Valencia et al., 2012). Correspondingly, if the drug remains dissolved in the polymer 
matrix, the polymer may interact with the drug (Izmailov et al., 1999). As a 
consequence, the state of the drug and the hosting polymer play an important role in 
determining the essential properties of the system, including the entrapment and 
release of the drug. In addition, the interactions of drugs and polymers in nano-
particulate systems are not as widely studied as in micro-particle systems (Teychené 
& Biscans, 2008). Therefore, this study was aimed to formulate a new strategy to 
enhance the drug entrapment onto NPs polymer matrix by the use of nanofillers.  
 
Microfluidic devices are designed to manipulate fluids in microchannels with a 
greatly reduced consumption of reagents, and they demonstrate intrinsically efficient 
heat and mass transfer due to high surface-area-to-volume ratios. Efficient mixing and 
rapid chemical reaction at the nanoliter to picoliter scales allow microfluidic devices 
to control the synthesis parameters better and thus the nanoparticle sizes and 
properties (Hung & Lee, 2007). However, this current method is not always applicable 
to all classes of nanoparticles, thus not all properties can be characterized, such as 
drug encapsulation and release, pharmacokinetics or biodistribution. This involves 
higher costs and complexities in fabrication and operation compared with the well 
plates, if they are not to be reusable, and if reusable, it would be difficult to keep them 
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sterile. For large-scale synthesis, it is difficult to build systems at low-cost that are 
comparable to a batch reactor which is able to prepare grams or kilograms of 
nanoparticles (Valencia et al., 2012). However, this problem can be solved by the 
application of a micro-engineered membrane that has been proposed in this study.   
 
Crystallisation from solution is a core technology in pharmaceutical industries. 
Usually, this process is a part of a wide processing system, including solid–liquid 
separation, particle design, and formulation. In the pharmaceutical industry, 
chemical engineers must develop a robust crystallisation process that delivers the 
active pharmaceutical ingredient (API) with both high yield and the appropriate 
attributes that are conducive to drug product development (e.g., purity, polymorph 
and particle size distribution). To reach this goal, it is essential that fundamental data 
on nucleation kinetics, crystal growth and phase transitions should be determined 
precisely. A technique extensively applied in production crystallisation to help 
control the crystals size distribution (CSD) and the number of crystals produced, as 
well as the polymorphic form, is “seeding”. Seed crystals are added to a crystallizer 
before nucleation occurs; they provide the surface area for crystal growth and 
nucleation, hence offering the advantage of being able to control the onset of 
crystallisation. Unseeded batches tend to exhibit batch-to-batch point of nucleation 
consistency problems (this is process dependent), which can have a dramatic 
influence on the size and number of crystals produced. This latter technique enables 
the generation of crystallisation containers with perfectly controlled operating 
conditions (Laval et al., 2007; Selimović et al., 2009; Teychené et al., 2011; Zheng 
et al., 2004).  
1.3 Objectives 
The overall objective of this research is to develop outstanding methods/techniques 
for the formation of engineered functional pharmaceutical nano/micro-particles by 
taking into account the theoretical selection of a “good solvent” applied in the 
precipitation method. Two different devices (glass capillary microfluidics and the 
micro-engineered dispersion cell) were used, with the aim of investigating both 
synthesis/nucleation and the production stage involved during the formation of the 
CHAPTER 1  
                                                                                                                 7
 
 
Rahimah Othman  2016 
 
nanoparticles, respectively. Computational fluid dynamic (CFD) simulation was then 
examined to validate the experimental results attained from each of the micro-
engineered dispersion device applications. Further study on the application of 
combined precipitation method and membrane dispersion cell was carried out by 
producing micro-crystals that could potentially be used as seeds in the batch 
crystallisation process with design efficient control strategies. This extension study is 
believed to be a new insight into the integrated membrane crystallisation system.  
 
Six (6) important aims have been identified that lead to a logical progression through 
the research: 
 
1. To measure the interaction between solvent-water-polymer for a better 
understanding on the selection of a “good solvent” and precipitation method.  
2. To investigate the efficacy of using the glass capillary microfluidic device for the 
formation of NPs by evaluating the effects of various process parameters on 
effective mixing.  
3. To examine the possibility of efficiently incorporating nanofillers and active 
ingredients (drug) into NPs by the microfluidic mixing/nanoprecipitation process.  
4. To elaborate the interaction between each of the process parameters involved in 
drug-NPs encapsulation experiment using a microfluidic device by design of 
experiment (DOE) simulation approach.  
5. To investigate the performance of membrane dispersion cell and the optimum 
process parameters involved in the formation of biodegradable NPs by 
nanoprecipitation method.  
6. To apply solvent displacement method combined with membrane dispersion cell 
for the formation of monodispersed size-tuneable micro-crystals.  
1.4 Research questions 
Questions related to the proposed study are as follows: 
 
1. What is the most suitable organic solvent and biodegradable polymer that can 
be used for the formation of nanoparticles by nanoprecipitation method? 
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2. How to apply two different micro-engineered dispersion devices and what are 
the optimum parameters for the formation of nano/micro-particles?  
3. What are the basic challenges in nano/micro-particle synthesis: firstly, to 
synthesise particles with the desired size/shape; and secondly, to reduce their 
polydispersity? The size and shape of the particles typically affects their physical 
and chemical properties.  
4. How to extend the application of precipitation-membrane technique from the 
crystallisation perspective? 
5. What is the appropriate numerical study that can be applied in order to verify the 
experimental observations? What are the significant parameters/model equations 
needed for this computational analysis?  
1.5 Research novelties 
The key contributions of this research are listed as follows:  
 
1. Microfluidic devices that are designed to manipulate fluids in microchannels with 
greatly reduced consumption of reagents and that demonstrate intrinsically 
efficient mixing and rapid chemical reaction at the nanoliter to picoliter scales.  
2. The miniaturization of synthesis systems provides new opportunities for 
advanced chemical synthesis, and also enables a broad range of biological and 
medical applications. 
3. The encapsulation of nanofillers and drugs onto the NPs polymer matrix 
potentially appears as a novel finding for the engineered pharmaceutical particles, 
which results in a large specific surface area, and exhibits good adsorption ability, 
cation exchange capacity, and drug-carrying capability.  
4. The use of micro-engineered membranes enables a better control over diffusive 
mixing at the liquid/membrane interface which may significantly provide fine 
control of particle size distribution and make it easier to extrapolate the results 
for industrial scale production.   
5. A new exploration and a good start for the development of an integrated 
membrane-crystallisation system.   
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1.6 Thesis structure  
This thesis is divided into ten main chapters as discussed briefly below: 
 
Chapter 1 gives a brief background to the work in this thesis as well as the objectives 
of this research. 
 
Chapter 2 introduces the detailed background of nano/micro-particles formation by 
precipitation methods which includes a review of polymers, organic solvents, active 
ingredients (drug) and typical particle synthesis methods/techniques. A brief 
description of a glass capillary device and a micro-engineered membrane cell for the 
formation of nano/micro-particles are also presented. Further details on micro-crystals 
formation produced by the membrane dispersion cell with appropriate control 
strategies have been summarised in this chapter.        
 
Chapter 3 explains the synthetic polymeric biodegradable nanoparticles produced by 
micro-mixing combined with nanoprecipitation in a co-flow glass capillary 
microfluidic device. The solubility criteria of the polymer and the concentration 
profiles found by numerical modelling indicated the locations at which the 
nanoparticles would form. The experimental results are in good agreement with the 
CFD simulation results showing a semi-spherical interface at a low organic phase flow 
rate and a widening jet at a high organic phase flow rate. The formation of spherically 
shaped nanoparticles and a narrow particle size distribution were shown significantly 
using dynamic light scattering, Nanoparticle Tracking Analysis (NTA) and 
microscopic observation.  
 
Chapter 4 presents the interaction between water-solvent-polymer and measurement 
which reveals the good and poor solvents for the polymers applied in the 
nanoprecipitation method. The in situ mixing process which occurred in a glass 
capillary microfluidic device was monitored using a microscope video system with 
comprehensive investigation on the effect of operating parameters, system geometry 
and surfactants on the final particle size distributions. 
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Chapter 5 evaluates the various formulation variables involved in the preparation of 
paracetamol (PCM) loaded nanoparticles by nanoprecipitation method using a glass 
capillary microfluidic device with a two-level factorial design approach. The 25-full 
factorial design was applied with five (5) different independent input variables 
included: (A) PCL concentration, (B) co-flow device orifice size, (C) flow rate ratios, 
(D) surfactant concentration and (E) acetaminophen percentage loading. These were 
investigated in order to obtain a mathematical model and the prediction of optimised 
formulations. The percentage encapsulation efficiency (Y1), % drug loading (Y2) and 
particle mean size, Zave (Y3) were used as the response variables. The produced PCM-
loaded PCL NPs were then characterised according to their morphology, particle size, 
encapsulation efficiency, drug loading and in vitro drug release behaviour. 
 
Chapter 6 investigates the possibility of efficiently incorporating nanofillers 
(nanoclay or also known as montmorillonite (MMT)) and paracetamol into polymeric 
NPs by microfluidic mixing/nanoprecipitation process. The effect of MMT on the 
physicochemical properties of the prepared NPs, the encapsulation efficiency of 
paracetamol inside the NPs and their in vitro drug release behaviour were examined.  
 
Chapter 7 elaborates the effect of different aqueous-to-organic phase volumetric 
ratios, agitation speeds, transmembrane fluxes, membrane type and pore size, polymer 
and surfactant concentrations on the development and optimisation of novel 
micromixing/nanoprecipitation methods applied in a micro-engineered membrane 
dispersion cell for the fabrication of polymeric NPs. The velocity and shear profiles 
in the vicinity of the membrane surface were evaluated using a commercial CFD 
software package (ANSYS FLUENT 14.5) in dimensional form, which revealed the 
better performance of the stainless steel ringed membrane compared to the whole 
nickel membrane. 
 
Chapter 8 presents the possibility of efficiently encapsulating immuno-suppressive 
agent of rapamycin (RAPA) onto poly(ε-caprolactone) (PCL) NPs matrix using a 
stainless steel ringed membrane that fitted into the dispersion cell, combined with the 
solvent displacement method. The effect of RAPA on the physico-chemical properties 
of synthesised NPs were evaluated using transmission electron microscopy (TEM), x-
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ray diffraction (XRD), differential scanning calorimetry (DSC) and attenuated total 
reflection-Fourier transform infrared spectroscopy (ATR-FTIR). The encapsulation 
efficiency of RAPA inside the NPs and the in vitro drug release behavior were 
determined. 
 
Chapter 9 explains the application of combined membrane-precipitation method for 
the formation of piroxicam, PRX monohydrate micro-crystals, than can be further 
used as seeds for a batch crystallisation process. The effect of PRX concentration, 
type and concentration of surfactant, different volume ratios and the effect of solvent 
removal are discussed in this chapter. A detailed comparison is drawn between bulk 
mixing, semi-batch, semi-batch membrane system and continuous membrane system 
applied for the formation of micro-crystals. The in-situ control strategy applied to the 
seeded-batch crystallisation system was evaluated using the PRX micro-crystals 
produced by the membrane dispersion cell.  
 
Chapter 10 concludes this research as well as providing recommendations for future 
work.
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CHAPTER 2  
 
LITERATURE REVIEW 
Chapter overview 
Functional pharmaceutical nano/micro-particles have evolved into an exciting area of 
research due to their potential in drug delivery systems (DDS). To convey a sufficient 
dose of drug to the lesion, suitable carriers of drugs are needed. Nano/micro-particle 
carriers have important potential applications for the administration of therapeutic 
molecules. This chapter provides an overview of engineered functional pharmaceutical 
particles including polymeric nano/micro-particles, micro-crystals and the addition of 
nanofillers (nanoclay) into the particulate matrix. Screening results for the types of 
biodegradable polymers and the active ingredients (drugs) are well described in this part. 
The methods used for the formation of particles are briefly reviewed as well as the 
physicochemical parameters associated with nanoparticles (NPs) formation. Two 
different techniques are also reviewed: (i) the glass capillary microfluidic device and (ii) 
the micro-engineered membrane dispersion cell application for the formation of 
nano/micro-particles. Brief reviews of the different analytical instruments applied to 
characterize the physicochemical properties of nano/micro-particles are described. An 
overview of pharmaceutical crystallisation fundamentals for the formation of micro-
crystals and their applications is given in this chapter. The techniques applied to 
characterise the crystal properties, including the main approaches to crystallisation 
operation and its control strategies, are described. The application of integrated 
membrane crystallisation is briefly discussed in this chapter.  
2.1 Introduction  
Rapid advancement in reducing colloidal drug carriers and Active Pharmaceutical 
Ingredients (API) has proved an efficient and reliable method of improving the 
bioavailability of relatively insoluble drugs that is often limited by poor dissolution rates. 
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Thus, by reducing the particles down to the micrometer or, in some cases, the nanometer 
(1/1000 of a micrometer) size, the particle surface area can be significantly improved, 
which corresponds to Noyes-Whitney equation, whereby the dissolution rate linearly 
depends on the surface area (Kohane, 2007; Lee, 2003). Functional pharmaceutical 
particles interacting with cells and the extracellular environment can trigger a sequence 
of biological effects. These effects largely depend on the dynamic physicochemical 
characteristics of nano/micro-particles, which determine the biocompatibility and 
efficacy of the intended outcomes (Barratt, 2000). The distinction is often made between 
micro- and nano- particles, which are particles with dimensions best described in 
micrometers and nanometers respectively (Naahidi et al., 2013). The major goals in 
designing these functional particles as a delivery system are to control the particle size, 
the surface properties and the release of the pharmacologically active agents in order to 
achieve the site-specific action of the drug at the therapeutically optimal rate and dose 
regimen. The API substance/drug can be dissolved, entrapped, encapsulated or attached 
to a nano/micro-particle matrix. 
 
The various advantages of nano/micro-particles are summarised as follows (Mohanraj & 
Chen, 2007; Madhav & Kala, 2011): 
i. The ability to maintain unaltered physicochemical characteristics for long periods 
allowing long-term storage  
ii. The possible administration through different routes (oral, intramuscular or 
subcutaneous) depending on their composition 
iii. Effective delivery of agents which are insoluble or sparingly soluble in water  
iv. Protect the drug from degradation 
v. Produce a prolonged release of the drug 
vi. Improve the bioavailability of the drug 
vii. Provide the targeted delivery of the drug 
viii. Decrease the toxic side effects of the drug 
ix. Offer an appropriate form for all routes of administration 
x. Allow rapid-formulation development  
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The development of effective drug delivery systems that can transport and deliver a drug 
precisely and safely to its site of action is becoming a highly important research area for 
pharmaceutical researchers. Thus, promising ways of delivering poorly soluble drugs, 
peptides and proteins have been devised. In addition, attractive drug delivery 
technologies, such as transdermal patches, nanodevices, bioadhesive systems, implants, 
micro-fabricated systems, cell encapsulation devices and novel nasal drug delivery 
systems are currently under intensive study (Labhasetwar, 2005; Parveen et al., 2012; 
Sahoo & Labhasetwar, 2003; Vasir & Labhasetwar, 2005). The aim of targeted drug 
delivery and controlled release is to improve the management of drug pharmacokinetics, 
pharmacodynamics, non-specific toxicity, immunogenicity and the biorecognition of 
systems in the quest for improved efficacy. However, advanced drug delivery systems 
are not restricted to the nanoworld (Jain, 2005; Labhasetwar, 2005; Vasir & Labhasetwar, 
2005). Fig. 2.1 schematically illustrates the long march of controlled drug delivery 
systems from the mid-19th century enteric coated pills and other systems in the 
macroscopic size range, through to microcapsules and micro-particles, and on to the nano-
domain (Yih & Al-Fandi, 2006). The late 1960s and early 1970s saw the advent of 
polymer microparticles based on acrylamide micelle polymerization (Crommelin & 
Florence, 2013).  
 
The diameter of particles administered into blood vessels, airways or gastro-intestinal 
tract dictates their velocity, diffusion and adhesion to walls (Goldsmith & Turitto, 1986; 
Lamprecht, Schäfer, & Lehr, 2001;  Patil et al., 2001). The movement of particles in 
tissues, whether arriving by migration or injection, is also limited by size due to steric 
hindrance in the extracellular matrix. The pathway of particle migration in the body 
directly impacts the final destination. When administrated intravenously, nanoparticles 
(NPs) should be sufficiently small (100–300 nm) to passively cross the tumour’s 
endothelial barrier and then be retained in the tumour bed for a prolonged time due to 
reduced lymphatic drainage, which is known as the enhanced permeability and retention 
effect (Kobayashi et al., 2014). Particles larger than 1 mm are not convenient for the 
intravascular delivery of drugs, since they can readily be opsonized with a possibility of 
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capillary occlusion, while NPs smaller than 5 nm can be cleared rapidly from the blood 
via extravasation or renal clearance (Elsabahy & Wooley, 2012). For pulmonary 
administration, 3 μm particles deposit deep in the alveolar region while larger particles 
accumulate in the upper airways and smaller particles are exhaled (Edwards et al., 1997). 
The particles having a size greater than 10 microns can be administered through nasal 
administration because they can get lodged in the nasal cavity, whereas particles that are 
too fine (having a size below 5 microns) should be warded off as they are inhaled directly 
into the lungs (Kushwaha et al., 2011). 
 
Fig. 2.1: A schematic representation of the progress from macro- and micro- delivery 
systems to the nano-domain over the period from the 19th century to today, showing the 
indefinite boundary between the two domains, straddled, for example, by liposomes. The 
dates given represent early discovery and significant events after discovery when there 
are several dates (LDL = Low-Density Lipoprotein) (Yih & Al-Fandi, 2006).  
2.2 Biodegradable functional pharmaceutical particles  
2.2.2 Polymeric nanoparticles 
The polymeric nanoparticles (NPs) are prepared from biocompatible and biodegradable 
polymers where the drug is dissolved, entrapped, encapsulated or attached to a 
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nanoparticle matrix. Depending upon the method of preparation, nanoparticles, 
nanospheres or nanocapsules can be obtained. Nanocapsules are systems in which the 
drug is confined to a cavity surrounded by a unique polymer membrane, while 
nanospheres are matrix systems in which the drug is physically and uniformly dispersed 
(Nagavarma et al., 2012). Fig. 2.2 shows the difference between nanospheres and 
nanocapsules. Polymer-based nanoparticles effectively carry drugs, proteins, and DNA 
to target cells and organs. Their nanometer size promotes effective permeation through 
cell membranes and also stability in the blood stream. Polymers are very convenient 
materials for the manufacture of countless and varied molecular designs that can be 
integrated into unique nanoparticle constructs with many potential medical applications 
(Peer et al., 2007). Abhilash (2010) and Peer et al. (2007) reviewed a few of the 
advantages of polymeric nanoparticles as follows:  
 They increase the stability of any volatile pharmaceutical agents. 
 They are easily and cheaply fabricated in large quantities by a multitude of methods. 
 They offer a significant improvement over traditional oral and intravenous methods 
of administration in terms of efficiency and effectiveness.  
 They deliver a higher concentration of pharmaceutical agent to a desired location.  
 The choice of polymer and the ability to modify the drug release from polymeric 
nanoparticles have made them ideal candidates for cancer therapy, the delivery of 
vaccines, contraceptives and the delivery of targeted antibiotics.  
 Polymeric nanoparticles can be easily incorporated into other activities related to 
drug delivery, such as tissue engineering.  
 
 
Fig. 2.2: Difference between the nanosphere and the nanocapsule (Courtesy of 
Nanomedicine (2010) Future Medicine Ltd). 
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Fig. 2.3 depicts the increasing number of publications based on the polymeric NPs’ 
unique properties, demonstrating that they are quickly expanding and playing a pivotal 
role in a wide spectrum of areas ranging from electronics to photonics, conducting 
materials to sensors, medicine to biotechnology and pollution control to environmental 
technology during the past few decades (Rao & Geckeler, 2011). Table 2.1 shows the 
types of synthetic and natural polymers that can be used for the formation of polymeric 
NPs. The polymers should be compatible with the body in terms of adaptability (non-
toxicity) and (non-antigenicity) and should be biodegradable and biocompatible (Rao & 
Geckeler, 2011). 
 
Fig. 2.3: Graphical representation of the number of publications cited in the Scopus® 
database on polymer nanoparticles during the period 1996–2010 (Rao & Geckeler, 2011). 
 
Table 2.1: Type of synthetic and natural polymers commonly used for the formation of 
NPs (Nagavarma et al., 2012). 
Synthetic Polymers Natural Polymers 
 Polylactides(PLA)   Poly(N-vinyl pyrrolidone)  Chitosan  
 Polyglycolides(PGA)   Poly(methyl methacrylate)   Gelatin  
 Poly(lactide co-glycolides) 
(PLGA) 
 Poly(vinyl alcohol)   Sodium alginate 
 Polyanhydrides   Poly(acrylic acid)   Albumin  
 Polyanhydrides   Poly acrylamide   
 Polyorthoesters   Poly(ethylene glycol)   
 Polycyanoacrylates   Poly(methacrylic acid)   
 Polycaprolactone    
 Poly glutamic acid    
 Poly malic acid    
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2.2.3 Polymeric micro-particles  
Drug delivery via biodegradable microparticles (mPs) benefits from both the protection 
of the encapsulated drug from hazardous conditions and the controlled release of the 
encapsulated drug, thereby reducing the administration frequency and improving patient 
compliance. ‘‘Microparticle’’ is defined as a spherical particle with a diameter in the 
micrometer range (typically from 1 µm to 1000 µm). With respect to the distribution of 
the active compound, there are two different categories of microparticles: 
‘‘microspheres’’ and ‘‘microcapsules’’ (Fig. 2.4). ‘‘Microspheres’’ refers to 
microparticles composed of a homogeneous mixture of active compound and raw 
material, while ‘‘microcapsules’’ have a core (where the active compound is placed) 
which is delimited by a different material (usually the raw material). The core may be 
solid, liquid, gas and one or more discrete domains of active compound may be found in 
the microcapsule core (Coelho et al., 2010).  
 
 
Fig. 2.4: Different categories of microparticle (Coelho et al., 2010). 
 
Polymeric mPs used as a drug delivery strategy have advantages over other systems that 
make them particularly suitable for microencapsulation: (i) the controlled release of 
encapsulated materials, (ii) the protection of the encapsulated materials against 
degradative reactions (e.g., oxidation, dehydration, UV, heat acids and bases) in the 
external environment, which can also result in an improved shelf life, (iii) masking the 
organoleptic properties such as the colour, taste and odour of encapsulated materials, (iv) 
easy handling of the resulting powder-like materials, and (v) safe handling of toxic 
encapsulated materials (Sri et al., 2012). Various types of materials, including drugs 
(Wischke & Schwendeman, 2008), proteins (Morita et al., 2000; Xie & Wang, 2007), 
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food materials (Patel et al., 2012; Taylor et al., 2009), pesticides (Pérez-Martínez et al., 
2001) and herbicides (Lobo et al., 2011), as well as cells (Mironov et al., 2009; Oliveira 
& Mano, 2011) can be encapsulated. Table 2.2 lists the types of natural and synthetic 
polymers commonly applied in the formation of microspheres.  
 
Table 2.2: List of polymers used for microsphere formation (Lohani & Chaudhary, 2012; 
Ramteke et al., 2012; Vilos & Velasquez, 2012). 
Natural polymer  Synthetic Biocompatible Biodegradable 
 Proteins: 
albumin, gelatin, 
and collagen  
 Carbohydrates: 
agarose, 
carrageenan, 
chitosan, starch 
 Chemically 
modified 
carbohydrates: 
poly (acryl) 
dextran, poly 
(acryl) starch 
 Polyvinyl 
 alcohol 
 Polyamides 
polycarbonates, 
 Polyalkylene glycols 
 Polyvinyl ethers, 
 Polymethacrylic acid 
 Polymethyl 
methacrylic acid 
 Methylcellulose 
 Ethylcellulose 
 Hydroxypropyl 
cellulose 
 Hydroxypropyl 
 Methylcellulose 
 Sodium 
carboxymethyl 
cellulose 
 Esters of 
hyaluronic 
acid 
 Polyvinyl 
acetate 
 Ethylene 
glycol 
 Poly (lactides) 
 Poly (glycolides) 
 Poly (lactideco-
glycolides) 
 Polycaprolactones 
 Polyalkyl 
cyanoacrylates 
 Polyorthoesters 
 Polyphosphoesters 
 Polyanhydrides 
 Polyphosphazenes 
 Chitosan 
 Polyethylene 
oxide 
The use of microparticles must initially take into account the chosen administration route. 
For oral administration, although there is no upper limit on microsphere size for 
administration, it has been found that decreasing the microsphere size from 7.2 µm to 2.1 
µm doubled gastrointestinal adsorption (Gaumet et al., 2009; Lamprecht et al., 2001; Wei 
et al., 2008a; 2008b). For the pulmonary route, microspheres should be around 3 µm to 
achieve good results (Mohamed & Van Der Walle, 2008; Rawat et al., 2008). For 
subcutaneous, intramuscular or intravitreal administration routes, microspheres should be 
in the range of 10–250 µm in order to avoid particle uptake by macrophage phagocytosis 
and to minimise any inflammatory reaction (Gasparini et al., 2008; Herrero-Vanrell & 
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Molina-Martinez, 2007; Katare et al., 2005; Thomas et al., 2010; Yamamoto et al., 2002). 
In the case of specific organs such as the brain, the microsphere size should not exceed 
100 µm so as not to disturb the 3D structure of the brain (Tatard et al., 2005). 
Microspheres must not be too large as they will cause discomfort upon administration, 
but they should be sufficiently large to contain a reasonable amount of active ingredient 
(Mitragotri & Lahann, 2009; Wang et al., 1997). The global market for microspheres in 
2010 was estimated at $2 billion (~£1.39 billion) and it was predicted to reach $3.5 billion 
(~£2.44 billion) by 2015 as reported by an extensive market research report entitled 
‘‘Microspheres: Technologies and Global Markets’’ (Lipovetskaya, 2010). According to 
the same report, the medical technology and life sciences industries were mentioned as 
emerging industries (Fig. 2.5). 
 
 
Fig. 2.5: Global market for microparticles, by industry, in 2010 and estimates for 2015 
(Lipovetskaya, 2010). 
2.2.4 Active pharmaceutical ingredients (API) microcrystals  
Drug powders containing micron-sized drug particles are used in several pharmaceutical 
dosage forms. Many drugs, especially newly developed substances, are poorly water 
soluble, which limits their oral bioavailability (Joshi, 2011). Many approaches have been 
attempted to reduce particle size, including mechanical micronization (Reis et al., 2014), 
the supercritical fluid technique (Tenorio et al., 2007) and controlled antisolvent 
precipitation (Chiou et al., 2007). Micronization is a term used to describe a size reduction 
technique where the resulting particle size distribution is less than 10 µm. Traditional 
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techniques for micronization focus on mechanical means, such as milling and grinding. 
The mechanical micronization methods need a high-energy input and shows some 
disadvantages in practice, such as electrostatic effects, broad particle size distributions, 
thermal degradation, agglomeration, reducing the available surface area, contamination 
and reproducibility problems among different batches (Varshosaz et al., 2013; Zhang et 
al., 2006). Thus, techniques that prepare the drug directly in the required particle size are 
of interest. Among them, antisolvent crystallisation has unique advantages because it can 
be carried out at ambient temperatures and in conventional crystallisation vessels. 
Antisolvent addition generates high supersaturation which favours rapid and abundant 
nucleation, and hence produces a large number of smaller crystals as compared with 
cooling and evaporation (Xie et al., 2010).  
 
In the anti-solvent method, briefly, the drug is firstly dissolved in the solvent and the 
formed solution is quickly poured into the miscible solvent (anti-solvent). Precipitation 
happens instantaneously by a rapid desolvation of the drug. Currently, aqueous solutions 
containing some stabilizers are commonly used as the anti-solvent. 
Hydroxypropylmethylcellulose (HPMC) stabilizer is offered as a potential stabilizer to 
stabilize the small drug particles. HPMC, which consists of methoxyl and hydroxypropyl 
groups, can form hydrogen bonds between the drug molecule and the polymer; the 
stabilizer in the aqueous solution is absorbed on the surface of the formed hydrophobic 
drug particles to inhibit crystal growth (Raghavan et al., 2003; 2001). This technique is a 
rapid and direct process (Rasenack & Müller, 2002; Rasenack et al., 2003a; 2003b), 
which can be performed with ease. Table 2.3 summarises the type of APIs (drug) used by 
various researchers for the formation of microcrystals. In this research, the nonsteroidal 
anti-inflammatory drug, piroxicam (PRX), will be applied for the formation of 
microcrystals by the anti-solvent method.  
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Table 2.3: List of APIs used for microcrystal formation. 
Type of API Type of surfactant References 
Becomethasone-17,21-
dipropionate (BDP), 
betamethasone-17-valerate (BV) 
hydroxypropyl methyl 
cellulose 
(HPMC) 
Raghavan et al. 
(2001) 
Prednisolone (PDL) HPMC Li et al. (2007) 
Paracetamol (PCM) HPMC Reis et al. (2014) 
Piroxicam (PRX) HPMC, Brij35 Varshosaz et al. 
(2013) 
Salbutamol sulfate (SS) Lechitin, Span 85, 
Polyvinylpyrrolidone 
(PVP) and HPMC 
Xie et al. (2010) 
Rifampicin  HPMC Viçosa et al. (2012) 
Budesonide HPMC Rasenack et al. 
(2003) 
Siramesine hydrochloride Sodium lauryl sulphate 
(SLS), hydroxypropyl 
methylcellulose 
(HPMC), and 
hydroxypropyl cellulose 
(HPC) 
Zimmermann et al. 
(2009) 
Prednisolone HPMC Li et al. (2007) 
Atorvastatin HPMC Zhang et al. (2009) 
Griseofulvin and fenofibrate] Methyl cellulose (MC), 
hydroxyethyl cellulose 
(HEC), HPMC, sodium 
dodecyl sulphate (SDS) 
Meng et al. (2009) 
2.2.5 Addition of nanofillers (MMT) into the particulate matrix 
There is poor solubility of numerous drugs in aqueous media and biological fluids, and 
thus their effects are lessened due to insufficient bioavailability. To improve their 
solubility, drug molecules can be incorporated into the interlayer space of layered clays 
or nanofillers (San Román et al., 2013). Montmorillonite (MMT) is a natural clay mineral 
that belongs to the smectite group, in which a central alumina octahedral sheet is 
sandwiched between two silica tetrahedral sheets with the thickness of the individual 
layers being ≤1 nm. MMT has a large specific surface area, and exhibits a good adsorption 
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capability, cation exchange capacity, and drug-carrying capability. MMT is thought to be 
a good delivery carrier of hydrophilic drugs. MMT is a potent detoxifier with excellent 
adsorbent properties due to its high aspect ratio. It can adsorb excess water from faeces 
and thus act as an anti-diarrhoeic. MMT can also provide mucoadhesive capability for 
the nanoparticles to cross the gastrointestinal barrier (Dong & Feng, 2005; Feng et al., 
2009). It has also been used as a controlled release system. MMT has been proved to be 
nontoxic by hematological, biochemical and histopathological analyses in rat models 
(Lee et al., 2005). MMT is utilised as a sustained release carrier for various therapeutic 
molecules, such as 5 Fluorouracil (Lin et al., 2002), sertraline (Nunes et al., 2007), 
vitamin B1 (Joshi et al., 2009a; 2009b) and buspiron hydrochloride (Joshi et al., 2010). 
 
In addition to the therapeutic attributes of some unmodified MMT, their hybrids with 
ionic active pharmaceutical ingredients (APIs), that may be intercalated in the MMT 
interlayer space (Li et al., 2004) in a non-crystalline, amorphous state, can provide 
advantages such as: (i) the increased apparent solubility of APIs with poor aqueous 
solubility, (ii) controlled API release and, (iii) improved bioavailabilty. It has been 
hypothesized (Aguzzi et al., 2007; Dong & Feng, 2005; Li et al., 2004; Suzuki et al., 
2001) that the addition of the MMT platelets (see Fig. 2.6)  may improve the overall API 
stability by providing a tortuous path (see Fig. 2.7) that would slow down the API’s 
diffusion into the body fluids in the presence or absence of a polymeric excipient. The 
decrease of the API’s mobility inside the polymeric excipient would also help to prevent 
or slow down the aggregation of the API molecules. Thus, the crystallisation of the API 
molecules, which may lead to their delayed dissolution, could be minimised and the long 
term drug stability improved. It should be noted that hydrophilic polymers are, in general, 
chosen as excipients for the purpose of improving the APIs’ dissolution rate. It follows, 
then, that hydrophilic pharmaceutical nanoclays, such as montmorillonite and 
hydrotalcite, would tend to disperse better in hydrophilic polymers due to their improved 
affinity (Ha & Xanthos, 2011). Fig. 2.8 depicts the clay-drug complexation and in vivo 
drug release mechanisms.  
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 (a) PLA nanocomposite with 3wt % MMT    (b) PLA nanocomposite with 5 wt % MMT 
 
Fig. 2.6: Transmission electron micrograph of the PLA nanocomposite with MMT 
showing a platelet structure (Duan et al., 2013). 
 
 
Fig. 2.7: Schematic diagram of Tortuous Path Model (Duan et al., 2013). 
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Fig. 2.8: Idealization of clay-drug complexation and in vivo drug release mechanisms. 
{clay mineral surface charge (-); compensating cations (a+); cationic drug (X+); drug 
associated anions (Y-); in vivo counter ions  (A+);  anions associated with the counter 
ions (B-)} (Suresh et al., 2010).  
2.3 Anti-solvent precipitation method applied in nano/micro-particle formation   
The properties of biodegradable nano/micro-particles have to be optimized depending on 
the particular application. Methods like solvent evaporation, salting-out, dialysis and 
supercritical fluid technology, involving the rapid expansion of a supercritical solution or 
rapid expansion of a supercritical solution into a liquid solvent, can be utilized for the 
preparation of functional particles from preformed polymers. These particles can be 
directly synthesized by the polymerization of monomers using various polymerization 
techniques such as micro-emulsion, mini-emulsion, surfactant-free emulsion and 
interfacial polymerization. Different preparation techniques for nano/micro-particles are 
given in Fig. 2.9, where the choice of preparation method is made on the basis of a number 
of factors such as the type of polymeric system, the area of application and the size 
requirement (Rao & Geckeler, 2011).  
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Fig. 2.9: Schematic representation of various techniques for the preparation of polymeric 
nano/micro-particles. SCF: supercritical fluid technology, C/LR: controlled/living radical 
(Rao & Geckeler, 2011). 
 
Table 2.4 presents the most used polymers in functional particle formation according to 
the common practical techniques. Table 2.5 summarises the descriptions, advantages and 
disadvantages of different particle preparation techniques. Fig. 2.10 depicts the schematic 
diagrams of the different techniques for the preparation of nanoparticles and Table 2.6 
summarises the screening results for the anti-solvent precipitation techniques applied by 
many researchers with different chemical formulations and strategies for the preparation 
of biodegradable polymeric NPs. This screening observation was used as a reference for 
further experimental investigation.  
 
 
 
 
Dispersion Polymerization
Precipitation
SCF
Salting-out
Dialysis
Solvent evaporation Emulsion
Micro-emulsion
Interfacial
C/LR
Mini-emulsion
MonomerPolymer
Particles
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Table 2.4: List of commonly applied polymers based on particle preparation techniques 
(Mora-Huertas et al., 2010; Rao & Geckeler, 2011).   
 
Polymer Nanoparticle preparation technique 
Synthetic polymers 
Polymerization 
Poly(alkyl cyanoacrylate)  
Poly(alkyl methacrylate) 
Polystyrene 
Poly(vinyl pyridine) 
Poly(ε-caprolactone) (PCL) 
Nanoprecipitation 
Polylactide (PLA) 
Poly(lactic-co-glycolic) acid (PLGA) 
Poly(methacrylate) (PCL) 
Poly(ε-caprolactone)  
Solvent evaporation 
Polylactide (PLA) 
Poly(lactic-co-glycolic acid) 
Poly(β hydroxy butyrate) 
Ethyl cellulose 
Poly(alkyl methacrylate)  
Salting out 
Ethyl cellulose 
Polylactide (PLA) 
Poly(lactic-co-glycolic) acid (PLGA) 
Polylactide (PLA) 
Supercritical fluids technology 
Natural polymers 
Albumins 
Casein 
Gelatine  
Solubilization, denaturation, ionic 
gelation 
Alginate 
Chitosan 
Ethyl cellulose 
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Table 2.5: Descriptions, advantages and disadvantages of different functional particle preparation techniques (Nagavarma et al., 2012; 
Reis et al., 2006; Rao & Geckeler, 2011). 
Techniques Descriptions Advantages Disadvantages 
 
1. Solvent Evaporation 
 
Emulsification-solvent evaporation involves 
two steps. The first step requires emulsification 
of the polymer solution into an aqueous phase 
(see Fig. 2.10 (i)). During the second step, the 
polymer solvent is evaporated, inducing 
polymer precipitation as nanospheres. 
 
 Can be used for different types of 
emulsions; oil/water emulsions are 
of interest because they use water as 
the nonsolvent; this simplifies and 
thus improves process economics as 
it eliminates the need for recycling, 
facilitating the washing step and 
minimizing agglomeration.  
 
 
 This method only can be applied 
to liposoluble drugs, and 
limitations are imposed by the 
scale-up of the high energy 
requirements in homogenization. 
2. Nanoprecipitation Nanoprecipitation is also called the solvent 
displacement method. It involves the 
precipitation of a preformed polymer from an 
organic solution and the diffusion of the organic 
solvent into the aqueous medium in the 
presence or absence of a surfactant (see Fig. 
2.10 (ii)). 
 Able to facilitate the formation of 
colloidal polymer particles during 
the first step of the procedure. 
 Allows the preparation of 
nanocapsules when a small volume 
of nontoxic oil is incorporated in the 
organic phase. 
 Applicable to lipophilic drugs 
because of the miscibility of the 
solvent with the aqueous phase. 
 
 Not applicable to encapsulate 
water-soluble drugs. 
 Limited to water-miscible 
solvents, spontaneous 
emulsification cannot be 
observed if the coalescence rate 
of the formed droplets is 
sufficiently high. 
Emulsification/Solvent 
Diffusion 
 
This is a modified version of the solvent 
evaporation method. The encapsulating 
polymer is dissolved in a partially water soluble 
solvent such as propylene carbonate and 
saturated with water to ensure the initial 
thermodynamic equilibrium of both liquids (see 
Fig. 2.10 (iii)). 
 
 High encapsulation efficiencies 
(generally >70%), no need for 
homogenization, high batch-to-batch 
reproducibility, ease of scale-up, 
simplicity, and narrow size 
distribution. 
 One is efficient in encapsulating 
lipophilic drugs. 
 
The high volumes of water to be 
eliminated from the suspension 
and the leakage of water-soluble 
drug into the saturated-aqueous 
external phase during 
emulsification, reduce 
encapsulation efficiency. 
Salting-out 
 
Salting out is based on the separation of a water 
miscible solvent from aqueous solution via a 
salting out effect. Polymer and drug are initially 
 It minimises the stress to protein 
encapsulants.  
 The greatest disadvantages are 
exclusive application to lipophilic 
CHAPTER 2  
                                                                                                                                   
 
 
Rahimah Othman  2016 
 
29 
dissolved in a solvent such as acetone, which is 
subsequently emulsified into an aqueous gel 
containing the salting-out agent (electrolytes, 
such as magnesium chloride, calcium chloride, 
and magnesium acetate, or non- electrolytes 
such as sucrose) and a colloidal stabilizer such 
as polyvinylpyrrolidone or 
hydroxyethylcellulose (see Fig. 2.10 (iv)). 
 
 Salting out does not require an 
increase of temperature and, 
therefore, may be useful when heat 
sensitive substances have to be 
processed. 
drugs and the extensive 
nanoparticle washing steps. 
Dialysis Dialysis offers a simple and effective method 
for the preparation of small, narrow-distributed 
PNs. The polymer is dissolved in an organic 
solvent and placed inside a dialysis tube with a 
proper molecular weight cut off. Dialysis is 
performed against a non-solvent miscible with 
the former miscible. The displacement of the 
solvent inside the membrane is followed by the 
progressive aggregation of polymer due to a 
loss of solubility and the formation of 
homogeneous suspensions of nanoparticles (see 
Fig. 2.10 (v)). 
 
 The solvent used in the preparation 
of the polymer solution affects the 
morphology and particle size 
distribution of the nanoparticles. 
 Allows the passive transport of 
solvents to slow down the mixing of 
the polymer solution with a non -
solvent 
 The mechanism of PNP 
formation by the dialysis method 
is not fully understood at present. 
Supercritical Fluid 
Technology (SCF) 
 Supercritical fluid and dense gas technology 
are expected to offer an interesting and 
effective technique of particle production, 
avoiding most of the drawbacks of the 
traditional methods (see Fig. 2.10 (vi)).  
 Two principles have been developed for the 
production of nanoparticles using 
supercritical fluids:  
1. Rapid expansion of supercritical solution 
(RESS)  
2. Rapid expansion of supercritical solution into 
liquid solvent (RESOLV). 
A simple, but significant modification 
to RESS involves expansion of the 
supercritical solution into a liquid 
solvent instead of ambient air, termed 
as RESOLV 
 Even though in the RESS 
technique no organic solvents are 
used for the formation of PNPs, 
the prime products obtained 
using this technique are 
microscaled rather than 
nanoscaled, which is the main 
drawback of RESS. In order to 
overcome this drawback, a new 
supercritical fluid technology 
known as RESOLV has been 
developed. 
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Fig. 2.10: Techniques of preparation for polymeric nanoparticles (Nagavarma et al., 
2012; Reis et al., 2006).  
 
 
 
(i)  Schematic representation of the 
solvent-evaporation technique. 
 
  
(ii) Schematic representation of the 
nanoprecipitation technique. Surfactant 
is optional. 
 
 
(iii) Schematic representation of the 
emulsification/solvent diffusion 
technique. 
 
 
(iv) Schematic representation of the 
salting out technique. 
 
 
 
 
(v) Schematic representation of osmosis 
based method for the preparation of 
polymer nanoparticles. 
 
 
(vi) Experimental set-up for the 
preparation of polymer nanoparticles by 
the rapid expansion of the supercritical 
fluid solution. 
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Table 2.6: Screening for the anti-solvent precipitation method formulations. 
Polymer Solvent 
Non-
Solv
ent 
Stabilizing 
agent 
Particle 
size 
(nm) 
Reference 
PLGA Acetone H2O PVA 95–560 
Yallapu et al. 
(2010)  
PBCA Acetone H2O  
Pluronic F 68 
Polysorbate 80 
Dextran 
269±4 
210±5 
238±5 
Yordanov et al. 
(2010)  
Allylic 
starch 
Acetone H2O - 270 Tan et al. (2009)  
PHB Acetone H2O Tween 80 
100–
125 
Deepak et al. 
(2009)  
Dextran 
ester 
Acetone H2O - 77 
Hornig et al. 
(2009)  
PLGA Acetone/ethanol H2O Tween 20 63–90 
Chang et al. 
(2009)  
PCL 
diol 
Chloroform H2O Pluronic F 127 17.4 Kim et al. (2009)  
Eudragit 
L100-55 
Acetone/absolute 
ethanol 
H2O - 120 
Nassar et al. 
(2009)  
PLGA 
Acetone 
Acetonitrile 
H2O - 
165±5 
164±4 
Nehilla et al. 
(2008) 
PCL Acetone H2O PVA 365±5 
Moinard-Chécot 
(2008)  
PCA Ethanol/water H2O - 150 
Stella et al. 
(2007)  
PLA THF H2O - 
100–
300 
Legrand et al. 
(2007)  
PCL Acetone H2O Span 20 
741–
924 
Limayem  et al. 
(2006)  
PCL Acetone H2O Polysorbate 80 266±11 Zili et al. (2005)  
PLA Acetone H2O Poloxamer 188 250±50 
Seyler et al. 
(1999)  
PCL Acetone H2O PE/F68 
308–
352 
Ferranti et al. 
(1999)  
* Note: H2O= water 
2.4 Theoretical consideration for the choice of solvent and polymer  
The selection of two solvents suitable for anti-solvent precipitation is based on the 
requirements of the method and the physicochemical characteristics of the polymer. 
The method dictates that the organic solvents must be able to dissolve the polymer, 
be miscible with water and have a low boiling point to facilitate their elimination by 
evaporation (Legrand et al., 2007). The main physicochemical parameters which may 
influence this ternary system, consisting of polymer, organic solvent and non-solvent 
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(water) solvent and polymer selections, is the effects of the polymer–solvent 
interactions that can be defined by the polarity of the solvent. In general, by increasing 
the polarity of the polymer solvents and by decreasing the concentration of the 
polymer in the solvent, the yield of particle production can be increased and the size 
of the particles reduced (Galindo-rodriguez et al., 2004; Legrand et al., 2007; 
Murakami et al., 1999). This method can also be elucidated in terms of the interfacial 
turbulence and “diffusion-stranding” processes between the two unequilibriated liquid 
phases (Bagley et al., 1971; Bordes et al., 2010; Legrand et al., 2007; Van Krevelen 
& Hoftyzer, 1976). The mechanism of particle formation can be described based on 
the water-solvent, water-polymer and solvent-polymer interactions (Galindo-
rodriguez et al., 2004; Legrand et al., 2007). More detailed information related to this 
study will be given in Chapters 3 and 4 with a number of sequential equations and 
significant correlations. The following table (see Table 2.7) is a list of research 
references, which elucidate comprehensively the theoretical observations.  
Table 2.7: References for physicochemical interaction studies. 
Polymer  Organic solvent  References 
Poly(ᴅ,ʟ-lactides) 
(PLA) 
Acetone (Ace) and 
tetrahydrofuran (THF) 
Legrand et al. (2007) 
Monomethoxy 
poly(ethylene glycol)-
poly(ε-caprolactone) 
block copolymer 
THF, acetonitrile, Ace Lee et al. (2009) 
E L100-55 Ethanol, di-methyl sulfoxide, 
isopropyl alcohol, acetone, ethyl 
lactate 
Galindo-rodriguez et al. 
(2004) 
Poly(ɛ-caprolactone) 
(PCL) 
Various of soluble, partially 
soluble, and non-soluble solvents 
Bordes et al. (2010) 
PCL Acetone Gomez et al. (2015) 
PCL, PLA THF Othman et al. (2015a) 
PCL, PLA Ace, THF, ethanol, dimethyl 
sulfoxide, isopropyl alcohol, 
ethyl lactate 
Othman et al. (2015b) 
2.5 Micro-engineered dispersion devices 
2.5.1 Glass capillary microfluidic device  
Glass capillary microfluidic devices were recently developed to control the fine 
properties at the nanoscale. The use of microfluidic devices for functional 
pharmaceutical particle synthesis is significantly advantageous in many aspects, 
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including (i) enhanced processing accuracy and efficiency, (ii) flexibility for multi-
step platform design (iii) rapid turnaround results for fine tuning properties of 
synthesized nanoparticles, (iv) cost savings from reduced consumption of source 
materials and reagents, and (v) safer operation and environmental friendliness since 
the process consumes much reduced hazardous chemicals and reagents (Hung & Lee, 
2007). To reach higher quality of chemical, physical, optical, and biological properties 
for various applications, researchers have resorted to miniaturization of reaction 
platforms (DeWitt, 1999). Nano/micro-particles are predominantly important to 
biomedical science since their critical size dimensions are close to cells, tissues, 
microorganisms, and biological molecules (Köhler & Henkel, 2005; Ratner & Bryant, 
2004; Shchukin & Sukhorukov, 2004). Nanoparticles also have applications in 
advanced drug delivery systems, biomolecular sensing, targeted imaging, and thin 
film coatings. In nanoscale, the chemical, physical and biological properties are 
strongly affected by size dimensions and shape morphologies (Green & O’Brien, 
1999; Song et al., 2006). Table 2.8 summarises the different type of microfluidic 
devices based on their geometries and structures. Fig. 2.11 depicts the schematic 
diagram for different type of microfluidic devices. 
 
Table 2.8: Type of microfluidic/microchannel devices (Vladisavljević et al.  2012). 
Planar 
microfluidic 
devices 
Microchannel 
array devices 
Edge-based 
droplet 
generation 
Three-dimensional 
axisymmetric microfluidic 
devices 
─ T junction 
─ Cross junction 
─ Y junction 
─ Microfludic flow 
focusing devices 
(MFFD) 
─ Grooved-type 
microchannel 
─ Straight-
through 
microchannel 
arrays  
─ Edge-based 
droplet 
generation 
(edge) 
devices 
─ PDMS and acrylic 
axisymmetric devices  
─ Glass capillary axisymmetric 
devices 
 Co-flow glass capillary 
device 
 Counter-current flow glass 
capillary device 
 Three-phase glass capillary 
device 
 
 
 
CHAPTER 2  
                                                                                                                                 34
 
 
Rahimah Othman  2016 
 
 
                             
 
 
(i)Planar microfluidic devices:  (a) droplet formation 
at a T junction, (b) droplet break up at a T junction, (c) 
merging of droplets with a target sample stream at a T, 
(d) mixing of two liquid streams within a droplet using 
two converging side channels, (e) mixing of three liquid 
streams within a droplet using three converging side 
channels, (f) droplet formation at a cross junction, (g) 
formation of droplets of alternating composition at a 
cross junction, (h) formation of droplets at a Y junction, 
(i) formation of two distinct fluid streams using a Y 
junction. 
 
 
 
 
 
 
 
 
 
(ii)Planar microfluidic devices (Microfluidic flow 
focusing devices (MFFD)): (a) constriction placed 
downstream of three coaxial inlet stream. Liquid B 
wets channel walls, (b) modified design with three 
coaxial streams for generation of core/shell droplets. 
Liquid C wets channel walls, (c) two consecutive 
flow focusing droplet generators (FFDGs). FFDGs 1 
and 2 are wetted by liquid B and C, respectively, (d) 
two parallel coupled FFDGs. 
 
 
(iii) Microchannel array devices (Grooved-type MC 
plates): (a) dead-end plate, (b) cross-flow plate. 
 
 
(iv) Microchannel array devices (Straight-
through MC plates): (a) symmetric plate with 
microslots on both sides, (b) asymmetric plate with 
circular channels on upstream side and slots on 
dowstream, (c) symmetric plate with micronozzles 
(MNs). 
 
 
Fig. 2.11: Schematic diagrams of different type of microfluidic devices 
(Vladisavljević et al., 2012). 
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(v) Edge-based droplet generation (edge) devices. 
 
 
 
 
 
 
 
 
 
(vii) Three-dimensional axisymmetric 
microfluidic devices (Axisymmetric glass 
capillary devices): (a) co-flow of two immiscible 
fluids, (b) countercurrent flow of two immiscible 
fluids with flow focusing, (c) combination of co-
flow and countercurrent flow of three immiscible 
fluids, (d) two sequential co-flow droplet generators, 
(e) injection of two distinct inner phases of double 
emulsions using a two-bore injection tube. 
 
 
 
 
(vi)Three-dimensional axisymmetric microfluidic 
devices (Axisymmetric flow focusing device (AFFD) 
fabricated in PDMS): (a) fabrication process; (b) 
operation of AFFD oriented vertically to avoid 
accumulation of droplets on the wall of the outlet 
channel. 
 
 
Fig. 2.11-cont’ Schematic diagrams of different type of microfluidic devices 
(Vladisavljević et al., 2012).  
2.5.2 Micro-engineered membrane dispersion cell 
Membrane dispersion technique has been previously applied for the preparation of 
emulsions (“membrane emulsification”) (Charcosset & Fessi, 2009; Charcosset et al. 
2004). It has also been reported for the preparation of polymeric nanospheres and 
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nanocapsules (Charcosset et al. 2005; Limayem Blouza et al., 2006), lipid 
nanoparticles (D’oria et al., 2009; Li et al., 2011), and liposomes (Jaafar-Maalej et al., 
2011; Laouini et al., 2011). This technique has been employed in bi-phase 
emulsification (Joscelyne & Trägårdh, 2000; Nazir et al., 2010). By pushing the to-
be-dispersed phase through a membrane into the cross-flowing continuous phase, an 
emulsion/particle is formed. The particle/droplet size can be controlled primarily by 
the choice of membrane, cross-flow velocity, and transmembrane pressure. Numerous 
advantages of this technique was  highlighted such as low shear stresses, low energy 
requirement, uniform droplet size, less surfactant needed, ease of design and scale-up 
(Jia & Liu, 2013). Literature reviews about membrane dispersion are available 
(Joscelyne & Trägårdh, 2000; Vladisavljević & Williams, 2005) with an agreement 
to the several factors that influencing the final droplet/particle size, as follows; (i) 
shear on the membrane surface, (ii) dispersed phase flux, (iii) surfactant 
concentration, (iv) membrane wettability, (v) membrane pore size (droplet size is 
directly proportional to the membrane pore radius and the proportionality constant 
equals 3−20 (Vladisavljević & Williams, 2005; Williams et al., 1998), and (vi) 
viscosities of both continuous and dispersed phase.  
 
Different values of shear stress significantly attributed to the higher drag force acting 
on the membrane surface area, which then help to detach droplets/particles from the 
membrane surface and allow better control over the droplet/particle size distribution. 
The surface shear can be generated by; (i) recirculating the continuous phase in cross-
flow (Fig. 2.12 (a)) (Joscelyne & Trägårdh, 2000; Nakashima et al., 2000), (ii) 
vibrating (Kelder et al., 2007) or rotating the membrane (Fig. 2.12 (b) and (e)) 
(Aryanti et al., 2009; Schadler & Windhab, 2006; Vladisavljević & Williams, 2006), 
(iii) vibrating an element (e.g. a wire or plate) in the continuous phase at a short 
distance from the membrane (Fig. 2.12 (c)) (Hatate et al., 1997) or (iv) stirring the 
continuous phase using a stirring bar (Fig. 2.12 (f) and (g)) (Higashi & Setoguchi, 
2000) or (v) a paddle stirrer (Fig. 2.12 (d)) (Kosvintsev et al., 2005; Stillwell et al., 
2007), (vi) oscillating the membrane (Fig. 2.12 (h)) (Holdich et al., 2010) or (vii) 
combining the cross-flow with pulsation of the continuous phase (Fig. 2.12 (i) 
(Holdich et al., 2013). Table 2.9 summarises the advantages and disadvantages of 
different techniques applied to create surface shear on the membrane surface area.  
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Fig. 2.12: Formation of surface shear in membrane dispersion cell. 
 
Table 2.9: A comparison of different techniques for shear stress generation. 
 Potential 
advantages 
Potential disadvantages References 
Cross-flow, 
Tortuous 
membranes 
Easy scale-up, 
constant shear 
stress at the 
membrane 
surface, modules 
widely available 
Droplets can be 
damaged during 
recirculation in pipes 
and pumps, long 
operation times for 
concentrated emulsions 
 
Joscelyne & 
Trägårdh (2000), 
Nakashima et al. 
(2000) 
Cross-flow + 
Membrane 
vibration 
Additional control 
over droplet 
detachment, 
decrease in mean 
droplet size as 
compared with a 
simple cross-flow 
 
Complicated design, no 
evidence that droplet 
size monodispersity is 
improved 
Kelder et al. (2007) 
Vibration in 
Continuous 
phase 
Simple set-up Poor control of shear 
stress, suitable only for 
small scale applications 
 
Hatate et al., 
(1997) 
Rotating 
microengineered 
membrane 
Suitable for 
creation of fragile 
particles and 
viscous emulsions 
Complicated and 
expensive design, high 
power consumption 
Aryanti et al. 
(2009), Schadler & 
Windhab (2006), 
Vladisavljević & 
Williams (2006) 
Stirring, tubular 
SPG membrane 
Volume of 
continuous phase 
liquid can be as 
Maximum 
transmembrane 
Higashi & 
Setoguchi (2000) 
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low as several 
mililitres 
pressure restricted to 
several bars, 
nonuniform shear stress 
at the membrane 
surface, batch operation 
 
Stirring, flat 
microengineered 
membrane 
High injection 
rates of dispersed 
phase through the 
membrane 
Membrane pore 
clogging, batch 
operation, nonuniform 
shear stress at the 
membrane surface 
 
Kosvintsev et al. 
(2005), Stillwell et 
al. (2007) 
Oscillating 
Candle 
microengineered
membrane 
 
High 
productivity, easy 
scale up 
Need for removal of 
produced droplets if 
high amounts are 
produced 
Holdich et al. 
(2010) 
Cross-flow + 
pulsation of the 
continuous 
phase tubular 
membrane 
High 
productivity, easy 
scale up 
Too long membrane 
can vibrate and 
therefore reduce the 
uniformity of the 
droplets 
Holdich et al. 
(2013) 
 
In this study, the production of size-tuneable polymeric nanoparticles and 
microcrystals by anti-solvent precipitation method using membrane dispersion cell 
was discovered. Further discussion and experimental results attained from this study 
will be explained comprehensively in Chapter 5 and 6.  
2.6 Analytical instruments 
2.6.1 Particle size analyser 
2.6.1.1 DelsaTM Nano HC  
The DelsaTM Nano HC Particle Analyser (Beck-man Coulter, High Wycombe, UK) is 
the primary instrument used for both particle sizing and surface charge determination. 
Particle sizing is accomplished using dynamic light scattering (DLS), measuring the 
rate of fluctuations in a laser that is passed through the sample. As light is passed 
through the sample, the photons are scattered in all directions via Rayleigh scattering. 
The particles then diffused in the solution and the scattered photons will started to 
interfere constructively and destructively the particles surrounding. The intensity of 
this scattering undergoes a time-dependent fluctuation due to the motion of the 
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particles in the sample. Fluctuations at a higher frequency are due to smaller particles 
while lower frequency fluctuations are due to larger particles, as illustrated in Fig. 
2.13.  
 
Fig. 2.13: Hypothetical dynamic light scattering of two samples: Larger particles on 
the top and smaller particles on the bottom (Submicron, 2011). 
2.6.1.2 Nanoparticle tracking analysis (NTA)  
Nanoparticle tracking analysis (NTA) is newly developed and was first 
commercialised in 2006. NTA is an optimal method for detection of spherical particles 
in a liquid based on laser-illuminated optical microscopy. The primary advantage of 
this method is its ability to detect, visualise in real-time, and directly analyse particles 
as they move in the liquid. All particles in liquid move by Brownian motion, and this 
principle is also applicable for NTA. As the particles moved by Brownian motion, a 
two-dimensional video is taken. This video is analysed by the NTA software on a 
frame-by-frame basis. The average speed and distance of movement of the particles 
is established and this information is used to calculate the diameter of each particle 
and thus a size distribution and concentration will also be evident. Since each particle 
is measured both simultaneously and individually, it is possible to measure both the 
particle size and the relative light scattering intensity, which provides a more precise 
result of liquid containing mixtures of different particle sizes, such as biological fluids 
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(Carr et al., 2009; Dragovic et al., 2011). In this study, nanoparticle tracking analysis 
(NTA) was performed using a NanoSight LM10 (NanoSight, Amesbury, UK).  
 
Positioned on top of the microscope is an electron multiplying charged-couple device 
(EMCCD) camera. The EMCCD camera has a frame rate of 30 frames per second and 
typically this video is 60 seconds in duration. The NanoSight LM10 is equipped with 
20 × magnification microscope objective just above the sample chamber, which is 
highlighted in Fig 2.14 (a). The sample chamber is equipped with an inlet where the 
sample is injected with a sterile syringe, and an outlet where the sample can be ejected 
through. The sample chamber is ~500 μm deep and can contain ~0.25 mL of sample. 
As Fig. 2.14 (b) illustrates, a laser beam passes through the sample chamber. The 
NanoSight LM10 system uses a finely focused 642 nm laser beam, which is 
introduced into the sample chamber through a glass prism-edged optical flat. The 
refractive index of the glass prism is as such that the laser beam is refracted just above 
the glass flat and into the liquid above it. This low angle refraction results in a thin 
laser beam that illuminates particles through the sample. The EMCCD camera collects 
the light scattered from each particles as it refracts the light in the field of view (see 
Fig. 2.14 (c)) (Carr et al., 2009; Dragovic et al., 2011).  
 
 
Fig. 2.14: (a) Illustration of the NanoSight LM10-HS device with the (b) sample 
chamber highlighted to the right. (c) The computer shows the NTA 3.0 software as it 
is analysing a sample. 
EMCCD 
camera
Sample 
chamber
Fine 
focused 
laser beam
The Nanoparticle Tracking Analysis (NTA) software in action-
number count of particle in a determined volume
(a)
(b
)
(c)
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2.6.1.3 Malvern Mastersizer 
The micron size of particles generated from membrane dispersion cell is measured by 
using Malvern Mastersizer, UK. It is based on light scattering: the particles passed 
through a laser beam and scatter light at an angle related to their size. Mastersizer 
2000 software analyses the data to determine the size and size distribution of particles 
based on measuring the angular variability and intensity of the laser beam scattered 
by a series of photosensitive detectors. When laser beams pass through a dispersed 
particulate sample, the scattering of light depends on particles size in the sample; 
larger particles gives smaller angles of scattering while smaller particles give larger 
angles of scattering (see Fig. 2.15). The laser diffraction instrument in this study 
employed ― Fraunhofer and Mie theory‖ to analyse the size of particles. This theory 
relies on the refractive indexes of dispersed particles and the dispersion medium 
(manufacturer personal communication). Deionized water and saturated monohydrate 
piroxicam solution were used as dispersion medium and their refractive index was 
~1.34. The Malvern Mastersizer enables to measure particles in the size range of 0.1 
to 10000 μm. The disadvantage of the Mastersizer is that it is an offline technique that 
needs sampling (Malvern Instrument Ltd., 2007). 
 
 
 
Fig. 2.15: Schematic illustration of light scattering from small and large particles 
(Malvern Instrument Ltd., 2007). 
Incident light
Large angle scattering
Incident light
Small angle scattering
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2.6.2 Physicochemical properties analyser 
2.6.2.1 Differential scanning calorimetry (DSC) 
The TA Instruments Q100 Differential Scanning Calorimeter (DSC) is a powerful and 
versatile thermal analyzer that allows for property measurements on a broad variety 
of materials from -150 to 600°C. The DSC determines the temperature and heat flow 
associated with material transitions as a function of time and temperature. It also 
provides quantitative and qualitative data on endothermic (heat absorption) and 
exothermic (heat evolution) processes of materials during physical transitions that are 
caused by phase changes, melting, glass transitions, crystallisation, oxidation, and 
other heat related changes. It is used to characterize melting, crystallisation, resin 
curing, loss of solvents, and other processes involving an energy change. Differential 
scanning calorimetry may also be applied to the processes involving a change in heat 
capacity, such as the glass transition. In DSC analysis, the sample is placed in an 
aluminium pan, and the sample pan and an empty reference pan are placed on small 
platforms within the DSC chamber (TA Instruments Q100, 2007). Thermocouple 
sensors lie below the pans. DSC thermogram can be used to reveal four critical points; 
(i) the glass transition temperature (Tg), (ii) the crystallisation temperature (Tc), (iii) 
the melting temperature (Tm), and (iv) the curing temperature, as depicted in Fig. 2.16. 
 
  
Fig. 2.16: An idealized DSC curve showing the shapes associated with particular 
phase transitions (TA Instruments Q100, 2007). 
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2.6.2.2 Thermal gravimetric analysis (TGA) 
Thermogravimetric analysis (TGA) or thermogravimetry is an analytical technique in 
which the changes of a substance mass are measured as a function of temperature 
whist the substance is subjected to temperature variation in a controlled atmosphere. 
The formal definition of thermogravimetry (TG is the preferred abbreviation, 
although TGA is also used) has been given by the Nomenclature Committee of the 
International Confederation for Thermal Analysis and Calorimetry (ICTAC) as “a 
technique in which the mass of a substance is measured as a function of temperature 
whilst the substance is subjected to a controlled temperature programme”. It is the 
most widely used experimental technique for determining the thermal change of 
solids. A high-precision scale is used to measure the mass loss of a very small sample. 
In thermal decomposition, the mass of reactants disappears and forms gaseous 
products and possibly a residue of char. The record is the TG curve; the mass is 
normally plotted on the ordinate, decreasing down toward the origin, and temperature 
(T) or time (t) is on the abscissa, increasing from left to right according to the basic 
rules for plotting any kind of graph. The purpose is to determine the kinetic parameters 
of thermal decomposition of the material (TA Instruments, 2008). In this study, the 
thermal stability of the nanoparticles was assessed by TGA (Q5000IR 
Thermogravimetric Analyzer) at a heating rate of 10 oC min-1 over the temperature 
range of 20−600 oC under dry nitrogen as the effluent gas. A typical TGA curve is 
shown in Fig. 2.17. 
 
Fig. 2.17: An example of typical TGA curve. 
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2.6.2.3 X-ray diffractometry (XRD) 
X-ray powder diffraction (XRD) is an alternative analysis method that derives its 
name from the fact the specimen is in the form of a crystalline powder. An X-ray 
diffractometer consist in an X-ray cathode tube, a sample holder, and a detector. X-
rays are generated by the cathode ray tube, filtered to produce monochromatic 
radiation, collimated to be concentrated, and then directed towards the sample. X-ray 
diffraction is based on constructive interference of monochromatic light and the 
crystalline sample. Operates based on Bragg’s law: nλ = 2d sinθ, where n is the order 
of the diffraction pattern; λ is the wavelength of the incident beam; d is the distance 
between the planes in the crystal; and θ is the angle of beam diffraction. When a 
monochromatic X-ray beam strikes a plane of atoms at an angle θ, the rays are 
diffracted at the same angle θ (see Fig. 2.18). These angles are corresponding to spaces 
between planes of molecules in the crystal lattice. Since no two compounds would 
form crystals in which their three-dimensional spacing of planes is the same in all 
directions, the technique is considered as the most conclusive by itself alone. If a 
single crystal is used, the technique is able to clearly differentiate between 
polymorphs, but high quality crystals of adequate size are hard to obtain. It allows 
observation of phase transitions such as polymorphic transformation and dehydration. 
 
Fig. 2.18: X-Ray diffracted by a crystalline lattice following Bragg’s law. 
2.6.2.4 ATR-FTIR spectroscopy 
Attenuated Total Reflectance (ATR) is today the most widely used FTIR sampling 
tool. ATR generally allows qualitative or quantitative analysis of samples with little 
reflected X-rayincident X-ray
Crystal planes
θ
d
θ
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or no sample preparation, which greatly speeds sample analysis. The main benefit of 
ATR sampling comes from the very thin sampling path length and depth of 
penetration of the IR beam into the sample (see Fig. 2.19). This is in contrast to 
traditional FTIR sampling by transmission where the sample must be diluted with IR 
transparent salt, pressed into a pellet or pressed to a thin film, prior to analysis to 
prevent totally absorbing bands in the infrared spectrum. The basic operation of the 
ATR-FTIR is similar to ATR-UV/Vis but it uses a radiation beam in the infrared 
region. The IR regions include the near-IR 12800−4000 cm−1, mid-IR 4000−200 cm−1 
and far-IR 200−10 cm−1. Since most compounds absorb radiation in the mid-IR range, 
its applicability to different systems is widespread. It operates by imposing the 
radiation beam on a sample and measuring the amount of IR light absorbed at different 
frequencies. The IR energy corresponds to the energy related to bond vibrations e.g. 
bond stretching, bending etc. The frequencies at which IR energy is absorbed is a 
characteristic of a molecule, this fact can be used to identify a compound and hence 
the term fingerprint is used. IR absorptivities occur in CH, OH and NH groups, either 
of these exist in any organic molecule.  
 
Fig. 2.19: ATR measurement geometry (Lewiner et al., 2001). 
2.6.2.5 Raman spectroscopy 
Raman spectroscopy is a characterization technique that is widely used in scientific 
field in recent years. This technique is also known as Raman radiation and was first 
observed by Raman & Krishnan in 1928 (Vankeirsbilck et al., 2002). It actually 
utilizes the unique Raman spectra for different components as a spectral “finger print” 
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to quantitatively determine polymorphic forms’ concentration in slurries or dry solid 
mixtures depends on the possibility of building a good calibration function using a 
correct experimental approach. This spectroscopic technique is, precisely, based on 
inelastic scattering of monochromatic light, usually from a laser source. The 
approximate spectral range of Raman spectroscopy is between 50−4000 cm−1. When 
monochromatic light is incident on a material, the majority of the light or photons 
undergo Rayleigh scattering (elastic scattering) with no change in the energy or 
frequency of photons. A very small quantity of photons (0.0001%) however, 
undergoes Stokes (inelastic scattering) and anti-Stokes scattering. When the energy 
of the photon is absorbed by the molecule, it is termed as Stokes scattering resulting 
in red-shifted scattered light. An electron in the ground state is excited and lifted to a 
higher vibrational energy level. In case of anti-Stokes scattering, molecules give 
energy to the photon, resulting in blue shifted light, with a shorter wavelength and 
higher energy. An electron in the ground state is lifted to a higher level through a 
virtual state and ends up at a low vibration energy level. The possible energy 
transitions for vibrational spectroscopy are shown in Fig. 2.20. 
 
Fig. 2.20: Schematic representation of energy transition in Raman and IR 
spectroscopy. Absorption of IR radiation, Rayleigh, Stokes and Anti-Stokes Raman 
scattering.  
2.6.2.6 Focused beam reflectance measurement (FBRM) 
FBRM is an extensively used in situ technique that gives information about 
nucleation, dissolution, metastable zone width, polymorphic transformation, crystals 
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growth and size distribution in particulate systems in real time (Bakar et al. 2009). 
The laser beam from FBRM is sent through fibre optics to an immersion probe tip 
where it is finely focused by a rotating lens, which causes the beam to scan in a circular 
path through a sapphire window at a fixed high speed. The beam then passes into the 
solution under study and when it hits a crystal suspended in the solution, light is 
scattered in many directions, but only light scattered back towards the probe is 
collected. The crystal continues to back-scatter the light until the beam reaches the 
opposite edge of the crystal (see Fig. 2.21 (a)). The variable measured is the chord 
length, which is related to the particle size and shape. The focused beam crosses the 
particles on a straight line between any two points on the edge of the particle as shown 
in Fig. 2.21 (b). Based on the rotating speed of the laser (vS and back scattering time 
(∆t), the chord length distribution (CLD) for the particles is obtained using equation; 
chord length = vS ∆t. The CLD obtained from FBRM is grouped in 90 channels from 
0.8–1000 μm. The readings obtained from FBRM can be displayed in a variety of 
formats from simple total number of counts per second to square weighted or cubic 
weighted distributions.  
 
Fig. 2.21: (a) Schematic of the mode of operation of an FBRM probe (b) chord length 
measurement of typical crystals. 
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2.6.2.7 Ultraviolet–visible spectroscopy (UV-VIS)  
Ultraviolet and visible spectrometers have been in general applied for the last 35 years 
and over this period have become the most important analytical instrument in the 
modern day laboratory, due to its simplicity, versatility, speed, accuracy and cost-
effectiveness. In this study, Lambda 35 UV/Vis spectrometer (Perkin Elmer, UK) is 
used with wavenumbers ranged 190−1100 nm and bandwidth between 0.5−4 nm 
(variable). The light generated from a Xenon flash lamp and is passed through the 
monochromator which splits the beam into different wavelengths out of the 
continuous spectrum, which can be explained by Beer-Lambert’s Law. The intensity 
‘I0’ measured by the fraction of beam redirected using beam splitter. The transmitted 
intensity ‘I’ of the light beam is measured at photodetector and the absorbance is 
calculated by the following formula. 
 
𝐴 = 𝐴 = 𝑙𝑜𝑔 (
𝐼𝑜
𝐼
) = 𝜖𝑐𝑙.                                                                                       (2.1)         
where is 𝐴 the absorbance, 𝐼𝑜 is the incident light intensity, 𝐼 is intensity of light 
leaving, 𝑐 is the molar concentration of the solute, 𝑙 is the path length (cm) and 𝜖 is 
the molar absorptivity. Based on this law absorbance is linearly dependent on 
concentration, provided that molar absorptivity and path length remain constant. 
However, absorbance also depends on the temperature. The presence of more than 
one absorbing species, interaction between solute and solvent can also cause 
deviations from this law. 
2.6.2.8 High performance liquid chromatography (HPLC) 
High performance liquid chromatography (HPLC) is a common technique to analyse 
liquid samples. It allows separation of analyte molecules is based on their differential 
partitioning between two non-miscible phases, i.e. the stationary phase and the mobile 
phase. Separation is governed by various interactions between the analyte and the 
stationary and mobile phases. These include: dispersion interactions (contributing to 
hydrophobic interactions); dipole-dipole interactions; hydrogen bonding; ionic 
(coulomb) interactions; and charged transfer or π−π interactions (Snyder et al. 2009). 
The stationary phase is either a solid, porous or surface-active material in small-
particle form or, more commonly, a viscous liquid immobilised on these particles and 
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is fixed in the system. The mobile phase is a liquid which carries the mixture to be 
separated. Liquid chromatographic techniques that utilise elevated pressure to force 
the mobile phase through the small-particle packed bed are collectively termed high-
performance liquid chromatography (HPLC) (Meyer, 2010). A simple schematic of 
an HPLC system is shown in Fig. 2.22. 
 
Fig. 2.22: Schematic of an HPLC system. 
 
A UV detector is placed at the end of the column for the quantification of each 
component. A selected UV wavelength is directed and absorbed by each component 
going out of the column. The non-absorbed light is then processed in order to quantify 
the amount of each component of the sample analysed using the Beer and Lambert 
law. The relative retention times are used to qualitatively identify each component of 
the sample. 
2.6.3 Microscopic image analyser 
2.6.3.1 Field emission gun scanning electron microscopy (FEG-SEM) 
A field emission gun scanning electron microscopy (FEG-SEM) is a type of electron 
microscope that produces images of a sample by scanning it with a focused beam of 
high energy electrons (see Fig. 2.23). The high-energy electrons interact with atoms 
in the sample, producing various signals which contain information about the sample's 
surface topography, orientation and composition. FEG-SEM equipment mainly 
detects secondary electrons that result from interactions of the electron beam with 
atoms at or near the surface of the sample. In the standard secondary electron imaging 
mode, the FEG-SEM can produce very high-resolution images of a sample surface, 
revealing details less than 1 nm in size. Due to the very narrow electron beam, FEG-
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SEM surface topographic images have a large depth of field yielding a characteristic 
three dimensional appearance useful for understanding the surface structure of a 
sample.  
 
In this study, the microscopic structure of functional particles is analysed by Leo 
Elektronenmikroskopie GmbH model 1530 VP with an EDAX Pegasus 
(EBSD/EDXA) unit. Samples were mounted onto conventional aluminium sample 
holders with a surface of approximately 1 cm in diameter. The chamber was evacuated 
to ~5 x 10−1 Pa, for imaging, Secondary Electron (SE) and Inlens detectors were used 
with accelerating voltages of 5−10 keV and a working distance of 5–10 mm, 
depending on type of sample. For general topographic images, SE imaging gave 
sufficient resolution. For higher resolution images, the Inlens detector was used. 
 
Fig. 2.23: A schematic diagram of FEG-SEM machine. 
2.6.3.2 Scanning electron microscopy (SEM) 
The Hitachi TM3030 benchtop Scanning Electron Microscope (SEM) is an advanced 
scanning electron microscope; it uses electron technology to deliver excellent 
microscopic images for the samples. It is a small, lightweight machine, controlled via 
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software installed on a computer. The sample is placed in a vacuum chamber, and 
then a beam of electrons is applied to the sample. The Hitachi microscope offers many 
features and techniques to obtain much better images than those taken by conventional 
devices. This machine is also capable of providing compositional elements analysis 
of the sample via Energy Dispersive X-ray spectroscopy (EDX), which is essential 
for deeper analysis of the sample, as an X-ray sensor detects the emitted x-ray from 
the sample to produce the spectrum diagram of the elements. The main features of this 
tabletop microscope are; (i) magnification: 15×−30.000× (digital zoom ×2 or ×4), (ii) 
resolution: 30 nm, (iii) maximum sample size is 70 mm in diameter, (iv) maximum 
sample height is 50 mm, and (v)  signal detection is based on high-sensitivity 
semiconductor 4-segment backscattered electron (BSE) detector. Fig. 2.24 shows a 
schematic diagram of SEM analysis. 
 
Fig. 2.24: A schematic diagram of scanning electron microscope. 
2.6.3.3 Transmission electron microscopy (TEM) 
In transmission electron microscope (TEM) a very thin specimen (less than 100 nm 
thick) is irradiated by a beam of high-energy electrons (between few tens of kV up to 
1 MeV). A schematic of a traditional TEM configuration is presented in Fig. 2.25. 
The TEM allows examination of specimens with an order of magnitude higher 
resolution than an SEM; the resolution of a non-aberration corrected TEM with field 
emission source is ∼1.2 Å, whereas contemporary aberration corrected systems have 
been shown improve resolution down to 0.5 Å. Crystallographic information can be 
obtained in TEM using either selected area or convergent beam diffraction modes; 
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elemental characterization can be obtained by utilizing either energy dispersive 
spectroscopy (EDS) or electron energy loss spectroscopy (EELS). An image is formed 
from the interaction of the electrons transmitted through the specimen; the image is 
magnified and focused onto an imaging device, such as a fluorescent screen, on a layer 
of photographic film, or to be detected by a sensor such as a charge-coupled device 
(CCD) camera. X-ray emission consequent to the interaction of the primary electron 
beam with the sample, can also be detected by an energy-dispersive spectrometer 
(EDX) within the TEM.  At smaller magnifications TEM image contrast is due to 
absorption of electrons in the material, due to the thickness and composition of the 
material. In this study, transmission electron microscope model JEOL, JEM-2000 FX 
operated at an accelerating voltage of 200 kV was used to characterize the morphology 
structure of functional particles.  
 
Fig. 2.25: A typical setup of a TEM instrument. 
2.7 Introduction to crystallisation process  
Crystallisation from solution is a widely applied unit operation in both the 
pharmaceutical and bulk chemical industries for solid-liquid separations (Mangin et 
al., 2006; Olesberg et al., 2000; Shi et al., 2005). Researchers generally spend 
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considerable time and effort for the development of batch crystallisation processes for 
the production of crystalline compounds with consistent crystal properties, i.e. purity, 
shape, size, habit, morphology, and size distribution. The shape of the crystal size 
distribution (CSD) of the product obtained from the crystallisation process strongly 
affects the efficiency of downstream operations such as filtration, drying and washing 
(Chung et al., 1999; Mullin, 2001; Wibowo & Ng, 2001), but may also have 
considerable impact on the bioavailability of the active pharmaceutical ingredient 
(API). Most of the product properties (e.g. dissolution rate, bulk density, flow-ability, 
packing properties, etc.) are also directly related to the crystal size distribution (Chung 
et al., 1999). 
2.7.1 Crystallisation mechanisms 
The phase relationship of the solute-solvent system can be illustrated by a phase 
diagram; a typical example is shown in Fig. 2.26. In the figure, a solution whose 
composition lies on the solubility curve is said to be saturated, whereas those that lie 
in the regions below and above the curve are termed undersaturated and 
supersaturated, respectively. The terms indicate the relative amount of dissolved solid 
as compared to the saturated solution. The supersaturated solution is unstable because 
the dissolved solid and solvent are not in equilibrium. Like all other nonequilibrium 
systems, the supersaturated solution tends to reach equilibrium and in doing so it 
removes the solids in the form of nuclei, which then grow into crystals. The generation 
of supersaturation is therefore regarded as the first step in the crystallisation process 
(Davey & Garside, 2000; Mullin, 2001).  
 
Fig. 2.26: A typical phase diagram of a solute in a solvent (R. Davey & Garside, 2000; 
Mullin, 2001). 
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2.7.2 Supersaturation  
Theoretically, knowledge about the solubility curve in a given solvent (or solvent 
system) is a crucial step in performing a successful crystallisation process. It is worth 
noting that for a given solute in a given solvent, the solubility curve is fixed 
thermodynamically; however, impurities can have an impact on the solubility, and as 
impurities’ profiles and levels can change during process development or as process 
feedstock change from plant-to-plant, it is quite possible that the solubility could 
change. Hence, it is worth assessing the solubility of your material in the mother liquor 
from which it is crystallised (Barrett et al., 2005). Supersaturation of the solution may 
able to generate using five different methods, as listed and briefly described in Table 
2.10. There are also combinational methods to generate supersaturation such as 
combined cooling–evaporation method, known as vacuum crystallisation and 
combined cooling anti-solvent addition method (Nagy et al., 2008). Generally, the 
choice of method for generation of supersaturation depends on the required product 
properties, as well as the economic aspects (Davey & Garside, 2000; Mullin, 2001).  
 
Table 2.10: Methods of supersaturation generation (Davey & Garside, 2000; Mullin, 
2001). 
Methods Descriptions 
Evaporation Removal of solvent from a solution by evaporation increases the 
concentration of solute in the solution, which results in 
supersaturation. 
 
Cooling If the solubility of a solid increases with increasing temperature, 
a saturated solution can be prepared at a higher temperature. The 
solution is then cooled and since the solubility decreases during 
cooling, the solution becomes supersaturated. 
 
Anti-solvent 
addition 
Addition of a second solvent that reduces the solubility of the 
solute in the resultant mixture. 
 
Chemical 
reaction 
When a new compound is formed by a chemical reaction, the 
concentration of this compound is higher than its solubility in a 
solution. Therefore, the solution becomes supersaturated with 
respect to the new compound. Variation of pH to produce a less 
soluble acid or base from a salt, or vice versa, can also generate 
supersaturation. 
 
Freezing Freezing of solvent from a solution increases the concentration 
of solute in the solution, which results in supersaturation. The 
frozen solvent can then be removed from a solution by 
sublimation under vacuum. 
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2.7.3 Nucleation 
The formation of nuclei is an attempt of the system to reach equilibrium. It occurs 
spontaneously when the supersaturation was increased. The process of forming nuclei 
is called nucleation, whereas the point at which the nucleation occurs spontaneously 
is called the metastable limit. The metastable limit depends on kinetic variables, such 
as the rate at which supersaturation was created, the agitator speed, and the presence 
of impurities (Kim & Mersmann, 2001; Titiz-Sargut & Ulrich, 2002). The zones in 
the supersaturation region in which spontaneous nucleation would or would not occur 
are termed labile and metastable, respectively. Fig. 2.27 shows a possible location of 
labile zone, metastable zone, metastable limit and metastable width on a concentration 
against temperature diagram. Vital concerns should be focused on the metastable zone 
width (MSZW) in crystallisation because it provides information on nucleation 
kinetics, so that the nucleation behaviour of a system can be understood. The MSZW 
also can be considered as a characteristic property for each crystallising system (R. 
Davey & Garside, 2000; Mullin, 2001). In practice it is normally expressed in term of 
temperature rather than concentration for simplicity. 
 
Fig. 2.27: A typical phase diagram showing labile zone, metastable zone, metastable 
limit and MSZW (Kim & Mersmann, 2001; Titiz-Sargut & Ulrich, 2002). 
 
Nucleation is usually classified into either primary or secondary nucleation and can 
be further divided as shown in Fig. 2.28. It takes place spontaneously from a clear 
pure solution is called a homogeneous nucleation, whereas one induced by foreign 
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particles or surfaces is called a heterogeneous nucleation (Rawlings et al., 1993). 
Homogeneous nucleation, however, rarely occurs in practice because solutions 
usually contain impurities that act as substrates for nucleation (Giulietti et al., 2001). 
Since the presence of impurities in a supersaturated solution is known to reduce the 
energy required for nucleation, nucleation in a heterogeneous system generally takes 
place at a lower supersaturation than in a homogeneous system (Davey & Garside, 
2000). 
 
Fig. 2.28: Overview of the different types of nucleation (Davey & Garside, 2000). 
 
Secondary nucleation occurs when a supersaturated solution is in contact with seed 
crystals of the solute. The seeds can either be deliberately added, or unintentionally 
present in the system. The latter crystalline resulted of initial breeding (the 
dislodgement of microcrystalline dust particles from the surface of the seed crystals), 
needle/dendrite breeding (the detachment of weak outgrowths from crystal surfaces), 
polycrystalline breeding (the fragmentation of a weak polycrystalline mass) or 
collision breeding, which is also known as contact nucleation (the collision of crystals 
with one another, with agitator blades, or with crystalliser’s wall) (Lounaci et al., 
2010). There are other sources of secondary nucleation, where the seed crystals 
catalyse the nucleation and as a result, nucleation takes place at a lower 
supersaturation than that for the primary nucleation. For this reason, the secondary 
nucleation can be controlled more easily (Giulietti et al., 2001). 
2.7.4 Crystallisation operation and control overview 
Ideally, the mechanisms that govern crystallisation processes (nucleation, growth, 
polymorphic transformation) as well as on the modeling and control of crystallisation 
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systems is a very crucial things to be considered by most of the researchers. This 
significant knowledge might be enabled by the development and broader applications 
of process analytical technology (PAT) tools and increase in computing power. The 
key developments have occurred in four broad categories; (i) modelling, (ii) 
monitoring, (iii) control, and (iv) novel crystallisation concepts. In the modelling area 
major developments occurred in the use of multi-dimensional population balance 
models for morphological modelling of crystallisation processes, as well as in the 
better understanding of crystallisation in impure media (Nagy et al., 2013). Table 2.11 
summarises the three main crystallisation approaches.  
 
Table 2.11: Generic breakdown of crystallisation control approaches (Nagy et al., 
2013). 
Modelling Monitoring Control 
─ Population balance 
modelling (PBM) of 
crystallisation systems: 
 
 Modelling the dynamics of 
2D and 3D particle sizes. 
 Modelling the many breakage 
and agglomeration 
phenomena resulting from 
multi-particle interactions 
prior to control crystals shape 
and CSD in real dispersed 
media and in particular, 
during crystallisation 
processes occurring under 
stirring. 
 Modelling the crystallisation 
and the separation of optically 
active molecules, notably for 
pharmaceutical R&D 
purposes. 
 Modelling the inhibiting or 
promoting effects of 
impurities or additives on 
nucleation and crystal growth. 
─ Process analytical 
technology (PAT): 
 It is defined by the 
U.S.Food and Drug 
Administration (FDA) 
as “a system for 
designing, analyzing, 
and controlling 
manufacturing through 
timely measurements 
(i.e. during 
processing) of critical 
quality and 
performance attributes 
of raw and in-process 
materials and 
processes, with the 
goal of ensuring final 
product quality”. 
 
─Imaging sensors. 
 
─ Image analysis 
strategies. 
─ Model-based control 
approaches: 
 Model-free control. 
 Simple linear cooling (constant 
antisolvent addition). 
 Supersaturation (concentration 
feedback) control (SSC/CFC). 
 Direct nucleation control (DNC). 
 Combined DNC and SSC 
approaches (simultaneous and 
sequential).  
 
─Model -based control: 
 Programmed cooling/antisolvent. 
 Open-loop optimal control (nominal 
and robust). 
 Model predictive control (nominal 
and robust. 
 
─Hybrid techniques: 
 Analytical CSD estimator based 
control of supersaturation controlled 
processes.  
 Application of SSC for intelligent 
experiments for parameter 
estimation. 
 Model-based optimization of 
optimal trajectories in the phase 
diagram. 
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2.8.4.1 Crystal nucleation in a particles based micro-channel crystalliser 
In the field of pharmaceutical industry, chemical engineers must develop a robust 
crystallisation process that delivers the active pharmaceutical ingredient (API) with 
both high yield and appropriate attributes that are conducive to drug product 
development (e.g., purity, polymorph and particle size distribution). To reach this 
goal, it is essential that fundamental data on nucleation kinetics, crystal growth and 
phase transitions should be determined precisely. Recent advances in the state-of-the-
art technology of micro-channel have led to the development of a glass made 
microfluidic chip to study nucleation and phase transition of organic materials 
confined in droplets of organic solvents. In fact, at the micrometric scale the two-
phases flow is only controlled by capillary and viscous forces. Thus, monodispersed 
droplets, used as crystallisation containers, can be generated without a surfactant. This 
point can be important when studying nucleation and crystal growth rates, as surface-
active molecules can have a significant effect due to molecular similarity (Davey et 
al., 1997) and can favour the appearance of an undesired polymorph or can alter the 
thermodynamic equilibrium (Yano et al., 2000). Table 2.12 summarises the examples 
of crystal nucleation based microfluidic devices for the formation of particles. 
 
Table 2.12: Examples of crystal nucleation based microfluidic devices. 
Type of 
microfluidic 
devices 
Crystal nucleation approached applied in 
microfluidic crystalliser 
References  
Microfluidic chip Crystal nucleation in a droplet  Teychené & 
Biscans (2012) 
Microfluidic chip An easy-to-use microfluidic with accurate 
method for metastable zone width measurement. 
Ildefonso et al. 
(2012) 
Microphotographs 
crystallisation in 
microfluidic 
devices with 
different channel 
heights  
The channel height dependent nucleation 
and crystal growth were able to demonstrate, 
whereby the deep channels favorite the 
nucleation while shallow ones favorite the 
crystal growth.  
Lounaci et al. 
(2010) 
T-junction 
micromixer 
Nanoparticles were synthesized as reactive 
crystallisation and anti-solvent 
recrystallisation examples, respectively, of 
using the microfluidic-based emulsion and 
mixing approach as a new avenue of 
Su et al. (2007) 
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continuously producing inorganic and 
organic nanoparticles. 
PDMS microfluidic 
chamber 
A good control of humidity can be achieved 
and protein crystals could be conserved over 
a long period without dehydration. 
 
Lounaci et al. 
(2007) 
2.8 Application of PAT in crystallisation process monitoring 
The application of process analytical technology (PAT) became extensively popular 
in 2004 when the Food and Drug Administration published the ‘‘Guidance for 
Industry’’. PAT is defined as tools that enable process understanding for scientific, 
risk-managed pharmaceutical development, manufacture, and product quality 
(Guidance for Industry, 2004). These tools offer significantly valuable information to 
facilitate process understanding, continuous improvement, and development of risk-
mitigation strategies. Spectroscopic techniques improved tremendously during the 
last decade. Ultraviolet (UV), visible, near-, mid- infrared, and Raman spectroscopy 
have been studied and implemented in manufacturing processes (Chew & Sharratt, 
2010; Nagy et al., 2013). Many PAT tools have been used to monitor and control 
crystallisation processes (Giulietti et al., 2001; Helmdach et al., 2014), in particular, 
focused beam reflectance measurement (FBRM) (Yang & Nagy, 2014), particle 
vision and measurement (PVM), nuclear magnetic resonance (NMR), attenuated total 
reflectance (ATR)-UV/Vis, ATR-FTIR, and Raman spectroscopy.  
 
Table 2.13 gives a brief summary of the most common PAT tools used in 
crystallisation processes of polymorphic compounds and in solid polymorphs 
screening. Raman, FTIR, and NIR are the most common techniques exploited to 
distinguish polymorphs, although FBRM, ATR-UV, and mid-IR can provide very 
useful information (Simone et al., 2014). Fig. 2.29 illustrates the first implementation 
of the crystallisation process informatics system (CryPRINS) concept with a 
composite sensor array (CSA) that consists of a focused beam reflectance 
measurement (FBRM), a particle vision and measurement (PVM), an ATR-UV/Vis 
and a Raman probe, developed at Loughborough University, UK. CSA or composite 
PAT array is used for simultaneously monitoring multiple process and quality 
properties at the same time, rather than one at a time by considering the combination 
of signals from various PAT measurements as a single bundle of complex information 
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(Nagy & Braatz, 2012). The complementary and redundancy in the acquired 
information provided by the CSA allow the implementation of robust crystallisation 
control strategies. 
 
Table 2.13: Summary of recent studies conducted using PAT tools for polymorph 
screening and transformation monitoring. 
Techniques Process studied References 
Raman Determination of the polymorphic 
ratio of solid mixtures 
Strachan et al. (2007) 
FT-Raman, FTIR Comparison between the two 
techniques in determining the 
polymorphic ratio of solid mixtures 
Hennigan & Ryder (2013) 
Raman Co-crystallisation of carbamazepine 
and nicotinamide monitoring  
Rodríguez-Hornedo et al. 
(2006) 
Raman Solvent-mediated polymorphic 
transformation monitoring 
Herman et al. (2012) 
Raman, FBRM, 
PVM 
Study on the impact of operating 
parameters on polymorphic 
transformation of D-mannitol 
Su et al.  (2010) 
Raman Measurement of the total solid 
concentration in a polymorphic system 
Caillet et al. (2008) 
Raman Measurement of solute concentration 
in a polymorphic system 
Cornel et al. (2008) 
FBRM Solvent-mediated polymorphic 
transformation monitoring 
Barthe et al. (2008) 
Raman Feedback strategies to control 
polymorphs of carvedilol 
Pataki et al. (2013) 
 
 
Fig. 2.29: An overview picture of a crystallisation system with a composite sensor 
array (CSA) and crystallisation process informatics systems (CryPRINS) (Nagy et al., 
2013). 
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2.9 Summary of overall research study 
Fig. 2.30 summarises all important techniques and methodologies applied in this study 
for the formation of biodegradable nanoparticles and microcrystals using different 
micro-engineered dispersion devices (i.e. glass capillary microfluidic device and 
membrane dispersion cell) by anti-solvent precipitation method. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.30: Summary of overall experimental works applied in this study. 
NANO/MICRO-PARTICLES SYNTHESIS 
1. Glass capillary 
microfluidic device 
2. Membrane 
dispersion cell  
Optimum parameters 
investigation (NPs formation) 
Computer simulation 
validation 
Incorporating active 
ingredients + nanofillers 
onto polymer NPs matrix 
Process parameters 
interaction-Design of 
experiment.  
FUNCTIONAL NANOPARTICLES  
Optimum parameters 
investigation (NPs formation) 
Computer simulation 
validation 
Incorporating active 
ingredients onto polymer 
NPs matrix 
FUNCTIONAL NANOPARTICLES  
Optimum parameters investigation 
(microcrystals formation) 
MICROCRYSTALS & APPLICATIONS  
SELECTION of “good” organic solvent Physicochemical/chemical contents 
Particles size analyser, zeta potential, TEM, FEG-SEM, 
XRD, DSC, ATR-FTIR, Raman, UV-Vis, RP-HPLC and etc. 
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CHAPTER 3  
 
PRODUCTION OF POLYMERIC NANOPARTICLES BY 
MICROMIXING IN A CO-FLOW GLASS CAPILLARY DEVICE  
This chapter was published in Chemical Engineering Journal 
Chapter overview 
Synthetic polymeric biodegradable nanoparticles were produced by micromixing 
combined with nanoprecipitation in a co-flow glass capillary device consisted of 
coaxial assembly of glass capillaries, fabricated by aligning a tapered-end round 
capillary inside a square capillary with 1 mm internal dimension. Micromixing of 
water and an organic phase (1 wt% polylactide or polycaprolactone dissolved in 
tetrahydrofuran) was modelled using a commercial software package Comsol 
MultiphysicsTM and experimentally investigated using dynamic light scattering, 
Nanoparticle Tracking Analysis (NTA) and in situ microscopic observation. The 
organic phase was injected through a nozzle with a diameter of 60 µm at the organic-
to-aqueous flow-rate ratios ranging from 1.5 to 10. The locations at which the 
nanoparticles would form were determined by using the solubility criteria of the 
polymer and the concentration profiles found by numerical modelling. The convective 
flux of the polymer in the radial direction was 2-3 orders of magnitude higher than 
the diffusive flux of the polymer; hence responsible for mixing the streams. The 
convective flux near the orifice was 3-4 orders of magnitudes higher than at the end 
of the computational domain. A maximum convective flux of 0.115 kg m-2 s-1 was found 
for polycaprolactone at the cloud point for the lowest flow rate ratio investigated. The 
numerical results were consistent with the experimental observations in terms of flow 
patterns and mean particle size. Narrower particle size distributions and smaller 
mean particle sizes were obtained at the higher organic-to-aqueous flow-rate ratios.  
3. 1 Introduction 
Advances in microfluidic technology in recent years have provided alternative process 
strategies in diverse fields, such as materials science, chemical synthesis, biomedical 
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diagnostics and drug screening (Stone et al., 2004; Mark et al., 2010; Song et al., 2006; 
Teh et al., 2008). Compared to conventional macro-scale reaction vessels, test tubes 
and microtiter plates, microfluidic technology offers many advantages: (i) possibility 
to use expensive or toxic chemicals due to picolitre fluid volumes; (ii) homogeneous 
reaction environments due to precise spatial control over process conditions; (iii) 
ability to continuously and systematically vary reaction conditions; (iv) fast reactions 
due to high heat and mass transfer rates as a result of high surface-to-volume ratios; 
and (v) ability to achieve high levels of parallelisation, integration, and automation of 
unit operations (DeMello, 2006; deMello & deMello, 2004; Karnik et al., 2008). 
 
Although microfluidic techniques are experimentally well-established, optimisation 
of geometry and operating parameters in microfluidic devices is still challenging 
(Stone et al., 2004; Pan et al., 2008; Tonomura et al., 2004). Computational fluid 
dynamics (CFD) has appeared as an effective tool in providing visualized information 
on flow phenomena in complex geometries at both macroscopic and microscopic level 
(Ahuja & Patwardhan, 2008; Yamaguchi et al., 2004). Yamaguchi et al. (2004) 
applied CFD to simulate laminar co-flow in a microchannel with hairpin bends and 
the simulation results were consistent with experimental data. Bally et al. (2012) 
performed experiments and CFD simulations to investigate production of methacrylic 
nanoparticles in a multi-laminating micromixer under different operating conditions. 
Gradl et al. (2006) combined direct numerical simulation with Lagrangian particle 
tracking to simulate nanoprecipitation in a T-mixer and predict the size distribution 
of the produced nanoparticles. However, CFD simulations of flow phenomena arising 
from interaction between miscible liquid streams in microfluidic channels are still 
lacking. These simulations can provide valuable insight for optimising particle 
synthesis in two-phase microfluidic and millifluidic devices. 
 
Synthesis of nanoparticles by bulk mixing (conventional method) typically leads to 
the lack of control over the mixing process, which may compromise the properties of 
the resulting nanoparticles (Pihl et al., 2005; Bałdyga & Pohorecki, 1995). Bulk 
mixing is accomplished in two stages, macromixing (mixing at the scale of the whole 
system driven by convection and turbulent dispersion) and micromixing (mixing at 
molecular scale governed by Fick’s law) (Chan & Fuerstnau, 1967). A feature of 
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microfluidic mixers is that the macromixing stage, which is less controllable, can be 
avoided and mixing can be accomplished solely by molecular diffusion. Microfluidic 
mixing processes can be divided into active and passive strategies. Active mixing is 
based on providing an external source of energy to enhance mixing such as electric 
field or ultrasound, whereas passive mixing is any technique that requires no 
additional energy input, other than energy existing in the fluid flow. This study deals 
with passive microfluidic mixing that takes advantage of small lateral dimensions of 
microfluidic channels, which dramatically increase the effect of diffusion (Capretto 
et al., 2011; Locascio,  2004; Zhang et al., 2008). 
 
Nanoprecipitation triggered by passive microfluidic mixing has been used to 
synthesise various nano-sized products, such as liposomes (Jahn et al., 2013; Jahn et 
al., 2008; Jahn et al., 2004; Jahn et al., 2010), solid lipid nanoparticles (Yun et al., 
2009; Belliveau et al., 2012), micelles (Capretto et al., 2013), chitosan nanoparticles 
(Majedi et al., 2012), nanocrystals (Dev et al., 2013; Génot et al., 2010), and drug 
nanoparticles (Zhao et al., 2007; Ali et al., 2009; Dev et al., 2012). Nanoprecipitation 
requires two miscible solvents, but both the excipient and active ingredient (e.g. a 
drug) must be soluble in only one of them. The process is associated with a rapid self-
assembly of macromolecules into nanoparticles occurring when a macromolecular 
excipient solution is added to a non-solvent phase, resulting in almost immediate drug 
entrapment within the nanoparticles (Fessi & Puisieux, 1989; Fessi et al., 1992). It is 
a single-step technique that allows production of nanoparticles from a wide range of 
preformed polymers (Bilati et al.,2005; Nagavarma et al., 2012). 
 
Microfluidic devices that have been used in nanoprecipitation processes are flow-
focusing devices and microfluidic Y- and T-junctions. Hydrodynamic flow focusing 
was used to synthesise PLGA-PEG nanoparticles by rapidly mixing polymer-
acetonitrile solution and water (Karnik et al., 2008). Two lateral water streams were 
combined with a central organic phase stream and a narrow width of the focused 
organic stream enabled rapid mixing through diffusion. Y-junction has been used to 
produce nano-sized drug particles, thereby enhancing bioavailability of poorly water-
soluble drugs (Zhao et al., 2007; Ali et al., 2009). The drug was dissolved in ethanol 
and then precipitated by mixing the organic phase with a non-solvent (water), which 
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resulted in amorphous spherical particles with a mean size of 500 nm (Zhao et al., 
2007). T-junction has been used to prepare barium sulphate nanocrystals over a size 
range of 18–30 nm and boehmite nanocrystals (Ying et al., 2008). 
 
To the best of our knowledge, this work is the first computational and experimental 
study dealing with the formation of polylactide (PLA) and polycaprolactone (PCL) 
nanoparticles by nanoprecipitation in a co-flow glass capillary device (Duncanson et 
al., 2012; Duncanson et al., 2012; Shah et al., 2008). Glass capillary devices have been 
mainly used for preparation of emulsions, emulsion-templated microparticles, and 
vesicles such as polymersomes, colloidosomes and liposomes (Duncanson et al., 
2012; Duncanson et al., 2012; Shah et al., 2008; Vladisavljević et al., 2014; 
Vladisavljević et al., 2012). Recently, glass capillary devices have been used for 
fabrication of liposomes with a mean vesicle size in the range of 73–131 nm 
(Vladisavljević et al., 2014). Compared to planar flow focusing polydimethylsiloxane 
(PDMS) microfluidic devices more often used in nanoprecipitation, glass capillary 
devices offer several advantages: (i) fabrication is cheaper and does not require a 
master mould; (ii) many solvents commonly used in nanoprecipitation, such as 
tetrahydrofuran and chloroform, swell PDMS to a large extent, whereas glass has 
excellent chemical resistance against organic solvents; (iii) 3D geometry positions the 
organic phase at the centre of the collection channel in all directions. 
 
When a 3D orifice is used (Fig. 3.1 (b)), the organic phase stream is completely 
surrounded by the aqueous phase and the walls of the collection channel are 
completely wetted by the aqueous phase. Since the particles are predominantly formed 
at liquid-liquid interface, which is fully displaced from the channel walls, 3D 
geometry minimises interaction between the particles and the walls. In a planar 
geometry (Fig. 3.1 (a)), the organic phase at the junction is focused in the substrate 
plane, but not in the vertical axis, which can lead to deposition of the particles on the 
walls of the collection channel and compromise control over the resultant particle size. 
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Fig. 3.1: Schematic diagram of the top and cross-sectional view of planar (2D) and 
axisymmetric (3D) co-flow device (- - - = cross-sectional line). 
3.2 Solubility parameters 
According to the “diffusion-stranding” mechanism, nanoprecipitation is caused by a 
rapid diffusion of the organic solvent to the aqueous phase, which is accompanied by 
the diffusion of the polymer in the same direction (Miller, 1988; Davies & Ridcal, 
1963). The polymer becomes stranded at the organic/aqueous phase interface, due to 
its low solubility in the aqueous phase. The solubility of polymers in pure solvents 
and solvent mixtures can be predicted from the Hansen solubility parameters of 
components involved in the process.  
 
Hansen divided the Hildebrand solubility parameter, , into three components arising 
from different types of cohesive forces: a dispersion force component, d, arising from 
van der Waals forces, a polar component, p, reflecting permanent dipole-permanent 
dipole forces, and a hydrogen bonding component, h, arising from hydrogen bonding 
(Hansen, 2007). Hansen solubility parameters can be considered as coordinates in a 
3D “solubility (Hansen) space” in which all liquid or solid substances may be 
localised. The more a solvent is close to the polymer in the “Hansen space”, the more 
likely the solvent will be a good solvent for the polymer (Hansen, 2007; Bordes et al., 
Organic
phase
PLANAR (2D) GEOMETRY 3D GEOMETRY
Organic
phase
Aqueous 
phase
(a) (b) 
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2010). Bagley et al. (Bagley et al., 1971) introduced the parameter δv = (δp2+δd2)1/2, 
which led to a 2D graph in which δh was plotted against δv (Van Krevelen & Hoftyzer, 
1976). It was found that good solvents must be included in the circle of a radius of 
five δ-units around the polymer (Sung & Lee, 2001; Choi et al., 2002; Van Krevelen 
& Hoftyzer,  1976; Hansen, 2007). Therefore, PLA or PCL are soluble in water-THF 
mixture if the following condition is satisfied: 
 
    225 P,hM,hP,vM,v                                                                         (3.1) 
where indices M and P denote the solubility parameters of the water-THF mixture and 
polymer, respectively. The partial solubility parameters of the polymers (PLA and 
PCL), good solvent (THF) and pure solvent (water) used in this work are listed in 
Table 3.1.  
 
The solubility parameters of THF-water mixture can be determined by averaging the 
solubility parameter values of the individual liquids by volume (Suh & Clarke ,1967):   
 
TFH,vTHFW,vWM,v                                                                                      (3.2) 
TFH,pTHFW,pWM,p                                                                                    (3.3) 
where Φ
W
 and Φ
THF
 are the volume fractions of water and THF in the solvent mixture. 
 
Table 3.1: The partial solubility parameters (δd, δp, δh, and δv) of water, 
tetrahydrofuran (THF), polylactide (PLA), and poly-ɛ-caprolactone (PCL). 
Solubility parameters (J cm-3)1/2 Water a THF a PLA b PCL c 
δd 12.28 16.77 17.62 17.00 
δp 31.30 5.71 9.70 4.80 
δh 34.17 7.96 11.77 8.30 
δv 33.62 17.72 20.11 17.66 
 
a The partial solubility parameters of the solvents taken from Jain (2000).  
b The partial solubility parameters of PLA calculated based on the classical method for Hansen 
solubility parameters (Lu & Chen, 2004). 
c The partial solubility parameters of PCL calculated based on the classical method for Hansen 
solubility parameters (Davies & Ridcal, 1963). 
δ solubility parameter, subscripts d, contribution of the dispersion forces; p, polar contribution; h, 
hydrogen bonding contribution; v, dispersion and polar contribution.  
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3.3 Experimental  
Co-flow microfluidic mixer used in this work consisted of two coaxial glass 
capillaries: (i) an inner tapered-end round capillary (1.15 mm outer diameter and 650 
μm inner diameter) and (ii) an outer square capillary (1.15 mm inner dimension). A 
two-component epoxy glue (Five Minute Epoxy, ITW Devcon Ltd.) was used to fix 
the outer capillary onto a glass microscope slide that was used as a platform for the 
device. The inner capillary was pulled using a P-97 Flaming/Brown micropipette 
puller (Sutter Instrument Co.) to produce a sharp tip with a small orifice. The inner 
diameter of the orifice was enlarged to 60 μm by sliding the tip against abrasive paper. 
During this process, the tip was observed with a Narishige’s MF-830 microforge 
(Linton Instrument, Norfolk, UK). The inner capillary was flushed with water to 
remove any glass debris and then inserted in the square capillary. The capillary was 
then treated with 2-[methoxy(polyethyleneoxy)propyl]trimethoxysilane 
(FluoroChem, UK) to enhance the hydrophilicity of the orifice. After subsequent 
cleaning and treatment, the round capillary was positioned inside the square capillary 
such that the orifice coincides with the longitudinal axis of the square capillaryThe 
device was placed on the stage of an inverted microscope (XDS-3, GX Microscopes) 
(Fig. 3.2 (a)), which was attached to a Phantom V9.0 high-speed camera (Vision 
Research, Ametek, US). Coaxial alignment of the two capillaries was ensured by 
measuring the distance from the edge of square capillary to the central axis of the 
round capillary. It was done by displaying live image from the camera on the 
computer’s screen. . Two syringe needles with plastic hubs (B-D Precisionglide®, 
Sigma-Aldrich, 2.5 mm O.D. and 0.9 mm I.D.) were glued onto the slide such that the 
entrances to each capillary were situated inside the hubs. Two syringe needles with 
plastic hubs (B-D Precisionglide®, Sigma-Aldrich, 2.5 mm O.D. and 0.9 mm I.D.) 
were glued onto the slide such that the entrances to each capillary were situated inside 
the hubs. 
 
Fig. 3.2 (b) is a schematic view of the device, showing the inner capillary partially 
inserted into the square capillary. Two syringe needles with plastic hubs were attached 
to the capillaries to serve as liquid inlets. The needle hub with a single groove was 
used to deliver organic phase to the opening of the inner capillary. The needle hub 
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with two grooves was used to deliver aqueous phase co-currently through the pockets 
between the two capillaries (Fig. 3.2 (c)). The organic phase was 1 mg ml-1 (1000 
ppm) solution of PCL or PLA in THF and the aqueous phase was Milli-Q water. 
 
The phase flow rates were controlled by two separate syringe pumps (Harvard 
Apparatus, model 11 Elite). The organic phase was delivered from a gas-tight syringe 
via a THF-resistant Teflon tubing (1.59 mm O.D. and 0.8 mm I.D.). Milli-Q water 
was delivered from another gas tight syringe via a polyethylene tubing (1.52 mm O.D. 
and 0.86 mm I.D.). The aqueous phase flow rate, Qaq, was constant at 5 ml h
-1 and the 
organic phase flow rate, Qor, varied from 3.3 to 0.5 ml h
-1. Therefore, the throughput 
of the NPs was 0.5–3.3 mg h-1.The mixing process was recorded by the camera at 25 
frames per second and 576 × 288 resolution. The particle size distribution was 
measured by dynamic light scattering using Delsa™ Nano HC particle analyzer 
(Beckman Coulter, Inc). Nanoparticle tracking analysis (NTA) was performed using 
a NanoSight LM20 (NanoSight, Amesbury, UK), equipped with a sample chamber 
with a 642-nm laser. The samples were injected in the sample chamber with sterile 
syringes (BD Discardit II, New Jersey, USA), and the measurement was performed at 
room temperature. The Transmission Electron Microscopy (TEM) measurements 
were carried out using a JEOL JEM-2000 FX transmission electron microscope 
operated at an accelerating voltage of 200 kV. The sample drop was deposited onto a 
carbon-coated copper mesh and left to dry before being observed. The mesh was 
coated by dipping it into a suspension of carbon particles in deionised water. 
                                        
(a) 
THF + 
polymer Water 
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Fig. 3.2: Geometry of the glass capillary device modelled in this work: (a) A 
photograph of the experimental equipment; (b) A schematic top view showing coaxial 
assembly of glass capillaries glued onto a microscope slide. The magnified image is 
a tapered section of the inner capillary with 60 μm diameter orifice; (c) A schematic 
cross-sectional view showing round inner capillary and square outer capillary. All 
dimensions are in μm. 
3.4 Computational modeling  
The computational domain used for the simulations is shown in Fig. 3.3. The flow 
passage created by inserting a round capillary inside a square capillary is not entirely 
axisymmetric; hence a 3-D domain is required. By considering planes of symmetry, a 
quarter of the geometry along the axis was used in this numerical study. Sufficient 
channel lengths upstream and downstream of the nozzle have been selected to avoid 
inlet and outlet boundaries affecting the flow field and species distribution in the 
vicinity of the nozzle. The upstream and downstream channel lengths from the nozzle 
for the computational domain were selected to be 2885 μm and 3455 μm respectively. 
This selection was confirmed by a preliminary simulation with 50 % longer channels 
and we found no effect on the dependent variables solved. 
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The x-axis is perpendicular to the walls of the square capillary and equivalent to y-
axis, due to coaxial alignment of the two capillaries. The x coordinate ranges from x 
= 0 at the capillary axes to x = r at the walls of the square capillary, where r = 576 μm 
according to Fig. 3.2. The z-axis is oriented in the direction of flow and coincides with 
the axes of the capillary. z = 0 corresponds to the orifice outlet position. 
 
Fig. 3.3: The model geometry (3-D) of the co-flow microfluidic device. 
3.4.1 Governing equations 
The governing equations are the continuity and incompressible Navier-Stokes 
equations for laminar flow coupled with convection and diffusion equation for species 
transport. Here, we assume that the transient interfacial tension between the two 
miscible liquids used in this study is negligible due to similar viscosities and densities. 
The fluid flow equations were specified as follows:  
 
 
𝜕𝝆
𝜕𝑡
+ 𝜌∇ ∙ 𝒖 = 0                                                                                                                   (3.4) 
        
 𝜌
𝜕𝒖
𝜕𝑡
+ 𝜌(𝒖. ∇)𝒖 = ∇ ∙ [−𝑝𝑰 + )(
Tuu  ]                                                      3.5) 
 
where u , p , I ,   and   denotes the velocity field, pressure, identity matrix, density 
and dynamic viscosity respectively.      
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The density of THF-water mixture, expressed in g cm-3, was calculated using the 
following quadratic polynomial expression (Belandria et al., 2009): 
cbyay  2                                                                                                      (3.6) 
 
where y  is the mass fraction of water in the mixture and 1025.0a  , 2118.0b , 
and 889.0c  are constants.   
 
The dynamic viscosity of THF-water mixture, in mPa s, was estimated based on the 
work of (Montgomery et al., 1949): 
   yyy 23                                                                                            (3.7) 
 
where 4983.4 , 9205.1 , 0109.3 , 5591.0 . For pure THF ( 0y ), 
THF = 0.559 mPa s. For pure water ( 1y ) water = 0.99 mPa s.  
 
The influence of mixture viscosity on the diffusion coefficient of the polymer was 
taken into account using Wilke-Chang equation (Wilke & Chang, 1955; Hayduk & 
Laudie, 1974): 
60
2
1
810 x 47
.
P
w
V
T)M(.
D


                                                                                       (3.8) 
where D is the diffusion coefficient in cm2 s-1, Mw is the molecular weight of solvent, 
ζ is the association parameter introduced to define the effective molecular weight of 
the solvent (for non-associated solvents  = 1 and for water  = 2.6), T is the absolute 
temperature,  is the dynamic viscosity of the mixture in mPa s, calculated from Eq. 
(3.7), and VP is the molar volume of the polymer at normal boiling point in cm
3 mol-
1. The diffusion coefficient was found to be equal to 4.88 and 13.5  10-7 cm2 s-1 for 
PCL in pure water and pure THF, respectively and 2.24 and 6.20  10-7 cm2 s-1 for 
PLA in pure water and THF, respectively.  
 
The convection diffusion equation was solved using Transport of Concentrated 
Species interface available in Comsol MultiphysicsTM. A mixture averaged diffusion 
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model based on multicomponent Maxwell-Stefan diffusivities was selected along 
with convection to solve for species transport: 
ii
i
t
ju 


)(
)(


                                                                                 (3.9) 
where i  denotes the mass fraction of species i  and ij  denotes the relative mass flux 
vector expressed as: 
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where 
T
iD  is the thermal diffusion coefficient of species i  and 
m
iD  is the mixture-
averaged diffusion coefficient, given by: 
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where ikD  are the multicomponent Maxwell-Stefan diffusivities, kx  is the mole 
fraction, and iM  is the molar mass of component i . 
3.4.2 Boundary conditions 
The boundary conditions for the fluid flow were set as follows: 
 
(i) no slip boundary conditions were applied on the walls of both capillaries; (ii) at the 
inlets, flow velocities and mass fractions for each liquid were set according to the 
experimental flow rates. The flow was assumed to be fully developed at the orifice 
and a parabolic profile for the axial velocity, vz, was specified; (iii) at the outlet 
boundary, pressure was set to zero (the solution flows at the outlet of the co-flow 
device at atmospheric pressure); (iv) axial symmetry conditions were specified where 
surfaces were created in slicing the geometry. 
3.4.3 Numerical method 
The problem was solved using finite element method to predict the flow fields of the 
organic phase and aqueous phase within the device. A model was developed using 
laminar flow model (for fluid flow) and Transport of Concentrated Species (for 
convection and diffusion) available in Comsol Multiphysics™ 5.0. The computational 
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domain was discretised using 2,282,636 tetrahedral mesh elements with a finer mesh 
closer to the nozzle region. The number of degrees of freedom (DOFs) solved was 
2,586,882. Mesh independency of the solution was confirmed by performing 
computations with a finer mesh of 3,178,218 elements. The variations between 
solutions for above two meshes were found to be less than 1 % throughout the domain. 
All the flow rate ratios considered in this study were solved in one simulation using 
Parametric Sweep feature available under study Extensions. The total computation 
time was approximately 135 min on an Intel Core i7 64-bit 2.7 GHz processor. 
 
Following the simulations, the results were analysed by plotting the nanoprecipitation 
lines for both PCL and PLA at five different aqueous to organic phase flow rate ratios 
(Qaq/Qor = 1.5, 3.0, 4.5, 7.0, and 10.0). The flow rate ratio between the organic phase 
and aqueous phase was varied using parametric continuation feature available in the 
package. 
3.5. Results and Discussion  
3.5.1 Bagley’s two-dimensional graph for solubility of polymers in THF-water 
solution 
Figs. 3.4 (a) and (b) are Bagley’s two-dimensional solubility graphs for PCL and PLA, 
respectively in interaction with pure water, pure THF and water-THF mixtures. As 
expected, water is located far outside the solubility circle of PCL or PLA, in 
agreement with the fact that water is a non-solvent for both polymers. The position of 
THF and PCL on the solubility graph in Fig. 3.4 (a) almost coincides (see also Table 
3.1), indicating that THF and PCL have high affinity for each other and thus, THF is 
a good solvent for PLA. The THF-water mixtures are all situated on a straight line 
connecting two pure liquids, at a point corresponding in distance to the volume ratio 
of the liquids in the mixture. The higher the water content in the mixture, the greater 
the distance between the mixture and the polymer; hence lower the solubility of the 
polymer in that mixture.  
 
As shown in Fig. 3.4 (a), a 50/50 THF/water mixture is a poor solvent for PCL since 
it is located outside the solubility circle, but a solution having 92 vol% of THF and 8 
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vol% of water is a good solvent for PCL. The mixture containing 84 vol% of THF lies 
on the solubility circle, which means that nanoprecipitation of PCL starts when the 
water content in THF-water mixture reaches 16 vol% (or 18 wt%). Fig. 3.4 (b) shows 
that nanoprecipitation of PLA starts when the amount of water in THF-water mixture 
reaches 31 vol% or 34 wt%. The different positions of PCL and PLA on the solubility 
graph reflect the fact that the polarity of PLA is higher than that of PCL, as can be 
seen from corresponding δp values in Table 3.1. The polarity of PLA and PCL is due 
to their polar ester groups, but PCL is more hydrophobic than PLA because it contains 
a longer hydrocarbon chain on each side of the ester group (–(CH2)5– as compared to 
–CH(CH3)–).  
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Fig. 3.4: Bagley’s two-dimensional graphs of partial solubility parameters for pure 
THF, water, and different water-THF mixtures with respect to: (a) PCL; (b) PLA. The 
solubility circle shown by the red dotted line (…) has a radius of 5  -units and the 
coordinates of its centre are 6617.v   and 804.p   for PCL and 1120.v   and 
709.p   for PLA. Liquids outside the solubility circle are non-solvents.  
3.5.2 Numerical simulation of two phase co-flow 
The distribution of flow velocities and concentrations in a microfluidic mixer depends 
on geometry of the device, physical and thermodynamic properties of the ternary 
system (polymer-water-THF), such as polymer solubility, diffusion coefficients, 
viscosity and density of the mixture, interfacial tension, and operating conditions 
(flow rates of the aqueous and organic phase and the flow rate ratio). In this work, the 
Korteweg stress contribution at the mixing region separating the two fluids is not 
accounted for due to similar viscosities and densities of the fluids used. The 
contribution of Korteweg stress term is proportional to the viscosity contrast of the 
two miscible fluids; hence advection arising from this term is negligible for low 
viscosity ratios (Valentini & Moore, 2009).   
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3.5.2.1 Distribution of flow velocities in the co-flow microfluidic device 
Fig. 3.5 shows velocity magnitude at a constant aqueous phase flow rate of Qaq = 5 
ml h-1 and at five different organic phase flow rates, Qor (0.5, 3.0, 4.5, 7.0, and 10.0 
ml h-1). The colour bar on the right side of the figure represents normalised velocity 
magnitude within the computational domain. The precipitation lines for PLA and PCL 
calculated from Bagley’s solubility criteria are shown in the figure as solid red (PLA) 
and yellow (PCL) dashed lines, respectively. The polymers start to precipitate when 
they reach the respecting precipitation line during diffusion and convection in the 
radial direction.   
 
A flow space downstream of the nozzle can be divided into two distinct regions 
separated by the precipitation lines: an unsaturated region located between the two 
precipitation (cloud point) lines, where a polymer is fully soluble in the liquid phase 
due to high concentration of THF and a supersaturated region situated between the 
precipitation lines and the wall of the collection capillary, where the polymer is 
insoluble and forms nanoparticles. As can be seen in Fig. 3.5, the unsaturated region 
is narrower for PCL than PLA, because PCL is less soluble in water and starts 
precipitating at the higher THF concentration compared to PLA.  
 
The average velocity of the organic phase emerging from the nozzle is given by: 
)/(4 2, NororN DQU  , where ND  is the inner diameter of the nozzle. For the 
conditions shown in Fig. 3.5, the average velocity of the organic phase in the nozzle 
ranged from 0.05 m s-1 at orQ = 0.5 ml h
-1 to 0.32 m s-1 at orQ = 3.3 ml h
-1. The average 
velocity of the aqueous phase at nozzle is given by: )]4/(/[
22
, oaqaqN DaQU  , 
where oD  is the outer diameter of the nozzle and a  is the inner dimension of the 
square capillary. For the conditions shown in Fig. 3.5, the average velocity of the 
aqueous phase at the injection point, aqNU , 0.001 m s
-1, is much lower than that of 
the organic phase, orNU , 0.05 m s
-1. As a result of the large difference in velocity 
between the two streams, momentum is exchanged between the fluid streams until a 
steady-state parabolic velocity profile is established downstream of the nozzle. 
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According to Fig. 3.5, the region where velocity exceeds 90% of the maximum 
velocity (represented by dark red colour) extends approximately 7 nozzle diameters 
downstream at orQ = 3.3 ml h
-1, but is limited to approximately 2 nozzle diameters at 
orQ = 0.5 ml h
-1. Also this high-velocity region changes its shape from an elongated 
ellipse at high orQ  values to a semi-sphere at low orQ  values. At the organic phase 
flow rates of 3.3 and 1.7 ml h-1, vortices are formed in the aqueous phase near the 
nozzle (Figs. 3.5 (a and b)), due to the large difference in velocity between the organic 
and aqueous phase. It is possible that nanoparticles formed near the nozzle in these 
cases be trapped within vortices and forced into circular motion instead of being 
immediately swept away, which may lead to much longer residence time of these 
particles compared to the ones formed further downstream. As a result of non-uniform 
residence time of particles in the device, a broader particle size distribution can be 
expected for higher organic flow rates (Fig. 3.5 (a) and (b)) compared to low organic 
flow rates shown in Fig. 3.5 (c-e), where vortices are absent. 
 
At orQ  = 3.3 ml h
-1 (Fig. 3.5 (a)), the unsaturated (solvent-rich) region is narrow near 
the nozzle and reaches a maximum thickness of ND28  downstream of the nozzle. This 
reflects the fact that the organic phase emerges from the nozzle at a relatively high 
velocity and a considerable distance is required for the velocities of the two phases to 
equilibrate. Once the maximum thickness is established, the unsaturated region 
remains unchanged until the end of the computational domain. At this point, mixing 
occurs mainly by diffusion in radial direction, therefore the effect of mixing is not 
visible. The mean residence time of fluid elements downstream the nozzle is inversely 
proportional to the total flow rate ( aqor QQ  ). At orQ  =0.5 ml h
-1 (Fig. 3.5 (e)), a 
maximum thickness of the unsaturated region is  ND5  and the organic phase velocity 
is quickly reduced to the equilibrium value. Since the fluid elements have 50 % longer 
mean residence time in Fig. 3.5 (e) than in Fig. 3.5 (a), the effect of mixing on the 
shape of the precipitation lines is clear and the unsaturated region is narrower at the 
end of the computational domain. It can be explained by the progressive replacement 
of organic phase by water through the interfacial area, leading to shrinkage of the 
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unsaturated region. At a sufficiently long distance downstream of the nozzle, the two 
precipitation lines will join together at the central axis, which means that the 
supersaturated region will occupy the entire cross section of the collection capillary.  
 
Fig. 3.6 shows velocity profiles at a cross-section one nozzle diameter downstream of 
the nozzle for the five different flow rate ratios. As shown in Fig. 3.6 (a), the axial 
velocity (
zU ) for all flow rate ratios decreases from a maximum value at the central 
axis ( x = 0) to zero at the wall (x = 576) of the capillary. A maximum axial velocity 
of 0.44 m s-1 was found for the lowest flow rate ratio (FR = 1.5) while a minimum 
axial velocity of 0.02 m s-1 is recorded for the highest flow rate ratio (FR = 10). These 
velocities are lower than the maximum axial velocities computed at the nozzle (0.64 
m s-1 for FR = 1.5 and 0.1 m s-1 for FR = 10) due to viscous dissipation over a distance 
of ND . For the given cross-section, precipitation of PLA or PCL starts 66 µm away 
from the central axis for FR = 1.5 and the corresponding axial velocity is 0.037 m s-1. 
For FR = 10, the polymer precipitation starts at 160 µm from the central axis, where 
zU   0.  
 
Fig. 3.6 (b) shows profiles of radial velocity ( xU ) at a cross-section one nozzle 
diameter downstream of the nozzle. Negative values of xU represents velocity vectors 
directed away from the central axis (towards the wall). At x = 0, the radial velocity is 
zero for all the flow rate ratios, as no flow across the central axis is possible due to 
axisymmetric geometry. The radial velocity is negative near the central axis, reflecting 
the fact that the organic phase stream expands after injection from the nozzle. The 
highest negative radial velocity is observed at the highest organic phase flow rate. The 
radial velocity becomes positive farther away from the central axis, since the aqueous 
phase flows towards the interface. The maximum fluctuation of radial velocity is 
observed for FR = 1.5 due to the vortices formed on either sides of the jet emerging 
from the nozzle. The radial velocity becomes zero at a distance between 50 and 150 
µm from the central axis, depending on the flow rate ratio, which roughly corresponds 
to the position of the interface.  
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Fig. 3.7 (a) shows axial velocity profiles ND12  downstream of the nozzle. At FR = 
1.5, the axial velocity at the central axis is 0.018 m s-1, which is 5 times greater than 
the maximum velocity for fully developed laminar flow through a square duct given 
by: 
2
max, /)(1.2 aQQU oraqz   = 0.0036 m s
-1. Thus, equilibrium velocity profile was 
not yet established ND12  downstream of the nozzle. Furthermore, due to vortices 
formed within the aqueous phase, the axial velocity is negative at x > 400 µm. For FR 
= 3, 4.5, 7 and 10, the axial velocity profile is parabolic with a maximum velocity at 
the central axis ranging from 0.0023 to 0.0035 m s-1, which is close to max,zU  values 
for fully developed steady-state laminar flows (0.0024 and 0.0029 m s-1) calculated 
from the above equation. Fig. 3.7 (b) shows the radial velocity ND12  downstream of 
the nozzle. Negative values indicate that the flow is diverted away from the central 
axis. Further down the capillary, fluid flow is fully developed and the radial velocity 
becomes zero. For FR values from 3 to 10, the absolute value of the radial velocities 
are less than 0.0005 m s-1, which indicates that fully developed velocity profiles are 
nearly established at 12 nozzle diameters downstream the nozzle. At FR = 1.5, the 
radial velocity exceeds 0.004 m s-1 at certain locations, indicating that hydrodynamic 
equilibrium is not yet established.  
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Fig. 3.5: The distribution of velocity magnitudes at: (a) Qaq/Qor =1.5, Qaq=5.0 ml h
-1, 
Qor = 3.3 ml h
-1; (b) Qaq/Qor = 3, Qaq = 5.0 ml h
-1, Qor = 1.7 ml h
-1; (c) Qaq/Qor = 4.5, 
Qaq = 5.0 ml h
-1, Qor = 1.1 ml h
-1; (d) Qaq/Qor = 7, Qaq = 5.0 ml h
-1, Qor = 0.7 ml h
-1; 
(e) Qaq/Qor = 10, Qaq = 5.0 ml h
-1, Qor = 0.5 ml h
-1. Surface: normalised velocity 
magnitude. Black contours: stream lines. Solid red lines and yellow dashed lines are 
the cloud point lines for PLA and PCL, respectively. Vertical green lines in (a) are 
sections considered in Figs. 3.6 and 3.7. (For interpretation of the references to colour 
in this figure legend, the reader is referred to the web version of this article.) 
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Fig. 3.6: (a) Axial velocity profiles and (b) radial (along x-axis) velocity profiles at 
one nozzle diameter downstream of the nozzle for five different flow rate ratios, FR, 
of the aqueous to organic phase. 
 
(a) 
(b) 
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Fig. 3.7: (a) Axial velocity profiles (along z-axis) and (b) radial velocity profiles 
(along x-axis) at 12 nozzle diameters downstream the nozzle for five different flow 
rate ratios (FR). 
3.5.2.2 Distribution of THF and polymer in the co-flow microfluidic device 
Fig. 3.8 shows distribution of mass fraction of THF at different flow rate ratios. The 
boundary between THF and water is very sharp near the nozzle, but becomes blurred 
(b) 
(a) 
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farther downstream due to countercurrent mass transfer of THF and water across the 
interface. At FR = 1.5, the organic phase flow rate is the highest leading to the thickest 
organic phase stream and consequently, the longest mixing length. The mixing time 
is proportional to the square of the width of the organic phase stream and inversely 
proportional to the diffusivity of THF (Karnik et al., 2008). At FR = 10, the organic 
phase stream is so narrow that the mass fraction of THF on the central axis is below 
0.9 at the end of the computational domain. At FR = 10, the organic phase stream is 
initially very thin, but widens further downstream as a result of its deceleration caused 
by the interaction with a slow-moving aqueous phase.  
 
Fig. 3.9 shows profiles of mass fraction of THF at two different cross sections located 
at NDz   and Wz 5  (W = width of the square capillary). At NDz   (Fig. 3.9 (a)), 
the mass fraction of THF in the liquid is 0.99 all the way from the central axis to the 
interface and then suddenly drops down to zero reflecting the fact that the mixing 
process has barely begun. However, for FR of 1.5, the mass fraction of THF is not 
zero between the interface and the wall, due to retention of small amount of THF 
within the vortices. At Wz  5.5  (Fig. 3.9 (b)), the concentration profiles show a 
gradual variation due to progression of the mixing. When the mixing process is 
complete, THF will be uniformly distributed over the whole cross section and the 
concentration profiles will become ‘flat’ with a mass fraction of THF ranging from 
0.37 at FR = 1.5 to 0.08 at FR = 10. According to Fig. 3.9 (b), the mass fraction of 
THF on the central axis is approximately 0.83, while the highest concentration was 
found at FR = 3. At FR = 1.5, mixing is enhanced by vortices formed and the 
concentration of THF is lower on the central axis than that at higher flow rate ratios. 
 
Fig. 3.10 shows distribution of PCL within the device at different flow rate ratios. 
Clearly, PCL and THF show similar distribution patterns as mass transfer of both 
species is governed by similar factors. The total flux of PCL is the sum of diffusive 
and convective fluxes arising from concentration gradient and bulk fluid motion, 
respectively. As shown in Table 3.2, the mass transfer of PCL from the organic phase 
to the aqueous phase is convection-dominated, since the convective flux is 13 orders 
of magnitude higher than the diffusive flux. A maximum radial convective flux of 
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0.115 kg m-2 s-1 was found for PCL at the nozzle for FR = 1.5. This is caused by 
vortices formed near the nozzle causing the radial velocity to reach a maximum (Figs. 
3.5 and 3.6). It is also evident that the convective flux is 34 orders of magnitudes 
higher near the nozzle than that at the end of the computational domain, as the radial 
velocity is much greater near the nozzle compared to any downstream location. The 
diffusive flux of PCL follows the same trend with the maximum diffusion rate near 
the nozzle, due to the largest concentration gradient, as shown in Fig. 3.9.  
3.5.2.3 Distribution of dynamic viscosities in the co-flow capillary device 
Fig. 3.11 shows the variation of dynamic viscosity within the domain at 25 oC. Before 
mixing the organic phase has a viscosity of 0.559 mPa s (or 5.59 mP), while pure 
water has a viscosity of 1 mPa s. The viscosity of the mixture is higher than that of 
the feed streams and is given by equation (3.7). A maximum viscosity of 2.1 mPa s 
occurs at 42 wt% THF while the viscosity at the cloud point is 1.14 and 1.63 mPa s 
for PCL and PLA, respectively. At FR = 1.5, radial mass flux near the nozzle is 
relatively high due to the vortices formed and thus, the viscosity of the mixture is 
higher in the vicinity of the nozzle than that observed for other flow rate ratios.  
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Fig. 3.8: Distribution of mass fraction of THF at: Qaq/Qor = 1.5, Qaq = 5.0 ml h
-1, Qor 
= 3.3 ml h-1; (b) Qaq/Qor = 3, Qaq = 5.0 ml h
-1, Qor = 1.7 ml h
-1; (c) Qaq/Qor = 4.5, Qaq 
= 5.0 ml h-1, Qor = 1.1 ml h
-1; (d) Qaq/Qor = 7, Qaq = 5.0 ml h
-1, Qor = 0.7 ml h
-1; (e) 
Qaq/Qor = 10, Qaq = 5.0 ml h
-1, Qor = 0.5 ml h
-1. Contours: Mass fractions of THF at 
0.1 increment (0.1, 0.2,. . ., 0.9). Vertical green line is a section considered in Fig. 
3.9(a).  
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Fig. 3.9: Profiles of mass fraction of THF for various flow rate ratios (FR) at a cross 
section located: (a) DN downstream from the nozzle; (b) 5.5W downstream from the 
nozzle (DN = internal diameter of the nozzle, W = width of the square capillary, and 
FR = Qaq/Qor).  
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Fig. 3.10: Distribution of mass percentage of PCL at: Qaq/Qor = 1.5, Qaq=5.0 mlh
-1, 
Qor = 3.3 ml h
-1; (b) Qaq/Qor = 3, Qaq = 5.0 ml h
-1, Qor = 1.7 ml h
-1; (c) Qaq/Qor = 4.5, 
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Qaq = 5.0 ml h
-1, Qor = 1.1 ml h
-1; (d) Qaq/Qor = 7, Qaq = 5.0 ml h
-1, Qor = 0.7 ml h
-1; 
(e) Qaq/Qor = 10, Qaq = 5.0 ml h
-1, Qor = 0.5 ml h
-1. Black lines: precipitation (cloud 
point) lines for PCL.  
 
Table 3.2: The radial component of diffusive and convective fluxes of PCL on the 
cloud line just after the nozzle z  0) and at the end of the computational domain (z 
= zmax) for two different flow rate ratios (FR=1.5 and 10). 
FR 
Diffusive mass flux of PCL/kg m-2s-1 Convective mass flux of PCL/kg m-2s-1 
z = 0 z = zmax z = 0 z = zmax 
1.5 37 × 10-5 0.27 × 10-5 11500 × 10-5 37 × 10-5 
10 25 × 10-5 0.047 × 10-5 1800 × 10-5 0.11 × 10-5 
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Fig. 3.11: Surface and contours of dynamic viscosity (in milipoise) at: Qaq/Qor = 1.5, 
Qaq = 5.0 ml h
-1, Qor = 3.3 ml h
-1; (b) Qaq/Qor = 3, Qaq = 5.0 ml h
-1, Qor = 1.7 ml h
-1; 
(c) Qaq/Qor = 4.5, Qaq = 5.0 ml h
-1, Qor = 1.1 ml h
-1; (d) Qaq/Qor = 7, Qaq = 5.0 ml h
-1, 
Qor = 0.7 ml h
-1; (e) Qaq/Qor = 10, Qaq = 5.0 ml h
-1, Qor = 0.5 ml h
-1.   
3.6 Experimental validation 
The video recordings of the process captured at Qaq = 5 ml h
-1 and Qor of 0.7 and 3.3 
ml h-1 (Figs. 3.12 (a) and (b)) are in good agreement with the presented numerical 
simulations. At low Qor value, the interface is hemispherical and corresponds to the 
high velocity region shown in Fig. 3.5 (d). Although the equilibrium interfacial 
tension between water and THF is zero, a temporary interface is clearly visible, 
formed due to sharp differences in density and composition when the two liquids are 
suddenly brought into contact. The formed nanoparticles can be seen in the aqueous 
phase near the interface. As expected, nanoparticles are not visible between the two 
cloud point lines due to high THF concentration in this region. Self-assembly of PCL 
into nanoparticles is almost instantaneous near the nozzle due to high gradients of 
concentration and high fluxes of PCL, which results in high concentration of 
nanoparticles in that region. The formation of vortex flow at high Qor value can be 
seen in Fig. 3.12 (b), as predicted in Fig. 3.5 (a).  
  
20.9 
5.2 
μm 
 
(d) 
(
e) 
μ
m 
 
μm 
 
μm 
 (e) 
CHAPTER 3  
                                                                                                                                 91
 
 
Rahimah Othman  2016 
 
The interface has a widening shape due to decreasing velocity of the organic phase, 
as predicted in Fig. 3.8 (a). As a result of vortex flow, the nanoparticles formed near 
the nozzle and forced into circular motion, which leads to much longer and non-
uniform residence time of these particles compared to the ones formed farther 
downstream. As a consequence, a broader particle size distribution and larger mean 
particle size was observed at the higher organic flow rate (Fig. 3.14). Fig. 3.12 (c) 
confirms the presence of monodisperse spherical nanoparticles with uniform size 
distribution at Qaq/Qor = 10.0 by tracking individual particles in liquid dispersions. 
The spherical shape of nanoparticles was clearly acquired from TEM analysis as 
presented in Fig. 3.13 for both synthesised PCL and PLA nanoparticles. 
 
Fig. 3.12: The flow patterns observed in the micromixer at different aqueous to 
organic phase volume ratio, Qaq/Qor: (a) 7.0; (b) 1.5 and (c) size distribution from 
NTA measurement of mixtures of monodisperse PCL nanoparticles with the 
corresponding video frame at Qaq/Qor = 10.0. The internal diameter of the nozzle was 
60 m. 
 
 
 
Fig. 3.13: Microscopic images of; (a) TEM image of individual PCL NPs; and (b) 
TEM image of individual PLA NPs. 
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Fig. 3.14: Particle size distributions of PCL particles prepared at various flow rate 
ratios by two different mixing strategies; (a) rapid mixing (co-flow device) and (b) 
bulk mixing. Each measurement was repeated for three times. The internal diameter 
of the nozzle was 60 m.  
3.7 Chapter summary 
It was demonstrated that a 3-D co-flow microfluidic device constructed by inserting 
a round capillary inside a square capillary is suitable for fabrication of biodegradable 
polymeric nanoparticles through anti-solvent nanoprecipitation. Using a two-
dimensional h  vs. v  graph, precipitation of PCL and PLA was found to start when 
the water content in the organic phase reaches 16 and 31 vol%, respectively. The 
(a) 
(b) 
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organic phase was injected at higher velocities than the aqueous phase to induce radial 
flow, which led to a significant increase in mass transfer but also in the formation of 
vortices near the nozzle at the flow rate ratio of 3 or lower.      
 
In general, mass transfer in microfluidic devices is dominated by diffusion. However, 
for the investigated geometry and operating conditions, it was found that the 
convective flux of PCL at the cloud point was 1-3 orders of magnitude higher than 
the diffusive flux in the radial direction. In addition, convective flux of the polymer 
was 3-4 orders of magnitudes higher near the nozzle compared to the downstream end 
of the computational domain, which reflects the fact that mixing predominantly occurs 
in the vicinity of the nozzle. The diffusive flux of the polymer followed the same trend 
with the maximum rate of molecular diffusion observed near the nozzle due to high 
concentration gradients. The experimental results are in good agreement with the CFD 
simulation results showing semi-sperical interface at low organic phase flow rate and 
widening jet at high organic phase flow rate. A broader particle size distribution with 
larger mean particle size was found at higher organic phase flow rate due to longer 
residence time of nanoparticles as a result of vortex flow. The formation of spherical 
shape nanoparticles were significantly verified through the use of TEM analysis.  
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CHAPTER 4  
 
PREPARATION OF BIODEGRADABLE POLYMERIC 
NANOPARTICLES FOR PHARMACEUTICAL APPLICATIONS 
USING GLASS CAPILLARY MICROFLUIDICS   
This chapter was published in Chemical Engineering Science Journal 
 
Chapter overview  
The aim of this study was to develop a new microfluidic approach for the preparation of 
nanoparticles with tuneable sizes based on micromixing/direct nanoprecipitation in a 
coaxial assembly of tapered-end glass capillaries. The organic phase was 1 wt% poly(-
caprolactone) (PCL) or poly(ᴅ,ʟ-lactide) (PLA) in tetrahydrofuran and the antisolvent 
was Milli-Q water. The size of nanoparticles was precisely controlled over a range of 
190-650 nm by controlling phase flow rates, orifice size and flow configuration (two-
phase co-flow or countercurrent flow focusing). Smaller particles were produced in a 
flow focusing device, because the organic phase stream was significantly narrower than 
the orifice and remained narrow for a longer distance downstream of the orifice. The 
mean size of PCL particles produced in a flow focusing device with an orifice size of 200 
m, an organic phase flow rate of 1.7 mL h-1 and an aqueous-to-organic flow rate ratio 
of 10 was below 200 nm. The size of nanoparticles decreased with decreasing the orifice 
size and increasing the aqueous-to-organic phase flow rate ratio. Due to higher affinity 
for water and amorphous structure, PLA nanoparticles were smaller and exhibited a 
smoother surface and more rounded shape than PCL particles. 
4.1 Introduction 
Biodegradable polymeric nanoparticles (NPs) have attracted considerable attention of the 
scientific community in the last several decades due to their high potential for a site-
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specific (targeted) drug delivery, especially for oral administration of proteins and 
peptides and gene therapy (Legrand et al., 2007; Douglas et al., 1987). Biodegradable 
polymeric NPs are solid carriers with a mean size of less than 1 mm, which are capable 
to dissolve, entrap, encapsulate or attach active ingredients to its nanoparticle matrix 
(Legrand et al., 2007). Depending upon the method of NPs preparation and formulation, 
nanospheres or nanocapsules can be obtained. Nanocapsules are carriers in which the 
drug is confined to a cavity surrounded by a polymeric shell, while nanospheres are 
matrix systems in which the drug is uniformly dispersed in a polymer matrix (Mohanraj 
& Chen, 2007; Soppimath et al., 2001). 
 
Polymeric NPs can be prepared from preformed polymers by emulsification-solvent 
evaporation, salting-out, dialysis, nanoprecipitation, and supercritical fluid technology or 
directly synthesised by polymerisation of monomers using polymerisation techniques 
such as micro-emulsion, mini-emulsion, surfactant-free emulsion and interfacial 
polymerisation (Nagavarma et al., 2012; Rao & Geckeler, 2011; Galindo-Rodriguez et 
al., 2004). In nanoprecipitation, two mutually miscible liquids are required, a solvent and 
non-solvent of the polymer, typically a volatile organic solvent and water, respectively. 
The NPs are formed almost instantly when the polymer solution is mixed with an excess 
of non-solvent, after which the solvent can be evaporated off. The method does not 
require high stirring rates, sonication, elevated temperatures or surfactants, and Class 1 
solvents can be avoided (Fessi et al., 1989, 1992; Jain, 2000). 
 
Bilati et al. (2005) have investigated the effect of the type of solvent and non-solvent, 
solvent/non-solvent volume ratio and polymer concentration on the nanoprecipitation of 
poly(ᴅ,ʟ-lactide) (PLA) and poly(ᴅ,ʟ-lactic-co-glycolic acid) (PLGA). The size of NPs 
was dependent of the type of non-solvent and increased in the following order: 
methanoloethanolopropanol. Lince et al. (2008) prepared poly-ɛ-caprolactone (PCL) 
nanoparticles in a Confined Impinging Jets Reactor (CIJR) and found a significant effect 
of mixing on the final particle size. The mixing efficiency increased with increasing the 
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flow rate of the liquid phases entering the CIJR, which favoured nucleation and led to a 
marked reduction in the particle size. 
 
In order to achieve a controlled drug release to the specific site of action at the 
therapeutically optimal rate, NPs should be prepared with a controlled size, adhesion 
properties and degradation rate (Mohanraj & Chen, 2007). The traditional bulk mixers 
lack precise control over the mixing process due to their relatively large volume, resulting 
in poor control over the particle size distribution. Microscale mixers/reactors handle very 
small fluid volumes, offering the possibility to achieve a homogeneous reac-tion 
environment, and have a larger surface-to-volume ratio than conventional bulk mixers, 
which can greatly reduce the mixing time that becomes comparable with the induction 
time for nucleation (Capretto et al., 2013). 
 
Ali et al. (2009) prepared hydrocortisone NPs in a microfluidic Y junction. The size of 
the generated NPs was controlled by the flow rates of solvent and anti-solvent, with 
smaller particles being formed at higher flow rates.  Su et al. (2007) prepared BaSO4 and 
2,2-dipyridylamine NPs using a microfluidic set-up composed of three T-junctions. 
Solvent and anti-solvent droplets were formed in two upstream T junctions and then 
merged together in a downstream T junction. Génot et al. (2010) positioned a glass 
capillary at the intersection of the two branches of a Y junction to construct a 3D 
microfluidic mixer that was used to prepare rubrene nanocrystals. Zhang et al. (2008) and 
Yun et al. (2009) produced solid lipid nanoparticles using flow focusing devices with 
cross junction geometry. The particle size was controlled by varying the flow rate ratio 
of the two phases and introducing gas bubbles downstream of the cross junction. Dev et 
al. (2013, 2012) used a microfluidic continuous flow rotating tube processor to produce 
NPs of meloxicam and curcumin by reactive crystallisation. 
 
Membrane micromixing is an alternative strategy of controlled mixing at molecular scale 
that was combined with nanoprecipita-tion to produce inorganic nanoparticles (Jia & Liu, 
2013), liposomes (Laouini et al., 2013a), micelles (Laouini et al., 2013c), and PCL 
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nanoparticles (Khayata et al., 2012). In a membrane-dispersion reactor, one liquid phase 
is dispersed through a microporous membrane into another liquid under controlled shear 
conditions and injection rate. 
 
In this work, a novel microfluidic strategy was developed for fabrication of PCL and PLA 
NPs based on bringing into contact two co-flowing or counter-current flowing streams in 
coaxial glass capillaries. Both polymers have been approved by FDA for drug delivery 
(Jain et al., 1998; Södergård & Stolt, 2002; Panyam & Labhasetwar, 2003) and widely 
used as excipients in nanoprecipitation processes (Jain, 2000; Lu & Chen, 2004).The 
main objectives of this study were: (i) to make appropriate choice of good and poor 
solvent of the polymers, (ii) to observe the mixing process in situ using a microscope 
video system, and (iii) to investigate the effect of operating parameters, system geometry, 
and surfactants on the final particle size distribution. 
4.2 Materials and methods 
4.2.1 Chemicals 
Tetrahydrofuran (THF) (HPLC grade, purity ≥ 99.9%) and poly(-caprolactone) (PCL, 
Mw = 14,000 g mol
-1 with a glass transition temperature of 60 oC) were purchased from 
Sigma-Aldrich (Dorset, UK). Poly(ᴅ,ʟ-lactide) (PLA, IngeoTM 4060D, Mw = 320,000 g 
mol-1) was supplied by Natureworks LLC (Minetonka, MN, USA). 4060D is an 
amorphous polymer with an average D-lactide content of 12 wt% and a glass transition 
temperature of 55-60 oC. Polyvinyl alcohol (PVA), polyvinyl pyrrolidone (PVP), Tween 
20 and Tween 80 were obtained from Sigma-Aldrich (Dorset, UK) and used as water 
soluble surfactants. All chemicals other than THF were of analytical grade. The 
antisolvent phase was pure water produced by reverse osmosis (Milli-Q®, Millipore) or 
aqueous surfactant solutions. The role of surfactant was to prevent agglomeration, 
coalescence and imperfect surface formation, as well as to reduce the size of the NPs. The 
organic phase was a homogeneous solution containing 1 g L-1 (1000 ppm) of the polymer 
(PCL or PLA) in THF.  
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4.2.2 Equipment 
The experiments have been carried out using two different types of glass capillary devices 
shown in Figs. 4.1 (b) and (c). The main body of the device was made up of two coaxial 
glass capillaries: an inner capillary with a circular cross section (1 mm O.D. and 0.58 mm 
I.D.) and an outer capillary with a square cross section (1 mm I.D.). One end of the inner 
capillary was shaped into a tapered orifice with an I.D. of 60, 150, 200, 300 or 400 µm. 
Further fabrication steps have been described in Section 3.3.  
4.2.3 Experimental set-up and preparation of polymeric NPs 
In a co-flow device (Fig. 4.1 (b)), the organic phase was delivered to the inner capillary, 
the aqueous phase flowed co-currently through the space between the square and inner 
capillary and the product suspension exited through the square capillary. In a flow 
focusing device (Fig. 4.1 (c)), the organic phase was delivered to the outer capillary, the 
aqueous phase flowed counter-currently through the space between the two capillaries 
and the product suspension was collected from the inner capillary. These two phases were 
delivered to the device using a standard method described in Section 3.3. 
 
NPs were formed downstream of the orifice when both streams were brought into contact. 
This was observed through an inverted microscope and recorded by a Phantom V9.0 high-
speed camera (Vision Research, Ametek, US) at 25 frames per second with 576  288 
resolution. The flow rates of the two phases and the orifice diameter were systematically 
varied in order to study their effects on the average size of the NPs and their particle size 
distribution. The fresh nanosuspension was collected in a vial via PTFE tubing (1.5 mm 
I.D.), after which the organic solvent was completely evaporated in a vacuum oven 
(Technico, Fistreem International Ltd, Loughborough, UK) under absolute pressures 
below 10 torr and the room temperature for about 30 min until the smell of THF had 
disappeared completely.  
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4.2.4 Characterisation of nanoparticles 
4.2.4.1 Particle size analysis 
The size distribution of NPs was determined by dynamic light scattering (DLS) using 
DelsaTM Nano HC Particle Analyser (Beck-man Coulter, High Wycombe, UK), which 
measures the fluctuations of scattered light as a function of time. NPs were diluted 5-fold 
by Milli-Q water before being transferred into a 4 mL disposable cuvette which was then 
placed into the instrument. The measurement time was 120 s. Each samples were analysed 
by following the standard procedures described in Section 2.6.1.1. 
4.2.4.2 Zeta potential determination 
The zeta potential of NPs was measured by electrophoretic light scattering (Laser Doppler 
electrophoresis) using a DelsaTM Nano HC Particle Analyser (Beckman Coulter, High 
Wycombe, UK). The measurements were repeated three times after sample dilution with 
Milli-Q water. The zeta potential was calculated from the electrophoretic mobility using 
the Helmholtz-Smoluchowski equation (Submicron, 2011). 
4.2.4.3 Microscopic observations (TEM and FEG-SEM)  
The internal structure and surface morphology of the NPs was investigated using 
Transmission Electron Microscopy (TEM) and high resolution Field Emission Gun 
Scanning Electron Microscopy (FEG-SEM). For TEM analysis, a sample drop was 
deposited onto a carbon-coated copper mesh and left to dry before being observed by a 
JEOL JEM-2000 FX transmission electron microscope operated at an accelerating 
voltage of 200 kV. The mesh was coated by dipping it into a suspension of carbon 
particles in deionised water. 
 
FEG-SEM images were obtained using a LEO 1530 VP (LEO Elektronenmikroskopie 
GmbH, Oberkochen, Germany) scanning electron microscope with an integrated EDAX 
TEAM™ Pegasus EBSD/EDXA (electron backscatter diffraction/energy dispersive x-ray 
analysis) system. FEG-SEM has the advantage over conventional SEM of providing 
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higher resolution images due to a smaller diameter of the electron beam, which gives a 
higher signal to noise ratio leading to improved spatial resolution. The samples were 
placed onto conventional aluminium sample holders with a diameter of ~1 cm. For NPs 
imaging, the chamber was evacuated to ~0.5 Pa and the images were taken using in-lens 
detector operating at an accelerating voltage of 5–10 keV and a working distance of 5–
10 mm. 
 
 
 
Fig. 4.1: (a) A schematic of the experimental set-up with a co-flow glass capillary device: 
(top) side view, (bottom) bird's-eye view; (b, c) Magnified views of a region near the 
orifice for: (b) co-flow; (c) flow focusing (c). Do = orifice diameter.  
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4.3 Results and Discussion 
4.3.1 Prediction of solvent-water interactions 
The choice of organic solvent is a crucial initial step that should be taken. The organic 
solvent must be able to dissolve polymer and must be miscible with water, which can be 
estimated using the combined solubility parameter (Van Krevelen & Hoftyzer, 1976): 
 
2/12
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,,
2
,, ])()()[( WhShWpSpWdSdwatersolvent                                     (4.1) 
 
where d  is the dispersion solubility parameter due to London dispersion forces resulting 
from the existence of induced dipoles as two molecules approach each other, p  is the 
polar solubility parameter due to Keesom forces occurring when two permanent dipoles 
are present, and h  is the hydrogen bonding solubility parameter (Bordes et al., 2010 
Hansen, 2007). The subscripts S and W refer to the organic solvent and water, 
respectively. Table 4.1 lists the combined solubility parameters of six potential volatile 
organic solvents: acetone (Ac), tetrahydrofuran (THF), ethanol (EtOH), dimethyl 
sulfoxide (DMSO), isopropyl alcohol (IPA) and ethyl lactate (EL), calculated from Eq. 
(4.1) using the partial solubility parameters from Table 4.1. The value of watersolvent  
increases in the following order: EtOH < DMSO < IPA < EL < Ac < THF. The smaller 
the watersolvent  value, the higher the affinity of solvent for water and the higher its 
solubility into the aqueous phase, hence smaller NPs can be produced.  
 
Solvent toxicity is another important aspect for pharmaceutical applications. All solvents 
in Table 4.1 except THF are categorised as class 3 by the U.S. Food and Drug 
Administration (FDA). The former permissible daily exposure (PDE) for THF was 121 
mg/day and THF was categorised as class 3 solvent. Based on new toxicological data, the 
PDE for THF is 7.2 mg/day, and the new FDA's recommendation is to move THF from 
class 3 to class 2. 
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To completely explain the behaviour of solvent in nanoprecipitation process, the solvent-
water interaction parameter must also be considered (Martin et al., 1993): 
 
2)( watersolvent
solvent
watersolvent
RT
V
                                                                             (4.2) 
 
where solventV  is the molar volume of the solvent, R is the universal gas constant (8314 J 
kmol-1 K-1), T is the absolute temperature, and solvent  and water  are the total solubility 
parameters of the solvent and water, respectively, provided in Table 4.1. The values of 
watersolvent  calculated using Eq. (4.2) increase in the following order: EtOH < DMSO < 
IPA < Ac < THF < EL. Solvents that have a high affinity for water, which is evidenced 
by low watersolvent  values, tend to promote solvent diffusion and polymer partition into 
the aqueous phase, which leads to the formation of smaller NPs (Legrand et al., 2007; 
Galindo-Rodriguez et al., 2004). watersolvent  and watersolvent  in Table 4.1 are in good 
correlation with each other, indicating that EtOH, DMSO and IPA have the highest 
affinity for water. On the other hand, Ac, THF and EL show a relatively low affinity for 
water, either due to their low polarity (e.g. THF), or low hydrogen-bonding preference 
(Ac) or several combined factors (EL). In addition to solvent-water interactions, the 
polymer interactions with solvent and water must also be considered.  
4.3.2 Prediction of polymer-solvent and polymer-water interactions 
The extent of polymer-solvent interaction can be estimated from a 2-D graph (Bagley et 
al., 1971), in which a hydrogen bonding solubility parameter, h  is plotted against 
Bagley's two-dimensional solubility parameter, v , where 
2/122 )( dpv   . The good 
solvents are those that are included within a circle of a radius of five δ-units around the 
polymer (Van Krevelen & Hoftyzer, 1976; Choi et al., 2002; Su et al., 2007). Fig. 4.2 
shows a Bagley’s two-dimensional solubility graph for two polymers (PLA and PCL), 
water and six organic solvents. The centre of the solubility circle of PLA corresponds to 
values of h  and v  in Table 4.1 listed under the heading PLA
a, calculated based on the 
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classical method for Hansen solubility parameters (Van Krevelen & Hoftyzer, 1976). As 
expected, water appears far outside the solubility circle of PLA and PCL, in agreement 
with the fact that it is a nonsolvent of these polymers. IPA and EtOH are also outside the 
both solubility circles, due to high h  values as a result of extensive hydrogen bonding 
between their molecules. Therefore, both solvents are bad solvents for PLA and PCL, but 
with the highest affinity for water among all the solvents studied. The solubility graph 
also suggests that acetone is a bad solvent for PLA, whereas DMSO is a bad solvent for 
PCL. Thus, only THF and EL are good solvents for both polymers and suitable for the 
formation of PLA and PCL NPs. In a good solvent, polymer chains are more disentangled 
from one another and extensively solvated. Conversely, in a poor solvent, polymer chains 
are more shrunken and their solvation is limited (Galindo-Rodriguez et al., 2004).  
 
The solubility of PLA and PCL in the investigated solvents can also be predicted using 
the Hansen sphere space theory. The distance between a solvent (S) and the polymer (P) 
in the “ d2 - p - h  solubility space” is given by:  
 
2/12
,,
2
,,
2
,, ])()()(4[ PhShPpSpPdSdD                                                    (4.3) 
The D  values for six selected organic solvents calculated from Eq. (4.3) are shown in 
Table 4.2. Good solvents for the given polymer lie within the solubility sphere of radius
0R , known as the interaction radius. The interaction radius for PCL with Mw = 14,000 g 
mol-1 is 7.1 (Bordes et al., 2010). From Table 4.2, EtOH, IPA and DMSO are nonsolvents 
for PCL ( 1.7D ), which agrees with the predictions from Fig. 4.2. The interaction radius 
for PLA at 25 C is 6.4 (Hansen, 2007), which means that EtOH, IPA, Ac, and DMSO 
can be regarded as nonsolvents for PLA.  
 
Polymer-water compatibility can be predicted from the combined polymer-water 
solubility parameter, waterpolymer : for a good compatibility, waterpolymer  must have a 
small value (Van Krevelen & Hoftyzer, 1976). The values of waterpolymer  in Table 4.1 
increase in the following order: PLAa < PLAb < PCL. Clearly, PLA shows higher 
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compatibility with water, because PLA is more polar than PCL ( PLA,p = 9.7 and PCL,p = 
4.8). The polarity of PLA and PCL originates from their ester bonds, but PCL has a longer 
nonpolar hydrocarbon chain between ester linkages, [–(CH2)5–], as compared to PLA, [–
CH(CH3)–].  
 
The combined polymer-solvent solubility parameters are shown in Table 4.3. For PLA
a, 
the solventpolymer  values increase as follows: EL < Ac < THF < IPA < DMSO < EtOH. 
Therefore, THF, Ac and EL show the highest compatibility with both polymers. The 
solvent-polymer Flory-Huggins interaction parameter, polymersolvent  is another measure 
of the interaction between polymer chains and solvent molecules and can be calculated 
as (Hansen, 2007): 
])()()[( 2,,
2
,,
2
,, PhShPpSpPdSd
solvent
polymersolvent
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V
                             (4.4) 
The values of polymersolvent  for six different solvents are summarised in Table 4.3. For 
polymersolvent  < 0.5, the polymer is soluble in a solvent over entire concentration range 
(Bordes et al. (2010) and if polymersolvent  > 0.5, the polymer is hardly soluble or insoluble. 
The results in Fig. 4.2 and Table 4.3 partially contradict each other, since Table 4.3 
implies that only EL is a good solvent for PLAa, while Fig. 4.2 suggests that THF, EL, 
and DMSO are all good solvents for PLAa. It may be attributed to large variations in PLA 
solubility depending on the degree of crystallinity, which is determined by the ratio of ᴅ 
to ʟ enantiomers. In this work, THF will be used as a solvent for PLA, since a 50:50 
mixture of the ᴅ and ʟ enantiomers is amorphous and soluble in THF, contrary to pure ᴅ 
or ʟ forms. In addition, THF has a boiling point of 66 oC, which is much lower than the 
boiling point of EL of 151 oC and therefore, can be readily removed from the suspension 
through vacuum evaporation. 
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Table 4.1: The partial solubility parameters, d , p , h , and v , and the total solubility parameters, t , of different solvents and polymers, 
the combined solubility parameters, watersolvent  and waterpolymer , and the interaction parameters, watersolvent  and waterpolymer  (Ac = 
acetone, THF = tetrahydrofuran, EtOH = ethanol, DMSO = dimethyl sulfoxide, IPA = isopropyl alcohol, EL = ethyl lactate, PLA = poly(ᴅ,ʟ-
lactic acid), PCL = poly-ɛ-caprolactone). 
Solubility parameters (J cm-3)1/2 Water Ac THF EtOH DMSO IPA EL PLAa PLAb PCLc 
V/Fdid    12.28 15.46 16.77 15.77 18.36 15.80 15.95 17.62 18.50 17.00 
V/)F( /pip
212   31.30 10.40 5.71 10.32 16.32 6.10 7.57 9.70 9.70 4.80 
21/
hih )V/E(   34.17 6.96 7.96 19.38 10.20 16.40 12.48 11.77 6.00 8.30 
2122 /
dpv )(    33.62 18.64 17.72 18.85 24.56 16.94 17.66 20.11 20.89 17.66 
21222 /
hdpt )(    48.08 19.90 19.42 27.03 26.60 23.58 21.62 23.31 21.73 19.52 
watersolvent  or waterpolymer  0.00 34.45 36.91 25.91 28.91 31.04 32.36 31.57 36.04 37.33 
watersolvent  or waterpolymer  0.00 23.93 27.33 10.61 13.45 18.84 32.94 6.85 6.46 7.13 
The partial solubility parameters of the solvents were taken from Burrell (1975). δ, solubility parameter; subscripts: t, total; d, contribution 
of the dispersion forces; p, polar contribution; h, hydrogen bonding contribution; v, dispersion and polar contribution. V, molar volume of 
the compound; i, structural groups within the molecule; diF  and piF , molar attraction constants due to dispersion and polar interactions, 
respectively; hiE , energy of hydrogen bonding.  
a The partial solubility parameters of PLA calculated using the classical method of Van Krevelen & Hoftyzer (1976). 
b  The partial solubility parameters of PLA calculated using the constrained nonlinear optimization method of Agrawal et al. 
(2004).  
c   The partial solubility parameters of PCL calculated using the classical method of Van Krevelen & Hoftyzer (1976). 
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Fig. 4.2: Bagley’s two-dimensional graph of the partial solubility parameters of the 
solvents with respect to the partial solubility parameters determined for PLA and PCL. 
(line     = solubility circle limit for PCL; line      = solubility circle limit for PLA). 
 
Table 4.2: The distance D  between a solvent (S) and the solute (P) in the “ d2 - p -
h ” space and the interaction radius, 0R . The points located outside of the solubility 
circle for the polymer are bolded. Abbreviations and superscripts have the same 
meaning as in Table 4.1.   
 Ac THF EtOH DMSO IPA EL 0R  
solventPLAa
D

 6.50 5.77 8.49 6.96 6.90 4.02 6.4 
solventPLAb
D

 6.19 5.63 14.47 7.84 12.26 8.52 10.5 
solventPCLD   6.53 1.08 12.62 11.99 8.55 5.44 7.1 
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Table 4.3: The combined polymer-solvent solubility parameters, δpolymer-solvent and the 
polymer-solvent interaction parameters, χpolymer-solvent. Abbreviations and superscripts 
have the same meaning as in Table 4.1. The values of polymersolvent  < 0.5 are bolded 
indicating a good solvent for the polymer. 
Solvent 
solventpolymer  (J cm
-3)1/2 polymersolvent  
PLAa PLAb PCLc PLAa PLAb PCLc 
Ac 5.32 3.26 5.96 0.85 0.32 1.07 
THF 5.58 4.77 1.00 1.04 0.76 0.03 
EtOH 7.86 13.67 12.44 1.48 4.48 3.71 
DMSO 6.84 7.84 11.75 1.36 1.79 4.03 
IPA 6.14 11.33 8.29 1.18 4.03 2.16 
EL 2.80 7.28 5.12 0.37 2.50 1.24 
4.3.3 Effect of organic solvent removal 
The average particle size, Zave and the polydispersity index (PDI) were measured in 
fresh nanosuspensions and the samples stored in a vacuum evaporator (Table 4.4). 
Due to evaporation of residual THF from PCL particles, the particle diameter 
decreased 11−14 % of its original size, which is equivalent to the volumetric shrinkage 
of 28−37 %. After nanoprecipitation, THF is redistributed between the liquid and solid 
phase. Since THFPCL  « waterTHF   ( THFPCL  =1.00 and waterTHF =36.91 J
1/2cm-
3/2 from Tables 4.1 and 4.3), THF is much more compatible with PCL than water. As 
a result, the content of THF in the liquid phase immediately after PCL precipitation is 
9.1 vol%, while its content in the swollen NPs is about 28–36 vol%. However, due to 
very small volume fraction of NPs of about 10−4, more than 99.9 vol% of THF added 
to the system is present in the liquid phase, and less than 0.01 vol% is absorbed within 
the swollen NPs. As THF evaporates, its concentration in the aqueous phase 
decreases, which causes a decrease in the chemical potential of THF in the liquid 
phase and further diffusion of THF to the liquid phase until the equilibrium is 
reestablished. The process of THF dissolution continues until virtually all THF is 
removed from the NPs. The shrinkage percentage was independent on the initial 
particle size, which means that THF was completely removed from the particles in all 
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cases. In all subsequent experiments, THF was completely removed from the NPs 
before analysis. The PDI values for the fresh samples were in the range of 0.178–
0.219 (Table 4.4). After solvent evaporation, the samples were significantly 
concentrated with a higher agglomera-tion tendency, which led to increased PDI 
values (0.219–0.294). 
 
Table 4.4: The average size of NPs before and after solvent removal and the resultant 
linear and volumetric particle size reduction as a function of orifice diameter in a co-
flow device at oraq QQ / = 10 ( aqQ = 5 mL h
-1, orQ = 0.5 mL h
-1). The organic phase 
was 1 g L-1 PCL in THF and the aqueous phase was Mili-Q water.    
Orifice 
diameter 
(μm) 
Without solvent removal With solvent removal Linear 
size 
reductio
n (%) 
Volume 
reducti
on 
(%) aveZ  (nm) PDI aveZ  (nm) PDI 
60 359 ± 52 0.210 ± 0.016 309 ± 46 0.219 ± 0.010 14 36 
150 471 ± 43 0.215 ± 0.008 418 ± 24 0.242 ± 0.014 11 30 
200 319 ± 14 0.178 ± 0.057 279 ± 9 0.237 ± 0.060 13 33 
300 396 ± 69 0.190 ± 0.008 355 ± 44 0.249 ± 0.025 10 28 
400 594 ± 25 0.219 ± 0.008 509 ± 14 0.297 ± 0.050 14 37 
 
4.3.4 Effects of aqueous-to-organic flow rate ratio, orifice size and polymer type 
4.3.4.1 Constant aqueous phase flow rate and variable organic phase flow rate 
In these experiments in a co-flow device, aqQ  was kept constant at 5 mL h
-1 and orQ  
ranged from 3.3 to 0.5 mL h-1 corresponding to oraq QQ /  ratio from 1.5 to 10, 
respectively. The size of NPs was found to decrease with increasing oraq QQ / , as 
shown in Fig. 4.3. At higher oraq QQ /  ratio, the particle nuclei are more diluted after 
formation, which suppresses the rate of particle growth given by: 
b
ig CCKdtdl )(/
* , where gK  is the particle growth rate constant and iC  and 
*C  
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are the polymer concentration on the particle surface and the saturation concentration, 
respectively. The value of the parameter b is usually between 1 and 3 (Zhao et al., 
2007). The increased water flow rate decreases the polymer concentration on the 
particle surface, iC , leading to a decrease in 
*CCi   and the rate of particle growth, 
thereby resulting in smaller ultimate particle size. The increased water volume also 
decreases the tendency for particle aggregation due to lower frequency at which 
particles collide with and stick to each other. The particle aggregation is most likely 
near the orifice, where the local particle concentrations are high. In addition, a higher 
flow rate ratio provides a more rapid mixing in a microfluidic system (Génot et al., 
2010). In a more rapid mixing process, the critical supersaturation needed for 
nucleation is reached faster, which allows for the generation of more nuclei, whose 
growth will be limited by the amount of available polymer in the liquid phase. 
Therefore, a larger number of nuclei will lead to smaller size of NPs. The smaller 
particle sizes at higher aqueous-to-organic volume ratios were also obtained by 
Laouini et al. (2013a, 2013b, 2013c) in the production of liposomes and polymeric 
micelles in membrane contactors and by Jahn et al. (2010) in the formation of 
liposomes in planar flow focusing microfluidic mixers.  
 
At constant oraq QQ /  ratio, the particle size was found to significantly increase with 
increasing the orifice size, oD  over the range of 200-400 m (Fig. 4.3). The mixing 
process is more efficient if the organic phase is injected through smaller orifice, due 
to greater shear stresses in the mixing zone and higher interfacial area per unit volume 
of the organic phase. At oraq QQ / =1.5 and oD = 60 m, the velocity of organic stream 
in the orifice is 0.324 m s-1 and the velocity of the surrounding aqueous phase is 1.4 
 10-3 m s-1. However, at oraq QQ / =1.5 and oD = 400 m, the organic phase velocity 
in the orifice is only 7.3  10-3 m s-1 and the aqueous phase velocity is 1.6  10-3 m s-
1. Due to small difference in velocity between the two streams, the mixing process is 
less efficient leading to higher particle size. At oD = 60 m, the particle size was 
somewhat larger than that at 200 m, which may be due to susceptibility of 60-m 
orifice to particle deposition and clogging, which may compromise the particle size. 
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Fig. 4.3: The average particle size, aveZ  of PCL nanoparticles produced at different 
flow rate ratios in a co-flow device with different orifice diameters, oD . The PCL 
concentration in the organic phase is 1 g L-1 and aqQ =5 ml h
-1. 
 
The micrographs of mixing zone in the device with a 60-m orifice size at various 
flow rate ratios are shown in Fig. 4.4. At oraq QQ / =10 (Fig. 4.4 (a)), the interface is 
spherical and resembles a familiar shape which can be seen when one immiscible 
liquid is introduced into another in the dripping regime (Vladisavljević et al., 2012). 
It is hard to explain this shape without acknowledging some type of interfacial tension, 
although THF and water are miscible in all proportions and should have zero 
equilibrium interfacial tension. In fact, when two miscible fluids are suddenly put into 
contact, gradients of composition and density at the boundary can give rise to tension 
between the contacted fluids, which is known as the transient interfacial tension or 
Korteweg stress (Joseph & Venkatachalappa, 1999), given by:  
 
 /2Ck                                                                                                          (4.5) 
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where k  is the proportionality constant, C  is the change in concentration over the 
transition zone between two miscible fluids and   is the thickness of the transition 
zone. The transient tension decreases rapidly during the process of dissolution in 
proportion to tD / , where D  is the diffusion coefficient and t  is the interfacial age. 
At each oraq QQ /  value, there is a certain equilibrium size of a droplet formed at the 
capillary tip. At equilibrium, the rate of diffusion of the organic phase from the 
interface, due to mutual mixing at the contact zone, is equal to the rate of convective 
flow from the orifice toward the interface. The produced NPs form dark concentric 
layers around the interface, due to capillary waves (Fig. 4.4 (a)). At oraq QQ / =4.5 (Fig. 
4.4 (b)), the organic phase forms a widening jet due to increased inertial force that 
overcomes the transient interfacial tension and elongates the interface. The organic 
phase velocity at the orifice, orU = 0.32 m s
-1, is much higher than the aqueous phase 
velocity, aqU = 1.4  10
-3 m s-1, leading to deceleration of the organic phase in the 
direction of flow and causing widening of the jet. With further increase in velocity of 
the organic phase, a flow instability phenomenon known as “viscous fingering” occurs 
(Fig. 4.4 (c)), which leads to distortion of the interface and formation of finger-like 
patterns. Such instability occurs typically when a less viscous fluid is injected into a 
more viscous one (it should be noted that the viscosity of THF at 293 K is 0.63 mPa 
s and the water viscosity is 0.99 mPa s). The penetration of the less viscous fluid is 
not uniform since part of the more viscous fluid forms fjords, named “viscous fingers” 
(Homsy, 1987). Viscous fingering was not observed when ethanolic solution of 
phospholipids was injected into water in the same type of capillary device 
(Vladisavljević et al., 2014), because the viscosity of ethanol of 1.25 mPa s was higher 
than the water viscosity. At oraq QQ / = 1.5, two symmetrical vortices were formed at 
the lower and upper parts of the capillary tube (Fig. 4.4 (d)), due to high shear stress 
at the interface, caused by high difference in velocity between the organic and aqueous 
phase.  
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Fig. 4.4: The shape of liquid/liquid interface in a co-current flow device with a 60-
µm orifice size at different flow rate ratios: (a) oraq QQ / =10.0; (b) oraq QQ / = 4.5; (c) 
oraq QQ / =3.0; and (d) oraq QQ / =1.5. The organic phase was 1 g L
-1 PCL in THF and 
the aqueous phase was Mili-Q water.  
 
The particle size distribution curves at oD =150 and 200 m are in good agreement 
with the above observations featuring the minimum particle size at the maximum flow 
rate ratio (Fig. 4.5), due to shortest mixing time. The growth of nuclei is more limited 
if the mixing process is faster, which will lead to smaller NPs. At oraq QQ / = 10, the 
mixing time is shortest due to the smallest amount of injected organic phase relative 
to aqueous phase. As a result, the interface disappears at the distance of just oD4.4  
downstream of the nozzle (Fig. 4.4 (a)) and the NPs have the minimum size. At 
oraq QQ / = 1.5, the mixing time is long due to high amount of injected organic phase. 
In addition, as a result of vortex flow, the nuclei formed near the nozzle are forced 
into circular motion, which can lead to their much longer residence time compared to 
the nuclei formed more downstream. As a consequence, the particle size distribution 
is very broad, as shown in Fig. 4.5 (a).  
 
The effect of polymer type on the size of NPs at the orifice size of 60 m is shown in 
Fig. 4.6 (a). PLA formed smaller particles than PCL, because PLA is more compatible 
2
00 µm 
(
a) 
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with water, as can be seen by the lower waterpolymer  value in Table 4.1. As a result, 
precipitation of PLA starts when the water content in THF reaches 31 vol%, while 
PCL starts precipitating out when the water content in THF is about 16 vol%. 
Therefore, PLA starts to precipitate from a more diluted polymer solution, which 
limits particle growth and leads to smaller particle size.  
4.3.4.2 Constant organic phase flow rate and variable aqueous flow rate 
In this set of experiments, the organic phase flow rate was kept constant at 1.7 mL h-
1 and the aqueous phase flow rate varied from 2.55 to 17 mL h-1, corresponding to 
oraq QQ /  value from 1.5 to 10 respectively (Fig. 4.6 (b-d)). At the same oraq QQ /  value, 
the particle size was smaller when the organic phase flow rate was maintained at 1.7 
mL h-1 compared to the fixed aqueous phase flow rate of 5 mL h-1. At orQ = 1.7 mL 
h-1, the total flow rate, oraq QQ   was in the range of 4.25-18.7 mL h
-1, whereas at aqQ
= 5 mL h-1, the total flow rate was 5.5-8.3 mL h-1. Probably, the mixing efficiency is 
higher at the higher flow rate in the collection capillary. Triple runs were carried out 
on each experiment to check reproducibility of the particle sizes and only small 
within-runs variations were observed, as indicated by small error bars. The opposite 
results were obtained by Jahn et al. (2010) in microfluidic preparation of liposomes, 
with smaller vesicle sizes obtained at smaller total flow rates. The minimum size of 
both PLA and PCL particles in a co-flow device was less than 250 nm and was 
achieved at oraq QQ / =10 and for a 60-m orifice size.  
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Fig. 4.5: The size distribution of PCL NPs as a function of aqueous-to-organic flow 
rate ratio in a co-flow device at aqQ =5 ml h
-1. The orifice size, oD : (a) 200 µm; (b) 
150 µm. The organic phase was 1 g L-1 PCL in THF and the aqueous phase was Mili-
Q water.   
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Fig. 4.6: (a) The average particle size, aveZ  as a function of flow rate ratio, oraq QQ /  
and orifice diameter, oD in a co-flow device. The flow rate of either organic or aqueous 
phase was kept constant in each series of experiments. The organic phase was 1 g L−1 
mm PCL or PLA in THF (Fig. a) or 1 g L 1 PCL in THF (Fig. b–d) and the aqueous 
phase was Milli-Q water. 
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4.3.5 Co-current flow versus counter-current flow focusing 
Micromixing in a glass capillary device has also been achieved by countercurrent flow 
focusing. The micrographs of the mixing zone of the device with an orifice size of 
400 µm at orQ = 1.7 mL h
-1 and variable aqueous phase flow rate are shown in Fig. 
4.7. Due to high velocity of aqueous phase, the jetting regime occurs at all flow rate 
ratios with very long widening jets and no signs of interfacial instability. The phase 
boundary is sharp at oraq QQ /  = 10 and 7, becomes blurred at oraq QQ / = 4.5 and almost 
completely disappears at oraq QQ / = 3. A sharp interface occurs due to sharp 
concentration gradients at the contact zone resulting from high velocity of aqueous 
phase in the tapered section of the inner capillary. At oraq QQ / =3, 0/ C  due to 
relatively long residence time of liquid elements and mutual mixing of THF and water 
upstream of the orifice and 0 ; thus, the phase boundary is hardly visible. At 
oraq QQ / = 1.5, the phase boundary is invisible (the image not shown here). The dark 
areas in Fig. 4.7 are the regions within the device where the NPs are formed at 
relatively high concentration. These regions are mainly contact zones between the two 
phases upstream of the orifice where the fluid velocities are relatively small due to 
large cross-sectional area available for flow. 
 
Fig. 4.8 provides a comparison of the average particle size, aveZ  in a co-flow and flow 
focusing device for the same flow rates and device geometry. Triple runs were carried 
out on each sample and small error bars in the graph indicate high reproducibility. 
The mixing time in a microfluidic flow focusing device is given by (Karnik et al., 
2008): Ddormix /
2 , where ord  is the diameter of the organic phase stream and D  
is the diffusivity of the solvent. The organic phase stream is wider at smaller oraq QQ /  
(Fig. 4.7), which results in longer mixing times and larger aveZ  value (Fig. 4.8). The 
smaller NPs were produced in a flow focusing device compared to co-flow device of 
the same orifice size, which was most pronounced at the orifice size of 400 m. In a 
flow focusing device, the diameter of the organic phase stream in the mixing zone is 
significantly smaller than the orifice diameter ( ord « oD ), while in a co-flow device 
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the diameter of the organic phase stream corresponds to the orifice diameter ( oor Dd 
). Therefore, under the same other conditions, mix  in flow focusing device is much 
smaller than that in a co-flow device. At oD = 60 m, there was no difference in 
performance between a co-flow and flow focusing microfluidic mixer. The orifice is 
prone to clogging in a flow focusing device by the particles formed upstream of the 
orifice, which can be deposited onto the inner walls of the collection capillary as they 
pass through the orifice. Therefore, the optimum diameter of the orifice in flow 
focusing device was about 200 m.  
 
 
    
 
 
 
 
 
 
 
 
 
Fig. 4.7: The shape of liquid/liquid interface in a counter-counter flow device with a 
400-µm orifice diameter at different flow rate ratios: (a) oraq QQ / = 10.0; (b) oraq QQ /
= 7; (c) oraq QQ / = 4.5; and (d) oraq QQ / = 3.0. The organic phase was 1 g L
-1 PCL in 
THF and the aqueous phase was Mili-Q water.   
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Fig. 4.8: (a) The comparison of average particle size, aveZ  in a co-current and counter-
current flow device at orQ = 1.7 mL h
-1 for the orifice diameter, oD  is: (a): 400 µm; 
(b) 200 µm; (c) 60 µm. The organic phase was 1 g L-1 PCL in THF and the aqueous 
phase was Mili-Q water.   
4.3.6 Effect of surfactant on NPs formation 
In this section, PCL NPs were produced in a co-flow device at at oD = 200 μm and 
oraq QQ / = 10 in the presence of four different types of hydrophilic surfactant, 
(a) 
(c) 
(b) 
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polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA), Tween 20 and Tween 80. The 
concentration of each surfactant in the aqueous phase was fixed at 1 wt%, which is a 
typical value in nanoprecipitation process (Xie & Smith, 2010). The minimum particle 
size of 387 ± 7.0 nm was achieved using PVA, followed by PVP, Tween 20 and 
Tween 80. The Zave value for the NPs produced under the same conditions without 
any surfac-tant was 279 ± 9 nm. The particle size was higher in the presence of 
surfactant in the aqueous phase which was due to the formation of surfactant layer on 
the particle surface. The presence of surfactant may also lead to an increase in the 
viscosity of aqueous phase which was reported to increase the particle size due to 
reduction in the rate of counter-diffusion of solvents (Tsukada et al., 2009). 
4.3.7 Stability of NPs  
The variation of the size of NPs with time is a good indicator of particle stability, since 
in most cases the particle size increases before macroscopic changes appear (Heurtault 
et al., 2003). In this study, the variations in mean particle size and zeta potential were 
measured over a storage period of 30 days at ambient temperature. Fig. 4.9 shows the 
average particle size, Zave and the zeta potential as a function of time for PCL NPs 
produced in a counter-flow device at oD = 200 μm and oraq QQ /  = 10 in the absence 
and presence of surfactant (PVP) in the aqueous phase. In the absence of any 
surfactant, the size of NPs increased from 244 to 486 nm, indicating that the presence 
of PVP in the aqueous phase was vital in order to improve the storage stability of NPs 
and prevent particle aggregation. In the presence of 1 wt% PVP, the initial particle 
size was higher, since each polymer particle was surrounded by the surfactant corona. 
Nevertheless, the Zave values increased only moderately over 30 days from 286 to 348 
nm with negligible change in zeta potential from −3.72 to −3.37 mV. The same range 
of zeta potentials was reported by Filipović et al. (2013) for PCL-PVP NPs. The 
surfactant molecules are absorbed onto the surface of the newly formed PCL NPs with 
some chains extending away from the particle surface, which provides steric barrier 
and prevents particle coalescence (Lebouille et al., 2013). 
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Fig. 4.9: The average size, aveZ , and zeta-potential of PCL NPs over a 30 day storage 
period at atmospheric pressure and ambient temperature. The particles were produced 
in a counter-current flow device at oraq QQ / =10, orQ = 1.7 mL h
-1, and oD =200 m. 
The organic phase was 1 g L −1 PCL in THF and the aqueous phase was Milli-Q water 
or 1 wt% PVP. 
4.3.8 Microscopic images of NPs 
Scanning electron micrographs of PCL and PLA NPs are shown in Fig. 4.10 (a) and 
(b). The PLA particle exhibits a nearly perfect spherical shape, as reported by Lai & 
Tsiang (2004). The PCL compared to the PLA NPs, due to crystallisation of PCL on 
the surface (Lin & Huang, 2001). The surface of PLA NPs was very smooth because 
a fully amorphous poly-(ᴅ,ʟ-lactide) was used for particle formation. In addition, PCL 
NPs are larger than PLA NPs, which is in a good agreement with the dynamic light 
scattering data for the two polymers. 
 
Fig. 4.10 (c) and (d) are TEM images of PCL and PLA NPs. The PLA particles in Fig. 
4.10(d) have a very smooth surface and almost perfect spherical shape, as a result of 
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surface energy minimization during their formation. The size of both NPs was within 
a range of 200−320 nm. When administrated intravenously, NPs should be 
sufficiently small (100–300 nm) to passively cross the tumour endothelial barrier and 
then retain in the tumour bed for pro-longed time due to reduced lymphatic drainage, 
which is known as the enhanced permeability and retention effect (Kobayashi et al., 
2014). Particles larger than 1 mm are not convenient for intravascular delivery of 
drugs, since they can readily be opsonized with a possibility of capillary occlusion, 
while NPs smaller than 5 nm can be cleared rapidly from the blood via extravasation 
or renal clearance (Elsabahy & Wooley, 2012). 
 
 
Fig. 4.10: (a) FEG-SEM micrograph of individual PCL particle; (b) FEG-SEM 
micrograph of individual PLA particle and; (c) TEM image of PCL NPs; (d) TEM 
image of PLA NPs.  
4.4 Chapter summary 
In this study, a new microfluidic method for the preparation of biodegradable 
nanoparticles was developed based on micromixing/nanoprecipitation in co-flow and 
flow focusing glass capillary devices. The particle size was precisely tuned by varying 
orifice size of the inner capillary, flow rate ratio and the total flow rate in the collection 
100 nm 100 nm 
  500 nm   500 nm 
(d) (c) 
(b) (a) 
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capillary. The higher the aqueous-to-organic flow rate ratio, the higher the dilution 
factor of the polymer in the liquid phase and the lower the rate of particle growth after 
nucleation, resulting in smaller particle size. At the same liquid flow rates, the mixing 
process was faster when the organic phase was injected through smaller orifice, which 
led to the generation of more nuclei, whose growth was limited by the amount of 
available polymer in the liquid phase, thereby resulting in smaller ultimate particle 
size. At constant flow rate ratio and orifice size, PLA formed smaller particles than 
PCL, because PLA is more compatible with water than PCL and starts to precipitate 
from a more diluted organic solution, which limits particle growth. The PLA particles 
exhibited a smoother surface and more regular spherical shape than PCL particles, 
which can be related to fully amorphous structure of ᴅ-ʟ type polylactide. 
 
In a co-flow device, a decrease in the aqueous-to-organic flow rate ratio led to the 
following sequential changes in the shape of the phase boundary: spherical interface 
 widening jet  viscous fingering  vortex flow. A spherical interface suggests 
that a transient interfacial tension occurs between two miscible fluids (water and THF) 
immediately after injection as a result of high concentration gradients at the contact 
zone. In a flow focusing device, a widening-jet regime prevailed at all flow rates. 
 
Smaller NPs were produced in a flow focusing device compared to a co-flow device 
of the same geometry, because in the former case the diameter of the organic stream 
was significantly smaller than the orifice diameter. PCL particles formed in flow 
focusing device with an orifice size of 200 μm at the organic stream flow rate of 1.7 
mL h −1 and a flow rate ratio of 10 were smaller than 200 nm. Such small NPs are 
capable of spontaneous accumulations in various pathological sites via the enhanced 
permeability and retention effect. The mean size of PCL NPs formed in a co-flow 
device of the same geometry under the same flow rates was 227 nm. 
 
Further experimental work will be focused on encapsulation of hydrophobic drug 
(acetaminophen) within biodegradable polymer matrix and the optimisation of 
process parameters using design of experiments (DOE) software and methods. The 
nanoparticles will be embedded with nanoclays to modify their internal structure and 
drug release patterns 
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CHAPTER 5  
 
DEVELOPMENT OF ACETAMINOPHEN LOADED 
MONODISPERSED NANOPARTICLES FORMULATION USING 
FACTORIAL DESIGN APPROACH PRODUCED IN A GLASS 
CAPILLARY MICROFLUIDICS DEVICE  
Chapter overview  
Nanoencapsulation of acetaminophen (PCM) onto poly(ɛ-caprolactone) (PCL) polymer 
matrix by nanoprecipitation (“diffusion-stranding” process) was studied using glass 
capillary microfluidic device consisted  of two different miscible liquids. PCL was chosen 
as a carrier for nanoparticle fabrication, because it is a biodegradable and bioresorbable 
polymer commonly used in pharmaceutical industry, while tetrahydrofuran (THF) was 
used as a water-miscible volatile solvent. Five (5) investigated  independent input 
variables included PCL concentration (A), co-flow device orifice size (B), flow rate ratios 
(C), surfactant concentration (D) and acetaminophen percentage loading (E) were 
evaluated. Percentage of encapsulation efficiency (Y1), % drug loading (Y2) and particle 
mean size, Zave (Y3) were used as the response variables. A 2
5-full factorial design was 
applied and allowed screening for the most influential variables. The optimum 
formulation with highest desirability percentage for each response was achieved by using 
the concentration of PCL (A) at 5.96 mg/ml, orifice size (B) at 60 μm, flow rate ratios, 
Qaq/Qor (C) at 10, PVP surfactant concentration (D) at 0.1 % (w/w) and acetaminophen 
loading (E) at 20 % (w/w). The size of PCM-loaded PCL NPs was 268 nm mean size with 
49.25 % encapsulation efficiency and 6.96 % of drug loading which is well correlated to 
the predicted results given by simulation. The in vitro drug release profile showed a 
sustained acetaminophen up to 140 hours indicating the suitability of PCL nanoparticles 
in controlled acetaminophen release. Transmission electron microscopy (TEM), field 
emission gun scanning electron microscope (FEG-SEM), differential scanning 
calorimetry (DSC) and X-ray diffractometry (XRD) analyses were successfully confirmed 
the properties of functionised PCM-loaded PCL NPs. 
5.1 Introduction 
Paracetamol (C8H9NO2), is used as an analgesic and antipyretic, in the treatment of a wide 
variety of arthritic and rheumatic conditions involving musculoskeletal pain and in other 
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painful disorders such as headache, dysmenorrhoea, myalgia and neuralgia (Billon et al., 
2000; Kashyap et al., 2011). The conventional oral dose of paracetamol for adults must 
be in the range of 325–1000 mg (650 mg rectally) with total daily dose should not exceed 
than 4000 mg (Kashyap et al., 2011). Scientifically, it is known as acetaminophen and its 
toxicity is the foremost cause of acute liver failure in the Western world, and accounts for 
most drug overdoses in the United States, the United Kingdom, Australia and New 
Zealand (Bateman et al., 2006; Daly et al., 2008; Hawton et al., 2001; Hughes et al., 2003; 
Jefferies et al., 2011; Larson et al., 2005; Morgan & Majeed, 2005; Thomas 1993; Ward 
& Alexander-Williams, 1999). Since an overdose of acetaminophen can lead to a fatal 
centrilobular liver injury, a prolonged and controlled release rate of acetaminophen 
warrants a study of its nanoencapsulation in polymeric nanorospheres. In previous works, 
acetaminophen has been encapsulated within anionic acrylic resin microspheres by a 
W/O/O emulsion-solvent diffusion method (Lee et al., 2000). Sustained release systems 
using acetaminophen as the model drug were also investigated by Shimokawa et al. 
(2013). Lai & Tsiang (2004) studied the controlled release rate of poly(ʟ-lactide) 
microspheres containing acetaminophen as the core material using the oil-in-water 
emulsification solvent-evaporation technique. Ward & Alexander-Williams (1999) also 
reported a new method to control acetaminophen and protein delivery at different stages 
from modified core–shell biodegradable microspheres produced by solvent evaporation 
method.  
 
Biodegradable polymer nanoparticles are of great interest as drug delivery systems 
because of their ability to be reabsorbed by the body. Synthetic aliphatic polyesters, such 
as poly-ε-caprolactone (PCL), are often used in biomedical applications because they are 
biocompatible and non-toxic (Wu et al., 2000) behaviour. The advantages of PCL include 
its high permeability to small drug molecules, and its negligible tendency to generate an 
acidic environment during degradation as compared to polylactide (PLA) and poly(lactic-
co-glycolic acid (PLGA). The degradation of PCL homopolymer is very slow as 
compared to other polyesters, making it more suitable for long-term delivery systems 
extending to a period of more than 1 year, and with appropriate blending the delivery can 
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be increased/decreased as desired (Abdolmohammadi et al., 2012; Woodruff & 
Hutmacher, 2010). PCL is a semi-crystalline polymer having a glass transition 
temperature (Tg) of −60 oC and melting point ranging between 59 and 64 oC, dictated by 
the crystalline nature of PCL which enables easy formability at relatively low 
temperatures. Recently, Tshweu et al. (2013) discovered new formulation parameters for 
the encapsulation of lamivudine into poly(ɛ-caprolactone) (PCL) nanoparticles matrix 
using a double emulsion spray drying technique for improving HIV treatment. Spherical 
nanoparticles with an average size of 215 ± 3 nm and polydispersity index (PDI) of 0.227 
± 0.01 were obtained in their study. Bilensoy et al. (2009) designed a cationic 
nanoparticulate carrier system between 180−340 nm in size by encapsulating an 
intravesical chemotherapeutic agent Mitomycin C (MMC) onto PCL-chitosan (CS-PCL) 
and PCL-poly-ʟ-lysine (PLL-PCL) matrix, respectively. Gupta et al. (2011) also 
developed a method to encapsulate influenza A virus (A/California/07/2009) H1N1 
hemagglutinin (HA) recombinant protein onto the PCL-chitosan nanoparticulate. Behera 
et al. (2013) also focused on the development and enhancement of entrapment efficiency 
of isoniazid loaded poly-ε-caprolactone nanoparticles for the treatment of tuberculosis. 
 
A central challenge in the development of drug-encapsulated polymeric nanoparticles is 
the inability to control the mixing processes required for their synthesis resulting in 
variable nanoparticle physicochemical properties (Karnik et al., 2008). The ability of 
microfluidics to rapidly mix reagents, provide homogeneous reaction environments, 
continuously vary reaction conditions, and add reagents at precise time intervals during 
reaction progression has made it an attractive technology for a myriad of applications 
(DeMello, 2006; deMello & deMello, 2004). Currently, Khan et al. (2013) succeeded to 
encapsulate high ketoprofen contents in acrylate-based copolymer microbeads by 
environment friendly UV induced free radical polymerization in off-the-shelf co-axial 
microfluidic device. Yeh et al. (2009) used a T-junction microfluidic chip for 
monodisperse calcium alginate microparticles and encapsulation of nanoparticles 
emulsification process. A microfluidic origami chip to synthesise monodisperse 
doxorubicin-loaded poly(lactic-co-glycolic acid) nanoparticles with optimum diameters 
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of ~100 nm for cellular uptake and anticancer efficacy was successfully demonstrated by 
Sun et al. (2013). Capretto et al.( 2013) also applied a hydrodynamic flow-focusing 
microfluidic device in the production of polymeric micelles for combined delivery of Dex 
and ascorbyl-palmitate (AP). Whilst, Jahn et al. (2007) produced liposome in a 
continuous-flow planar microfluidic network with precise control of size over the 
diameter range of 50−150 nm through the manipulation of liquid flow rates.  
 
Solvent evaporation, monomer polymerization, nanoprecipitation and salting out 
procedure are some of the common methods applied for the preparation of nanoparticles 
from biodegradable polymers (Quintanar-Guerrero et al., 1998). However, 
nanoprecipitation method was developed by Fessi et al. (1989) represents an easy and 
reproducible technique and very often used to prepare colloidal carriers both matricidal 
(nanosphere) and vesicular type (nanocapsules). This method was based on the interfacial 
deposition of a polymer following diffusion of a semi-polar and miscible solvent in the 
aqueous medium in the presence of a surfactant (Barichello et al., 1999). Several 
important factors contribute to the effectiveness of this method in preparing particles with 
acceptable size range, shape and the percentage of the drug load, namely the amount of 
polymer, percentage of surfactant and volume of organic and aqueous phases. It is 
difficult to assess the effect of each variables or their combination, thus  deriving a 
mathematical model suitable for establishing a quantitative relationship between the 
formulation variables is seemingly promising (Derakhshandeh et al., 2007; Yang & Zhu, 
2002; Seth & Misra, 2002).  
 
Limited number of studies has been reported on numerical analysis especially for the 
encapsulation of hydrophilic drug onto the polymeric nanoparticles matrix using flow-
focusing approach. For instance, Thi et al. (2013) developed a new solution in optimizing 
the taste-masked formulation of acetaminophen using sodium caseinate and lecithin by 
24−full factorial experimental design by taking into account the inlet variables; 
temperature (X1), the spray flow (X2), the sodium caseinate amount (X3) and the lecithin 
amount (X4). Derakhshandeh et al. (2007) also demonstrated the effects of individual 
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input variables or in combination by deriving a suitable mathematical model for 
establishing a quantitative relationship between the formulation variables for 9-
nitrocamptothecin (a novel anticancer drug) encapsulation in poly(ᴅ,ʟ-lactide-co-
glycolide) nanoparticles. The effects of dependent variables drug-polymer ratio (X1) and 
surfactant concentration (X2) on particle size and encapsulation efficiency of Glipizide 
loaded PCL nanoparticles were also studied by Lokhande & Mishra (2013) using a 32−full 
factorial design.  Kalani et al. (2011) optimised the process parameters resulted in 
production of nanoencapsulated paracetamol in ʟ-polylactide including pressure, 
temperature, and polymer concentration, to produce fine small spherical particles with a 
narrow particle size distribution using a supercritical antisolvent method. While, Riddin 
et al. (2006) explained the analysis of inter- and extracellular formation of platinum 
nanoparticles by Fusarium oxysporum f. sp. lycopersici using experimental design for the 
response surface methodology. Zu et al. (2009) also tried to optimize the preparation 
process of vinblastine sulfate (VBLS)-loaded folate conjugated bovine serum albumin 
(BSA) nanoparticles for tumor-targeted drug delivery Design- Expert® Version 7.0.0 
software.   
  
In light of these above observations, this study is aimed to evaluate various formulation 
variables involved in the preparation of acetaminophen loaded nanoparticles by 
nanoprecipitation method using glass capillary microfluidic device. A two-level factorial 
design experiment was used for obtaining a mathematical model and prediction of 
optimized formulations. A 25-full factorial design was applied with five (5) different 
independent input variables included; (A) PCL concentration, (B) co-flow device orifice 
size, (C) flow rate ratios, (D) surfactant concentration and (E) acetaminophen percentage 
loading were evaluated. Percentage of encapsulation efficiency (Y1), % drug loading (Y2) 
and particle mean size, Zave (Y3) were used as the response variables. The produced PCM- 
loaded PCL NPs (hereinafter called the PCM-PCL NPs) were characterised according to 
their morphology, particle size, encapsulation efficiency, drug loading and in vitro drug 
release behaviour. 
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5.2 Materials and methods  
5.2.1 Materials 
Tetrahydrofuran (THF) (for HPLC, purity ≥ 99.9 %) was supplied by Sigma-Aldrich Co., 
UK. Poly(ɛ-caprolactone) (PCL) (Mw=14,000 g mol−1) in flakes form was purchased from 
Sigma-Aldrich Chemical Co. with a glass transition temperature (Tg) of 60 
oC. 
Polyvinyl pyrrolidone (PVP) with Mw= 360 000 gmol
−1 in powder form was purchased 
from Sigma-Aldrich Co., UK applied as the surfactant in the aqueous phase. 
Acetaminophen (PCM) (purity ≥ 99.9 %) in powder was purchased from Fisher 
Scientific, UK. All chemicals and solvents used were of analytical grade. The aqueous 
phase used as an anti-solvent in microfluidic experiments was distilled water produced 
by reverse osmosis (MiliQ®, Millipore).  
5.2.2 Preparation of acetaminophen loaded nanoparticles using co-flow device 
The experimental set-up used for the experiments is shown in Fig. 5.1. Two 11 Elite 
syringe pumps (Harvard Apparatus, UK) were used to deliver the organic and aqueous 
phase from SGE syringes to their respective capillaries. The organic phase containing 
0.3–0.6 % (w/w) polymer and 0.02–0.07 % (w/w) acetaminophen in THF was injected 
through the inner capillary tube with a tapered cross section culminated in a circular 
orifice via a Teflon (polytetrafluoroethylene, PTFE) tubing (1.59 mm O.D. and 0.8 mm 
I.D.), which was highly resistant to THF. While, the aqueous phase consisted of 0.2–0.5 
% (w/w) PVP (surfactant) dissolved in Milli-Q water was delivered co-currently through 
the outer square capillary. 
 
The formation of encapsulated nanoparticles occurred instantaneously in the outer 
capillary when both of the phases were brought into contact. These two phases were 
delivered to the device using a standard method explained in Section 3.3. This was 
observed through a Phantom V9.0 high-speed camera as described in Section 4.2.3. The 
size of orifice and the organic phase flow rate (Qor) were varied in order to study their 
effects on the size of obtained nanoparticles. Initially, the aqueous phase flow rate (Qaq) 
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was fixed at 5 mL h−1 and the organic phase flow rate ranged from 0.5 to 3.3 mL h−1 
corresponding to the aqueous to organic phase volume ratio (Qaq/Qor) from 1.5 to 10.0.  
 
 
Fig. 5.1: Experimental set-up for the preparation of acetaminophen encapsulated 
nanoparticles by nanoprecipitation method using flow focusing device. 
5.2.3 Determination of the drug content 
The nanosuspension was separated using ultracentrifugation (Beckman L-8 60M 
Ultracentrifuge) at 15 000 rpm for 1 h at 20 oC. The supernatant containing the dissolved 
free drug was discarded and transferred to UV–visible spectrophotometer (UV-2550, 
Shimadzu, Japan) for drug content analysis. The pellet was then freeze-dried (Edwards 
Modulyo Freeze- drier) for 48 h for further characterisation analyses. A stock solution of 
acetaminophen (10,000 mg/L) was used to prepare ten standard solutions in the range 
from 5–50 mg L−1 with milli-Q water. The following equations were applied in order to 
calculate the drug loading (DL) and the encapsulation efficiency (EE). 
 
D.L. (%) = [(W1-W2)/Wt] × 100 %                                                                               (5.1) 
 
where W1 is the initial weight of drug that was incorporated into the nanoparticles, W2 is 
the weight of free drug (unincorporated drug) and Wt is the weight of nanoparticles.  
 
E.E. (%) = [1− (WT/Wi)] ×100 %                                                                                 (5.2) 
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where WT is the total amount of drug in release medium and Wi is the total theoretical 
quantity of drug added initially during preparation (Calvo & Remunan-Lopez, 1997; 
Douglas & Tabrizian, 2005; Muthu et al., 2009; Zheng et al., 2009; Kumar et al., 2012).  
5.2.4 Full factorial experimental design  
Based on preliminary study of the effect of parameters on the drug loading of nanosphere, 
the experiments were performed by nanoprecipitation method using a two-level full 
factorial design. Design-Expert® Version 7.1.5 software was applied for designing the 
experiment. Five (5) parameters included the poly(ɛ-caprolactone) (PCL) concentration, 
mg/ml (A), orifice size, μm (B), flow rate ratios, Qaq/Qor (C), PVP surfactant 
concentration, (w/w) % (D), and the percentage (%) of paracetamol amount (E). Each 
factor is set at one of two levels i.e. low (−1) and high (+1) level as shown in Table 5.1.  
 
Table 5.1: Values for the low (−1) and high (+1) levels of input variables investigated in 
the factorial design. 
Input variables Coded units Low level (−) High level (+) 
PCL concentration (g L-1) A 3 6 
Orifice size (μm) B 60 200 
Flow rate ratios, Qaq/Qor C 1.5 10 
PVP surfactant concentration (% w/w) a D 0.1 0.5 
Paracetamol amount (% w/w) b E 20 70 
* Note: a = Percentage values were calculated based on mass of aqueous phase (mili-Q water).  
             b = Percentage values were measured based on amount of polymer (PCL). 
 
In this screening step, a full factorial design involving five experimental variables was 
conducted to identify the processing and formulation parameters that have significant 
influence on the investigated responses. The full factorial required hence 25 or 32 
experiments of which the experimental conditions are listed in Table 5.2, with five 
variables and three different responses; encapsulation efficiency (Y1), % drug loading (Y2) 
and particle mean size, Zave (Y3). Triple runs were carried out on each batch of 
experiments to check reproducibility.  
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Table 5.2: Experimental design and percentage of three different responses (n = 3). 
Run A B C D E Y1 (%) Y2 (%) Y3 (nm) 
1 3 60 1.5 0.1 20 18.52 3.09 290.5 
2 6 60 1.5 0.1 20 42.57 7.09 312.9 
5 3 60 10 0.1 20 26.48 4.41 275.6 
6 6 60 10 0.1 20 50.10 8.35 289.4 
9 3 60 1.5 0.5 20 22.02 3.67 274.8 
10 6 60 1.5 0.5 20 39.16 6.53 428.2 
13 3 60 10 0.5 20 25.28 4.21 259.2 
14 6 60 10 0.5 20 56.13 9.35 411.3 
17 3 60 1.5 0.1 70 50.70 20.57 419.1 
18 6 60 1.5 0.1 70 51.47 21.19 350.2 
21 3 60 10 0.1 70 42.94 17.68 305.5 
22 6 60 10 0.1 70 49.03 20.19 335.1 
25 3 60 1.5 0.5 70 52.30 21.54 445.4 
26 6 60 1.5 0.5 70 50.74 20.89 476.6 
29 3 60 10 0.5 70 49.09 20.21 335.9 
30 6 60 10 0.5 70 50.05 20.61 423.3 
3 3 200 1.5 0.1 20 33.16 5.53 347.2 
4 6 200 1.5 0.1 20 47.09 7.85 419.9 
7 3 200 10 0.1 20 20.41 3.40 347.2 
8 6 200 10 0.1 20 36.22 6.04 416.9 
11 3 200 1.5 0.5 20 32.83 5.47 499.5 
12 6 200 1.5 0.5 20 55.10 9.18 459.8 
15 3 200 10 0.5 20 25.06 4.18 409.6 
16 6 200 10 0.5 20 41.44 6.91 357.5 
19 3 200 1.5 0.1 70 43.08 17.74 336.9 
20 6 200 1.5 0.1 70 8.36 3.44 343.2 
23 3 200 10 0.1 70 36.21 14.91 318.7 
24 6 200 10 0.1 70 14.77 6.08 336.9 
27 3 200 1.5 0.5 70 49.74 20.48 421.6 
28 6 200 1.5 0.5 70 24.35 10.03 436.4 
31 3 200 10 0.5 70 46.41 19.11 379.2 
32 6 200 10 0.5 70 28.20 11.61 425.9 
* Note: Each batch was prepared three times (n = 3) and the mean response values were determined.    
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5.2.5 Characterisation of the encapsulated acetaminophen nanoparticles 
5.2.5.1 Particle size analysis  
The size of nanoparticles was determined by dynamic light scattering (DLS) using 
DelsaTM Nano HC Particle Analyzer (Beckman Coulter, Inc), which measures the 
fluctuations of scattered light as a function of time. Nanoparticles were diluted 5-fold by 
Mili-Q water before being transferred into a 4 mL disposable cuvette which was then 
placed into the instrument. The measurement was repeated three times for each of the 
measurement time was 120 s at 25 °C. Each samples were analysed by following the 
standard procedures described in Section 2.6.1.1. 
5.2.5.2 Microscopic Observations (TEM and FEG-SEM)  
The biodegradable polymeric NPs images and its microscopic structures were 
investigated using two different microscopic analysers; (i) Transmission Electron 
Microscopy (TEM) and (ii) Field Emission Gun Scanning Electron Microscope (FEG-
SEM). Each samples were analysed by following the standard procedures described in 
Section 4.2.4.3.  
5.2.5.3 Differential scanning calorimetry (DSC) 
The thermal analyses were performed with a TA Instrument Q100 DSC. ~5−10 mg of 
pure PCL, pure acetaminophen, physical mixture of PCL and acetaminophen and 
encapsulated nanospheres. The encapsulated nanoparticles sediments obtained from 
ultracentrifugation process were then solidified using freeze-drier for 48 h before 
transferring to DSC analysis. The samples were individually put in aluminum pans and 
hermetically sealed. These sample pans were heated and compared against an empty pan 
from 30−220 oC at a heating rate of 10 oC min−1, with dry nitrogen as the effluent gas (60 
mL min−1). Triple runs were carried out on each sample to check reproducibility. 
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5.2.5.4 X-ray diffractometry (XRD) 
X-ray diffractometer, Bruker D8 diffractometer (Bruker, Germany), was used for 
diffraction studies. XRD studies were performed by exposing samples to CuKa radiation 
(40 kV, 20 mA) and scanned from 2o to 70o, 2 at a step size of 0.02o and step time of 5 
s. Samples used for XRD analysis were the same as those used for DSC analysis. The 2θ 
range was from 10−40° at a scanning speed of 0.5° min−1. Samples for wide angle X-ray 
diffraction were injection molded under nitrogen at 100 °C and transferred at ambient 
temperature to a circular mold with a diameter of 20 mm and a thickness of 1 mm. 
Samples for this analysis can be either in the solid or liquid form.  
5.2.5.5 In vitro drug release measurement 
The in vitro release profile of acetaminophen-loaded nanospheres was determined as 
follows. An exact amount of nanospheres (after 30 minutes collection time) from 
microfluidic experiment was subjected to vacuum for 30 minutes in order to remove any 
excess organic solvents from the nanosuspension samples. The samples were then 
transferred to ultracentrifugation (Beckman L-8 60M Ultracentrifuge) at 15 000 rpm for 
1 h at 20 oC. The supernatant water containing the dissolved free drug was removed from 
centrifugation tube and analysed for its acetaminophen content using an UV–visible 
spectrophotometer (UV-2550, Shimadzu, Japan) at absorbance of 243 nm (Wang et al., 
2010) while the sediment (encapsulated nanoparticles) was remained in the centrifugation 
tube for further release experiment. Two different dissolution mediums (Mili-Q water and 
phosphate buffer (PBS) (0.01M, pH 7.4)) were applied in this study and the samples were 
incubated in a shaking bath at 50 rpm at 37 °C. The dissolution medium was withdrawn 
at precise intervals and replenished with fresh Mili-Q water or PBS to keep the releasing 
medium volume constant. UV-vis spectrophotometry was used to measure amount of 
drug released.  
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5.3 Results and discussion 
5.3.1 Acetaminophen standard calibration by UV-Vis spectroscopy analysis 
The acetaminophen (PCM) stock solutions in Mili-Q water were prepared for two 
different concentrations (1000 ppm and 10000 ppm) at various concentrations of standard 
samples from 5−50 ppm. In this analysis, the acetaminophen concentration detection limit 
and qualification was at 55 g mL−1. Two replications were determined and their mean 
values were calculated for each of the stock calibration solutions in order to ensure the 
accuracy of the standard calibration curve. The solutions were scanned in the wavelength 
range of 200−300 nm using UV–visible spectrophotometer. Fig. 5.2 depicts the standard 
calibration curve obtained for two different concentrations of pure PCM stock solutions 
at different investigated initial concentrations. Both standard curves were linear within 
investigated concentration range (y = 0.063x, r2 > 0.9) and there was almost no difference 
was detected for both graphs.     
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Fig. 5.2: Pure acetaminophen (PCM) standard calibration curve. 
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Further analysis was then elucidated the interference of blank PCL nanoparticles 
existence on UV-Vis absorbance signal. Different concentrations of PCM were applied 
together with certain amount of suspended PCL nanoparticles was applied in this analysis. 
The PCM-W solution was added into PCL-W solution at various PCM concentrations 
before being transferred to UV-Vis spectroscophy for absorbance detection. Fig. 5.3 
explicates the PCM-PCL NPs standard calibration at different concentration of PCM. 
Note that the PCL nanoparticles existence was found significantly interfered the UV-Vis 
signal with much higher detectable UV-Vis light was appeared compared to individually 
pure PCM component. The same observation was considered in Govender et al. (1999) 
experimental works for encapsulated PLGA nanoparticles. This finding significantly 
proved that slight amount of the drug was re-adsorbed or closes to the surface of the 
nanoparticles after the evaporation of organic solvents, a phenomenon recently by the 
other authors (Brigger et al., 2001) and not totally entrapped in the polymeric core. 
Although, centrifugation technique was applied to separate nanosuspension, it is entirely 
impossible to remove the most of the nanoparticles from the sample solution due to its 
tiny size.  
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Fig. 5.3: Pure paracetamol (PCM) and PCM-PCL NPs standard calibration curves.  
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5.3.2 Measurement of the marker concentration percentage reduction  
Regan & Mulvihill (2009) evaluated the suitability of methylene blue and vitamin B12 
(Vit-B12) as water soluble inner aqueous phase (W1) markers for measuring the 
encapsulation efficiency and stability of water-in-oil-in-water (W1/O/W2) double 
emulsions stabilized by sodium caseinate (NaCN). The same technique was applied in 
this research in order to investigate the intrinsic PCM absorption effect onto the polymeric 
nanoparticles surface via blank experiment method by considering PCM as the marker. 
In this experiment, PCM was inversely dissolved in the aqueous phase with PVP as 
surfactant and in the organic phase, the polymer (PCL) was dissolved in organic solvent 
(tetrahydrofuran, THF). The blank experiment was done using co-flow microfluidic 
device at different flow rate ratios and concentration of PCL (3 g L−1 and 6 g L−1). No 
intrinsic PCM absorption effect was detected on nanoparticles surface at 1 g L−1 
concentration of PCL.  
 
Different standard calibration graphs were performed at various PCM concentration 
values in aqueous phase at different flow rate ratios in order to measure the reduced 
concentration factors (% R). The concentration of each marker (PCM concentration) in 
the recovered outer aqueous phase was measured from the absorbance values by referring 
to the standard curve for each marker. Fig. 5.4 (a−b) shows, the % R values for 3 g L−1 at 
flow rate ratio of Qaq/Qor = 1.5 and Qaq/Qor =10.0, respectively. While, Fig. 5.4c−d depicts 
the % R values for 6 g L−1 at flow rate ratio of Qaq/Qor = 1.5 and Qaq/Qor =10.0, 
respectively. The % R values were then subtracted from the actual concentration 
measured from encapsulation experiment prior to get the real encapsulation efficiency. 
Equations; [% R = 0.004 CPCM + 80.306] and [% R = 0.002 CPCM + 81.252], with CPCM 
as the marker concentration can be considered for both 3 g L−1 and 6 g L−1 organic phase 
concentration, respectively.   
5.3.3 Statistical analysis by 25 factorial design 
A technique of two-level factorial design offers the possibility of investigating five 
independent variables at two levels after performing only thirty two (32) batches of 
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different combinations were prepared by taking values of selected variables: A, B, C, D 
and E at two levels as shown in Table 5.1. The mathematical models of each response 
variables generated by the design are given in the following Eqs. 5.3−5.4.  
 
% Encapsulation efficiency (Y1) = 38.09 + 2.20 × A − 4.19 × B − 0.73 × C + 2.40 × D 
+ 2.37 × E − 4.17 × AB − 8.05 × AE − 2.08 × BC + 1.59 × BD − 4.88 × BE − 0.15 × CE 
− 2.46 × ABE + 2.97 × BCE      
                                                                                                                                … (5.3) 
  
% Drug loading (Y2) = 11.30 − 0.34 × A − 1.80 × B + 0.83 × D + 5.34 × E − 1.52 × AB 
− 2.05 × AE − 1.92 × BE − 1.23 × ABE  
                                                                                                                                … (5.4) 
 
Particle size, nm (Y3) = 371.54 + 17.43 × A + 19.48 × B− 19.84 × C + 31.22 × D + 9.08 
× E − 8.89 × AB + 7.19 × AD + 1.44 × BD − 25.25 × BE − 19.51 × ABD 
        … (5.5) 
 
The analysis of variance (ANOVA) was applied to determine the significance and the 
magnitude effects of the main variables and their interactions on the response variables 
(Zu et al.,  2009). The summary of the ANOVA factorial design is presented in Table 5.3. 
Note that the lack of fit of each model was statistically significant if the values of "Prob 
> F" less than 0.0500. Values greater than 0.1000 indicate the model terms are not 
significant. For the first response (Y1), the model F-value of 32.71 implies the model is 
significant with individually input variables and combination variables; A, B, D, E, AB, 
AE, BC, BD, BE, ABE, BCE are significant model terms. The "Pred R-Squared" of 0.7375 
is in reasonable agreement with the "Adj R-Squared" of 0.8013.While, for second model 
(Y2), the model F-value of 68.11 implies the model is significant with influence variables; 
B, D, E, AB, AE, BE, ABE. The "Pred R-Squared" of 0.9216 is in reasonable agreement 
with the "Adj R-Squared" of 0.9454. Final response (Y3) showed 9.37 model F-value 
indicates as significant model with influenced parameters A, B, C, D, BE, ABD. The "Pred 
R-Squared" of 0.5747 is in reasonable agreement with the "Adj R-Squared" of 0.7296. 
Out of five different variables, parameter A (PCL concentration), B (orifice size), D (PVP 
concentration) and E (PCM concentration) were found significantly effects for each 
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responses and individual parameter C (flow rate ratio) is the only relevant to response Y1 
(% encapsulation efficiency) and Y3 (particle size, nm). Thus, any changes in flow rate 
ratio will not give pronounced effect to Y2 (% drug loading) response. This is due to only 
minor differences were detected from response Y2 corresponded to the parameter C. In 
fact, extremely small changes and indistinguishable values were detected in weight of 
nanoparticles over the percentage of drug loading (Y2). Nevertheless, parameter C also 
must be considered for response Y2 as this response was intially defined by response Y1.  
 
The optimum formulations also offered by this software as shown in Table 5.4. The 
encapsulation efficiency (% Y1) response was set as the maximum and the other two 
responses (% Y2 and Y3, nm) were set as the minimum target. This simulation strategy 
was applied based on the experimental results obtained by Govender et al. (1999). The 
calculated desirability factor for offered formulations was nearly 1.00 indicating 
suitability of the designed factorial model. Run 1 shows the selected optimum formulation 
for acetaminophen encapsulation nanoparticles. The concentration of PCL (A) is at 5.96 
g L−1, orifice size (B) at 60 μm, flow rate ratios, Qaq/Qor (C) at 10, PVP surfactant 
concentration (D) at 0.1 % (w/w) and acetaminophen loading (E) at 20 % (w/w). The 
effect of the polymer concentration (A) increment values on the nanoparticles size appears 
mainly to be due to the higher resultant organic phase viscosity, which leads to larger 
nanoparticles’ formation. Meanwhile, the increasing values in drug content of the 
nanoparticles with increased theoretical drug loading (E) may have resulted in the 
increased particle sizes (Y3) displayed. The low drug incorporation percentage values (% 
Y2) may be attributed to the water soluble nature of paracetamol. This led to its rapid 
partitioning into the aqueous phase and hence decreased entrapment into the nanoparticles 
during polymer deposition. The large surface area of the nanoparticle geometry may have 
also contributed to loss of drug into the aqueous phase during preparation. Low drug 
incorporation efficiency (drug loading) of another water soluble drug, 5-fluorouracil, into 
PLGA nanoparticles has also observed by Niwa et al. (1993).  
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The smaller orifice size (B), 60 μm was appeared as the optimum size in order to produce 
smaller particle size. The small value in flow rate ratio (C), 10 also profoundly induced 
the smaller size of particle size as requested in this study. Theoretically, the polymer in 
the organic phase will be more viscous and its tendency to form a much smaller particle 
is higher. In fact, the formation of more diluted nanoparticles suspension will hinder the 
fusion of small polymeric nanoparticles to larger particles. Mora-Huertas et al. (2010) 
also summarised a suggested composition of stabilizer agent within the range of 0.2–0.5 
% of non-solvent in the preparation of nanocapsules by nanoprecipitation method. 
However in this study, 0.1 % (w/w) of surfactant (C) indicated as the optimum value in 
the formation of paracetamol encapsulated nanoparticles. This value is principally 
acceptable and helps to hinder the formation of particle agglomeration which potentially 
can be occurred simultaneously by the increasing amount of surfactant. The value of % 
Y1 also increased with the increasing polymer concentration (A). Similar observation was 
reported in other research works (Mehta et al., 1994); Li et al., 1999); Rafati et al., 1997). 
High viscosity and fast solidification of the dispersed phase contributed to reduce porosity 
of the nanoparticles as well as delays the drug diffusion within the polymer particles 
(Bodmeier & McGinity, 1988). The concentrated polymer will also tend to precipitate 
faster on the surface of the dispersed phase and prevents drug diffusion across the phase 
boundary (Rafati et al., 1997).  
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Fig. 5.4: Calibration curves of reduced concentration factor (%) for 3 g L−1 at flow rate 
ratio of (a) Qaq/Qor = 1.5 and (b) Qaq/Qor =10.0. Reduced concentration factor (%) for 6 
g L−1 at flow rate ratio of (c) Qaq/Qor = 1.5 and (d) Qaq/Qor =10.0. 
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Table 5.3: Analysis of variance for a 25 Full-factorial design experiment for evaluation of some variables’ effect on acetaminophen 
encapsulated nanoparticles.   
Response 1: % Encapsulation efficiency (% Y1) Response 2: % Drug loading (% Y2) Response 3: Particle size, nm (Y3) 
Variables 
Sum of 
squares 
df* 
F 
value 
p-value 
Sum of 
squares 
df* 
F 
value 
p-value 
Sum of 
squares 
df* 
F 
value 
p-value 
Model 5185.78 13 32.71 
< 0.0001 
(significant) 
1417.13 8 68.11 
< 0.0001 
(significant) 
1.051 x 
105 
10 9.37 
< 0.0001 
(significant) 
A 155.54 1 12.75 0.0022 3.69 1 1.42 0.246 9716.18 1 8.66 0.0078 
B 562.38 1 46.11 < 0.0001 103.75 1 39.89 < 0.0001 12144.61 1 10.82 0.0035 
C 17.07 1 1.4 0.2522 − − − − 12600.78 1 11.23 0.003 
D 184.27 1 15.11 0.0011 21.81 1 8.39 0.0081 31187.53 1 27.79 < 0.0001 
E 179.88 1 14.75 0.0012 914 1 351.42 < 0.0001 2635.38 1 2.35 0.1404 
AB 555.19 1 45.52 < 0.0001 73.51 1 28.26 < 0.0001 2527.61 1 2.25 0.1483 
AD − − − − − − − − 1653.13 1 1.47 0.2384 
AE 2072.88 1 169.96 < 0.0001 134.23 1 51.61 < 0.0001 − − − − 
BC 138.65 1 11.37 0.0034 − − − − − − − − 
BD 80.87 1 6.63 0.0191 − − − − 66.7 1 0.059 0.8098 
BE 762.94 1 62.56 < 0.0001 117.58 1 45.21 < 0.0001 20402 1 18.18 0.0003 
CE 0.69 1 0.057 0.8143 − − − − − − − − 
ABE 193.8 1 15.89 0.0009 48.56 1 18.67 0.0003 − − − − 
ABD − − − − − − − − 23570.86 1 10.85 0.0035 
BCE  281.62 1 23.09 0.0001 − − − − − − − − 
df, degrees of freedom. 
* Significance level based on 1 df; p < 0.01. 
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Table 5.4: Factorial design optimised formulations. 
Run A B C D E 
Y1 
(pre.) 
Y1 (exp.) 
Y2 
(pre.) 
Y2 (exp.) 
Y3 
(pre.) 
Y3(exp.) 
33 5.97 60.01 10.00 0.10 20.00 50.34 49.25 ± 2.17 6.98 6.87 ± 1.30 268.34 258.00 ± 3.70 
34 5.81 60.06 10.00 0.10 20.02 49.58 47.30 ± 4.59 6.76 6.56 ± 3.88 267.85 256.57 ± 4.19 
35 5.96 60.00 9.99 0.10 20.47 50.55 48.24 ± 4.56 7.08 6.84 ± 3.44 268.43 259.14 ± 3.48 
36 5.71 60.00 10.00 0.10 20.13 47.14 45.04 ± 4.47 6.65 6.23 ± 2.94 267.99 256.11 ± 4.38 
37 6.00 69.00 10.00 0.10 20.00 46.65 44.71 ± 4.15 6.99 6.11 ± 3.77 275.04 252.62 ± 5.81 
38 5.47 60.09 10.00 0.10 20.00 50.80 50.73 ± 0.14 6.30 7.12 ± 1.04 268.41 271.84 ± 3.09 
39 5.29 60.00 9.90 0.10 20.01 48.56 48.48 ± 0.18 6.07 7.20 ± 0.88 268.41 255.65 ± 5.64 
40 6.00 60.33 9.41 0.10 20.00 48.57 48.32 ± 0.51 7.00 6.93 ± 0.41 270.75 274.03 ± 2.94 
41 6.00 77.54 10.00 0.10 20.02 50.84 48.91± 3.79 6.97 7.16 ± 5.97 281.41 279.19 ± 3.28 
42 5.09 60.00 10.00 0.11 20.00 49.03 48.77 ± 0.53 5.84 6.96 ± 0.28 269.72 270.54 ± 2.78 
* Note: 1. Each batch was prepared three times.  
             2. Run 1 is the selected combined parameters for optimum formulation.  
5.3.4 Nanoparticles characterisations 
5.3.4.1 Differential scanning calorimetry (DSC) analysis 
The DSC thermograms corresponding to acetaminophen, PCL, physical mixture of 
PCL and acetamnimophen and acetaminophen encapsulated nanoparticles are shown 
in Fig. 5.5. This analysis is aimed to characterise the physical state of PCM 
encapsulated nanoparticles. The PCL thermogram displayed an endothermic peak at 
60 oC, corresponding to the polymer melting point (Tm). The DSC curve of PCM 
(acetaminophen) showed a single melting peak at 169 oC and started to degrade as it 
melted. Very small PCM melting peak was visible in the case of drug loaded 
nanoparticles. This might be due to amorphous state of the drug dispersed in the 
nanoparticles. Since there was no shift in the Tm of the polymer, it can be concluded 
that there is no significant interaction occurring between the drug and the polymer. 
For physical mixture small peak was detectable at the melting point of PCM as PCM 
just mixed together with polymer. Since glass–liquid transition of PCL occurs at 
relatively lower temperature (− 60 oC), it is possible that at higher temperatures 
molecular dispersion of drug in polymer occurs during DSC process. The same 
observation was observed by Thi et al. (2013), Lai & Tsiang (2004) and 
Derakhshandeh et al. (2007).  
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Fig. 5.5: Differential scanning calorimetry (DSC) thermograms obtained for 
acetaminophen, polymer, acetaminophen-polymer physical mixture and encapsulated 
nanoparticles. 
5.3.4.2 X-ray diffractometry (XRD) analysis 
To confirm these results XRD was performed and results are presented in Fig. 5.6. As 
shown XRD patterns of PCM and physical mixture exhibit a sharp peak at about 2 
scattered angle 13.5 indicating crystalline nature of acetaminophen (PCM). This 
characteristic peak for drug was found nearly disappeared for the encapsulated 
nanoparticle XRD pattern which suggesting no crystal can be observed on the 
encapsulated particle surface. This finding indicates that the drug seems to be well 
entrapped in the polymeric nanoparticles core. This remarkable result was also 
reported by  Zhang et al. (2006) and Derakhshandeh et al. (2007).  
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Fig. 5.6: XRD patterns of acetaminophen, polymer, acetaminophen-polymer physical 
mixture and encapsulated nanoparticles. 
5.3.4.3 Microscopic image observation (FEG-SEM and TEM images) 
The microscopic observations on blank PCL and acetaminophen encapsulated PCL 
nanoparticles presented in Fig. 5.7 (a-b) using FEG-SEM. Both nanoparticles showed 
a spherical shape of nanoparticles as well as individually distributed with 
homogeneous particle size distribution. Minor agglomerations were detected in these 
images probably due to the effect of the vacuum during free drying stage on the 
formed nanoparticles. The structure of blank PCL nanoparticles were nearly spherical 
compared to encapsulated nanoparticles, whereas the structure of encapsulated 
nanoparticles seems has been distorted by the encapsulated drug contents. The same 
observation was presented by Wang et al. (2010) and Lai & Tsiang (2004) for 
acetaminophen encapsulation microspheres using PLA and poly(lactic-co-glycolic 
acid (PLGA) polymer, respectively. The size of PCL nanoparticles was much larger 
compared to the encapsulated nanoparticles. These results showed a good results with 
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values obtained using DelsaTM Nano HC particle size analyzer with dynamic light 
scattering (DLS) approach of the measurement.  
 
Similar observation was acquired for Transmission Electron Microscopy (TEM) 
images, as depicted in Fig. 5.8 (a-b) for blank PCL and acetaminophen encapsulated 
PCL nanoparticles, respectively. The spherical shape of nanoparticles can be seen 
clearly in Fig. 5.8 (a) for blank PCL and slight deformed structure was detected for 
the encapsulated nanoparticles due to the drug content. The size of PCL nanoparticles 
looks much bigger than PLA nanoparticles within the same magnification. The size 
of measured nanoparticles in this analysis was within the range of 200–280 nm for the 
encapsulated PCL nanoparticles which significantly similar with synthesised 
encapsulated nanoparticles (268 nm) at the optimum conditions.   
5.3.4.4 In vitro release of encapsulated acetaminophen nanoparticles 
The amount of acetaminophen released from nanoparticles was evaluated using two 
different dissolution mediums (Mili-Q water and phosphate buffer (PBS) (0.01M, pH 
7.4)) and the samples were incubated in a shaking bath at 50 rpm at 37°C in order to 
mimic the normal blood stream conditions. The cumulative release profiles of 
acetaminophen from PCL nanoparticles are shown in Fig. 5.9. About 30 % of drug 
showed burst released over a period of 24 hours, followed by a distinct prolonged 
release up to more than 140 hours. The followed delayed release may be attributed to 
diffusion of the dissolved drug within the PCL core of the nanoparticle into the 
dissolution medium. The drug was dissolute and diffused from the polymer matrices 
to the aqueous phase due to the concentration gradient between dissolution medium, 
hence nanoparticles matrix was started to erode resulting from degradation of 
polymer. Minor different profiles were discovered for both dissolution mediums 
(water and buffer, pH 7.4). However, the release profile in buffer solution was much 
faster compared to the water solution because of its different concentration and charge 
dissimilarity. The drug profile exhibited nearly constant changes once it achieved 60 
% cumulative drug release at 24 hours release period and kept persistent until 140 
hours. This indicates that the drug was most likely amended onto the polymer core-
matrix and a sustained drug release from PCL nanospheres could also be achieved due 
to the presence of the polymer layer.     
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Fig. 5.7: FEG-SEM images of; (a-b) blank poly(ɛ-caprolactone (PCL) and (c-d) 
acetaminophen encapsulated PCL nanoparticles at various magnifications. 
 
 
 
  
        
 
 
 
 
 
 
Fig. 5.8: TEM images of; (a) blank PCL nanoparticles and (b) PCM encapsulated 
PCL nanoparticles at the same magnifications. 
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Fig. 5.9: In vitro release profile of acetaminophen from PCL NPs in two different 
release mediums (water and buffer solution in pH 7.4), data presents means (n = 3). 
5.4 Conclusions 
In the present study, the preparation and characterisation of nanoparticles of 
acetaminophen as an analgesic and antipyretic drug was carried out. For simultaneous 
analysis of the influence of different factors on the properties of the nanoparticles and 
to find optimum formulations, the formulation was optimized using a 32 factorial 
experimental design. The polymer amount, drug content and surfactant had a statically 
significant influence on the drug encapsulation efficiency and particle size. The 
optimum formulation with highest desirability percentage for each response was 
achieved by using the concentration of PCL (A) at 5.96 g L−1, orifice size (B) at 60 
μm, flow rate ratios, Qaq/Qor (C) at 10, PVP surfactant concentration (D) at 0.1 % 
(w/w) and acetaminophen loading (E) at 20 % (w/w). In vitro release studies showed 
that PCL nanoparticles could successfully control the release of acetaminophen up to 
more than 140 h. In general the results show that the PCL nanoparticles may be 
considered as a promising carrier system for controlled release in clinical application. 
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CHAPTER 6  
 
FABRICATION OF COMPOSITE POLY(ᴅ,ʟ-
LACTIDE)/MONTMORILLONITE NANOPARTICLES FOR 
CONTROLLED DELIVERY OF ACETAMINOPHEN BY SOLVENT-
DISPLACEMENT METHOD USING GLASS CAPILLARY 
MICROFLUIDICS  
This chapter was published in Colloids and Surfaces B: Biointerfaces Journal  
Chapter overview 
Paracetamol (PCM)-loaded composite nanoparticles (NPs) composed of a 
biodegradable poly(ᴅ,ʟ-lactide) (PLA) polymer matrix filled with organically 
modified montmorillonite (MMT) nanoparticles were fabricated by antisolvent 
nanoprecipitation in a microfluidic co-flow glass capillary device. The incorporation 
of MMT in the polymer improved both the drug encapsulation efficiency and the drug 
loading, and extended the rate of drug release in simulated intestinal fluid (pH 7.4). 
The particle size increased on increasing both the drug loading and the concentration 
of MMT in the polymer matrix, and decreased on increasing the aqueous to organic 
flow rate ratio. The drug encapsulation efficiency in the NPs was higher at higher 
aqueous to organic flow rate ratio due to faster formation of the NPs. The PCM-
loaded PLA NPs containing 2 wt% MMT in PLA prepared at an aqueous to organic 
flow rate ratio of 10 with an orifice size of 200 m exhibited a spherical shape with a 
mean size of 296 nm, a drug encapsulation efficiency of 38.5 % and a drug loading of 
5.4 %. The encapsulation of MMT and PCM in the NPs was confirmed by 
transmission electron microscopy, energy dispersive x-ray spectroscopy, x-ray 
diffraction, differential scanning calorimetry, thermogravimetric analysis and 
attenuated total reflection-Fourier transform infrared spectroscopy. 
6.1 Introduction 
Many drugs are insoluble in aqueous media and biological fluids and, thus, their 
effects are diminished due to poor bioavailability. To enhance their solubility, drug 
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molecules can be incorporated in the interlayer space of layered clays (San Román et 
al., 2013). Montmorillonite (MMT) is a natural clay mineral that belongs to the 
smectite group, in which a central alumina octahedral sheet is sandwiched between 
two silica tetrahedral sheets with a thickness of individual layers of 1 nm. The 
imperfection of the crystal lattice and the isomorphous substitution of Mg2+ for Al3+ 
induces a net negative charge that leads to the adsorption of alkali and alkaline-earth 
metal cations in the interlayer space (Joshi et al., 2009a). These cations can be 
exchanged with cationic forms of therapeutic molecules and drugs. The examples of 
such active species adsorbed onto MMT by cationic bonding are protonated forms of 
amino acids (Kollár et al., 2003), promethazine chloride (Seki & Yurdakoç, 2006), 
timolol maleate (Joshi et al., 2009b), buformin hydrochloride (Fejér et al., 2001), 5-
fluorouracil (Lin et al., 2002), sertraline (Nunes et al., 2007), vitamin B1 (Joshi et al.,  
2009a; 2009b) and buspiron hydrochloride (Joshi et al., 2010). Anionic drugs can be 
intercalated into the interlayer space of MMT by hydrogen bonding between their 
functional groups and hydroxyl groups or oxygen atoms in MMT. For example, 
ibuprofen was adsorbed due to hydrogen bonding between its COO– groups and 
hydroxyl groups of MMT (Zheng et al., 2007). 
 
MMT exhibits high drug loading capacity due to high specific surface area, and 
provides mucoadhesive properties required for drug delivery across the 
gastrointestinal barrier (Carretero, 2002; Dong & Feng, 2005; Datta, 2013). MMT has 
been proved to be nontoxic by hematological, biochemical and histopathological 
analyses (Lee et al., 2005). MMT is a highly efficient detoxifier which has been used 
in the treatment of open wounds, hemorrhoids, stomach ulcers, intestinal problems 
and other diseases (Lee & Chen, 2004; Lee & Fu, 2003; Lin et al., 2002). 
 
Paclitaxel- and docetaxel-loaded PLGA/MMT nanoparticles (NPs) have been 
prepared by an emulsion/solvent evaporation method using dichloromethane as 
organic solvent for PLGA (Dong & Feng, 2005; Feng et al., 2009). MMT was added 
to the aqueous phase and adsorbed onto the surface of the polymer NPs after solvent 
evaporation. Due to its hydrophilic nature, MMT is incompatible with most polymers 
and must be chemically modified to be incorporated within the polymer matrix. MMT 
can be rendered hydrophobic by replacing inorganic cations in the interlayer space 
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with organic alkylammonium or alkylphosphonium cations (Datta, 2013; Suresh et 
al., 2010; Duan et al., 2013). Lee et al. (2000) encapsulated paracetamol within 
Eudragit S100 microspheres using water-in-oil-in-oil double emulsion-solvent 
evaporation method. Shimokawa et al. (2013) prepared gelatin microcapsules loaded 
with the pain-relieving drug phenacetin by a simple coacervation technique. Lai & 
Tsiang (2004) produced PLA microcapsules containing paracetamol using O/W and 
W/O/W emulsion-solvent evaporation methods.  
 
In this work, nanoprecipitation induced by microfluidic micromixing was used to 
produce novel composite paracetamol-loaded NPs consisting of organically modified 
MMT incorporated into poly(ᴅ,ʟ-lactide) (PLA) NPs (hereinafter called the 
PLA/MMT NPs). PLA is a biodegradable and bioresorbable polymer (San Román 
et al., 2013) widely used as a drug carrier. The inclusion of organically modified MMT 
into the polymer matrix has proven to be a viable strategy to improve the thermal, 
mechanical, and barrier properties of PLA sheets (Duan et al.,  2013; Pluta, 2004). In 
this work, MMT was incorporated into PLA NPs to increase drug bioavailablity and 
modify its release. Paracetamol (acetaminophen, C8H9NO2) was chosen as a model 
drug due to its significant therapeutic effects against a wide variety of arthritic and 
rheumatic conditions involving musculoskeletal pain and other painful disorders 
(Kashyap et al., 2011; Billon et al., 2000; Ward & Alexander-Williams, 1999). 
 
Nanoprecipitation (solvent displacement) is a low-energy process for preparation of 
NPs driven by spontaneous counter-diffusion of polymer-laden amphiphilic organic 
solvent and water (Fessi et al., 1989; Galindo-Rodriguez et al., 2004; Chorny et al., 
2002). Nanoprecipitation gives smaller polymeric NPs than emulsion-solvent 
evaporation and allows the use of non-halogenated organic solvents which are less 
toxic than halogenated solvents typically used in emulsion-solvent evaporation. 
 
A crucial challenge in nanoprecipitation is to control the mixing conditions in order 
to produce uniformly sized particles (Karnik et al., 2008). The capability of 
microfluidic devices to rapidly mix fluids, continuously vary reaction conditions, and 
provide homogeneous reaction environments and small reactor volumes has made 
them attractive tools for a myriad of applications (DeMello, 2006; deMello & 
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deMello, 2004). Flow focusing polydimethylsiloxane (PDMS) devices are widely 
used for production of NPs (Karnik et al., 2008). However, PDMS swells in contact 
with organic solvents and the fabrication of PDMS devices by soft lithography 
requires the use of a master mould that must be manufactured using expensive 
photolithographic techniques. In this work, axisymmetric glass capillary devices were 
used (Utada et al., 2007) that are cheap to fabricate and have superior solvent 
resistance and optical properties for in-situ visual control of the process. These devices 
have been used by our group to prepare liposomes loaded with vitamin E 
(Vladisavljević et al., 2014), polymeric micelles (Laouini et al., 2013) and 
polycaprolactone NPs (Othman et al., 2015a; 2015b).  
 
The aim of this study was: (i) to investigate the possibility of efficiently incorporating 
MMT and paracetamol into PLA NPs by microfluidic mixing/nanoprecipitation; (ii) 
to study the effect of MMT on the physical properties of the prepared NPs; and (iii) 
to investigate the encapsulation efficiency of paracetamol inside the NPs and their in 
vitro drug release behaviour.  
6.2 Materials and methods  
6.2.1 Materials 
Poly(ᴅ,ʟ-lactide) (PLA, IngeoTM 4060D) was supplied by Natureworks LLC 
(Minetonka, MN, USA). 4060D is an amorphous polymer with a content of ᴅ- and ʟ 
-lactide of 12 and 88 mol%, respectively, a density of 1,240 kg m-3, a glass transition 
temperature of 55-60oC, and a weight-average molecular weight (Mw) of 89,000 g 
mol-1, as determined by gel permeation chromatography. Tetrahydrofuran (THF), 
HPLC grade (purity≥99.9%) was purchased from Sigma-Aldrich, UK. 
Polyvinyl pyrrolidone (PVP, Mw = 360,000 g mol
-1) obtained from Sigma-Aldrich 
was used as a stabiliser to prevent agglomeration and coalescence of the NPs. 
Paracetamol (PCM) (purity ≥ 99.9%) was purchased from Fisher Scientific, UK.  
 
MMT used in this work was Cloisite® 30B with a density of 1,980 kg m-3 obtained 
from Southern Clay Products (Gonzales, TX, USA). It is MMT organically modified 
with N,N-Bis(2-hydroxyethyl)-N-methyl-N-tallow ammonium chloride to improve 
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its compatibility with the polymer matrix. PLA/MMT nanocomposite films were 
prepared by melt intercalation (Duan et al., 2013). Briefly, PLA granules were dried 
at 60 °C in a vacuum oven and then melt blended with 20 wt% of organo-MMT at 
170 °C to make a masterbatch. The masterbatch was then mixed with dried PLA 
granules at 170 °C to form nanocomposites containing 2, 5, and 20 wt% of the clay. 
The organic phase was prepared by dissolving PCM and pure PLA or PLA/MMT 
composite film in THF and contained 6 g L-1 of the excipient (PLA or PLA/MMT) 
and 1.2−4.2 g L-1 of PCM. The aqueous phase was 0.2 wt% PVP dissolved in Milli-
Q water.  
6.2.2 Preparation of PCM loaded PLA and PLA/MMT NPs 
The NPs were prepared using a co-flow glass capillary device consisting of a round 
capillary with a tapered tip inserted into a square capillary (Fig. 6.1 (a)). The organic 
phase was injected through the inner capillary (1 mm O.D. and 0.58 mm I.D.) with an 
orifice diameter of 200 m via a Teflon tubing, which is highly resistant to THF. The 
aqueous phase was delivered co-currently through the outer square capillary (1.05 mm 
inner dimension). PLA precipitated almost instantaneously in the square capillary 
when the two fluids were brought into contact. This was observed through an inverted 
microscope as elucidated in Section 4.2.3. The aqueous phase flow rate (Qaq) was 5 
mL h-1 and the organic phase flow rate (Qor) ranged from 0.5 to 3.3 mL h
-1 to give 
Qaq/Qor between 10 and 1.5. These two phases were delivered to the device using a 
standard method described in Section 3.3. The duration of each experiment was 30 
min. 
 
A micrograph of the mixing zone within the glass capillary device at Qaq/Qor = 1.5 
captured by the high-speed camera is shown in Fig. 6.1 (a). The interface between the 
aqueous and organic phases is visible, although THF and water are miscible in all 
proportions and have zero equilibrium interfacial tension. When two miscible liquids 
are suddenly put into contact, concentration gradients at the boundary give rise to a 
transient tension between the liquids,   given by (Joseph & Hu, 1999):  /2Ck
, where k  is the proportionality constant, C  is the change in concentration over the 
interfacial layer and   is the thickness of the boundary layer. The interface was found 
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to be blurred on the front side of the jet because of better mixing near the axis of the 
collection capillary due to high fluid velocities. The distortion of the interface known 
as “viscous fingering” is also noticeable. When a less viscous fluid is injected at high 
velocity into a more viscous one, a part of the more viscous fluid forms finger-like 
patterns due to non-uniform penetration. At 293 K, the viscosities of THF and water 
are 0.63 and 1 mPas respectively, supporting this assumption. Due to the 3D 
geometry of the micromixer, the continuous phase fully surrounds the organic phase 
and de-wets it from the walls (Fig. 6.1 (a)). Since the liquid/liquid interface is fully 
displaced from the walls and the NPs are formed at this interface, the deposition of 
the NPs onto the reactor walls is minimised. In a planar geometry, the organic phase 
wets the channel walls at the inlet, which can compromise the resultant particle size 
due to particle deposition onto the walls. A possible structure of encapsulated PCM-
PLA/MMT NPs is depicted in Fig. 6.1 (b) with Na+ ions replaced by quaternary 
ammonium cations on the surface of the platelets. Paracetamol molecules and PLA 
chains are present between individual MMT platelets.  
6.2.3 Determination of drug content 
The organic solvent was completely evaporated from the prepared nanosuspension 
using a vacuum oven (Technico, Fistreem International Ltd, Loughborough, UK) at 
room temperature under a pressure of less than 10 Torr. The nanosuspension was then 
ultracentrifuged (Heraeus Labofuge 400R centrifuge, Thermo Scientific) at 15,000 
rpm (23,000g) for 1 h. The supernatant containing the dissolved free drug was 
separated from the sediment, diluted with milli-Q water by a factor of 16 and analysed. 
The concentration of PCM in the supernatant was determined using a Shimadzu model 
UV-2550 UV-visible spectrophotometer at a wavelength of 243 nm (Wang et al., 
2010). The drug encapsulation efficiency was calculated as: 
 
 %)]M/M([.E.E% TR 1001                                                                        (6.1) 
 
where MR is the mass of drug in the supernatant and MT is the total mass of drug in 
the sample (Zheng et al., 2009; Wang et al., 2010; Behera et al., 2013). The drug 
loading of the NPs was determined as:  
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%)]M/)MM[(.L.D% NPRT 100                                                                 (6.2) 
 
where MNP is the total mass of NPs in the sample (Othman et al., 2015).  
6.2.4 Characterisation of the prepared NPs 
6.2.4.1 Particle size measurement 
The size distribution of the NPs was determined by dynamic light scattering using a 
DelsaTM Nano HC Particle Analyzer (Beckman Coulter, Inc), which measures the 
fluctuation in the intensity of scattered light as a function of time. Smaller particles 
cause the intensity to fluctuate more rapidly than large particles. The nanosuspension 
was diluted 5-fold by Mili-Q water before being transferred into a 4 mL disposable 
cuvette and placed into the instrument. The measurement time was 120 s. Each 
samples were analysed by following the standard procedures described in Section 
2.6.1.1. 
6.2.4.2 Transmission electron microscopy (TEM) and energy-dispersive X-ray 
spectroscopy (EDS) 
The internal structure of the NPs was investigated using TEM. Each samples were 
analysed by following the standard procedures described in Section 4.2.4.3. 
6.2.4.3 Differential scanning calorimetry (DSC) 
Differential Scanning Calorimeter (DSC) was performed using a TA Instruments 
Model Q100. 5-10 mg of the sample (pure PLA, pure PCM, physical mixture of PLA 
and PCM, PCM-loaded PLA NPs and PCM-loaded PLA/MMT NPs) was used. PCM-
loaded NPs were prepared by freeze-drying the sediment after centrifugation in a 
freeze dryer (Edwards, type EF4 Modulyo). Each samples were analysed by following 
the standard procedures described in Section 5.2.5.3. 
6.2.4.4 Thermogravimetric analysis (TGA) 
The thermal stability of the NPs was assessed by TGA (Q5000IR Thermogravimetric 
Analyzer) at a heating rate of 10 oC min-1 over the temperature range of 20−600 oC 
under dry nitrogen as the effluent gas.  
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Fig. 6.1: Synthesis of NPs in a co-flow glass capillary device: (a) experimental set-up 
consisting of two syringe pumps, plastic tubing and two coaxial capillaries glued onto 
a microscope slide. (b) Possible structure of encapsulated PCM-PLA/MMT NPs. 
Polycaprolactone (PCL) chains and paracetamol (PCM) are present between 
individual MMT platelets modified with a quaternary ammonium salt. 
6.2.4.5 X-ray diffractometry (XRD) 
Each samples were analysed by following the standard procedures described in 
Section 5.2.5.4.  
200 μm
(a)
Organic phase
Aqueous phase
Microscope slide
HubInner round
capillary
Qaq/Qor =1.5
Do = 200 μm
Nano-
suspension
Viscous fingers
A
A Section A-A
Top view Cross-sectional
view
Schematic of the mixing region in the device
Basal 
spacing 
1.47 nm
Nanoclay platelets
Drug
Polymer chain
PCM-PLA/MMT NPs structure
Note:
Micrograph of the mixing zone
(b)
    
    
PCL (polymer) PCM (drug)
Quaternary
ammonium
cation
MMT platelet
MMT platelet
Quaternary
ammonium
cation

= H3C N
+
OH
OH
OH
O
CHAPTER 6  
                                                                                                                                 156
 
 
Rahimah Othman  2016 
 
6.2.4.6 Attenuated total reflection-Fourier transform infrared (ATR-FTIR) 
spectroscopy  
ATR-FTIR spectra in the range of 4000−400 cm-1 were recorded on a Thermo 
Scientific Nicolet iS50 ATR spectrometer with a monolithic diamond crystal. 2−3 mg 
of the powdered sample was placed onto the Universal diamond ATR top-plate and 
the spectrum was acquired within 32 s. Triple runs were carried out on each sample 
to check reproducibility.  
6.2.4.7 In vitro drug release measurements 
In-vitro drug release tests were carried out using PCM-loaded PLA and PLA/2 wt% 
MMT NPs in two different release media: Mili-Q water (the control fluid) and 0.01 
M sodium phosphate-buffered saline (PBS) at pH 7.4 (the simulated intestinal fluid). 
Simulated intestinal fluid (pH=7.4) was chosen since paracetamol is a weak acid and 
should have a higher solubility in intestinal fluid than in simulated gastric fluid 
(pH=1.2). An aliquot of the prepared suspension was vacuum-evaporated in order to 
remove THF. The suspension was then transferred in a test tube and incubated in a 
shaking bath at 50 rpm and 37 °C to mimic the human blood stream conditions 
(Behera et al., 2013). At predetermined time intervals, the test tube was taken out of 
the shaker and centrifuged at 15,000 rpm for 1 h at room temperature. The supernatant 
was removed and used to measure the amount of drug released. The dissolution 
medium was replenished with fresh Mili-Q water or PBS to keep the total volume of 
the release medium constant.  
6.3 Results and discussion 
6.3.1 Control over the average size of the prepared NPs 
Table 1 shows the effect of drug-to-excipient ratio in the organic phase and the type 
of excipient on the average particle size, drug encapsulation efficiency and drug 
loading of the prepared NPs at the flow rate ratio of 10. The average particle size 
increased from 285 to 398 nm for PLA and from 296 to 428 nm for PLA/2 wt% MMT 
with an increase in the drug-to-excipient ratio in the organic phase from 0.2 to 0.7. 
The average size of composite NPs was bigger than that of the pure PLA NPs, due to 
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the incorporation of MMT into the polymer matrix. A similar effect has been reported 
for docetaxel-loaded NPs when MMT was incorporated into the polymer matrix (Feng 
et al., 2009).  
 
The drug loading in PLA NPs increased from 5.9 to 10.9 % as the drug-to-excipient 
ratio in the organic phase increased from 0.2 to 0.7 (Table 6.1). However, the drug 
encapsulation efficiency decreased from 35 to 27 % on increasing the drug loading in 
the NPs. Low drug encapsulation efficiencies can be attributed to the high solubility 
of PCM in water of 12.8 mg mL-1 at 20 C (Granberg & Rasmuson, 1999). Since the 
concentration of PCM in the organic phase was 1.2−4.2 g L-1 and Qaq/Qor was 10, the 
concentration of PCM in the suspension after THF evaporation was 0.12−0.42 mg 
mL-1, which is only 1−3% of the saturation point of PCM in water. Therefore, without 
entrapment within the NPs, all PCM added to the organic phase would dissolve 
completely in the aqueous phase. The specific surface area of the prepared NPs is 
another factor contributing to the significant loss of PCM into the aqueous phase. A 
decrease in drug entrapment with increased drug loading was probably due to the more 
porous polymer matrix formed as a result of the dissolution of PCM from the surface 
regions of the NPs. Owing to the increased amount of drug loaded, a more porous 
matrix may be formed through which the drug can easily escape to the aqueous phase, 
thereby decreasing the content of PCM encapsulated (Witschi & Doelker, 1998). 
Niwa et al. (1993) also observed decreased drug entrapment at high drug loadings due 
to enhanced drug leakage into the aqueous phase.  
 
Table 6.2 shows the effect of Qaq/Qor and the type of carrier on the particle size and 
drug loading. Some initial research has been done to determine the particle size in 
THF of organo-modified non-intercalated MMT and dissolved PLA/MMT composite 
films. The size of intercalated/exfoliated MMT particles prepared by dissolving 
PLA/MMT films in THF at 1 g L-1 was (41 ± 6.1), (39 ± 4.0), and (78 ± 8.4) nm for 
the composite films containing respectively 2, 5, and 20 wt% of MMT. The particle 
size of pure MMT in THF was (426 ± 21.2) nm at 0.25 g L-1. After 
intercalation/exfoliation, MMT platelets are partially or fully separated from each 
other and therefore, the size of polymer-intercalated MMT particles is smaller than 
the size of non-intercalated/agglomerated particles. This observation proves that PLA 
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was successfully intercalated into MMT and that PLA/MMT composite films were 
more suitable as drug carriers than a mechanical mixture of MMT and PLA powders. 
In all cases, the size of MMT NPs in the organic phase was significantly lower than 
the orifice diameter (200 m). 
 
The size of PLA/MMT NPs increased on increasing the content of MMT in the 
polymer matrix from 2 to 20 wt% and was larger than the size of pure PLA NPs (Table 
6.2). The size of NPs decreased as the flow rate ratio increased, which was more 
pronounced for composite NPs. A higher flow rate ratio provides more rapid mixing 
due to higher flow rate in the collection capillary (British Standards Institution, 1997; 
Zheng et al., 2009). When fluids are mixed more rapidly, the critical degree of 
supersaturation needed for nucleation is reached faster, which leads to the generation 
of more nuclei per unit time. Since the growth of nuclei is limited by the amount of 
available polymer in the liquid phase, it results in smaller NPs. In addition, at higher 
oraq QQ /  values, the NPs are more diluted after formation, which suppresses the rate 
of particle growth and agglomeration, due to the lower frequency at which the NPs 
collide with each other. Smaller NPs at higher oraq QQ /  values have also been reported 
in membrane contactors (Laouini et al., 2013a; Laouini et al., 2013b; Laouini et al., 
2013c) and flow focusing microfluidic devices (Jahn et al., 2010).  
 
Table 6.2 also includes the drug encapsulation efficiency and drug loading at a PCM 
concentration in the organic phase of 20 wt% for various Qaq/Qor values and two 
different drug-carriers, pure PLA and PLA/2 wt% MMT. The drug encapsulation 
efficiency and drug loading in the NPs increased with increasing Qaq/Qor, probably 
due to faster nucleation and faster inclusion of drug molecules within the polymer 
matrix. The incorporation of MMT into the polymer matrix improved both the drug 
entrapment efficiency and drug loading. This was due to reduced porosity of the 
composite polymer matrix compared with that of the pure polymer (Ekanem et al., 
2015; Batra et al., 2011), adsorption of PCM onto the nanoclay particles and an 
increased diffusion path length of PCM molecules within the polymer. 
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Table 6.1: The effect of paracetamol-to-excipient mass ratio in the organic phase and 
the type of excipient on the average particle size, drug encapsulation efficiency and 
drug loading of the prepared NPs at Qaq/Qor = 10.   
PCM/excipient mass 
ratio in organic phase 
Type of excipient  
PLA PLA/ 2% MMT PLA 
Average size of NPs, Zave (nm) E.E. (%) D.L. (%) 
0.20 285 ± 13.4 296 ±10.4 35.2 5.9 
0.45 320 ± 19.4 357 ± 11.0 32.8 10.2 
0.70 398 ± 12.6 428 ± 29.4 26.6 10.9 
*Note: Each analysis was repeated three times (n = 3) and the average particle sizes were determined. 
The error bars are standard deviations. 
 
 
Table 6.2: The effect of Qaq/Qor and MMT content in the polymer matrix on the 
average particle size, drug encapsulation efficiency and drug loading.  
 PCM/excipient ratio = 0  
PCM/excipient mass ratio 
= 0.2 
Excipient PLA 
PLA/ 
2% 
MMT 
PLA/ 
5% 
MMT 
PLA/ 20% 
MMT 
PLA 
PLA/ 2% 
MMT 
Qaq/Qor Average size of blank NPs, Zave (nm) 
E.E. 
(%) 
D.L. 
(%) 
E.E. 
(%) 
D.L. 
(%) 
1.5 270 ± 34 431 ± 7 434 ± 54 666 ± 65 27.6 4.6 29.4 4.9 
3.0 276 ± 21 383 ± 11 441 ± 37 629 ± 64 27.2 4.5 31.1 5.2 
4.5 237 ± 2 379 ± 5 393 ± 36 604 ± 88 32.5 5.4 34.3 5.7 
7.0 316 ± 7 327 ± 4 348 ± 11 575 ± 62 30.7 5.1 34.7 5.8 
10.0 265 ± 24 296 ± 10 308 ± 14 512 ± 10 35.2 5.9 38.5 6.4 
*Note: Each analysis was repeated three times (n = 3) and the average particle sizes were determined. 
The error bars are standard deviations. 
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6.3.2 Characterisation of the NPs  
6.3.2.1 TEM and elemental analysis of the NPs 
Fig. 6.2 shows the transmission electron micrographs of the NPs containing different 
concentrations of MMT in the polymer matrix. Only PLA and PLA/ 2wt% MMT NPs 
were found to have a spherical shape with a smooth surface. Clay platelets are visible 
in all NPs containing 2 wt% MMT, but the clay is incorporated entirely in the interior 
of the NP.  
 
Due to the 2D structure of MMT platelets and their very low thickness compared with 
the diameter of a composite nanoparticle (individual platelet thicknesses are just 1 nm 
and the particle diameter was at least 300 nm), although 80% of the particle cross 
section was occupied by the MMT platelets, it was found that the volume of MMT 
was very low compared with the total particle volume. As a result of higher loading 
of MMT in the polymer matrix, the shape of NPs containing 5 and 20 wt% of MMT 
in the polymer matrix is distorted and significantly deviates from a spherical shape. 
The last two figures in Fig. 6.2 show TEM images of drug-loaded NPs prepared with 
the drug-to-excipient mass ratio in the organic phase of 1:5. Drug-loaded PLA NPs 
are spherical and exhibit a smooth surface and homogeneous interior indicating that 
the drug nanocrystals are finely and uniformly dispersed within the polymer matrix. 
Drug-loaded NPs containing 2 wt% MMT in the matrix are not perfectly spherical, 
due to inclusion of both MMT platelets and PCM nanocrystals in the polymer matrix. 
The polydispersity index of the NPs in all samples was less than 0.25.  
 
The TEM images in Fig. 6.2 indicate that the nanoclay was successfully incorporated 
in the host polymer. Additional evidence came from the elemental analysis of the NPs 
(Table 6.3). The octahedral sheet of MMT has Al as the central atom (partly 
substituted by Mg and Fe) and the tetrahedral sheets have Si as the central atom. That 
is why Al, Mg, Fe and Si were all detected in MMT/PLA NPs but not in PLA NPs. A 
disproportionately high content of carbon and copper in all samples was due to 
carbon-coated copper grids used to hold the samples for EDS analysis. The 
significantly higher amount of carbon in drug-loaded NPs compared with blank PLA 
CHAPTER 6  
                                                                                                                                 161
 
 
Rahimah Othman  2016 
 
and PLA/MMT NPs was due to the higher mass fraction of C in paracetamol 
(C8H9NO2) compared with that in PLA, (C3H4O2)n. 
 
 
Fig. 6.2: TEM images of multi-functionalised NPs composed of different ratio of 
MMT and drug-loaded NPs prepared using the drug-to-excipient mass ratio in the 
organic phase of 0.2 at various magnifications. 
 
Table 6.3: Elemental composition of different samples of the prepared NPs obtained 
using EDS.  
Chemical 
element 
(wt%) 
PLA 
PLA+2 
w% 
MMT 
PLA+5w% 
MMT 
PLA+20w% 
MMT 
PCM-
loaded 
PLA 
PCM-
loaded 
PLA + 2 
w% MMT 
C 85.9 70.0 21.5 24.1 95.0 91.1 
O 2.59 12.0 37.1 33.6 2.34 0.17 
Mg 0.00 0.29 1.83 0.69 0.00 0.03 
Al 0.00 1.62 9.72 12.1 0.00 0.81 
Si 0.00 4.22 16.8 16.8 0.00 2.20 
K 0.00 0.20 4.62 2.10 0.00 0.02 
Fe 0.00 2.67 2.61 2.39 0.00 0.15 
Cu 11.5 8.04 5.76 8.15 2.69 5.49 
*Note: Each analysis was repeated three times (n = 3) and the average values were determined. The 
error bars are standard deviations. 
100 nm
PCM-loaded PLA 
+ 2 w% MMTPCM-loaded PLAPLA/ 20wt% MMT
200 nm
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500 nm
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6.3.2.2 XRD analysis 
The crystallinity of the fabricated NPs was investigated by XRD, as shown in Fig. 
6.3a. The crystalline drug (PCM) shows sharp peaks at 13.6o, 16.4o, 23.2o, 23.8o, 
26.2o, 26.9o and 30.8o, which are in good agreement with the reported values 
(Khanmohammadi, et al., 2010). The degree of crystallinity of PCM was very high 
(90.2 %), but less than 100 % because inevitably some amorphous content is generated 
during the processes of milling, wet granulation, drying, re-crystallisation and 
compaction. The diffraction pattern of pure PLA powder includes only a broad ‘hump’ 
at 14.8o, due to the amorphous nature of poly(ᴅ,ʟ-lactide). MMT shows a 
characteristic diffraction peak at 2θ of 6.4° corresponding to the 001 plane with a ‘d’ 
spacing of 1.36 nm (Datta, 2013). This peak cannot be seen because the 2θ axis starts 
at 10o, but two minor peaks at 19.5o and 36o are visible and they agree with previous 
results (Ekanem et al., 2015). The diffraction pattern of the PLA/MMT composite 
film shows a wide ‘hump’ between 2θ values of 10° and 25° and the degree of 
crystallinity of 69.6 % is lower than that of pure MMT (76.4 %). As a result of 
intercalation of PLA in the interlayer spacing, there is an increase in ‘d’ spacing. The 
physical mixture of PCM and PLA exhibits two characteristic sharp peaks of PCM at 
13.6o and 23.2o, but also a broad hump due to the contribution from PLA. However, 
PCM peaks disappear in the diffraction pattern of PCM-loaded PLA NPs, indicating 
that PCM was completely incorporated inside the polymer matrix. On the other hand, 
PCM-loaded PLA/MMT NPs produce a series of small peaks, which reveal the 
presence of crystalline MMT platelets protruding from the surface of the NPs.  
6.3.2.3 DSC analysis 
Fig. 6.3 (b) shows the thermograms of the prepared NPs, raw materials and physical 
mixtures of the drug and the polymer. The samples were heated above the melting 
points (Tm) of PCM. Pure PCM powder exhibited a large endothermic peak of melting 
with a maximum at 170oC and a shallow, broad endothermic peak at 60 oC 
corresponding to the glass transition temperature (Tg) of poly(ᴅ,ʟ-lactide). No peak 
was observed in the thermogram of pure MMT due to its high thermal stability. Two 
endothermic peaks corresponding to the Tm of PCM and the Tg of PLA were detected 
in the physical mixtures of PLA and PCM, and PLA/MMT and PCM, respectively. 
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The peaks of PCM-loaded PLA and PLA/MMT NPs were shifted to lower 
temperatures (160 oC) indicating that PCM entrapped in the NPs was in an 
amorphous or disordered-crystalline phase. Moreover, the appearance of a single peak 
for the loaded NPs indicates that PCM was uniformly distributed in the NPs.   
6.3.2.4 TGA 
TGA was performed to determine the thermal stability of the prepared NPs. The TGA 
curve of MMT (Fig. 6.4 (a)) shows two inflection points, at 270 oC due to free water 
evaporation and at 370 oC due to the release of structural (hydroxyl) water (Joshi et 
al., 2009; Joshi et al., 2009) with 22% weight loss recorded at 600 oC. For pure PLA 
powder, 10 % degradation occurred at 319 oC, which signifies the onset of 
degradation. The midpoint was at 346 oC and the powder was totally decomposed to 
CO2 and H2O at 370 
oC. PLA/MMT composite film with 2 wt% MMT was more 
thermally stable than pure PLA powder and the amount of non-volatile residue at 600 
oC was 3 %. The TGA curve for PCM showed a steep decrease between 230 and 300 
oC with 99 % mass loss recorded at 600 oC. PLA NPs were less thermally stable than 
pure PLA powder due to their lower degree of crystallinity, as a result of fast polymer 
precipitation. It has been found that fast removal of polymer-dissolving organic 
solvent inhibits crystallisation of the polymer, because the polymer chains have less 
time to pack together in an organized manner (Izumikawa, et al., 1991). The PCM-
loaded PLA NPs started to degrade at lower temperature than the blank PLA NPs due 
to the presence of PCM in the polymer matrix, which is another indicator of PCM 
encapsulation. PCM-loaded PLA/MMT NPs were fully degraded only at 370 oC and 
were more stable than the blank PLA and PCM-loaded PLA NPs, whose complete 
degradation occurred at 260 and 270 oC, respectively. The amount of non-volatile 
residue in PCM-loaded PLA/MMT NPs was 2 wt%, which corresponds to the amount 
of MMT in the composite film, indicating that MMT was efficiently entrapped in the 
NPs.  
6.3.2.5 ATR-FTIR spectroscopy 
The FTIR spectra of the prepared NPs and raw materials are shown in Fig. 6.4 (b). 
The IR peak of pure PLA at 1760 cm-1 was due to the stretching vibration of the C=O 
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bonds along the PLA chain and this peak had the same position in all samples 
containing PLA. The FTIR spectrum of MMT showed an absorption band at 3600 cm-
1 due to the stretching vibration of the O-H bond in Al−OH and Si−OH. The two bands 
that appear at 2930 and 2850 cm-1 can be attributed to the asymmetric and symmetric 
stretching of the methylene groups (-CH2-) in the quaternary ammonium compound 
used to modify MMT. The band at 1465 cm-1 corresponds to the bending vibration of 
the methylene groups of the quaternary ammonium compound. The most intense band 
in the FTIR spectrum of MMT occurred near 1000 cm-1 can be attributed to the 
stretching vibrations of the Si-O groups in tetrahedral sheets. The bands at 915, 875 
and 836 cm-1 were attributed to Al-Al-OH, Al-Fe-OH and Al-Mg-OH bending 
vibrations, respectively (Patel et al., 2007) and the band near 500 cm-1 may result from 
the stretching of the Al-O bonds.  
 
No peak shifts or new peaks appeared in the spectra of the blank PLA NPs compared 
with PLA powder, which means that FTIR could not reveal any change in the 
molecular structure of PLA as a result of dissolution and nanoprecipitation, as 
opposed to XRD and TGA analysis. New peaks between 670 and 400 cm-1 detected 
in the spectra of PLA/MMT composite film and PCM-loaded PLA/MMT NPs, as 
compared with the spectrum of PLA powder, were caused by Al−O and Si−O bonds 
in MMT and verify the inclusion of MMT in PLA. The characteristic absorption peaks 
due to carbon−carbon stretching vibrations in the aromatic ring of PCM were visible 
in the region between 1265 and 1660 cm-1 for all PCM-loaded NPs. This indicates 
that PCM was encapsulated within the NPs, but has not strongly interacted with PLA 
and MMT since no peak shifts occurred (Zheng et al., 2007).  
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Fig. 6.3: (a) X-ray diffractograms and (b) DSC thermograms of; (1) pure PCM; (2) 
pure PLA; (3) physical mixture of PCM and PLA; (4) PCM-loaded PLA NPs; (5) 
physical mixture of PCM and PLA/MMT; (6) PLA/MMT composite film; (7) pure 
MMT and (8) PCM-loaded PLA/MMT NPs. 
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Fig. 6.4: (a) TGA curves and (b) FTIR spectrums of: (1) pure MMT; (2) pure PCM; 
(3) pure PLA; (4) PLA/MMT composite film; (5) blank PLA NPs; (6) PCM-loaded 
PLA NPs; (7) PCM-loaded PLA/MMT NPs. 
6.3.3 In vitro release of PCM from nanoparticles 
The amount of PCM released from plain PLA and hybrid PLA/MMT NPs was 
measured over 190 h by recording the absorbance at 243 nm (Fig. 6.5). Zero-time 
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corresponds to the start of the incubation period, but the amount of PCM plotted in 
Fig. 6.5 excludes the amount of drug released during the nanoprecipitation process. 
For the conditions in Fig. 6.5, the total amount of drug released during the processes 
of fabrication and storage ranged between 84 and 90 %. A fast drug release was 
observed over the first 9 h which can be attributed to relatively high solubility of PCM 
in water. It was followed by a very slow release over a long period of time due to 
diffusion of the drug from the PLA cores into the dissolution media. The rate of drug 
release from nanoclay-loaded NPs was reduced compared to plain PLA NPs due to 
the more compact polymer matrix (Batra et al., 2011), a physical adsorption of PCM 
onto MMT and a tortuous path of drug molecules due to obstacles imposed by non-
permeable clay particles randomly distributed in the polymer matrix (Fig. 6.1 (b)). 
Slightly faster PCM release rates were found for Milli-Q water, probably due to higher 
solubility of PCM in pure water compared with PBS and different swelling properties 
of NPs in different solutions.  
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Fig. 6.5: In vitro release profile of paracetamol (PCM) from: (a) PLA NPs in Milli-Q 
water; (b) PLA NPs in phosphate-buffered saline (pH 7.4); (c) PLA/MMT NPs in 
Milli-Q water; (d) PLA/MMT NPs in phosphate-buffered saline (pH 7.4). The error 
bars represent the standard deviations of three repeated measurements (n = 3). 
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6.4 Conclusions 
In this study, antisolvent nanoprecipitation in a co-flow 3D glass capillary device was 
used to produce paracetamol-loaded PLA/MMT NPs composed of a biodegradable 
polymer matrix filled with organically modified MMT clay. The size of the 
intercalated/exfoliated MMT particles in the organic phase was 41−78 nm. The 
incorporation of nanoclay in the polymer matrix improved both the drug 
encapsulation efficiency and drug loading in the final formulation, and extended the 
rate of drug release into simulated intestinal fluid. The particle size increased on 
increasing the drug loading and the content of MMT in the polymer matrix, and 
decreased with increasing aqueous to organic flow rate ratio in the glass capillary 
device. In addition, the drug encapsulation efficiency and drug loading in the NPs 
increased with increasing aqueous to organic flow rate ratio, due to more rapid mixing 
and faster formation of the NPs.  
 
The 2 wt% PLA/MMT composite film was found to be the most suitable drug carrier 
due to the spherical shape of the fabricated NPs and almost complete inclusion of the 
nanoclay platelets inside the host polymer. The composite nanoclay-loaded NPs were 
significantly more thermally stable than the plain PLA NPs. The incorporation of 
MMT and PCM into PLA was confirmed by the new peaks detected in the FTIR 
spectra of the drug-loaded composite NPs in the regions between 670 and 400 cm-1 
(MMT), and 1265 and 1660 cm-1 (PCM). In future work, the production rate of the 
NPs will be improved using microengineered membranes with regular pore spacing 
that will be used instead of glass capillaries.  
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CHAPTER 7  
 
FORMATION OF SIZE-TUNEABLE BIODEGRADABLE 
POLYMERIC NANOPARTICLES BY SOLVENT 
DISPLACEMENT METHOD USING MICRO-ENGINEERED 
MEMBRANES FABRICATED BY LASER DRILLING AND 
ELECTROFORMING  
This chapter was published in Chemical Engineering Journal 
Chapter overview 
Biodegradable poly(ε-caprolactone) (PCL) drug-carrier nanoparticles (NPs) were 
produced by rapid membrane micromixing combined with nanoprecipitation in a 
stirred cell employing novel membrane dispersion. The organic phase composed of 
0.1−0.6 wt% PCL dissolved in tetrahydrofuran was injected into the aqueous phase 
(Mili-Q water or 0.2−1 wt% poly(vinyl alcohol) using two microfabricated 
membranes with different pore morphologies and spatial pore arrangements: ringed 
stainless steel membrane of reduced (annular) operating area with a square array of 
cylindrical laser-drilled pores and electroformed nickel membrane of full operating 
area with a hexagonal array of conical, funnel-shaped pores. The size of the NPs was 
precisely controlled over a range of 159−394 nm by changing the aqueous-to-organic 
volumetric ratio, stirring rate, transmembrane flux, the polymer content in the organic 
phase, membrane type and pore size. The smallest and most uniform particles with a 
Z-average of 159 nm and a polydispersity index of 0.107 ± 0.014 were obtained using 
a 10 lmpore-sized stainless steel membrane at the transmembrane flux of 140 L m−2 
h−1, a stirring rate of 1300 rpm, and an aqueous-to-organic phase volume ratio of 10 
using 1 g L−1 PCL in the organic phase. The existence of the peak shear stress within 
a transitional radius and a rapid decline of the shear stress away from the membrane 
surface were revealed by numerical modelling. 
7.1 Introduction 
Biocompatible functional nanoparticles (NPs) for drug delivery have attracted 
growing interest in the past several decades (Chaubal, 2004; Zhang et al., 2006; 
Barratt, 2000). These NPs should be able to preserve the drug from leakage while it 
is transported to a desired therapeutic site, so that the drug will not interact with non-
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targeted cells or tissues and cause side effects, and they should be degraded or 
eliminated from the body after the drug has been released (Ghosh, 2000; De Jong & 
Borm, 2008). Polymeric NPs have been extensively studied as drug nanocarriers 
(Moinard-Checot et al., 2006; Quintanar-Guerrero et al., 1998; Legrand et al., 2007; 
Letchford & Burt, 2007). Synthetic aliphatic polyesters, such as poly-ε-caprolactone 
(PCL) and polylactide (PLA), are highly suitable polymers for these applications due 
to their good mechanical properties, biodegradability, nontoxicity (Sinha et al. 2004), 
and good compatibility with other polymers and inorganic nanofillers (Othman et al., 
2016). PCL and PLA have been approved by the U.S. Food and Drug Administration 
(FDA) for use as drug carriers. The PCL biodegradation product, 6-hydroxycaproic 
acid, can be completely metabolised via the citric acid cycle, but the rate of 
degradation is very slow, which makes PCL ideally suited for long-term drug delivery.  
 
Polymeric drug-loaded NPs can be fabricated using different methods (Nagavarma et 
al.,  2012; Reis et al., 2006; Rao & Geckeler, 2011), including: (i) dispersion of 
preformed polymers (nanoprecipitation, emulsification-solvent 
evaporation/extraction/diffusion, salting-out, dialysis, spray drying, and supercritical 
fluid technology), (ii) polymerization of monomers, (iii) associative interactions 
among charged hydrophilic polymers (ionotropic gelation and complex coacervation), 
and (iv) particle replication in non-wetting templates (PRINT) (Rolland et al., 2005). 
Emulsification-solvent removal methods are associated with high energy 
consumption and the use of surfactants and toxic organic solvents. Nanoprecipitation 
is less energy demanding method that does not require surfactants and usually 
involves less toxic (Class 2 and Class 3) organic solvents. The process is based on the 
interfacial deposition due to the displacement of the polymer solvent by a non-solvent 
which is miscible with the polymer solvent (Fessi et al., 1989).  
 
Membrane and microfluidic micromixing combined with nanoprecipitation have 
opened up new possibilities to prepare size-controlled NPs (Jia & Liu, 2013; Chen et 
al.,  2004; Charcosset & Fessi, 2005; Pham et al., 2012; Jaafar-Maalej et al., 2011). 
Microfabricated membranes consisting of regular arrays of equally spaced pores 
manufactured by electroforming (Kosvintsev et al., 2005), percussion laser drilling 
(Vladisavljević & Williams, 2006) and etching (Kobayashi et al., 2005) have been 
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increasingly used for the preparation of emulsions (Nazir et al., 2011), microparticles 
(Imbrogno et al., 2015), and NPs (Laouini et al., 2013). They enable uniform liquid 
dispersion in micromixing processes, due to ordered pore arrays and uniform pore 
size, high flux through the membrane, and suppression of internal pore fouling due to 
thin and non-tortuous pores. Microfabricated pore arrays are similar to massively 
parallel T junctions, through which one fluid may be introduced into another at an 
overall much higher flow rate than is possible in individual channels (Vladisavljević 
et al., 2012). The mixing rate can be enhanced by providing a controlled shear at the 
membrane surface using cross flow (Laouini et al., 2011), stirring (Kosvintsev et al., 
2005), flow pulsations (Holdich et al., 2013), radially or axially oscillating membrane 
tubes (Silva et al., 2015; Holdich et al., 2010), and rotating membrane (Vladisavljević 
& Williams, 2006). However, the role of different pore arrangements, pore shapes and 
fabrication methods on the performance of microfabricated membrane in 
micromixing process has not yet been systematically investigated. 
 
In this study, membrane micromixing/nanoprecipitation process has been investigated 
using two microfabricated membranes (stainless steel membrane with laser drilled 
pores and electroformed nickel membrane) with different pore patterns (square and 
hexagonal), pore shapes (conical and cylindrical) and operating areas (reduced ringed 
area and full circular area). 
 
The main objectives were to evaluate the effect of pore morphology and operating 
parameters on the particle size distribution of PCL nanoparticles and to investigate 
velocity and shear profiles in the vicinity of the membrane surface using 
computational fluid dynamics (CFD). The mathematical model was solved using a 
commercial software package CFD package ANSYS FLUENT 14.5 in dimensional 
form. 
7.2 Materials and methods  
7.2.1 Chemicals 
Tetrahydrofuran (THF, HPLC grade, purity ≥ 99.9 %), poly(-caprolactone) (PCL, 
Mw = 14,000 g mol
−1 with a glass transition temperature of 60 oC) and polyvinyl 
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alcohol (PVA, Mw = 13,000 − 23,000 g mol−1, 87 − 89 % hydrolysed) were purchased 
from Sigma-Aldrich (Dorset, UK). PLA was used as a water soluble stabiliser to 
prevent agglomeration and imperfect surface formation of the NPs and THF was used 
as a solvent for PCL. The anti-solvent phase was pure water produced by reverse 
osmosis (Mili-Q®, Millipore) or 0.2 − 1 wt% aqueous solution of PVA. All chemicals 
other than THF were of analytical grade. 
7.2.2 Membrane dispersion cell 
The NPs were prepared using a flat, disc-shaped membrane installed in a stirred cell 
shown in Fig. 7 ((a) – (b)). The cell and membranes were supplied by Micropore 
Technologies Ltd (Redcar, UK). The stirrer was driven by a 24 V DC motor (Instek 
model PR-3060) and its rotation speed was controlled between 200 and 1300 rpm by 
the applied voltage. A nickel (Ni) membrane with an effective diameter of 3.3 cm and 
an operating area, Am, of 8.55 cm
2 had 24,690 hexagonally arranged pores with a 
diameter of 10, 20, and 40 m, spaced apart at a constant distance of 200 m (Fig. 7 
(d) and S2 (a–c)). A ringed stainless steel (SS) membrane had the same dimensions 
and a reduced operating (active) area of 2.76 cm2 occupying space on the membrane 
surface between two concentric circles of radius r1 = 9 mm and r2 = 13mm (Fig. S1 
(b)). SS membrane contained ~6912 pores with a diameter of 10 lm arranged in a 
square array with a pitch of 200 m (Fig. 7 (e)). The number of pores was estimated 
from Eqs. (S1) and (S2) given in the supplement. 
7.2.3 Experimental set-up and preparation of polymeric NPs 
The cell was filled with 30–60 mL of mili-Q water or aqueous PVA solution and the 
stirring rate was adjusted to achieve the peak shear stress at the membrane surface 
between 0.7 and 14 Pa. The organic phase was 0.1–0.6 wt% PCL in THF and was 
injected through the membrane using a Cole-Parmer model 230 VAC syringe pump. 
The organic phase flow rate ( Q ) through the nickel membrane was 2–5 mL min−1 and 
thus, the transmembrane flux ( mA/Q ) was 140–351 L m
−2 h−1. To achieve the same 
flux through the ringed membrane, the organic phase flow rate was reduced to 0.64–
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1.6 mL min−1, calculated from the equation:  QA/AQ mRR  , where RA  and mA are 
the operating areas of the ringed and whole membrane, respectively. 
 
The experiments were run until a predetermined aqueous-to-organic phase volumetric 
ratio was achieved. For the whole membrane, the operating time ranged from 2.6 min 
at the minimum flux to 6.5 min at the maximum transmembrane flux. For the ringed 
membrane, the operating times were 3.1 times longer than those for the whole 
membrane and ranged between 8.1 and 20.3 min. The aqueous phase turned cloudy 
as soon as the organic phase was brought in contact with the aqueous phase due to 
rapid exchange of two solvents at the interface, i.e. THF diffused from the organic to 
the aqueous phase and water diffused in the opposite direction (Fig. 7.1 (c)). THF was 
evaporated from the suspension in a vacuum oven at ambient temperature under a 
pressure of less than 10 Torr (Fistreem International Ltd, Loughborough, UK) until 
the smell of THF had disappeared (30 min). Each experiment was repeated at least 
three times. 
 
After each experiment, the membrane was rinsed with Mili-Q water and then 
sonicated in THF for 30 min using a Fisher Scientific ultrasonic bath (model FB 
15046) in order to remove any NPs leftovers from the membrane surface. The 
membrane was then rinsed again with Milli-Q water and finally washed with Milli-Q 
water in an ultrasonic bath for 5 min to restore its hydrophilic properties. The contact 
angle between water and the surface of the Ni membrane was measured after each 
cleaning step using a Krüss Model DSA 100 Advanced Drop Shape Analyser 
(Hamburg, Germany) and was found to be 86o ± 2.2o before cleaning, 68o ± 1.4o after 
treatment with THF and 59o ± 1.1o at the end of the cleaning process. Therefore, the 
membrane surface became progressively more hydrophilic as the cleaning progressed. 
The membrane should be hydrophilic during experiments to minimise wetting of the 
membrane surface by the organic phase and pore clogging by the deposited 
hydrophobic polymer. 
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Fig. 7.1: (a) A schematic diagram of the membrane dispersion cell with a paddle 
stirrer fitted above a micro-engineered membrane; (b) Formation of NPs by rapid 
solvent displacement above the membrane surface (yellow colour = solvent); (c) 
Optical micrograph of a 10 μm pore-sized nickel membrane; (d) Optical micrograph 
of a 10 μm pore-sized stainless steel membrane. 
7.2.4 Characterisation of the prepared NPs 
7.2.4.1 Particle size analysis 
The particle size distribution was measured using a DelsaTM Nano HC Particle 
Analyser (Beckman Coulter, High Wycombe, UK) by dynamic light scattering (DLS) 
method, which measures the fluctuations in scattered light intensity as a function of 
time (Submicron, 2011). Smaller particles move faster than larger particles and 
therefore, the timescale of intensity fluctuations is shorter for smaller particles. A 
THF-free nanosuspension sample was transferred into a 4 mL disposable cuvette 
which was then placed into the instrument. The measurement time was 120 s. Each 
samples were analysed by following the standard procedures described in Section 
2.6.1.1. 
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7.2.4.2 Zeta potential determination  
The zeta potential of the NPs was measured using a Malvern Instruments Zetasizer 
3000 HAS particle size analyser. The measurements were repeated at least three times 
after sample dilution in water. The zeta potential was calculated from the 
electrophoretic mobility using the Helmholtz-Smoluchowski equation (Hunter et al., 
2001).  
7.2.4.3 Microscopic observations (TEM, FEG-SEM and Benchtop SEM) 
2-D micrographs of the prepared NPs were acquired using Transmission Electron 
Microscopy (TEM) and high resolution Field Emission Gun Scanning Electron 
Microscopy (FEG-SEM). Each samples were analysed by following the standard 
procedures described in Section 4.2.4.3. 
 
3D micrographs of cross-section of the micro-engineered membranes were obtained 
using a Hitachi model TM3030 benchtop SEM fitted with an Oxford Instruments 
Swift ED3000 Silicon drift detector (SDD) operated at 5−15 kV voltage. A stage 
movement was controlled by a high resolution stepper motor with a 10 nm step size 
and a repositioning accuracy of 1 μm. The NPs were sputtered with gold to become 
electrically conductive and placed on a copper stub prior to the SEM imaging.  
7.3 Computational modeling 
The computational domain model geometry used to simulate fluid flow is shown in 
the supplementary material (Figure S2). A 3D simulation model is developed using 
the CFD package ANSYS FLUENT 14.5, constructed using ANSYS Design 
Modeller. Meshing pre- processor was used for the generation of the computational 
mesh. Considering the geometrical constraints, the fluid domain was meshed with 
tetrahedral cells while for the solid body (blades) hexahedral meshing scheme was 
used. The entire flow domain was then meshed using approximately one million cells. 
This was achieved by investigating the optimum number of cells that provide 
computational results which are independent of the number of cells and distribution 
of the computational grid. Hence, a grid independency test was performed. The 
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governing equations used for modelling are provided in the supplementary material 
(see S3.1). 
7.4 Results and discussion 
7.4.1 Effect of the aqueous-to-organic phase volumetric ratio  
In this series of experiments, 6 mL of the organic solution composed of 1 g L-1 of PCL 
in THF was injected at constant flux of 140 L m-2 h-1 through a 20-μm Ni membrane 
into 9, 18, 27, 42, and 60 mL of water to achieve an aqueous-to-organic phase 
volumetric ratio of 1.5, 3.0, 4.5, 7.0 and 10.0, respectively. The Z-average decreased 
with an increase in oraq V/V  (Fig. 7.2), which can be explained by the fact that the size 
of a NP formed during solvent displacement is a result of the relative rates of 
nucleation, particle growth, and agglomeration. The promotion of particle growth 
over nucleation leads to fewer and larger particles. The rate of particle growth is: 
 
g*
PCLPCLg )CC(KG                                                                                            (7.1) 
 
where gK  is the growth constant, PCLC  and 
*
PCLC  are the local concentration and 
solubility of PCL in the solvent mixture, respectively, and g is typically between 1 
and 2 for organic systems (Zhao et al., 2007). The rate of nucleation is given by: 
b*
PCLPCLb )CC(KB  , where bK  is the nucleation constant, and the index b lies 
between 5 and 10. Since b » g, lower supersaturations, 
*
PCLPCL CC  , promote particle 
growth over nucleation, leading to fewer and larger particles, whereas higher 
supersaturations promote nucleation, resulting in a larger population of smaller 
particles. The organic phase was initially brought in contact with pure water and the 
rate of solvent exchange was very high. However, since THF gradually accumulates 
in the aqueous phase, the rate of solvent exchange decreases leading to lower 
supersaturations. The THF concentration in the aqueous phase at any time was higher 
for smaller oraq V/V  values, resulting in lower supersaturations and the formation of 
larger NPs under these conditions. In addition, at higher THF concentrations in the 
aqueous phase, the rate of Ostwald ripening was higher due to greater solubility of 
PCL, which may also play a role in the formation of larger NPs at smaller oraq V/V  
CHAPTER 7  
                                                                                                                                 177
 
 
Rahimah Othman  2016 
 
ratios (Seo et al., 2015). Agglomeration is another important factor in 
nanoprecipitation. Agglomerates form when growing NPs collide with each other and 
fuse together to form larger particles. Agglomeration is more pronounced at smaller 
oraq V/V  values, because the collision frequency of particles is proportional to the 
second power of their number density.  
 
Fig. 7.3 shows particle size distribution of the samples prepared at different aqueous-
to-organic ratios and rotation speeds. Smaller and more uniform NPs were formed at 
higher aqueous-to-organic volumetric ratios. The same behaviour in membrane 
micromixing was observed by Du et al. (2011) in the preparation of SiO2 NPs, Huang 
et al. (2013) in the preparation of ZnO NPs and Laouini et al. (2013a; 2013b; 2013c) 
in the production of liposomes and polymeric micelles. The same trend was obtained 
when NPs were fabricated in microfluidic devices (Othman et al., 2016; 2015a; 
2015b). 
7.4.2 Effect of agitation speed of aqueous phase 
As shown in Fig. 7.2, an increase in the agitation speed from 200 to 1300 rpm caused 
a decrease in the Z-average, which can be attributed to the higher rate of solvent 
displacement, and hence higher supersaturation that can be achieved. Higher rotation 
speeds also helped to reduce agglomeration of freshly formed sticky particles near the 
membrane surface by providing higher mass transfer rates away from the membrane 
surface. The smallest Z-average (196 ± 5 nm) and PDI (0.128 ± 0.012) values were 
obtained at the highest rotation speed of 1,300 rpm and oraq V/V  = 10. On the other 
hand, the broadest particle size distribution with a PDI of 0.269 ± 0.023 and the largest 
Z-average value were obtained at the lowest agitation speed of 200 rpm and oraq V/V  
=  1.5. 
7.4.3 Effect of transmembrane flux  
Fig. 7.4 shows the effect of flux on the particle size distribution, Z-average, and PDI 
at an agitation speed of 1300 rpm, an aqueous-to-organic phase volumetric ratio of 
10, and a PCL concentration in the organic phase of 1 g L−1. With an increase in flux 
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from 140 to 351 L m−2 h−1, a significant broadening of the particle size distribution 
was observed with PDI rising from 0.128 to 0.164. The increase in the organic phase 
flow rate leads to an increase in the rate of PCL mass transfer to the aqueous phase, 
which is given by: oroQC , where oC  is the PCL concentration in the organic phase 
and orQ  is the organic phase flow rate. The higher the PCL influx into the aqueous 
phase, the higher the concentration of particles near the membrane surface after 
polymer precipitation and hence, the higher the likelihood of the particle aggregation, 
which explains a broader particle size distribution at higher flux. On the other hand, 
the higher influx of PCL into the aqueous phase led to higher supersaturation, which 
is why the Z-average remained constant in the investigated range of transmembrane 
flux. Similar trends were observed for other NPs formed in membrane contactors 
(Laouini et al. 2011; Laouini et al., 2013a; Khayata et al., 2012; Sheibat-Othman et 
al., 2008).  
 
 
Fig. 7.2: The average particle size, aveZ  of PCL NPs produced at different aqueous-
to-organic phase volumetric ratios and different agitation speeds using a 20-μm Ni 
membrane. The PCL concentration in the organic phase is 1 g L-1 and the 
transmembrane flux is 140 L m-2 h-1. 
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7.4.4 Effect of polymer concentration  
The effect of PCL concentration in the organic phase on the Zaverage and PDI at a 
rotation speed of 1300 rpm and a flux of 140 L m−2 h−1 is presented in Table 7.1. NPs 
with the largest Zaverage (347 ± 11 nm) and PDI (0.243 ± 0.023) values were obtained 
at 6 g L−1. As discussed above, the size of the NPs is dependent of the rate at which 
organic solvent diffuses into the aqueous phase and the rate at which the particle 
nuclei collide and fuse together. At higher polymer concentration in the organic phase, 
more nuclei per unit volume were formed and hence, particle aggregation was more 
pronounced. In addition, at higher PCL concentration the viscosity of the organic 
phase was higher which resulted in reduced diffusion rate of THF into the aqueous 
phase and reduced supersaturation. At low supersaturation, polymer nuclei grow 
faster than they nucleate resulting in larger NPs. Similar behaviour was observed by 
Khayata et al. (2012) and Jaafar-Maalej et al. (2011) who prepared PCL NPs and 
liposomes using SPG membrane. Laouini et al. (2011) have prepared liposomes in a 
hollow fibre membrane contactor and found an increase in the mean vesicle size from 
114 to 228 nm when the phospholipid concentration in the organic phase increased 
from 20 to 80 mg mL−1. 
7.4.5 Effect of membrane pore size 
The effect of the pore size of nickel membrane on the particle size at an agitation 
speed of 1300 rpm, an aqueous-to-organic volumetric ratio of 10, a flux of 140 L m−2 
h−1 and a polymer concentration in the organic phase of 1 g L−1 is shown in Table 7.1. 
In membrane emulsification, the mean droplet diameter, 
dd in dripping regime is 
proportional to the mean pore diameter, pd : pd dcd  , where c is the proportionality 
constant that can vary between 2 and 10 (Charcosset et al., 2004). In 
nanoprecipitation, the fundamental role of membrane is to provide good mixing of 
solvent with antisolvent: since nucleation is much faster than mixing, the generation 
of nuclei is governed by the rate of mixing step. Poor mixing results in low nucleation 
rates and a small population of large NPs, whereas good mixing results in high 
nucleation rates and a large population of small NPs. Smaller pores provide better 
mixing and thus smaller NPs, probably because the organic phase is split into thinner 
jets after passing through the membrane and the mixing time increases with the square 
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of diffusion distance. On the other hand, smaller pore sizes can enhance membrane 
wetting, clogging and fouling, which can compromise the process. In this work, the 
Z-average decreased from 234 to 196 nm on reducing the pore size from 40 to 20 m 
at oraq V/V  = 10, revealing that the particle size in this pore size range was affected 
by the width of the jets formed at the pore outlets. However, the NPs formed using a 
10 μm membrane were larger than those formed using a 20 μm membrane (Table 7.1), 
probably due to fouling that had occurred within the 10 μm pores. As can be seen 
from the SEM image of the membrane cross section in Fig. 7.7 (b), the pores of a 
nickel membrane have a conical shape and may be more prone to fouling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7.3: The volume-weighted particle size distribution of PCL NPs as a function of 
aqueous-to-organic phase volumetric ratio. The pore size of Ni membrane is 20 μm, 
the transmembrane flux is 140 L m-2 h-1 and the PCL concentration in the organic 
phase is 1 g L-1. 
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Fig. 7.4: The effect of transmembrane flux through a 20 μm nickel membrane on: (a) 
the volume-weighted particle size distribution, and (b) the Z-average and 
polydispersity index, PDI. The agitation speed was 1300 rpm, the aqueous-to-organic 
phase volume ratio was 10, the PCL concentration in the organic phase was 1gL-1.  
 
Table 7.1: The effect of the PCL concentration, the membrane pore size and the 
aqueous-to-organic volumetric ratio on the Z-average and polydispersity index, PDI. 
The agitation speed was 1,300 rpm and the transmembrane flux through a nickel 
membrane was 140 L m-2 h-1.  
PCL 
concentration 
(mg mL-1) 
Membrane 
pore size (μm) 
Volumetric 
ratio, Vaq/Vor 
aMean 
size, Zave 
(nm) 
aPolydispersity 
index, PDI 
1 20 10 196 ± 5 0.128 ± 0.01 
3 20 10 278 ± 7 0.221 ± 0.01 
6 20 10 347 ± 11 0.242 ± 0.02 
1 10 10 218 ± 13 0.160 ± 0.04 
1 10 7 234 ± 16 0.177 ± 0.05 
1 10 4.5 242 ± 9 0.198 ± 0.04 
1 10 3 277 ± 5 0.219 ± 0.01 
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1 10 1.5 331 ± 16 0.245 ± 0.04 
1 20 7 215 ± 5 0.144 ± 0.01 
1 20 4.5 225 ± 2 0.162 ± 0.01 
1 20 3 235 ± 3 0.174 ± 0.01 
1 20 1.5 274 ± 1 0.186 ± 0.01 
1 40 10 234 ± 20 0.218 ± 0.04 
1 40 7 254 ± 11 0.244 ± 0.02 
1 40 4.5 329 ± 8 0.270 ± 0.02 
1 40 3 382 ± 13 0.327 ± 0.03 
1 40 1.5 464 ± 11 0.389 ± 0.04 
a: Each value is a mean of three repeated measurements. The error bars are standard 
deviations. 
7.4.6 Effect of polyvinyl alcohol (PVA)  
NPs can be stabilised by adding an amphipathic compound to the non-solvent that 
adsorb at the interface and provide a steric barrier against particle growth and 
aggregation. In this work, amphipathic polymer PVA was added to the aqueous phase 
in the amount between 0.1 and 1.0 wt% and the NPs were prepared under optimum 
conditions specified in the caption to Fig. 7.5. The produced NPs were stored at 
ambient temperature over a period of 36 days to investigate the effect of PVA 
concentration on the long-term stability of the NPs. 
 
Partially hydrolysed PVA is a copolymer of poly(vinyl acetate) and poly (vinyl 
alcohol) with considerable block copolymer character (Sahoo et al., 2002). The 
hydrophobic vinyl acetate part is preferentially attached to a hydrophobic surface of 
PCL, leaving the more hydrophilic vinyl alcohol segments dangling in the aqueous 
phase. At relatively low PVA concentrations (CPVA  0.1 wt%), when surface 
coverage is much below the saturation, NPs were highly unstable due to bridging 
flocculation as a result of the tendency of PVA chains to adsorb onto the surface of 
two or more NPs simultaneously (Seo et al. 2015). As CPVA increased to 0.2 wt% and 
the surface of the NPs became covered by PVA to more than 50 % of the saturation 
coverage, steric stabilization dominated over bridging flocculation and the NPs were 
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stable throughout the investigated period (Fig. 7.5 (a)). The probability of forming 
flocs during bridging flocculation is proportional to θ(1−θ) (Kim et al., 2011), where 
θ = Γ/Γmax is the fraction of the NP surface coated with adsorbed flocculant. This 
function shows a maximum at θ = 50 %, which implies that bridging flocculation is 
the most dominant for the surface coverage of 50 %, but becomes increasingly less 
likely as the surface coverage approaches 100 %. 
 
However, with a further increase in CPVA above 0.2 wt%, nonadsorbed PVA 
molecules play an increasingly dominant role by introducing depletion attraction, 
which gives rise to a depletion flocculation. The magnitude of depletion attraction is 
proportional to the osmotic pressure in the aqueous phase, leading to increased particle 
instability between 0.2 and 1 wt% PVA (Fig. 7.5 (a)). Further increase in CPVA above 
1 wt% would stabilize the particles again, which is termed as depletion stabilization 
(Kim et al., 2015). However, high PVA concentrations in the aqueous phase lead to 
large particle size, due to high viscosity of the aqueous phase so the PVA 
concentrations above 1 wt% were not investigated in this work. The presence of PVA 
in the aqueous phase contributed to an increase in the Zaverage size at day 0, from 196 
± 5 nm (without PVA) to 202 ± 1 nm for 0.2 wt% PVA, 219 ± 8 nm for 0.4 wt% PVA, 
232 ± 4 nm for 0.6 wt % PVA, 252 ± 13 nm for 0.8 wt% PVA, and 313 ± 14 nm for 
1.0 wt% PVA. There are several reasons that may contribute to this effect, such as 
depletion flocculation, coating of the NPs by a PVA layer and increase of the viscosity 
of the aqueous phase. 
 
The effect of PVA concentration in the aqueous phase on the zeta-potential of PCL 
NPs during storage is shown in Fig. 7.5b. The negative charge of NPs was probably 
due to acidic nature of hydrogen atoms attached to alpha carbon atoms of residual 
acetate groups in the PVA chains, which remained after the manufacture of PVA by 
the hydrolysis of polyvinyl acetate (Wiśniewska, 2011). The zeta potential of the 
particles stabilized by 0.2 wt% PVA remained nearly unchanged within the storage 
period, revealing that the particle size was stable. The zeta potential has the highest 
negative value for 0.6–0.8 wt% PVA, but slightly decreased with time due to particle 
aggregation. It should be noted that PVA is a steric stabilizer, which means that low 
zeta potential values for 0.2 wt% PVA are not indication of poor particle stabilization. 
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Fig. 7.5: Effect of concentration of PVA in the aqueous phase on the storage stability 
of NPs at ambient temperature: (i) 0.2 wt% PVA, (ii) 0.4 wt% PVA, (iii) 0.6 wt% 
PVA, (iv) 0.8 wt% PVA and (v) 1.0 wt% PVA. The PCL NPs were prepared at a 
transmembrane flux of 140 L m-2 h-1, a stirring rate of 1300 rpm, and an aqueous-to-
organic phase volumetric ratio of 10 using a 20 μm pore-sized nickel membrane. The 
PCL concentration in the organic phase was 1 g L-1. 
7.4.7 Effect of pore shape and membrane fabrication process 
The effect of membrane type on the average particle size, Zave and particle size 
distribution is shown in Fig. 7.6. The smallest Z-average (159 ± 8 nm) and most 
uniform particles (PDI = 0.107 ± 0.014) were obtained using a ringed 10 μm-SS 
(a) 
(b) 
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membrane, followed by 20 μm-Ni membrane (
aveZ = 196 ± 5 nm, PDI = 0.128 ± 0.012) 
and 10 μm-Ni membrane (
aveZ = 218 ± 13 nm, PDI = 0.160 ± 0.019). Khayata et al. 
(2012) produced vitamin E loaded PCL NPs stabilized with 12.5% (w/v) Tween® 80 
using cross-flow SPG membrane with a pore size of 0.9 μm and obtained the smallest 
particle size of 165 nm and the smallest PDI of 0.18. Different particle sizes obtained 
using the same pore size but different membrane type can be attributed to different 
pore shapes arising from the different techniques used for membrane fabrication. 
 
Laser drilling of pores occurs through rapid melting and vaporisation of stainless steel 
due to absorption of energy from a focused laser beam. The melt is expelled from the 
hole once the gas pressure in a cavity overcomes surface tension forces. A re-
solidified material (dross) that cannot be fully ejected from the hole due to high 
viscosity of the molten material was formed at the pore exits (Fig. 7.7 (b) and Fig. S1 
(d) in the appendix). Formation of dross can be minimised by using shorter 
wavelengths and pulse duration of laser beam. However, dross deposits did not have 
any adverse effect on the membrane performance, since the surface of the membrane 
on the laser exit side was in contact with incoming organic phase. Although the exit 
diameter of the pores was smaller than the inlet diameter, the pores were not 
significantly tapered, and thus the organic phase was injected from the pores at 
relatively high exit velocity contributing to the high mixing efficiency. 
 
The main fabrication steps for Ni membrane are photolithography, nickel 
electroplating and membrane release. Photolithography starts with spin coating 
positive photoresist which is then irradiated with UV light through a mask that 
determines the geometry of the pores. The photoresist is then developed to remove 
the irradiated parts of the photoresist leaving cylindrical photoresist islands shown in 
Fig. S1 (d) in the supplement. The sieve is then electroformed in a nickel 
electroplating bath by depositing a Ni film in the voids left by the removed photoresist. 
The pores of nickel membrane had a conical shape with significant broadening toward 
the downstream side of the membrane (Fig. 7.7 (a)). The reason for that is that during 
electroforming not only upward growth between the photoresist islands, but also 
lateral overgrowth over the photoresist islands occurred. Shallow cylindrical cavities 
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on the upstream side of the membrane that can be seen in Fig. 7.7 (a) are the footprints 
of these photoresist islands. If the nickel growth takes place exclusively between the 
photoresist islands, the pore diameter would be equal to the diameter of these islands 
(~135 µm). A smaller pore size (10–40 µm) has been achieved by continuing to 
deposit Ni after the layer has reached the top of the resist pattern. The nickel then 
started to grow over the resist islands in the horizontal direction as well as in the 
vertical direction, as a result of which the pores became smaller and conical. Not all 
pores in Fig. 7.7 (a) are conical, since the membrane was not cut through the centre 
of each pore. If the cut edge is not perpendicular to the membrane surface and does 
not go through the centre of each pore, the cross section of some pores will be 
cylindrical rather than conical and the pores will not extend across the entire cross 
section of the membrane. Conical pores were more prone to fouling and less efficient 
in mixing than straight pores due to lower exit velocity of the organic phase. 
 
Another reason for the formation of smaller NPs using SS membrane is that the pores 
of this membrane were strategically arranged over a reduced annular area on the 
membrane surface corresponding to the maximum shear stress. 
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7.6: Effect of membrane type and pore size on: (a) volume-weighted particle size 
distribution, (b) average particle size, Zave (nm). The NPs were prepared at a 
(a) (b) 
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transmembrane flux of 140 L m-2 h-1, a stirring rate of 1,300 rpm, and an aqueous-to-
organic phase volumetric ratio of 10. The PCL concentration in the organic phase was 
1 g L-1 and no stabilizer was used. 
 
Fig. 7.7: Scanning electron microscope (SEM) images of membrane cross sections at 
various magnifications: (a) whole nickel (Ni) membrane; (b) stainless steel (SS) 
ringed membrane. 
7.4.8 Effect of membrane cleaning procedure 
Membrane cleaning was performed using the procedure described in Section 7.2.3 in 
order to restore the original contact angle and remove all residual polymer particles 
from the membrane surface. By keeping a low contact angle, the membrane was 
preferentially wetted by the aqueous phase, which prevents the organic phase from 
spreading over the membrane surface and ensures that tiny jets of the organic phase 
emerging from the pores penetrate directly into the aqueous phase. Fig. S2 in the 
supplementary material shows optical micrographs of the downstream membrane 
surfaces before and after cleaning at different magnifications. The membranes were 
significantly fouled before cleaning with large particle aggregates deposited near the 
pore exits or inside the pores. After cleaning no particle could be seen on the 
200 μm 70 μm
100 μm
100 μm 80 μm(a) 
(b) 
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membrane surfaces and all pores were unclogged, indicating that the cleaning 
procedure was appropriate. 
7.4.9 TEM and SEM images of produced nanoparticles 
The FEG-SEM and TEM images of the NPs are shown in Fig. 7.8. As can be seen, 
PCL NPs have a spherical shape and relatively uniform size which is smaller than 200 
nm. This particle size is in good correlation with the results obtained by static light 
scattering shown in Table 7.1 and Fig. 7.4 (a). FEG-SEM provided a 3-D image, while 
TEM produced a flat (2-D) image of the synthesised PCL NPs. 
 
 
Fig. 7.8: Micrographs of the formed PCL NPs: (a) FEG-SEM image; (b) TEM image. 
7.4.10 CFD simulation validation 
In this section, the results of numerical modelling are reported in order to validate the 
experimental results and to better understanding flow pattern in the cell. Fig. 7.9 
shows flow parameters in two different cross sections located above the membrane at 
the heights of 30 mm (vicinity of the blades) and 2 mm (vicinity of the membrane). 
Fig. 7.9 (a-i) shows the flow velocity vectors in the vicinity of the blades. The velocity 
is increasing by getting closer to the tips of the blades and decreases progressively by 
moving away from the blades. On the blade surface the velocity is roughly equal to 
the blade’s angular speed (𝜔𝑟). The pressure contours around the blades are presented 
in Fig. 7.9 (a-ii). The highest pressure is on the leading faces near the tips of the blades 
because of the highest drag force. The pressure around trailing faces of the blades is 
low because of high velocity of the flow. Fig. 7.9 (a-iii) shows flow streamlines in the 
1 μm 1 μm
(a) (b) 
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vicinity of the blades. Two nearly symmetrical vortices were formed at the trailing 
edge of the blades near the tip because of high velocity. Cavitation occurs when the 
suction pressure on the back of the blades reaches the vaporisation pressure and the 
contours of cavitation-induced vapour volume fraction are shown in Fig. 7.9 (a-iv). 
Fig. 7.9 (b-i) illustrates velocity vectors of the flow in the plane near the membrane 
surface. The velocity vectors are parallel to the wall of the cell. The local velocity 
increases radially towards the wall until it reaches a maximum value and then 
suddenly drops to zero on the wall surface because of the no-slip boundary condition. 
 
The pressure distribution in the plane positioned 2 mm above the membrane surface 
is shown in Fig. 7.9 (b-ii). The pressure is high near the wall of the cell due to 
generated centrifugal force and low in the centre. Therefore, the pressure distribution 
is axisymmetric, since the centrifugal acceleration, 𝑎𝑐, is proportional to the distance 
from the axis of rotation (𝑎𝑐 = 𝜔
2𝑟c). The pressure distribution in Fig. 7.9 (b-ii) is 
much more uniform than that in Fig. 7.9 (a-ii), because the flow near the membrane 
is more organised and less chaotic, Fig. 7.9 (b-i), indicating that the distance provided 
between the membrane surface and the impeller is adequate. Moreover, the pressure 
within the active region of the ringed membrane is very uniform, with local variations 
of less than 20 %, which ensures uniform flow distribution in the pores. 
 
Fig. 7.10 is a plot of the shear stress on different planes parallel to the membrane 
surface as a function of the radial distance from the axis of rotation at 1300 rpm. The 
shear stress on the membrane surface (z = 0) increases substantially towards the wall 
of the cell, reaches a peak value of 11.4 Pa at the transitional point, and then sharply 
declines to zero at the wall surface. The peak shear stress decreases exponentially with 
height and has a value of less than 2 Pa at the height of just 0.2 mm above the 
membrane surface. Therefore, the mixing rate is high on the membrane surface, where 
nucleation occurs and much smaller away from the membrane surface, which is useful 
because it limits the rate of particle aggregation. 
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Fig. 7.9: Flow in the cell at 1300 rpm rotation speed simulated at: (a) the cross section 
in the vicinity of the blades (z = 30 mm), and (b) the cross section in the vicinity of 
the membrane (z = 2 mm), with (i) velocity vectors, (ii) pressure contours, (iii) 
streamlines, (iv) vapour volume fraction contours (cavitation zones). All results are 
for counter-clockwise movement of blades and z is the vertical distance from the 
membrane surface. 
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Fig. 7.10: Local shear stress as a function of the radial distance from the axis of 
rotation at a stirrer speed of 1300 rpm for different distances from the membrane 
surface (CFD results). 
 
Table 7.2 provides a comparison of numerical and analytical solutions for the 
transitional radius and peak shear stress on the mem brane surface. The analytical 
solutions were derived using Eqs. (S18) – (S22) in the supplementary material. There 
is a good agreement between the numerical and analytical results with the peak shear 
stress on the membrane surface ranging between 11.4 and 14.0 Pa and the transitional 
radius between 10.7 and 13.3 mm. These values for the transitional radius are within 
or very close the operating region of the ringed (SS) membrane. Because the pores of 
SS membrane were located only in the high shear region near the rotational radius, 
the average shear stress was higher for that membrane than for the nickel membrane. 
Therefore, ringed membrane should provide better micromixing performance than the 
nickel membrane, as confirmed by the experimental results. 
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Table 7.2: Comparison of the numerical and analytical solutions for the transitional 
radius and the peak shear stress on the membrane surface at 1300 rpm (angular 
velocity, ω =136 rad s-1). The shear stress at the membrane surface reaches a 
maximum value at the transitional radius.  
Parameter CFD results 
Analytical results 
(Nagata, 1975) 
Transitional radius, 
transr  (mm) 
13.3 10.7 
Maximum shear stress, 
max  (Pa) 
11.4 14.0 
Average shear stress, 
  (Pa) 
- 
7.03 (for whole membrane) and 13.1 
(for ringed membrane) 
 
7.5 Conclusions 
New process for the preparation of biodegradable polymeric nanoparticles has been 
developed, which employed dispersion of a polymer-containing amphiphilic organic 
solvent into the aqueous phase through a micro-engineered membrane combined with 
nanoprecipitation. The particle size distribution has been precisely tuned by the 
membrane pore size and shape, the location of active region of the membrane, 
aqueous-to-organic volumetric ratio, agitation speed, transmembrane flux and 
polymer concentration in the organic phase. The higher the aqueous-to-organic 
volumetric ratio, the higher the nucleation rate and the lower the rate of particle 
growth and aggregation, resulting in a larger population of smaller particles. At the 
same aqueous-to-organic volumetric ratio, the interdiffusion rate of two phases was 
higher at the higher agitation speed, resulting in higher supersaturation and smaller 
particle size. Increase in the flux through the membrane and polymer concentration in 
the organic phase led to domination of particle agglomeration over nucleation and 
formation of fewer and larger particles. Steric stabilization of PCL particles has been 
achieved by adding 0.2 wt% PVA to the aqueous phase, with the lower and higher 
PVA concentrations causing fast bridging and depletion flocculation, respectively. 
 
The ringed stainless steel membrane with laser drilled pores was found to provide 
better performance than whole nickel membrane due to straight pores localized at the 
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high shear stress region on the membrane surface. The numerical and analytical 
modelling revealed the existence of peak shear stress on the membrane surface at the 
transitional radius and rapid reduction in the shear stress by moving away from the 
membrane surface. Due to significant overgrowth of the resist islands during 
electroforming, nickel membrane had funnel-shaped pores, which led to less efficient 
mixing process probably due to lower exit velocity of the organic phase in the pores. 
The membrane cleaning procedure was highly efficient and enabled to restore fully 
the original membrane properties and remove all residual particles from the membrane 
surface. 
 
The future work will be directed towards encapsulation of an immunosuppressive 
drug (rapamycin) within biodegradable polymer matrix using a ringed stainless steel 
membrane under the optimal operating conditions established in this study. 
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CHAPTER 8  
 
PREPARATION OF FUNTIONAL NANOPARTICLES LOADED 
WITH IMMUNOSUPPRESSIVE DRUG USING ENGINEERED 
MEMBRANE MICROMIXING COMBINED WITH SOLVENT 
DISPLACEMENT METHOD  
Chapter overview 
Immunosuppressive agent, rapamycin (RAPA) loaded polycaprolactone (PCL) 
nanoparticles (NPs) were successfully synthesised by antisolvent nanoprecipitation 
method combined with micro-enginereed membrane dispersion cell. Stainless steel 
(SS) ringed micro-engineered membrane was applied due to well-defined maximum 
shear stress provided from its effective micro-mixing surface area, thus improving 
mixing process between aqueous-organic phase and leading to the production of 
smaller particle size. The incorporation of RAPA onto PCL NPs matrices under 
optimum operational parameters (rotation speed = 1300 rpm, aqueous-to-organic 
phase volumetric ratio = 10 and transmembrane flux = 140 L m−2 h−1) and process 
variables (PCL concentration = 6 g L−1, RAPA concentration = 0.4 w/w over mass of 
PCL excipient and PVA surfactant concentration in the aqueous phase = 0.2 wt%) 
resulted in the average particle size of 204.0 ± 1.2 nm, encapsulation efficiency, 
%E.E. of 98.91 % and drug loading of %D.L. of 28.26 %, which are significantly 
suitable for intravascular delivery. The particle size increased on increasing both the 
drug loading in the polymer matrix at higher aqueous-to-organic volumetric ratio. 
0.4 w/w of RAPA concentration was considered as the optimum drug loading for PCL 
NPs as it showed small differences in the percentage of drug loading, if up to this 
amount. The encapsulation of RAPA in the NPs was confirmed by transmission 
electron microscopy, X-ray diffraction, differential scanning calorimetry and 
attenuated total reflection-Fourier transform infrared spectroscopy.  
8.1 Introduction 
Rapid progress in the field of nanomedicine in recent years offers new promising 
approaches in systematic delivery of poor water solubility and poor bioavailability of 
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active ingredients, as well as in instability and dosing problems (Barratt, 2000). A 
wide selection of nanoscale materials such as polymeric nanoparticles (Soppimath et 
al., 2001), liposomes (Samad et al., 2007), polymeric micelles (Kevin et al., 2009) and 
dendrimers (Svenson & Tomalia, 2012) have been employed as drug carriers with a 
broad variety of useful properties, such as longevity in the body, specific targeting to 
certain disease sites, enhanced intracellular penetration, contrast properties allowing 
for direct carrier visualization in vivo, stimuli-sensitivity, and others (Torchilin, 
2009). Biodegradable polymeric nanoparticles (NPs), such as poly-ᴅ,ʟ-lactide-co-
glycolide (PLGA), polylactide (PLA), poly-ɛ-caprolactone (PCL), poly-alkyl-
cyanoacrylates, chitosan and gelatin are frequently used due to their 
controlled/sustained release property, subcellular size, biocompatibility with tissue 
and cells, stable in blood, non-toxic, nonimmunogenic, noninflammatory and 
applicable to various water insoluble drugs (Kumari et al., 2010). Polymeric NPs with 
size in the range of 10–1000 nm can be easily prepared by spontaneous solvent 
displacement or nanopreciptation technique, which is less extensive, less energy 
consuming and more facile, as well as widely applicable technique in the 
presence/absence of a surfactant or any additives. The formation started by fast 
diffusion of solvent and non-solvent phases, leads to the instantaneous formation of a 
colloidal suspension (Fessi et al., 1992; Fessi et al., 1989; Jain, 2000).  
 
Owing to the numerous advantages of applying polymeric NPs as a drug-carrier and 
an innovative therapeutic strategy discovered from rapamycin as a potent 
immunosuppressive agent to suppress organ transplant rejection and in treatment 
tumors (Zhang et al., 2013), rapamycin-loaded nanoparticles (NPs) with appropriate 
size and high loading capacity become more reliable to sustain drug delivery after 
surgical or transplantation procedures with smaller dose in an effective form and 
controlled drug administration within the body (Acharya et al., 2009). Rapamycin or 
also known as sirolimus is a triene macrolide antibiotic with immunosuppressive 
activity, was isolated from Streptomyces hygroscopicus in 1978 (Kim et al., 2011). 
Delivery is impeded by rapamycin’s poor solubility in water (2.6 μmL-1 at 25 °C) 
(Simamora et al., 2001), and by its low bioavailability (Napoli et al., 1997) and dose-
limiting toxicity, which eventually could be overcome by the use of polymeric NPs 
as its carrier. In addition, rapamycin is very unstable in phosphate-buffered saline and 
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HEPES buffer under all conditions; their degradation effect on the drug is slower at 4 
°C−8 °C and fastest at 37 °C with almost all drugs will be destroyed within 24 hours 
(Kim et al., 2011).  
 
Currently, a number of studies demonstrated various types of biodegradable polymers 
with self-assembly capacity to solubilise rapamycin (RAPA) into hydrophobic 
polymer core and thus protect RAPA against inactivation in biological conditions and 
improve its bioavailability. Luderer et al. (2011) determine the applicability of RAPA-
loaded biodegradable poly(ᴅ,ʟ-lactide) (PDLLA) nanoparticles as drug carriers to 
prevent restenotic processes after stent implantation with average 250 nm sized 20% 
(w/w) RAPA-loaded nanoparticles were extensively characterised with regard to in 
vitro degradation, biocompatibility and in vitro drug release. RAPA-loaded polymeric 
poly(lactide-co-glycolide) (PLGA) nanoparticles were also prepared by Zou et al. 
(2011), Shi et al. (2014) and Acharya et al. (2009) for sustained  inhibition in coronary 
surgical bypass and cancer treatment. Zweers et al. (2006) fabricated rapamycin-
loaded nanoparticles from poly(ethylene oxide) and poly(ᴅ,ʟ-lactic-co-glycolic acid) 
block copolymers (PEO-PLGA) without additional stabilizer by salting-out method 
and further in-vivo release study in PBS (pH 7.4) at 37 °C. RAPA-loaded poly(e-
caprolactone)-poly(ethylene glycol)-poly(e-caprolactone) nanoparticles were also 
prepared and characterised by Zhang et al. (2013) purposely for corneal 
transplantation. Yuan et al. (2008) synthesised RAPA-loaded chitosan/PLA 
nanoparticles for immunosuppression in corneal transplantation with size of about 300 
nm in diameter through nanoprecipitation method using cholesterol-modified chitosan 
as a stabilizer. Meanwhile, Macedo et al. (2012) developed tolerogenic dendritic cells 
(tolDC) to minimize the chronic administration of immunosuppression (IS) drugs 
(RAPA) in transplantation and autoimmune disease. Chen et al. (2013) also prepared 
rapamycin encapsulated in dual-responsive micelles for cancer therapy with 
extensively release profiles, uptake and in vitro/in vivo study.   
 
With the emerging technologies applied for the formation of different pharmaceutical  
nanoparticles, such as polymeric nanospheres and nanocapsules (Charcosset & Fessi, 
2005; Limayem et al., 2006), lipid nanoparticles (Charcosset et al. 2005; D’oria et al., 
2009), liposomes (Laouini et al., 2011; Jaafar-Maalej et al., 2011), metal nanoparticles 
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(Wagner et al., 2004), polymeric nanoparticles (Gasparini et al., 2008; Wei et al., 
2008), barium sulfate nanoparticles (Chen et al., 2004) and silver nanoparticles 
(Kakazu et al., 2010), produced using different type of micro-porous membranes (i.e. 
shirasu porous glass (SPG), nickel (Ni), stainless steel (SS) membrane) 
(Vladisavljević & Williams,  2005) fitted in a membrane contactor combined with 
different physicochemical production process (i.e. solvent displacement, salting-out, 
emulsification-solvent evaporation) (Nagavarma et al., 2012), a narrower controllable 
particle size distribution and highly monodispersed particles formation is now 
seemingly feasible. In addition, the optimal sizes of a nano-sized agent, which can 
deliver an adequate dose of drugs distributed homogeneously and thus, induce the 
most efficient therapeutic, is reportedly should be between diameters of 100–300 nm 
or less for intravascular delivery which primarily relied on exploiting the well-known 
enhanced retention and permeability (EPR) effects (Kobayashi et al.,  2014; Allen & 
Cullis, 2004; Decuzzi et al., 2009). 
 
Recently, a new micro-engineered stainless steel, SS membrane, consisting of an array 
of regularly spaced, rectilinear pores and a perfect rectangular array of uniform pores 
fitted in a dispersion cell was introduced by the Micropore Technologies Ltd. This 
micro-engineered membrane is analogous to an array of parallel microfluidic channels 
which allow a much more uniform and controllable injection of organic phase 
(dissolved polymer and drug in organic solvent) into an aqueous phase at overall much 
higher flow rate than is possible in microfluidic devices (Laouini et al., 2013). A 
micro-engineered SS membrane is technically prepared by pulsed laser drilling drilled 
pores (Disperse Technologies Ltd, UK) (Geerken et al., 2008; Vladisavljević & 
Williams, 2005; Dowding et al., 2001) or end-milling (Kobayashi et al., 2008), which 
comprise of significantly straight-through pores.  
 
The purposes of this study were: (i) to investigate the possibility of efficiently 
encapsulating rapamycin (RAPA) onto poly(ε-caprolactone) (PCL) NPs matrix 
(hereafter denoted as RAPA-PCL NPs) using SS ringed membrane that fitted in the 
dispersion cell combined with solvent displacement method; (ii) to study the effect of 
RAPA on the physical properties of the synthesised NPs using various 
physicochemical analytical methods, like transmission electron microscopy (TEM), 
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x-ray diffraction (XRD), differential scanning calorimetry (DSC) and attenuated total 
reflection-Fourier transform infrared spectroscopy (ATR-FTIR); and (iii) to 
investigate the encapsulation efficiency of RAPA inside the NPs and their in vitro 
drug release behavior. Both RAPA and PCL are Food and Drug Administration (FDA) 
approved, so it is relatively easy to translate these methods to clinical application. 
PCL was chosen to serve as a most stable hydrophobic biodegradable polyester drug-
carrier due to its suitability for the encapsulation of poorly water soluble drug, owing 
to its high permeability to small drug molecules and its negligible tendency to generate 
an acidic environment during the degradation process as compared to polylactids and 
polyglicolids, which led to the generation of inflammatory reactions (Lemoine et al., 
1996; Woodruff & Hutmacher, 2010). Polyvinyl alcohol (PVA), one of the most 
popular stabilizers for the production of PCL nanoparticles was also selected for 
hindering aggregation and agglomeration between each newly synthesised particles 
(Woodruff & Hutmacher, 2010). 
8.2 Materials and methods 
8.2.1 Materials 
Poly(ε-caprolactone) (PCL, Mw = 14,000 g mol−1 with a glass transition temperature 
of 60 oC) and hydrophilic surfactant, tetrahydrofuran, THF (HPLC grade, purity ≥ 
99.9%), polyvinyl alcohol (PVA, MW 13−23 kDa) were purchased from Sigma-
Aldrich (Dorset, UK). Acetone (Ace) (HPLC grade, purity ≥ 99.8%), acetonitrile 
(HPLC grade, purity ≥ 99.9%), methanol HPLC grade, purity ≥ 99.8%), and acetic 
acid (HPLC grade, purity ≥ 99.7%) were purchased from Fisher Scientific Ltd. 
(Loughborough, UK). Rapamycin (RAPA) (sirolimus, purity ≥ 99 %) was provided 
by Chunghwa Chemical Synthesis & Biotech Co. Ltd. (New Taipei City, Taiwan). 
All chemicals were of analytical grade. The antisolvent phase was pure water 
produced by reverse osmosis (Mili-Q®, Millipore) or aqueous surfactant solutions. 
The hydrophilic surfactant was used to prevent agglomeration, coalescence and 
imperfect surface formation, as well as to reduce the size of the NPs. The organic 
phase was prepared by dissolving RAPA and pure PCL in Ace and contained 6 g L-1 
of the excipient (PCL) and 0.6−3.0 g L-1 of RAPA. The aqueous phase was 0.2 wt% 
PVA dissolved in Milli-Q water.  
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8.2.2 Membrane and membrane module 
The RAPA-PCL NPs were prepared using a membrane stirred dispersion cell with a 
flat disc SS ringed membrane fitted under the paddle blade stirrer as shown in Fig. 8.1 
(a). Both stirred cell and membrane were supplied by Micropore Technologies Ltd. 
(Derbyshire, UK). The agitator was driven by a 24 V DC motor and power supply 
(INSTEK model PR 3060) with the paddle rotation speed could be controlled by the 
applied voltage at 1300 rpm, which corresponding to the 13 Pa average shear stress 
on the membrane surface. Stainless steel (SS) ringed micro-engineered membrane 
containing uniform cylindrical pores with a diameter of 10 μm arranged at a uniform 
spacing of 200 mm with effective diameter difference was 0.6 cm (r1 = 9 mm, r2 = 13 
mm) with 2.76 cm2 affective area were used for the optimum operating parameters 
investigation. A perfectly rectangular array of pores located circularly within the 
ringed area of the membrane surface as can be seen on the micrograph in Fig 8.1 (b).    
8.2.3 Preparation of rapamycin-loaded PCL nanoparticles  
Rapamycin-loaded PCL NPs were prepared by a solvent displacement technique 
(nanoprecipitation) as described in detail by Fessi et al. (1989). Briefly, 6 g L-1 of 
organic phase containing a homogeneous solution of 0.6 % (w/w) PCL and 0.06–0.3 
% (w/w) of RAPA was accurately weighted and dissolved in acetone. This organic 
solution was then injected through the membrane using a high pressure single-syringe 
infusion pump, 230 VAC syringe pump (Cole-Parmer Instrument Co. Ltd., UK) and 
the flow rate of 0.65 mL min-1, corresponding to a dispersed phase flux of 38.8 m-2 h-
1. The cell was filled with 60 mL of mili-Q water or dissolved surfactant in aqueous 
solution (PVA, 0.2 wt%) and the experiment was run until predetermined aqueous-to-
organic phase volumetric ratio, Vaq/Vor of 10 was achieved. The aqueous phase 
immediately turned cloudy as soon as the organic phase brought into contact with the 
aqueous phase, indicating the formation of nanoparticles suspension. Once the desired 
amount of organic phase had passed through the membrane, both pump and the 
agitator was switched off and the nanosuspensions were collected for further 
physicochemical analyses. Fig. 8.1 (b) showed a rapid solvent displacement 
mechanism occurred during the formation of NPs and a photomicrograph of 10 μm-
SS ringed membrane. Blank PCL NPs also prepared by the same method without 
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adding rapamycin at any stage of the preparation. Every preparation was repeated at 
least three times.  
 
After each experiment, the membrane was sonicated in acetone for 30 min, followed 
by treatment with Mili-Q water in an ultrasonic bath for 5 min (in order to improve 
the hydrophilicity of the membrane surface). While for storage purpose, the 
membrane was soaked in acetone purposely to remove all unwanted residuals.    
8.2.4 Determination of encapsulation efficiency and drug loading 
The newly formed nanosuspension must be evaporated in a vacuum oven (Technico, 
Fistreem International Ltd, Loughborough, UK) under absolute pressures below 10 
Torr at room temperature for about 30 min until the smell of Ace had completely 
vanished. The nanosuspension was then ultracentrifuged (Heraeus Labofuge 400R 
centrifuge, Thermo Scientific) at 15,000 rpm (23,000 g) for 1 h. The supernatant 
containing the dissolved free drug was separated from the sediment and analysed by 
an established RP-HPLC method. Typically, 20 μL samples were injected on a 
Symmetry® C-8 column (4.6 × 50 mm; 3.5 μm; Waters, UK) eluted with 
methanol/1%(v/v) acetic acid in deionised water (75/25 v %) at a flow rate of 1.0 mL 
min-1. A LC-10Avp Shimadzu UV-VIS detector was used to detect RAPA at 278 nm 
and ambient temperature. The amount of RAPA in the sample was calculated using a 
standard curve of RAPA in acetonitrile at various concentrations. The drug 
entrapment efficiency (E.E.) and drug loading (D.L.) were calculated from equations 
(8.1) and (8.2), respectively. The determinations were carried out in triplicate and the 
results were expressed as mean ± SD (n = 3). 
 
%)]M/M([.E.E% TR 1001                                                                        (8.1) 
 
where MR is the mass of drug in the supernatant and MT is the total mass of drug used 
in the sample (Zhang et al., 2013; Yuan et al., 2008; Chen et al., 2013). The drug 
loading of the NPs was determined as:  
 
%)]M/)MM[(.L.D% NPRT 100                                                                 (8.2) 
where MNP is the total mass of NPs in the sample (Othman et al., 2016; Othman et al., 
2015).   
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8.2.5 Characterisation of the prepared NPs 
8.2.5.1 Particle size analysis 
The polymeric NPs size was measured determined by dynamic light scattering (DLS) 
(DelsaTM Nano HC Particle Analyser (Beckman Coulter, High Wycombe, UK), by 
measuring  the fluctuations of scattered light as a function of time (Submicron, 2011) 
with 120 s detecting time was allocated for each runs. Each samples were analysed by 
following the standard procedures described in Section 2.6.1.1. This method was 
developed by Provencher et al. (1978) describes bimodal and smooth distribution 
without the need of additional information, such as an initial estimate for the particle 
size.    
8.2.5.2 Transmission electron microscopy (TEM) 
The morphology structure of rapamycin-loaded PCL NPs was characterised by JEOL 
JEM-2000FX transmission electron microscopy (TEM), fitted with an Oxford 
Instruments Inca EDX system. Each samples were analysed by following the standard 
procedures described in Section 4.2.4.3. 
8.2.5.3 Differential scanning calorimetry (DSC) 
The physical state of ~ 5 mg pure RAPA, pure PCL, blank PLC NPs, the physical 
mixture of blank PCL NPs and RAPA as well as RAPA-PCL NPs was characterised 
using a differential scanning calorimetry (DSC) thermogram analysis (TA 
Instruments, Model Q100 DSC). RAPA-loaded PCL NPs and blank PLC NPs were 
lyophilised by freeze-drying the sediment after centrifugation in a freeze dryer 
(Edwards, type EF4 Modulyo). Each samples were analysed by following the standard 
procedures described in Section 5.2.5.3. 
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Fig. 8.1: Experimental set-up for the preparation of encapsulated polymeric 
biodegradable nanoparticles with; (a) membrane dispersion cell rig with a 
photomicrograph of 10 μm stainless steel, SS ringed micro-engineered membrane and 
(b) rapid solvent displacement mechanism during the formation of nanoparticles.    
8.2.5.4 X-ray diffractometry (XRD) 
X-ray diffraction (XRD) spectra of pure RAPA, pure PCL, blank PLC NPs, the 
physical mixture of blank PCL NPs and RAPA as well as RAPA-PCL NPs was 
detected using a Bruker D8 diffractometer by exposing samples to CuKa radiation (40 
kV, 20 mA) over the 2 range from 5o to 50o. Each samples were analysed by 
following the standard procedures described in Section 5.2.5.4.  
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8.2.5.5 Attenuated total reflection-Fourier transform infrared (ATR-FTIR) 
spectroscopy 
2-3 mg of the individually powdered sample (pure RAPA, pure PCL, blank PLC NPs, 
the physical mixture of blank PCL NPs and RAPA, RAPA-PCL NPs) was analysed 
its ATR-FTIR spectra using Thermo Scientific Nicolet iS50 ATR spectrometer.  Each 
samples were analysed by following the standard procedures described in Section 
6.2.4.6. 
8.2.5.6 In vitro drug release studies 
In-vitro drug release studies were carried out using 0.3 % (w/w) of RAPA-loaded PCL 
NPs using two different concentrations of N, N-Diethylnicotinamide (DENA) in 3 M 
and 5.8 M were used as a release media. 0.3 % (w/w) RAPA-nanocrystals without 
PCL NPs host was also analysed as a control sample with dissolution medium of 3 M 
DENA. Briefly, DENA solution has been identified as an excellent hydrotropic agent 
for poorly soluble drugs, which also known as an amphiphilic agent that comprised 
of both hydrophilic and hydrophobic parts (Shukla et al., 2014). Recently, many 
studies have reported an increase use of DENA solution as a hydrotrope to accelerate 
the paclitaxel and rapamycin dissolution rate from drug-incorporated biodegradable 
stent matrices (Simamora et al., 2001; Alexis et al., 2004; Baek et al., 2004). 
Phosphate Buffer Saline (PBS) having pH 7.4 similar to pH of human blood 
previously has been applied as a release medium, but incomplete drug release due to 
lower solubility of drug in PBS was a major crisis for in vitro drug release study 
(Tailor et al., 2008). It may also be necessary to use hydro-alcoholic media, such as 
ethanol, ethanol and isopropyl alcohol to accelerate the dissolution rate (Alexis et al., 
2004). In this study, a mixture of DENA solution, ethanol, hydrophilic surfactant 
(Tween-80), ethanol and PBS (pH = 7.4) was used as a dissolution/release medium in 
order to improve the RAPA solubility, hence to accelerate the RAPA dissolution rate. 
A known amount of lyophilised sample (5 mg) was dispersed in a centrifugation tube 
that consists of 5 mL prepared dissolution medium. The tube was then incubated in a 
shaking bath at 50 rpm and 37 °C to mimic the human blood stream conditions 
(Behera et al., 2013). At predetermined time intervals, the test tube was taken out of 
the shaker and centrifuged at 15,000 rpm for 30 min at −4 oC. The supernatant was 
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removed and the amount of drug released was quantified by RP-HPLC method as 
described above. The dissolution medium was replenished with fresh dissolution 
medium to keep the total volume of the release medium constant. All samples were in 
triplicate and the results were expressed as a mean value ± S.D. 
8.3 Results and discussion 
8.3.1 Optimum operational parameters validation 
The selection of good organic solvent is a crucial initial step that should be taken for 
the formation of polymeric NPs by nanoprecipitation method. The good organic 
solvent must be able to dissolve polymer and must be miscible with water (Van 
Krevelen & Hoftyzer, 1976). Due to the higher solubility of RAPA in acetone and the 
incapability of THF to dissolve RAPA, this study was run to validate the optimum 
operational parameters (rotation speed = 1300 rpm and transmembrane flux = 140 L 
m-2 h-1, aqueous-to-organic volumetric ratio = 10) that have been obtained from the 
previous study. However, these optimum parameters were only obtained with the use 
of THF as the organic solvent. The variations on the average particle size of blank 
PCL NPs were investigated with the increasing of volumetric aqueous-to-organic 
phase ratio using two different organic solvents (Ace and THF) by applying 10-μm 
SS ringed membrane and the operational parameters, as can be seen in the Fig. 8.2. 
Indeed, at the higher aqueous-to-organic volumetric ratio, PCL from the organic phase 
become more diluted after mixing with the aqueous phase, which may result in the 
formation of smaller particles. Similar results were obtained were obtained by Seo et 
al. (2015) in itraconazole NPs formation using SPG membrane, Du et al. (2011) for 
SiO2 NPs production using a microfiltration membrane dispersion microreactor, 
Huang et al. (2013) in ZnO NPs formation and Laouini et al. (2013a, 2013b, 2013c) 
in the production of liposomes and polymeric micelles by membrane contactors. 
 
Minor increasing in the average particle size was observed with nearly 3.4−7.5 % 
different in acetone compared to THF solvent, as can be seen in Fig. 8.2. This result 
was well correlated with the solubility distance, DPCL-solvent calculated from Bagley's 
two-dimensional  solubility circle as defined by Bordes et al.( 2010) and Othman et 
al. 2015), where DPCL-Ace for acetone was 6.53 and for THF, DPCL-THF was 1.08. The 
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particle size was much smaller in THF as it was found to be a good solvent for PCL 
NPs formation by nanoprecipitation method. Nevertheless, acetone also can be 
concluded as a good solvent for PCL as well as for rapamycin. No further 
investigation has to be done for finalising the optimum operating parameters that 
should be applied in the rapamycin encapsulation experiment.  
1.5 3.0 4.5 7.0 10.0
0
50
100
150
200
250
300
350
A
v
er
a
g
e 
p
a
rt
ic
le
 s
iz
e,
 Z
a
v
e 
(n
m
)
Volumetric ratio, Vaq/Vor
 THF
 Acetone
 
Fig. 8.2: The average particle size, aveZ of blank PCL nanoparticles produced using 
different organic solvents (THF and acetone) at different volume ratio and constant 
agitation speed, 1300 rpm using 20 μm size of SS ringed micro-engineered membrane. 
The PCL concentration in the organic phase is 1 g L-1 and the transmembrane flux is 
at 140 L m-2 h-1. 
8.3.2 Drug encapsulation efficiency and drug loading  
Rapamycin was successfully encapsulated into PCL NPs matrices using SS ringed 
micro-engineered membrane dispersion cell combined with solvent displacement 
method under   optimum operational parameters of; rotation speed = 1300 rpm, 
aqueous-to-organic phase volumetric ratio = 10, transmembrane flux = 140 L m-2 h-1 
at different amount of rapamycin content dissolved in 6 g L-1 of organic phase. As 
presented in Table 8.1, it was clearly observed that the average particle size of 
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rapamycin-loaded PCL NPs increased from 189.4 ± 4.0 nm to 217.9 ± 5.0 nm and 
PDI ranged from 0.006 ± 0.025 to 0.073 ± 0.023 with an increase in the feed ratio of 
drug to polymer, which caused by more rapamycin molecules being attached to PCL 
NPs matrices. More hydrophobic aggregates were presumably formed at the higher 
concentration of RAPA, leading to the increment value of PDI. Meanwhile, RAPA 
was efficiently loaded in PCL NPs, reaching encapsulation efficiency, % E.E. in the 
ranged of 98.79 to 98.93 % with the increasing amount of drug loading from 0.1 to 
0.5 w/w (see Table 8.1), due to the stronger hydrophobic interaction between RAPA 
and PCL. The drug loading, % D.L. was increased rapidly from 8.98 % (0.1 w/w 
RAPA content) to approximately 32.98 % (0.5 w/w RAPA content), proving that 
almost RAPA were successfully retained in the PCL NPs matrices. Small difference 
in % D.L. (nearly ~ 4.72 %) was observed from 0.4 w/w to 0.5 w/w RAPA content 
compared to the other loadings, thereby indicating 0.4 w/w as the optimum 
concentration of RAPA to be encapsulated. Zhang et al. (2013) showed similar trends 
with an increment in particle size (170 to 180 nm), encapsulation efficiency (84.1 to 
99.7 %) and drug loading (5.03 to 14.91 %) by the increasing percentage of RAPA to 
polymer feed ratio from 5 to 15 %. Theoretically, the amount of drugs bound to NPs 
and the type of interaction between drugs and nanoparticles was reported significantly 
depend on the chemical structure of the drug, chemical structure of the polymer and 
the conditions of drug loading (Mahapatro & Singh, 2011).     
 
Table 8.1: The effect of rapamycin-to-excipient mass ratio in the organic phase on 
the average particle size, drug encapsulation efficiency and drug loading of the 
prepared NPs at volume ratio, Vaq/Vor = 10. The PCL concentration in the organic 
phase is 6 g L-1 (n = 3).   
RAPA/excipient 
mass ratio in 
organic phase 
Volumetric ratio, Vaq/Vor = 10 
E.E. (%) D.L. (%) 
Average size of 
NPs, Zave (nm) 
Polydispersity 
index (PDI) 
0.1 98.79 8.98 189.4 ± 4.0 0.006 ± 0.025 
0.2 98.80 16.47 194.8 ± 3.8 0.040 ± 0.031 
0.3 98.92 22.83 198.5 ± 6.7 0.030 ± 0.024 
0.4 98.91 28.26 204.0 ± 1.2 0.066 ± 0.035 
0.5 98.93 32.98 217.9 ± 5.0 0.073 ± 0.023 
* Note: Each analysis was repeated three times (n = 3) and the average particle sizes 
were determined. The error bars are standard deviations.    
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8.3.3 Characterisation of the NPs 
8.3.3.1 TEM analysis of the NPs 
TEM micrographs exhibited discrete spherical shape of blank PCL NPs and RAPA-
loaded PCL NPs, whilst disordered shape for RAPA nanocrystal without PCL host, 
as can be seen clearly in Fig. 8.3. The RAPA-loaded PCL NPs showed significantly 
larger particle size compared to the blank PCL NPs, proving that RAPA was 
successfully emended or solubilised onto PCL NPs matrices which are coherent with 
the values detected by light scattering particle size analyser. No free crystals were 
detectable. Some agglomerations and deteriorated shape of particles were detected in 
RAPA nanocrystal sample with bigger size of particle (≥ 500 nm), due to the absence 
of PCL host/excipient that leading to the aggregation of free RAPA. These TEM 
images were also well correlated with the intensity size distributions detected by 
dynamic light scattering particle analyser, as depicted in Fig. 8.4. Uniform and 
narrower intensity size distributions presenting how monodisperse was the particle 
were attained from both blank PCL NPs and RAPA-loaded PCL NPs. Conversely, a 
broader intensity size distribution was obtained from RAPA nanocrystal sample 
which attributable to its bigger size and uniformity.  
8.3.3.2 XRD analysis 
XRD analysis was used to check the changes in the rapamycin crystal morphology 
with the respect to a polymorphic transition and thereby to understand the solid state 
of nano-crystals of rapamycin drug (Chauhan & Cauchan, 2014). The crystallinity of 
blank PCL NPs, physical mixture of RAPA-PCL NPs and RAPA-loaded PCL NPs 
were inspected by XRD with pure PCL and RAPA samples as the references. As 
depicted in Fig. 8.5, the diffraction pattern of pure rapamycin showed characteristic 
high-intensity peaks at 7.2°, 9.9°, 10.3°, 11.1°, 12.5°, 14.5°, 15.3°, 15.5°, 16.2°, 20.0°, 
20.4°, 21.8° and 23.5° were observed, while the specific peaks of pure PCL were 
attributed to 21.4° and 23.8°, accordingly. Similar results for both pure RAPA and 
PCL were attained by Kim et al. (2011) and Yeo et al. (2012), respectively. However, 
the characteristic peaks of blank PCL NPs were found slightly shifted from the pure 
PCL sample, with reducing crystalinity from 68.9 % to 67.1 %. This is due to the 
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polymer precipitation caused by rapid diffusion of organic phase to the outer phase 
and fast evaporation of polymer-dissolving organic solvent, which significantly 
reducing polymer network arrangement time and, thus inhibit the crystallisation 
process (Izumikawa et al., 1991).  
 
In the spectrum of mixture of blank PCL NPs and RAPA, specific peaks of both blank 
PCL NPs and RAPA at 7.2°, 10.3°, 14.2°, 9.3°, 21.4° and 23.8° were observed, 
suggesting that rapamycin was in microcrystalline form in the mixture and that there 
was an absence of any possible interaction with PCL NPs. Nevertheless, in the 
spectrum of RAPA-loaded PCL NPs, only the specific peaks of PCL NPs 
nanoparticles at 21.4° and 23.8° were detected, while specific peaks of rapamycin 
disappeared, indicating that rapamycin was amorphously dispersed into the core of 
the PCL NPs and that the drug had a great affinity for PCL. This was also proved by 
the reducing crystalinity percentage obtained from pure RAPA (78.9 %) to RAPA-
PCL mixture (71.3%) and RAPA-loaded PCL NPs (63.7%) sample.    
8.3.3.3 DSC analysis 
DSC is a thermal analysis instrument that widely used in the pharmacology and 
nanoscience to measure the material transitions and properties of materials/substances 
(Gill et al. 2010) as well as to gain more information about the crystallinity and 
possible interactions between PCL and the drug. The DSC profiles of pure RAPA, 
pure PCL, blank PCL NPs, mixture of RAPA-PCL NPs and RAPA-loaded PCL NPs 
are presented in Fig. 8.5. Pure rapamycin showed an endothermic peak in the region 
of 183−205 °C, corresponding to its melting point. The split peaks at 183 °C and 197 
°C might be related to the two different crystal forms of rapamycin (Rouf et al., 2011). 
As expected, pure PCL polymer exhibited an endothermic peak at 60 °C, 
corresponding to the melting point of PCL, which was in accordance with previous 
findings (Guilherme et al., 2014). Blank PCL NPs endothermic peak were 
significantly shifted to 52 °C which revealing the reduction in crystallinity percentage 
of PCL obtained from XRD analysis. Two-peaked melting exoterm of individual 
RAPA and blank PCL NPs were detected in the physical mixture of RAPA−PCL (Fig. 
8.5 (b)) with a shallow, broad endothermic peak detected between 180 °C to 200 °C. 
The thermogram peaks of RAPA-loaded PCL NPs (Fig. 8.5 (b)) were shifted to lower 
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temperatures (∼ 50 °C) indicating that RAPA completely entrapped in the PCL NPs 
hydrophobic core was in an amorphous or disordered-crystalline phase. Moreover, the 
appearance of a single peak for the loaded NPs indicates that PCM was uniformly 
distributed in the NPs. Similar observations were also reported by Zhang et al. (2013 
and Kim et al. (2011). 
 
Fig. 8.3: TEM images of; (a) blank PCL NPs; (b) rapamycin (RAPA) encapsulated 
PCL NPs; and (c) RAPA nanocrystal without PCL host at various magnifications 
prepared using the drug-to-excipient mass ratio in the organic phase of 0.4. 
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Fig. 8.4: The intensity size distributions of blank PCL NPs, RAPA-PCL NPs and 
RAPA nanocrystals produced in a membrane dispersion using 10 μm size of stainless 
steel micro-engineered membrane at the transmembrane flux is at 140 L m-2 h-1, 
rotation speed 1300 rpm. The PCL concentration in the organic phase is 6 g L-1. 
CHAPTER 8  
                                                                                                                                 211
 
 
Rahimah Othman  2016 
 
 
Fig. 8.5: (a) X-ray diffractograms; and (b) DSC thermograms of; 1- pure RAPA; 2- 
pure PCL; 3-blank PCL NPs; 4- physical mixture of RAPA; and 5- RAPA-loaded 
PLA NPs. 
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8.3.3.4 ATR-FTIR spectroscopy 
FTIR analysis was used to characterise any chemical interactions that occurred in the 
polymer due to the addition of drug during the synthesis reaction (Acharya et al., 
2009). The FTIR spectra of pure rapamycin, blank PCL NPs, mixture of RAPA-PCL 
NPs and RAPA-loaded PCL NPs are shown in Fig. 8.6. Characteristic bands due to 
different functional groups in pure rapamycin, appeared at 3418 cm−1, due to O–H 
stretching vibrations, and 2875 and 2932 cm−1, due to C–H stretching vibrations, 
while the peak 1718 cm−1 corresponded to C=O carbonyl stretching, whereas the peak 
at 1377 cm−1 was due to –CH bending/deformation, conjugated double bond at 1635 
cm−1 and 995 cm−1, in which the peak of 1635 cm−1 is the stretching vibration of 
conjugated ethylene bond and a peak of 995 cm−1 is the bent vibration of C−H as a 
proof of trans-substitutive double bond existing. There are wide peaks of stretching 
and bent vibration of methylene, which show that there are many methylenes in the 
rapamycin structure (Acharya et al., 2009). Meanwhile, the peaks which appeared at 
2942.37 cm−1 and 2867.18 cm−1 are due to the C–H stretching appeared in pure PCL 
spectrum. Beside, a strongest ester carbonyl absorption band, C=O stretching 
vibration located at 1719.54 cm−1 and 1722.17 cm−1 respectively. An asymmetrical 
C–H bending vibration in CH3 group showed an absorption band at 1453.33 cm−1 and 
1466.56 cm−1, respectively. C–O–H bond shows a peak at 1378.95 cm−1 and 1365.30 
cm−1 respectively. Additionally, FTIR spectra peaks present at 1181.48 cm−1 and 
1167.31 cm−1 are attributed to C–O stretching, as reported by Liau et al. (2014).   
 
No bifurcation of peaks or any bends of peaks detected in the spectra of the blank PCL 
NPs compared with pure PCL sample, which means that FTIR could not prove any 
changes in the internal crystal structure of PCL as a result of dissolution and 
nanoprecipitation, that proposed by XRD and TGA analyses. New small peak at 995 
cm−1 was detected in the spectra of RAPA-PCL NPs mixture, which corresponding to 
the bent vibration of C−H inherited from pure RAPA sample. The characteristic 
absorption peaks due to conjugated ethylene bond stretching vibration at 1635 cm−1 
in the RAPA constituent were seemingly visible in the region between 1600 and 1635 
cm−1 for all RAPA-loaded PCL NPs. This indicates that RAPA was encapsulated 
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within the PCL NPs matrices, but has not strongly interacted with PCL polymer since 
only small vibrations detected with no peak shifts occurred. 
 
Fig. 8.6: ATR-FTIR spectrums of: 1- pure RAPA; 2- pure PCL; 3- blank PCL NPs; 
blank PCL NPs; 4- physical mixture of blank PCL NPs-RAPA; and 5- RAPA-loaded 
PCL NPs. 
8.3.4 In vitro release of RAPA from nanoparticles 
Efficient release of encapsulated drug from nanoparticles is an important parameter 
in developing successful formulations. In-vitro release of rapamycin from PCL NPs 
was measured over 18 h by recording the absorbance at 278 nm (Fig.8.7). Zero-time 
corresponds to the start of the incubation period by neglecting the amount of RAPA 
released during the nanoprecipitation process. The total amount of drug released 
during the processes of NPs and RAPA nanocrystals formation by nanoprecipitation 
method and incubation time was 100 % for RAPA nanocrystals without PCL NPs 
host, 91.34 % and 93.78 % for RAPA-loaded PCL NPs sample in 3 M and 5.8 M of 
DENA concentration in dissolution medium, respectively. As expected, with the 
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existence of higher DENA concentration in the release medium, RAPA tends to be 
soluble and more RAPA could be easily released (Baek et al., 2004). A burst drug 
release was observed over the first 2 h which can be attributed to relatively high 
solubility of RAPA in the dissolution mediums. It was followed by very slow drug 
diffusion over a long period of time from hydrophobic PCL cores into the dissolution 
media. The fastest released was observed from RAPA nanocystals attributed by the 
absence of PCL core and RAPA dissolution. After 18 h of release, about 6.2 to 8.7 % 
rapamycin still remained in the nanoparticles, both for 5.8 M and 3 M of DENA 
concentration, which can be explained by the rapamycin still being embedded into the 
core of the nanoparticles with slow diffusion out from the PCL nanoparticles 
occurring in the release medium. Slow degradability of PCL polymer associated with 
the polymer matrix erosion mechanisms also contributed to this slower sustains 
release of rapamycin present inside the core of nanoparticles (Holland & Tighe, 1992; 
Musumeci et al., 2006; Yuan et al., 2008).   
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Fig. 8.7: In vitro release profile from; (a) rapamycin (RAPA) nanocrystals in 3 M 
DENA solution; (b) RAPA-PCL NPs in 3M DENA solution and; (c) RAPA-PCL 
NPs in 5.8 M DENA solution. The error bars represent the standard deviations of 
three repeated measurements (n = 3). 
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8.4 Conclusions 
In this study, rapamycin-loaded PCL NPs was successfully synthesized by anti-
solvent displacement method combined with micro-engineered membrane dispersion 
cell. A monodispersed (referring to the PDI and narrower particle size distributions) 
and spherical shape of nanoparticles within the size range of 153.4 ± 4.2 nm to 204.0 
± 1.2 nm, for blank PCL NPs and RAPA-loaded PCL NPs, respectively were 
produced under optimum operating parameters/conditions; rotation speed = 1300 rpm, 
aqueous-to-organic phase volumetric ratio = 10, transmembrane flux = 140 L m−2 h−1, 
PVA surfactant concentration in the aqueous phase = 0.2 wt%, PCL concentration = 
6 g L−1 and RAPA concentration = 0.4 w/w over mass of PCL excipient. The particle 
size increased on the increasing drug loading content in the polymer matrix, and 
decreased with increasing aqueous-to-organic volumetric ratio in the membrane 
dispersion cell. 0.4 w/w of RAPA concentration was considered as the optimum drug 
loading to be encapsulated onto PCL NPs matrices with encapsulation efficiency, 
%E.E. of 98.91 % and drug loading, %D.L. of 28.26 %. The encapsulation of RAPA 
in the PCL NPs was confirmed by transmission electron microscopy (TEM), X-ray 
diffraction (XRD), differential scanning calorimetry (DSC), and attenuated total 
reflection-Fourier transform infrared spectroscopy (ATR-FTIR). In-vitro release 
studies indicated that the rapamycin was released from PCL nanoparticle in a 
sustained manner over a period of 18 h. Rapid drug release was observed from the 
RAPA nanocrystal samples with 100 % release in 2 h, due to the absence of PCL NPs 
host.  
 
Thus, we conceived that the rapamycin-loaded PCL NPs might be useful in clinical 
application primarily for intravascular delivery of anti-restenosis drugs. In future 
work, the potential of integrating micro-engineered membrane dispersion systems that 
consists of regular pore spacing membrane with the crystallisation system will be 
investigated in order to achieve smaller and more uniform size of active ingredients 
(drug) crystals growth.  
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CHAPTER 9  
 
REVERSE ANTISOLVENT PRECIPITATION OF SIZE-
TUNEABLE MICRO-CRYSTALS BY MEMBRANE 
DISPERSION MICROMIXING L: A NEW INSIGHT INTO 
INTEGRATED MEMBRANE CRYSTALLISATION SYSTEM  
Chapter overview 
Reverse antisolvent precipitation of nonsteroidal anti-inflammatory drug, 
monohydrate piroxicam (PRX) microcrystals were investigated using novel 
engineered membrane dispersion micromixing process.  The organic phase 
comprising of 1.5−2.5 wt% PRX dissolved in acetone was injected into the aqueous 
phase (Mili-Q water or 0.1−0.5 wt% hydrophilic surfactant solution) using two 
micro-fabricated membranes with different pore morphologies and spatial pore 
arrangements of 10 μm pore-sized ringed stainless steel (SS) membrane fitted in a 
semi-batch membrane dispersion cell and 40 μm pore-sized whole nickel (Ni) 
membrane applied in a membrane continuous dispersion system. The size of 
monohydrate PRX microcrystals were precisely controlled over a range of 7–34 µm 
by controlling PRX concentrations, aqueous-to-organic phase volume ratios 
(Vaq/Vor), type and concentration of surfactants (hydroxypropyl methyl cellulose 
(HPMC), polyvinyl alcohol (PVA), and pluronic-123 (P-123)). Smaller crystals (< 10 
µm) with uniform crystals size distribution (CSD) that are significantly suitable as 
inhaled drugs were produced using ringed SS membrane at the optimum process 
parameters of 25 g L−1 PRX concentration, 0.06 wt % HPMC and Vaq/Vor of 20. The 
monohydrate PRX microcrystals exhibited an elongated-rhombohedral shape at 0.06 
wt % HPMC were confirmed by optical micrographs and scanning electron 
microscopic (SEM) images. Clear characterisation peaks of monohydrate PRX 
microcrystals were successfully verified by Raman spectroscopy and differential 
scanning calorimetry (DSC). A semi-batch membrane dispersion system indicated 
better performance in producing PRX crystals over the other designed systems (i.e. 
bulk mixing, semi-batch, and continuous membrane dispersion system. Further 
application of these PRX microcrystals also have been investigated in a controllable 
seeded crystallisation system.   
9.1 Introduction  
An increasing number of newly developed active pharmaceutical ingredients (APIs) 
suffer from poor water solubility with too low oral bioavailability and erratic 
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absorption (Douroumis & Fahr, 2007; Merisko-Liversidge et al., 2003; Müller & 
Peters, 1998). An estimated 40 % of APIs fall under 
Biopharmaceutical Classification System (BCS) Class 2 or Class 4 for low solubility 
and low permeability (Löbenberg & Amidon, 2000; Varshosaz et al., 2013). These 
substances usually characterised by low bioavailability due to their low dissolution in 
gastrointestinal fluid (Teeranachaideekul et al., 2008). PRX is one of the most potent 
nonsteroidal anti-inflammatory drugs categorised in BCS Class 2 drug with high 
membrane permeability but low water solubility (Javadzadeh et al., 2007).  The 
solubility and dissolution rate in water can be improved by producing salts, co-crystals 
or amorphous particles by increasing the surface area of the drug(Merisko-Liversidge 
et al., 2003; Müller et al., 2001). A very common way to increase drug substance 
surface area is via micronization, which produces particles in the size range of less 
than 10 microns (Joshi, 2011).  
 
Many approaches have been tested to reduce particle size, including (i) mechanical 
micronization, such as milling or grinding (Krause & Müller, 2001), (ii) supercritical 
fluid technique (Tenorio et al., 2007) and (iii) controlled antisolvent precipitation 
(Chiou et al., 2007). However, these first two techniques show inevitable drawbacks, 
including the tendency of the produced particles to agglomerate, require a high-energy 
input, electrostatic effects, broad particle size distributions, thermal degradation, 
contamination and poor reproducibility among different batches, low yield and high 
equipment cost (Varshosaz et al., 2013; Viçosa et al., 2012). Nevertheless, with the 
use of antisolvent precipitation, the ultrafine drug particles formation for inhaled drug 
delivery is seemingly possible, thus appeared as the most pormissing technique (Dong 
et al., 2009; Zhang et al., 2006). The key motivation for producing these particles is 
to create conditions that favour very rapid particle formation and little or no particle 
growth. This technique is a straightforward method, rapid and easy to perform, does 
not require high stirring rates, sonication, elevated temperatures or surfactants, and 
Class 1 solvents can be avoided (Fessi et al., 1989; Othman et al., 2016a; 2016b; 
2015a; 2015b). It has been successfully used to prepare several drugs, such as 
budesonide (Rasenack et al., 2003), danazol (Zhao et al., 2007), beclomethasone 
dipropionate (Wang et al., 2007), prednisolone (Li et al., 2007), atorvastatin (Zhang 
et al., 2009), griseofulvin and fenofibrate (Meng et al., 2009), salbutamol sulfate (Xie 
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et al., 2010), L-glutamic acid (Lindenberg et al., 2008), and paracetamol (Reis et al., 
2014).  
 
PRX((4-hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-
dioxide) is one of the safest and most potent nonsteroidal anti‐inflammatory drug that 
is most widely used in the treatment of rheumatic conditions like inflammation, pain 
due to injury, menstrual cramps, arthritis, and other musculoskeletal conditions and 
non-rheumatic conditions like biliary and ureteric colic, dysmenorrheal inflammation 
and fever (Kini et al., 2011; Silva et al., 2012). PRX inhibits two cyclooxygenase 
isozymes (COX-1 and COX-2) by accelerating the prostaglandins (PG) synthesis that 
helps to mediate many physiological functions of the body, including control of blood 
pressure, respiratory and gastrointestinal tract smooth muscles (Simmons et al., 2004). 
COX-1 is involved in maintaining the physiological function of the gastrointestinal 
and renal tracts and COX-2 participates in the pain and inflammation (Frölich, 1995). 
Anti-inflammatory actions of PRX are due to the inhibition of COX-2 only whereas 
the inhibition of COX-1 leads to the unwanted side-effects like dyspepsia, heartburn, 
nausea and vomiting (Brooks, 1998). PRX indeed can be formed into three anhydrous 
polymorphic forms (I, II and III) and one monohydrate form (Hansen & Qu, 2015; 
Liu et al., 2014). Among the four polymorphs, forms I and II can be produced by 
simple crystallisation from solution, whereas forms III and IV can be prepared by 
melt/quench cooling or by spray drying from amorphous piroxicam. However, form I 
is not stable in the used solvents, thus, transformation into the monohydrate form is 
significantly encouraging especially to store any suspension samples for extended 
periods (Hansen & Qu, 2015). Since polymorphism can change the pharmacokinetic 
and pharmacodynamics characteristics of PRX (Shet et al., 2004), it is important to 
develop a fast and effective technique/system for controlling the PRX polymorphism, 
as suggested in this study.  
 
Despite of focussing on the antisolvent precipitation/crystallisation processes for the 
formation of monohydrate PRX microcrystals, the number of publications were also 
dedicated to the integrated membrane antisolvent precipitation/crystallisation 
processes in order to improve the performance of crystallisation operations 
(Charcosset et al., 2010; Curcio et al., 2003; Gugliuzza et al., 2009). The main features 
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of this integrated system are; (i) to control and limit the maximum level of 
supersaturation due to defined mass transfer across the membrane, so that crystal 
nucleation and growth is more uniform and predictable; (ii) to act as heterogeneous 
nucleation-inducing substrates; (iii) to control solid features such as size, structure 
(polymorphism), shape, and purity and level of agglomeration; and (iv) to reduce 
energy consumption compared to cooling or evaporative crystallisation (Charcosset 
et al., 2010; Ye et al., 2013). Several membrane techniques have been reported; 
reverse osmosis, membrane distillation, membrane contactor, and membrane 
templates (Charcosset et al., 2010; Drioli et al., 2012). Depending on the chemical–
physical properties of the membrane and on the process parameters (e.g. temperature, 
concentration, flowrate, etc.), the solvent evaporation rate, and hence supersaturation 
degree, nucleation and growth rate can be controlled very precisely, by choosing a 
broad set of available kinetic trajectories in the thermodynamic phase diagram, that 
are not readily achievable in conventional crystallisation methods (Di Profio et al., 
2007a; 2007b) .  
 
Integrated membrane crystallisation processes are frequently presented as a new 
alternative strategy to attain favourable crystals product. However, these studies are 
merely focused on the crystallisation or precipitation of a few model compounds (such 
as lysozyme, NaCl, carbonates, etc.) using a limited number of membrane materials 
(polypropylene (PP), polyvinylidene fluoride (PVDF), polyamide, and etc.) 
(Chabanon et al., 2016). To the best of our knowledge, this work is the first 
experimental study dealing with the formation of monohydrate PRX microcrystals by 
micro-engineered membrane dispersion cell, fitted with either ringed stainless steel 
(SS) or whole nickel (Ni) membrane. The same technique was successfully 
implemented for the formation of lipid nanoparticles (Charcosset et al., 2005), 
nanocapsules (Charcosset & Fessi, 2005), gel microbeads (Zhou et al.,  2007), 
microcapsules (Wagdare et al., 2011), liposomes (Jaafar-Maalej et al., 2011; Laouini 
et al., 2013), polymeric nanoparticles (Othman et al., 2016) and barium sulfate 
nanoparticles (Chen et al., 2004).  
 
In the reverse antisolvent crystallisation/precipitation procedure described in this 
work the membrane does not act as a sieving barrier for the selective transport of 
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specific components, but as a physical support that enable the generation and 
sustenance of a controlled supersaturated environment in which crystals can nucleate 
and grow. The effects of the composition of both the organic and aqueous phases and 
the operating conditions of the dispersion cell on the size distribution, agglomeration 
and morphology of the microcrystals produced were investigated in this study. 
Furthermore, both a semi-batch and a continuous membrane 
crystallisation/precipitation process were tested and compared. A novel membrane 
crystallisation technique that allows the production of micro-crystals with narrow size 
distribution and low degree of agglomeration is presented in this work. This approach 
is believed to be a very valuable alternative for the production of particles for 
inhalation because of its low cost, simplicity, the possibility to run in continuous and 
the high level of control on particle size and characteristics.  
9.2 Materials and methods  
9.2.1 Materials 
Acetone (Ace, purity ≥ 99.98 %) was purchased from Fisher Scientific 
(Loughborough, UK), Piroxicam (PRX) (99% purity) for Form I and II were obtained 
from Hangzhou Hyper Chemicals Limited (Zhejiang, China).  Polyvinyl alcohol 
(PVA, Mw = 13,000-23,000 g mol
-1, 87-89 % hydrolysed), poly(ethylene glycol)-
block-poly(propylene glycol)-block-poly(ethylene glycol) (Pluronic® P-123, Mn ~ 
5,800) and hydroxylpropyl methylcellulose (HPMC, typical Mw = 10,000) were 
supplied by Sigma-Aldrich, Inc. (Dorset, UK) and used as water soluble surfactants. 
The antisolvent phase was deionized water obtained by reverse osmosis (Milli-Q®, 
Millipore) or aqueous surfactant solutions. The role of surfactant was to prevent 
agglomeration, coalescence and imperfect surface formation, as well as to reduce the 
size of the microcrystals. The organic phase was a homogeneous solution containing 
15 − 25 g L−1 of PRX drug in Ace.  
9.2.2 Membrane dispersion cell 
Two different sets of experimental system (i.e. semi-batch and continuous membrane 
system) were performed in this study, as shown in Fig. 9.1.  
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In the first of experiment, the PRX microcrystals were initially prepared using a flat 
disc-shaped membrane fitted in a semi-batch stirred cell shown in Fig. 9.1 (a-(i-ii)). 
The cell and membranes were supplied by Micropore Technologies Ltd (Redcar, UK). 
The stirrer was driven by a 24 V DC motor (Instek model PR-3060) and its rotation 
speed was controlled at 1,500 rpm by the applied voltage. A ringed stainless steel (SS) 
membrane had the same dimensions and a reduced operating (active) area of 2.76 cm2 
containing 6,912 pores with a perfectly rectangular array of 10 μm pores located 
circularly within the ringed area of the membrane surface with a pitch of 200 m (Fig. 
9.1 (a-iii)).  
 
While, for the continuous membrane dispersion system (Fig. 9.1 (b-(i-ii))), a nickel 
(Ni) membrane with an effective diameter of 3.3 cm and an operating area, 
mA , of 
8.55 cm2 with 24,690 hexagonally arranged pores with a diameter of 40 m, spaced 
apart at a constant distance of 200 m was applied. Comprehensive observations on 
these two membranes have been clearly explained in our previous work (Othman et 
al., 2016a).    
 
 
Fig. 9.1: Schematic diagram of; (a) Semi-batch membrane dispersion cell containing 
paddle stirrer above a 10-μm of flat disc SS micro-engineered membrane with; (i) 
photomicrograph of 10-μm membrane, (ii) schematic diagram of the experimental set- 
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up, (iii) rapid solvent displacement mechanism during the formation of PRX 
microcrystals; (b) Continuous membrane dispersion cell with a simple paddle stirrer 
above a 40-μm of flat disc Ni micro-engineered membrane with (i) photomicrograph 
of 40-μm membrane, (ii) schematic diagram of the experimental set-up for the 
formation of PRX microcrystals.  
9.2.3 Experimental set-up and semi-batch preparation of monohydrate PRX 
microcrystals 
The cell was filled with 30−180 mL of mili-Q water or aqueous surfactant solution 
and the experiment was run until a predetermined aqueous-to-organic phase volume 
ratio was achieved. The organic phase was 2.5−1.5 wt% PRX in Ace and was injected 
through the membrane using 11 Elite syringe pumps (Harvard Apparatus, Cambridge, 
UK). The organic phase flow rate, Q  through the ringed SS membrane was fixed at 
18 mL min-1 in order to achieve the same maximum transmembrane flux of 4000 L 
m-2 h-1 as acquired from the whole Ni membrane. To reach the same flux through the 
ringed membrane, the organic phase flow rate was reduced to 18 mL min-1, calculated 
from the equation: Q)A/A(Q mRR  , where RA  and mA  are the operating areas of the 
ringed and whole membrane, respectively. The stirring speed was fixed at the 
maximum value of 1500 rpm, which generated a shear stress on the membrane surface 
of 17.5 Pa. The aqueous phase simultaneously turned bright yellow and cloudy as 
soon as the organic phase was brought in contact with the aqueous phase due to rapid 
exchange of two solvents at the interface, i.e. Ace diffused from the organic to the 
aqueous phase and water diffused in the opposite direction (Fig. 9.1 (a-ii)). Each 
experiment was repeated at least three times.The maximum organic phase flow rate 
was applied in order to allow a rapid contact between the two phases and, thus, a faster 
generation of supersaturation that is associated to the precipitation of smaller crystals. 
The high shear stress at the membrane surface generated by the maximum stirring 
rate, instead, determines a quick removal of the newly formed crystals from the 
membrane surface, which is characterized by a high supersaturation, and their 
migration to the water-rich phase where crystal growth is not possible because of the 
low solute concentration. That also generates smaller crystals and a narrower size 
distribution. 
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After each experiment, the membrane was rinsed with Mili-Q water and then 
sonicated in Ace for 30 min using a Fisher Scientific ultrasonic bath (model FB 
15046) in order to remove any microcrystals leftovers from the membrane surface. 
The membrane was rinsed again with Milli-Q water and then finally washed with 
Milli-Q water in an ultrasonic bath for 5 min to restore hydrophilic properties of the 
used membrane. The membrane surface was found progressively turn to hydrophilic 
throughout the cleaning procedures as has been proved in our previous study by 
measuring the membrane surface contact angle (Othman et al., 2016a). The membrane 
should be hydrophilic during experiments to minimize wetting of the membrane 
surface by the organic phase and pore clogging by the deposited hydrophobic drug. 
9.2.4 Experimental set-up for seeded batch crystallisation experiment  
The 350 g cooling crystallisations were carried out using a 400 mL jacketed glass 
vessel equipped with overhead stirring at 325 rpm (PTFE pitch blade turbine). Fig. 
9.2 shows a schematic of the rig used for the experiments. 
 
 
Fig. 9.2: Schematic of the rig used for the experiments. 
 
The temperature was controlled using a PT-100 temperature probe connected to a 
Huber Ministat 125 thermoregulator. A PAT array was used, consisting of an RXN1 
Raman analyser with immersion probe and 785 nm laser (Kaiser with iC Raman 4.1 
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software), G400 Mettler Toledo Focused Beam Reflectance Measurement (FBRM) 
probe (5-2000 microns equipped with iCFBRM software version 4.3) and a particle 
vision and measurement (PVM) V819 probe (Mettler Toledo) with an on-line image 
acquisition software (version 8.3). The pre- and post-processing of the data was done 
with Matlab R2013, iC Raman 4.1 and Excel 2010. The data from the FBRM and the 
Huber is transmitted in real-time to the CryPRINS software (Crystallisation Process 
Informatics System) which allows real time temperature control and simultaneous 
monitoring of signals from different probes (FBRM, ATR-UV/Vis, thermocouple, 
conductivity probes and pH-meter). The solvent for the seeded cooling crystallisation 
experiments was chosen based on solubility data as well as the available literature on 
piroxicam crystallisation (Hansen & Qu, 2015; Liu & Hansen, 2014). 
 
A mixture of water and an organic solvent needs to be used in order to be able to grow 
crystals of the monohydrate form of PRX without excessively reducing its solubility 
(this compound is almost insoluble in pure water). Mixtures of 20 % water in acetone 
were used in this work since this solvent composition allows nucleation and growth 
of the monohydrate form (Hansen & Qu, 2015). The PRX solubility is still 
considerably increasing as the temperature rises, which is a required condition to grow 
crystals by cooling crystallisation. PRX solutions saturated at 40 °C (4.4 g of 
piroxicam in 350 g of solvent) were prepared and heated up to 50 °C. Temperature 
was kept constant for around 30 min to allow complete dissolution of solid piroxicam. 
After that, the solution was cooled down to 37 °C and seeded. The amount of seeds 
was 2 % of the total mass of PRX in solution in order to minimize crystal 
agglomeration right after seeding. Additional experiment using 6 % seeds was 
performed with the membrane crystallisation seeds for comparison.  
9.2.5 Preparation of PRX microcrystals seed for crystallisation process 
9.2.5.1 Membrane crystallisation 
Monohydrate PRX microcrystals were prepared at the PRX concentration of 15 g L−1, 
rotation speed of 1500 rpm (17.5 Pa), organic phase injection rate of 18 mL min−1 
(maximum transmembrane flux = 4000 L m-2 h-1) and aqueous-to-organic phase 
volume ratio, Vaq/Vor was 5 (i.e. Vor = 6 mL, Vaq = 30 mL) without surfactant addition 
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by antisolvent precipitation method using a flat disc-shaped 40 µm of whole Ni 
membrane installed in a stirred cell. Similar experimental set-up, as shown in Fig. 1A 
was applied in this experiment. These operative conditions allow producing micro-
crystals in the size range of 25−35 μm (volume mean diameter from Malvern 
Mastersizer). This slurry microcrystals were collected via pipette and inserted directly 
in the vessel during the seeded batch experiments 
9.2.5.2 Antisolvent crystallisation 
Seeds from antisolvent crystallisation were produced pumping water in a solution of 
PRX in water (concentration of 35 mg g−1 acetone). The solution was prepared by 
dissolving solid PRX at 40 °C in the 400 mL vessel described in the Section 9.2.4. A 
peristaltic pump (Masterflex L/S 7544–06 drive, L/S 14 pump head, Cole-Parmer, IL, 
UK) was used to pump water in the PRX solution at a rate of 2.5 mL min−1. The rate 
was chosen after few preliminary experiments in order to obtain pure monohydrate 
PRX at the end of the batch. Both faster and slower flow rates determined nucleation 
of form II. FBRM was used during the experiments to monitor nucleation, 
agglomeration and shape of the particles. Crystals at the end of the experiment were 
filtered and dried. The CSD was measured using a Malvern Mastersizer. 
9.2.5.3 Polymorphic transformation 
Piroxicam form I (fine powder as purchased) was suspended in water and let transform 
to monohydrate. A total amount of 2.2 g of piroxicam was suspended in 500 g of water 
at 20 °C. The Raman immersion probe described in Section 9.2.4 was used to monitor 
the polymorphic transformation. At the end of the experiments the crystals were 
filtered and dried. Their CSD was measured by Malvern Mastersizer 
9.2.6 Characterisation of the prepared microcrystals 
9.2.6.1 Particle size analysis 
The crystals size distribution (CSD) was assessed using a Malvern Mastersizer 2000 
(Malvern Intstrument Ltd, Malvern, Worcesterhire, UK. This instrument uses laser 
diffraction and the full Mie theory to give an accurate CSD. The sample can be 
dispersed in a liquid and sent to the optical bench, which captures several scattering 
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patterns in order to average the results. The outcome of the analysis is the relative 
distribution in volume percentage of the sample particles in the size classes, expressed 
in μm. The results can be post-processed to calculate the surface, length or number 
distribution or relevant statistics such as the derived diameters D [m,n]: 
𝐷[𝑚, 𝑛] = [
∑ 𝑉𝑖𝑑𝑖
𝑚−3
∑ 𝑉𝑖𝑑𝑖
𝑛−3 ]
1
𝑚−𝑛
                                                                                        (9.1) 
 
where 𝑉𝑖 is the relative volume in class 𝑖 with mean class diameter of 𝑑𝑖. In particular, 
D [4,3] is defined as the Volume Weighted Mean and D [3,2] as the Surface Weighted 
Mean. Other relevant statistics are the standard deviation, the volume concentration 
and the specific surface area (particle total area divided by total weight). The relative 
span of a crystals size distribution was used to express the degree of crystals size 
uniformity: (Malvern Instrument, 2007).  
 
span =  
[𝑑 (𝑣,0.9) − 𝑑 (𝑣,0.1)]
𝑑 (𝑣,0.5)
                                                                                      (9.2) 
where 𝑑 (𝑣, 0.1), 𝑑 (𝑣, 0.5) and 𝑑 (𝑣, 0.9) are the values of the particles diameter at 
10 %, 50 % and 90 % of the cumulative distribution. 
 
In this work, a saturated solution of piroxicam monohydrate in water at room 
temperature was used as dispersant. The micro-crystals produced in the cell were 
collected into a small Becker and then transferred to the wet dispersion unit using a 
pipette. The final size distribution was the result of averaging two consecutive 
measurements. 
9.2.6.2 Raman microscopy  
The polymorphic discrimination of the PRX crystalline structures was performed 
using a Thermo Scientific DXR Raman Microscope (Thermo Scientific, UK) with 
780 nm laser. The Raman spectrums were analysed with the accompanying version 
8.3 of the Omnic software (Thermo Scientific, UK). Each spectrum was the results of 
the averaging 10 measurement collected with 10 s scan time using a laser power of 15 
mV. 10x Olympus of objective lens were applied in order to aquire higher samples 
detection focus (Thermo Scientific, 2013). 
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9.2.6.3 Focused beam reflectance measurement (FBRM)  
FBRM is an extensively used in situ technique that gives information about 
nucleation, dissolution, metastable zone width, polymorphic transformation, crystals 
growth and size distribution in particulate systems in real time. Based on the rotating 
speed of the laser (vS and back scattering time (∆t), the chord length distribution 
(CLD) for the particles is obtained using equation; chord length = vS ∆t. The CLD 
obtained from FBRM is grouped in 90 channels from 0.8–1000 μm. The readings 
obtained from FBRM can be displayed in a variety of formats from simple total 
number of counts per second to square weighted or cubic weighted distributions. 
9.2.6.4 Differential scanning calorimetry (DSC)  
Differential Scanning Calorimeter (DSC) analysis was performed using a TA 
Instruments Model Q100 to examine polymorphic purity and to validate the results 
obtained from Raman spectroscopy analysis. 5 − 10 mg of the sample (pure PRX and 
monohydrate PRX microcrystals) were accurately weighed into aluminium pans and 
hermetically sealed. Monohydrate PRX microcrystals produced by membrane 
dispersion cell were lyophylized by freeze-drying the sediment in a freeze dryer 
(Edwards, type EF4 Modulyo). The sample pan was heated from room temperature to 
350 oC using a scanning rate of 10 oC min−1 and a similar empty pan was used as the 
reference. Dry nitrogen at 60 mL min−1 was used as the purge gas. Triple runs were 
carried out on each sample to check reproducibility. 
9.2.6.4 Scanning electron microscopy (SEM) 
Electron micrographs of PRX microcrystals samples precipitated using micro-
engineered membrane dispersion cell without and in the present of surfactants (i.e. 
PVA, P-123 and HPMC) were obtained using a Hitachi model TM3030 benchtop 
SEM. Each samples were analysed by following the standard procedures described in 
Section 7.2.4.3. 
9.3 Monohydrate PRX microcrystals formation system validation 
In this study, a new insight into the integrate membrane crystallisation system can be 
fundamentally elucidated by comparing a few type of systems (System-1: bulk 
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mixing, System-2: semi-batch cell, System-3: semi batch membrane dispersion cell, 
and System-4: continuous membrane dispersion system). Two ultimate challenges of 
developing this integrated system have been addressed in several reports and reviews; 
(i) Product quality issues (quality by design) with the aims of achieving the desired 
polymorphic form, the CSD and the crystal shape factor to be mastered (Hermanto et 
al., 2007; Mangin et al., 2009; Variankaval et al., 2009; Roberts & Debenedetti, 2002; 
Tung, 2013), and (ii) Process issues include batch to continuous breakthrough 
approaches, scale up challenges, intensification and green engineering developments 
(Calabrese & Pissavini, 2011; Roberts & Debenedetti, 2002; Variankaval et al., 2009). 
Table 9.1. summarises the operating parameters/conditions utilised in each system 
(System-1, System-2, Sytem-3 and System-4) with the average shear stress on the 
membrane surface was calculated based on the equations given in our previous study 
(Othman et al., 2016a). System-1 (bulk mixing) was conducted spontaneously without 
the aid of macro mixing effect (e.g. stirring speed) in order to represent the 
conventional technique. While, system-2 and -3 (as can be seen in Fig. 9.1 (a-i) were 
purposely investigated to validate the efficacy and impotency of using a micro-
engineered membrane during the formation of microcrystals.  
 
An extended observation/idea towards the development of an integrated membrane 
crystallisation system was further examined in System-4 (continuous membrane 
dispersion system), as depicted in Fig. 9.1 (b-i). This system was contributed by 
Micropore Technologies Ltd. (Redcar, UK), with the organic phase consisted of 15 g 
L−1 PRX in Ace and was injected through the membrane using a peristaltic pump 
(Masterflex L/S 7544–06 drive, L/S 14 pump head, Cole-Parmer, IL, UK) at a 
constant flow rate of 18 mL min−1 corresponding to the 1293 L m-2 h-1. The stirring 
speed was fixed at maximum value of 1500 rpm, which generated a shear stress on 
the membrane surface of 8.7 Pa. The aqueous phase was pumped into the cell at a 
constant flow rate of 90 mL min−1, which is equivalent to the aqueous-to-organic 
phase flow rate ratio, Qaq/Qor of 5. Spontaneous formation of PRX microcrystals 
started as soon as the organic phase was brought in contact with the aqueous phase. 
The PRX suspension was kept under stirring within the residence time of ~ 0.93 min 
(nearly 1 min) and finally the suspension was collected and its particle size was 
analysed using Malvern Mastersizer 2000 at different predetermined time intervals. 
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For clear observation and to prevent from having any agglomeration during the 
formation of PRX microcrystals, the organic phase was fixed at 15 g L−1 PRX in Ace, 
no surfactant was added in the aqueous phase and 40-µm of whole Ni was applied in 
System-3 and -4.  
 
Table 9.1: The operating parameters and conditions utilised in each systems (System-
1: bulk mixing, System-2: semi-batch cell, System-3: semi batch membrane 
dispersion cell, and System-4: continuous membrane dispersion system) and the 
volume weighted mean size (μm) of PRX microcrystals. The organic phase was 15 g 
L−1 PRX in Ace and the aqueous phase was Milli-Q water. No membrane was applied 
in System-1 and -2, whereas 40 µm whole Ni membrane for System-1 and -4.  
Systems 
Vaq/Vor 
or 
Qaq/Qor 
Stirring 
speed 
(rpm) 
Average 
shear 
stress, τ 
(Pa) 
Injection 
rate 
(mL 
min−1) 
Flux 
(L m−2 
h−1) 
D [4, 3] 
(µm) 
Span 
1 5 - - - - 86 ± 7.6 2.3 ± 0.21 
2 5 1500 - 18 - 33 ± 1.2 1.3 ± 0.06 
3 5 1500 8.7 18 1293 29 ± 0.7 1.1 ± 0.04 
4a 5 1500 8.7 18 1293 39 ± 1.4 1.4 ± 0.01 
* Note: Each experiments were repeated at least thrice with the error bars measured 
as the standard deviations. D [4,3] = volume weighted mean size (μm) of PRX 
microcrystals. a = data collection at 1 minute microcrystals formation in a membrane 
continuous system.  
9.4 Results and discussion 
9.4.1 Effect of the PRX concentration    
The effect of different PRX concentration in the organic phase (ranged from 15 to 25 
g L−1) on the volume weighted mean size, D [4, 3] at a rotation speed of 1500 rpm 
and a transmembrane flux of 4000 L m−2 h−1 through a 10 µm ringed SS membrane at 
a constant aqueous-to-organic phase ratio, Vaq/Vor = 10 is presented in Fig. 9.3(a). The 
microcrystals size, D [4, 3] decreased with an increase in PRX concentration with the 
highest size of 35 ± 1.0 µm was obtained at 15 g L-1 with span value of 1.5 ± 0.06 and 
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the smallest crystals size of 24 ± 1.5 µm and span (1.1 ± 0.01) values were obtained 
at 25 g L−1. The size of a microcrystals formed during antisolvent precipitation method 
is dependent on the rate of at which organic solvent diffuses into the aqueous phase 
and the relative rates of nucleation, crystals growth, and agglomeration. The 
promotion of crystals growth over nucleation leads to fewer and larger crystals. The 
rate of crystals growth is given by: 
g
PRXPRXg CCKG )(
* , where gK  is the growth 
constant, 
PRXC  and 
*
PRXC  are the local concentration and solubility of PRX in the 
solvent mixture, respectively, and g is typically between 1 and 2 for organic systems. 
The rate of nucleation is given by: 
b
PRXPRXb CCKB )(
* , where bK  is the nucleation 
constant, and b lies between 0.5 and 2.5. Since b » g, lower supersaturations,
*
PRXPRX CC  , should promote particle growth over nucleation, leading to fewer and 
larger particles, whereas higher supersaturations will promote nucleation, resulting in 
a larger population of smaller particles (Davey & Garside, 2000; Kurup & Raj, 2016; 
Mohameed et al., 2001; Zhao et al., 2007).  
 
The volume crystals size distribution (CSD) depicted in Fig. 9.3 (b) are in a good 
agreement   with the above observations featuring the minimum particle size at the 
maximum concentration of PRX, due to the higher creation of supersaturation level 
and a faster nucleation rate that resulting in smaller particle sizes. A uniform and 
narrow CSD was clearly shown at the higher concentration of PRX (25 g L−1) with 
the smallest span value (1.1 ± 0.01). The same observations were also obtained by 
Park & Yeo (2010) in the observation of Roxithromycin crystal habit, Cho et al. 
(2010) in megestrol acetate microcrystals formation and Wang et al., (2007) in the 
preparation of ultrafine beclomethasone dipropionate by ant-solvent precipitation 
method.  
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Fig. 9.3: Effect of different PRX concentrations to; (a) the volume weighted mean 
size (µm), and (b) the volume size distribution at constant rotation speed = 1500 rpm, 
volume ratio and Vaq/Vor = 10, organic phase injection rate = 18 ml min
−1 using 10 μm 
size of SS micro-engineered membrane. No surfactant was added. 
9.4.2 Effect of different type and concentration of surfactant 
Monohydrate PRX microcrystals were prepared by reverse antisolvent precipitation 
using three type of surfactants such as PVA, P-123 and HPMC at constant PRX 
concentration (25 g L−1), aqueous-to-organic phase volume ratio (Vaq/Vor = 10), 
organic phase injection rate (18 mL min−1) and rotation speed of 1500 rpm (17.5 Pa). 
Three different concentrations (0.1 wt %, 0.25 wt % and 0.5 wt %) of each surfactants 
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were used and additional experiments were carried out with HPMC for further 
investigation on the optimum surfactant concentration. Fig 9.4 (a) shows the effect of 
different surfactant type on the volume weighted mean crystals size, D [4, 3] at various 
concentrations. The main intention of this study was to find stabilizing agents which 
can stop the molecular association and the crystal growth by forming a protective 
layer around the nucleation germs in order to obtain micron-sized crystals, and indeed 
to hinder crystals agglomeration. This effect can be explained by the fact that the 
addition of surfactants may contribute to a reduction in mean particle size, from 24 ± 
1.5 µm (without surfactant) to 16 ± 2.0 µm (at 0.1 wt % HPMC surfactant), due to the 
surface-active properties of the surfactants (Lim & Kim, 2002; Won et al., 2005).  
 
By comparing experiments performed at the same concentration of different polymers 
(Fig. 9.4 (a)) it is clear that the most effective surfactant among those screened was 
HPMC with the smallest size of crystals reached at the end of the semi-batch 
experiments for a concentration of 0.1 wt% over the total PRX and a reduction of the 
D [4, 3] of around 10μm compared to experiments conducted without the use of 
polymers. PVA and P-123 did not reduce significantly the size of the microcrystals 
produced compared to experiments carried out with similar operating conditions but 
in the absence of any kind of surfactant (D [4, 3] around 25 μm). Furthermore, 
different concentrations of these two polymers generated very similar final CSD 
showing a very limited inhibition effect on growth and nucleation kinetics of PRX 
within the range of concentration used (see Fig. 9.5). The difference in action is 
probably due to the different strength and nature of interactions between each polymer 
and the surface of the microcrystals. Sahoo et al. (2002) explained that PVA is a 
partially hydrolyzed copolymer of poly(vinyl acetate) and poly (vinyl alcohol) with 
considerable block copolymer character. While, P-123 is a triblock polymer with the 
structure poly(ethylene glycol)-block- poly(propylene glycol)-block-poly(ethylene 
glycol) and is a nonionic surfactant (Zhang et al., 2009). Varshosaz et al. (2013) also 
revealed that when the CP-123 increases, the concentration of the block copolymer 
increases and a great many particles come into being seriously agglomerated, P-123 
molecules fragmentation reactions take over and the micelles are much longer, 
causing them to overlap and to form a transient network.  
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The inhibiting effect of HPMC on the kinetic of nucleation of PRX monohydrate was 
already showed elsewhere (Hansen & Qu, 2015) but it is worth noticing how HPMC 
concentration higher than 0.1 generated an increase in the size of the microcrystals 
with a final CSD very similar to the one obtained in the absence of surfactants. Since 
this trend is not in agreement with most of the literature (Trasi & Taylor, 2012; 
Ilevbare et al., 2012a; 2012b; 2012c; Reis et al., 2014) a series of further experiments 
at lower concentration of HPMC was performed. The results are shown in Fig. 9.4 (b) 
where it can be observed that the addition of very small amounts of HPMC decreased 
the size of PRX microcrystals up to around 10 μm, obtained at a concentration of 0.06 
wt% over the total PRX. This trend is in agreement with the previous literature. 
However, above this concentration the size of PRX microcrystals starts increasing 
again as the concentration of HPMC increases. 
 
Optical images of the microcrystals obtained at those concentrations showed that the 
increase in size or the microcrystals is not due to increase of agglomeration. Therefore, 
it can be concluded that the inhibiting effect of HPMC decreases for concentrations 
above 0.06 wt % over the total PRX. A possible reason for this behaviour is an 
increase in the intermolecular interactions among polymer molecules (associated to 
higher HPMC concentrations) that reduces the contact with the surface of the 
microcrystals and, therefore, reduces the inhibition effect. However, further 
investigation is needed to elucidate this peculiar effect of HPMC concentration on the 
size distribution of PRX microcrystals. 
9.4.3 Effect of different volume ratio 
In this section, monohydrate PRX microcrystals were produced at the optimum 
operating parameters of; PRX concentration (25 g L−1), HPMC surfactant 
concentration (0.06 wt %) and rotation speed of 1500 rpm (17.5 Pa) with 6 mL of 
PRX in Ace (organic phase) was injected at constant maximum flux of 4000 L m−2 
h−1 though a 10 µm ringed SS membrane into 30, 60, 90, 120, and 180 mL of HPMC 
hydrophilic aqueous solution to achieve an aqueous-to-organic phase volumetric ratio 
of 5, 10, 15, 20, and 30 3.0, 4.5, 7.0. The D [4, 3] was drastically decreased with the 
increasing value of Vaq/Vor, from 5 to 20 (see Fig. 9.6 (a)). When the drug solution is 
added to the anti-solvent, rapid reduction in the drug concentration occurs with an 
CHAPTER 9  
                                                                                                                                 234
 
 
Rahimah Othman  2016 
 
increase in the amount of anti-solvent leading to rapid precipitation of the drug into 
microcrystals. Furthermore, a greater amount of anti-solvent lead to a greater 
nucleation rate and produces smaller nuclei and simultaneously the growth occurs. In 
the subsequent growth, the higher anti-solvent amount increases the diffusion distance 
for growing species and consequent diffusion becomes the limiting step for the growth 
nuclei (Kakran et al., 2012; Li et al., 2011). The nucleation rate is more dependent on 
supersaturation in comparison with the crystal growth rate and greatly affects the final 
particle size distribution. There is an inversely proportionality between the critical 
size and the logarithm of the supersaturation ratio. Therefore, high supersaturation 
condition results in small particles due to the formation of large number of nuclei 
(Paulino et al., 2013). However, a sudden increase in crystals size was detected as the 
volume ratio increases to 30, due to undistributed shear stress which predominantly 
hindered the effective rapid micromixing process, thus leading bigger size of crystals. 
These results can be also proved by the optical micrograph of monohydrate PRX 
microcrystals produced at different volume phase ratio, as depicted in Fig. 9.7, with 
highly uniform monodispersed crystals were detected at Vaq/Vor = 20.  
9.4.4 Effect of organic solvent removal 
Fig. 9.6 (b) revealed the effect of organic solvent removal during the preparation of 
monohydrate PRX microcrystals at constant optimum operating parameters; PRX 
concentration (25 g L−1), HPMC concentration (0.06 wt %), rotation speed of 1500 
rpm (17.5 Pa), organic phase injection rate (18 mL min−1) and Vaq/Vor = 20. As Ace 
(with boiling point 56 oC) evaporates using Rotavapors R-210 (Büchi Labortechnik, 
Oldham, UK), the tendency of Ace to diffuse into the liquid phase was decreased until 
the equilibrium crystals growth was achieved. No significant difference in the crystals 
size distribution (CSD) was observed in the microcrystals suspension before and after 
solvent removal, which means that the crystals formation process was mainly 
controlled and driven by the rate of inter diffusion of the two phases. Microcrystals 
were formed once the organic phase was brought into contact with the aqueous phase, 
irrespective of the acetone removal rate. Indeed, the critical concentration of PRX in 
the acetone–water mixture was reached without solvent evaporation, simply by 
dilution of the organic phase with water present in the cell. Therefore, as no difference 
was detected in CSD, it was not necessary to optimize experimental conditions in the 
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rotary evaporator such as evaporation temperature, pressure, rotation speed of the 
flask, and etc. 
9.4.5 Reproducibility test 
Throughout the previous findings, the size-tuneable uniform monodispersed 
monohydrate PRX can be achieved at the operating parameters of; PRX concentration 
(25 g L−1), HPMC concentration (0.06 wt %), rotation speed of 1500 rpm (17.5 Pa), 
organic phase injection rate (18 mL min−1) and Vaq/Vor = 20 and without organic 
solvent removal using ringed SS membrane. The experiment conducted under these 
optimum conditions was repeated thrice in order to test the reproducibility of the 
technique. The resulting data, presented in Fig. 9.6 (c), revealed very good 
reproducibility and repeatability, in terms of crystals size distribution (CSD) between 
different microcrystals batches produced at the optimum formulation parameters. 
Similar observations were also obtained by previous researchers (Laouini et al., 2013; 
Othman et al., 2015) with an agreement that no size alteration occurred during the 
organic solvent removal method.  
9.4.6 Effect of membrane cleaning procedure 
Membrane cleaning was performed using the procedure described in Section 9.2.3 in 
order to restore the original hydrophilicity of the membrane surface after being used 
in the formation of monohydrate PRX microcrystals. The reason for this treatment 
was to prevent the organic phase from being spread over the membrane surface and 
to ensure that tiny jets of the organic phase emerging from the membrane pores 
penetrate thoroughly into the aqueous phase without any obstruction. A clear 
scientific finding on the membrane cleaning procedures with intensive contact angle 
measurements were revealed in our previous study (Othman et al., 2016b)  No 
difference in the monohydrate PRX microcrystals size distribution was observed 
between the two membranes, which means that the membrane properties were 
completely restored after cleaning, as depicted in Fig. 9.6 (c). The membrane was 
found significantly fouled before cleaning with large crystals aggregates deposited 
near the pore exits or inside the pores. After cleaning no particle could be seen on the 
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membrane surfaces and all pores were unclogged, indicating that the cleaning 
procedure was appropriate. 
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Fig. 9.4: Volume weighted mean size (µm) of PRX micro-crystals at different; (a) 
type of surfactant for 0.1, 0.25, 0.5 wt %, and (b) concentration of HPMC surfactant 
from 0.03−0.5 wt % at constant rotation speed = 1500 rpm, volume ratio, Vaq/Vor = 
10, organic phase injection rate = 18 ml min−1 using 10 μm size of SS micro-
engineered membrane. PRX concentration in organic phase was 25 g L−1. 
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Fig. 9.5: The volume distribution of monohydrate PRX micro-crystals as a function 
of particle size (µm) for different type of surfactants; (a) P-123, (b) PVA) and (c) 
HPMC at different concentration of surfactant, 0.1, 0.25 and 0.5 wt %, respectively. 
The rotation speed was fixed at 1500 rpm, volume ratio, Vaq/Vor = 10, organic phase 
injection rate = 18 ml min−1 using 10 μm size of SS micro-engineered membrane.  
PRX concentration in organic phase was 25 g L−1. 
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Fig. 9.6: (a) Effect of different aqueous-to-organic phase volume ratio; (b) effect of 
organic solvent evaporation on monohydrate PRX microcrystals size (µm), and (c) 
experimental data reproducibility at constant rotation speed = 1500 rpm, organic 
phase injection rate = 18 ml min−1 using 10 μm size of SS micro-engineered 
membrane. HPMC surfactant concentration was 0.06 wt % and PRX concentration in 
organic phase was 25 g L−1. The volume ratio, Vaq/Vor = 10 for (b) and (c) was 10.  
 
CHAPTER 9  
                                                                                                                                 239
 
 
Rahimah Othman  2016 
 
 
Fig. 9.7: Optical micrograph of monohydrate PRX microcrystals produced at different 
aqueous-to-organic phase volume ratio; (a) Qaq/Qor = 5, (b) Qaq/Qor = 10, (c) Qaq/Qor 
= 20, and (d) Qaq/Qor = 30. The rotation speed was fixed at 1500 rpm, organic phase 
injection rate = 18 ml min−1 using 10 μm size of SS micro-engineered membrane. 
HPMC surfactant concentration was 0.06 wt % and PRX concentration in organic 
phase was 25 g L−1.  
9.4.7 SEM images of produced monohydrate PRX microcrystals 
SEM micrographs of monohydrate PRX microcrystals synthesised at the optimum 
formulations of; PRX concentration (25 g L−1), rotation speed of 1500 rpm (17.5 Pa), 
organic phase injection rate (18 mL min−1) and Vaq/Vor = 20) are shown in Fig. 9.8 
without and in the present of different surfactant type at the optimum concentration 
(0.06 wt %). As can be seen, for each samples, the monohydrate PRX microcrystals 
exhibited an elongated-rhombohedral shape. Without surfactant addition, the 
microcrystals tend to be agglomerated because of crystals instability and smaller size 
of crystals (see Fig. 9.8 (a)). However, a full steric stabilisation was detected at 0.06 
wt % HPMC surfactant, whereas a bad saturated surface coverage was exhibited for 
100 μm
(a)
(c)
100 μm
(d)
100 μm
(b)
100 μm
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the microcrystals produced in the present of P-123 and PVA, respectively. These 
observations confirmed that the microcrystals size uniformity can be controlled at low 
concentration of HPMC surfactant and also showed a good correlation with the 
crystals size results obtained in Fig. 9.4.  
9.4.8 Monohydrate PRX microcrystals properties validation  
As shown in Fig. 9.9 (a), the Raman spectra of the various forms showed enough 
differences to distinguish among form I, form II, and the monohydrate. The PRX 
polymorphs and monohydrate exhibited characteristic peaks in the Raman spectrum. 
The characteristic peaks of forms I and II are at 1335 and 1523cm–1 and at 1543 and 
1568cm–1, respectively. The monohydrate PRX microcrystals showed characteristic 
peaks at 1007 and 1400cm–1. This result confirmed that a complete transformation of 
PRX can be easily done in a micro-engineered membrane dispersion cell without 
elevating the temperature or in supercritical conditions. Similar results were also 
obtained by (Hansen & Qu, 2015; Liu et al., 2014). 
 
Fig. 9.9 (b) shows the DSC thermograms of pure PRX (Form I) and monohydrate 
PRX microcrystals synthesised at the optimum formulations. A specific and sharp 
endothermic peak of pure PRX (From I) sample was identified at 203 oC due to its 
melting point. One single endothermic peak was also detected at 280 oC represents 
the degradation temperature of pure PRX. The DSC thermogram of the monohydrate 
showed a broad endothermic peak at 131 oC associated with the loss of the water 
molecule which is consistent with the literature (Lavric et al., 2010; Vrečer et al., 
2003). A single endothermic peak represents the pure PRX composition also can be 
seen in the monohydrate PRX microcrystals thermogram. 
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Fig. 9.8: Scanning electron microscope (SEM) images of monohydrate PRX 
microcrystals synthesised by different formation methods; (a) without surfactant, (b) 
with HPMC surfactant, (c) with P-123 surfactant, and (d) with PVA surfactant 
addition inside an aqueous phase.  The rotation speed was fixed at 1500 rpm, organic 
phase injection rate = 18 ml min−1, PRX concentration in organic phase was 25 g L−1 
using 10 μm size of SS micro-engineered membrane with  0.06 wt % constant 
surfactant concentration.   
200 µm 200 µm
200 µm 200 µm
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Fig. 9.9: (a) Raman spectra of anhydrous form I, form II and monohydrate piroxicam 
microcrystals and (b) DSC thermograms of anhydrous form I and monohydrate 
piroxicam microcrystals. 
9.4.9 Formation of monohydrate PRX microcrystals using different systems 
Three different systems (i.e. System-1, System-2, System-3, and System-4) were 
studied for their efficacy in producing monohydrate PRX microcrystals. Table 9.1 
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summarises the operating parameters and conditions applied with volume weighted 
mean size, D [4, 3] and span values obtained from each systems. The D [4, 3] for 
System-1, -2, -3 and -4 were 86 ± 7.6 µm, 33 ± 1.2 µm, 29 ± 0.7 µm, 39 ± 1.4 µm, 
respectively with the span values for each system were 2.3 ± 0.21, 1.3 ± 0.06,  1.1 ± 
0.04 and 1.4 ± 0.01. Indeed, these results elucidated that the crystals polydispersity 
(uniformity) and the crystals size distribution (CSD) increased in the bulk mixing and 
semi-batch system without the use of micro-engineered membrane, due to the lack of 
effective rapid micromixing intensity induced the supersaturation condition during the 
formation of monohydrate microcrystals (see Fig. 9.10). Although only minor 
differences in D [4, 3] were detected from System-2 and -3 (without and with the 
membrane present), a clear dissimilarity can be seen in CSD results, whereby two 
peaks were appeared from System-3 instead of a narrow and uniform CSD obtained 
from System-2, represented highly monodispersed size of monohydrate PRX 
microcrystals. 
 
The initial crystals size attained from the continuous system (System-4) showed 
slightly larger compared to the other semi-batch systems, due to highly contact and 
interaction between the organic and aqueous phases during the continuous system 
flow. As the continuous flow system approached 8 minutes of the operating time, the 
crystals size was getting constant and no crystals growth was detected. This system 
was implemented in order to have a new insight into the continuous crystals seeds 
production, which can be further connected to the crystallisation system. The optical 
images of monohydrate PRX microcrystals (Fig. 9.11) produced by each systems 
showed an agreement with these size observations, with a polymorphic mixture of 
Form II (needle like crystals) and monohydrate PRX microcrystals was found in the 
bulk mixing system (System-1). Uniform monodispersed monohydrate PRX 
microcrystals were obtained in the System-3, resulted by the effective rapid 
micromixing and intense shear stress on the membrane surface area.                      
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Fig. 9.10: Different type of system validation; 1- Bulk mixing system, 2- Semi-batch 
membrane dispersion cell without membrane, 3- Semi-batch membrane dispersion 
cell with 40 µm pore size of Ni membrane, and 4- Continuous membrane dispersion 
system with 40 µm pore size of Ni membrane towards monohydrate PRX 
microcrystals volume weighted mean size (µm).  The rotation speed was fixed at 1500 
rpm, organic phase injection rate = 18 ml min−1, PRX concentration in organic phase 
was 15 g L−1 with aqueous-to-organic phase volume ratio, Vaq/Vor = 5 for System-1 
until System-3 and flow rate ratio, Qaq/Qor = 5 for System-4. No surfactant was added. 
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Fig. 9.11: Optical images of monohydrate PRX microcrystals produced using 
different fabrication system; (a) System-1: bulk mixing system, (b) System-2: semi-
batch membrane dispersion cell without membrane, (b) System-3: semi-batch 
membrane dispersion cell with 40 µm pore size of Ni membrane, and System-4: 
continuous membrane dispersion system with 40 µm pore size membrane at operating 
time of 1 min. The rotation speed was fixed at 1500 rpm, organic phase injection rate 
= 18 ml min−1, PRX concentration in organic phase was 15 g L−1 with aqueous-to-
organic phase volume ratio, Vaq/Vor = 5 for System-1 until System-3 and flow rate 
ratio, Qaq/Qor = 5 for System-4. No surfactant was added. 
9.4.10 Application of PRX microcrystals in seeded crystallisation process 
The three different types of seeds prepared by different methods (i.e. membrane 
dispersion system, anti-solvent and polymorphic transformation) were used for batch 
temperature cycling crystallisation experiments. Fig. 9.12 (a-c) depicts the optical 
images of monohydrate PRX microcrystals produced by each methods with crystals 
size distributions (CSD) for each crystals. A uniform monodispersed elongated-
rhombohedral shape of monohydrate PRX crystals (Fig. 9.12 (a)) were produced by 
100 μm
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(d)
100 μm
(b)
100 μm
(a)
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micro-engineered membrane dispersion cell over the other methods, with D [4,3] of 
25 − 35 μm. The seeds obtained by antisolvent crystallisation and polymorphic 
transformation ((Fig. 9.12 (b-c)) showed highly agglomerated with irregular shape of 
crystals. The transformation took almost two days and generated fine monohydrate 
crystals considerably agglomerated. Fig 9.12 (d) presented CSD results of each 
monohydrate PRX microcrystals after formation process, whereby a narrower CSD 
was generated by micro-engineered membrane compared to the other methods. Table 
9.2 summarises the size of crystals produced by each methods, which confirmed the 
smallest and uniform CSD acquired from membrane method (D [4,3]= 34.81 µm; 
span =1.03). The crystals size obtained by antisolvent and polymorphic 
transformation were D [4,3] = 54.98 µm with span = 1.16, D [4,3] = 133.83 µm with 
span = 1.28, respectively.    
 
Fig. 9.12: Optical images of monohydrate PRX microcrystals produced by different 
methods; (a) Micro-engineered membrane dispersion cell, (b) antisolvent 
crystallisation of PRX with water flow rate of 2.5 mL min−1, and (c) polymorphic 
transformation from form I PRX to monohydrate PRX. (d) Crystal size distribution 
(CSD) for each seeds.   
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Table 9.2: Monohydrate PRX microcrystals diameter size at 10 %, 50 % and 90 % of 
the cumulative distribution obtained by Malvern Mastersizer. Volume and surface 
weighted mean diameters. All measurements are expressed in μm. 
Seeds production d(0.1) d(0.5) d(0.9) Span D[4, 3] D[3, 2] 
Membrane 19.77 32.49 53.08 1.03 34.81 30.22 
Transformation 28.75 50.61 87.52 1.16 54.98 46.03 
Antisolvent 65.58 121.16 220.88 1.28 133.83 101.35 
 
9.4.10.1 Seeded growth experiments 
The three different types of seeds prepared were used for batch cooling crystallisation 
experiments. Solutions of saturation temperature around 40 °C were prepared and 
heated up to 50 °C for the complete dissolution of the solids. Seeds were added after 
cooling down to 37 °C and then the solutions were further cooled down to 10 °C at a 
rate of -0.1 °C/min. The temperature was kept constant until complete consumption 
of the supersaturation. The solute concentration was monitored using Raman 
spectroscopy. In particular the peak intensity at 1443 − 1438 cm−1 (after calculation 
of second derivative and smoothing) was associated to the amount of PRX dissolved 
in solution. An inferential solubility curve was determined by measuring values of 
intensity of the solute Raman peak for several saturated solutions of monohydrate 
PRX at different temperatures. Data were interpolated using a polynomial function 
(shown in Fig. 9.13 (b)).   
 
The complete consumption of supersaturation by growth, secondary nucleation and, 
partly, by agglomeration took around 8-10 hours, indicating slow kinetics of growth 
and nucleation. In order to remove fine crystals and induce de-agglomeration 
temperature cycling (nine cycles of 20 °C amplitude) was applied. Fig. 9.13 exhibits 
the evolution of the total counts/meas. during the experiment while the most 
significant FBRM statistics. A stable oscillatory trend for the total counts/meas. and 
mean of the squared weighted chord length distribution is reached after two cycles. 
The counts between 50 − 150 and 150 − 300 μm, mainly representing the size of 
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monohydrate agglomerates, also reached a stable trend after the same amount of 
cycles.  
 
Fig. 9.13: Seeded crystallisation with monohydrate PRX microcrystals produced by 
micro-engineered membrane. (a) Total counts and temperature during the seeded 
experiments with 3% seeds, (b) intensity of the Raman peak corresponding to 
dissolved PRX (solute), (c) chord length distribution from FBRM during the 
experiment, and (d) statistical total counts grouped at different range of counts 
monitored by FBRM. 
 
The trends for the total counts/meas. for the other three seeded cooling and cycling 
experiments are shown in Fig. 9.14. It is worth noting that a stable oscillating trend in 
the total counts/meas. was reached in a longer time compared to the seeded 
experiments with 2% membrane seeds in all cases. In fact, for the antisolvent addition 
(Fig. 9.14 (b)) and 6% membrane seeds (Fig. 9.14 (a)) nine cycles are not enough to 
reach a stable oscillating trend. With the polymorphic transformation seeds a stable 
trend is reached after around four temperature cycles (Fig. 9.14 (c)). It can be noticed 
(a)
(c)
(b)
(d)
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that in this last case the maximum amount of total counts reached after 10 hrs at 10 
°C is around 2100 #/meas., which is considerably lower than the maximum reached 
for all the other experiments (between 5000 and 7000 #/meas.). Fig. 9.15 presents the 
microscopic images of crystals obtained at the end of every cycling experiment for a 
better comparison, with the smallest and uniform crystals size detected for the seeds 
produced by membrane method (Fig. 9.15 (a)) compared to the others (Fig. 9.15 (b-
d)). Although, the lowest degree of agglomeration is visible in the crystals obtained 
with seeds from antisolvent crystallisation (Fig 9.15 (d)) and polymorphic 
transformation (Fig 9.15 (d)), a larger size of crystals was still obtained at the end of 
experiment.  
 
 
Fig. 9.14: (a) Total counts and temperature profile for the seeded experiment with 6% 
membrane seeds (b) 2% antisolvent addition seeds (c) polymorphic transformation 
seeds. 
 
(a)
(c)
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Fig. 9.15: Microscopic images of final monohydrate PRX microcrystals products 
manufactured by different methods; (a) micro-engineered membrane cell (3% of the 
total mass of PRX) (b) micro-engineered membrane cell (6% of the total mass of 
PRX) (c) antisolvent crystallisation, and (d) polymorphic transformation. 
 
Fig. 9.16 shows the crystal size distributions (CSD) for all the samples obtained at the 
end of the cycling experiments. The crystals seeds produced by membrane and the 
polymorphic transformation methods generated narrow and unimodal distributions, 
whereas the antisolvent seeds led to a very broad CSD with higher amount of fines. 
The highest increment in D [4, 3] were observed from membrane method (119.29 µm 
(for 2% seeding amunt) and 106.30 µm (for 6% seeding amount)) to antisolvent 
method (195.13 µm). A decrease in span values (from membrane to antisolvent 
method) were in agreement with the above observations, which indicates the 
narrowness of CSD obtained by each methods. Therefore, monohydrate PRX 
microcrystals produced by micro-engineered membrane dispersion cell appeared as a 
new novel method in order to obtain a uniform and smaller size of desired 
polymorphic crystals.  
(a)
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Fig. 9.16: Crystal size distributions (CSD) of the crystals products obtained at the end 
of the seeded experiments with volume weighted mean size, D [4, 3] and span values. 
9.5 Conclusions 
In this study, a new technique for the formation of monohydrate PRX microcrystals 
were developed by promoting a uniform rapid micromixing process due to ordered 
pore array and uniform pore size, high flux through the membrane, and suppression 
of internal pore fouling due to thin and non-tortuous pores. The size of monohydrate 
PRX microcrystals, a stable polymorphic  nonsteroidal anti-inflammatory drug was 
precisely controlled over a range of 7–34 µm by controlling PRX concentrations, 
aqueous-to-organic phase volume ratios (Vaq/Vor = 5 to 30), type of surfactants 
(hydroxypropyl methyl cellulose (HPMC), polyvinyl alcohol (PVA), and pluronic-
123 (P-123)) and concentrations of each surfactants. The higher the drug 
concentration, the higher supersaturations will be achieved, which leads to the 
promotion of nucleation and a larger population of smaller particles. At the higher 
aqueous-to-organic phase volume ratio increases the diffusion distance for growing 
0
5
10
15
20
25
30
10 100 1000
%
 V
o
lu
m
e
Equivalent diameter (μm)
Membrane 2% final Membrane 6% final
Antisolvent final Transformation final
Sample D [4, 3] Span
Membrane 2% 119.29 0.76
Membrane 6% 106.30 0.83
Transformation 153.46 0.72 
Antisolvent 195.13 1.49
CHAPTER 9  
                                                                                                                                 252
 
 
Rahimah Othman  2016 
 
species and consequent diffusion becomes the limiting step for the growth nuclei. 
Smaller particles (< 10 µm) were obtained using SS ringed membrane at the optimum 
process parameters of 25 g L−1 PRX concentration, 0.0.6 wt % HPMC and aqueous-
to-organic phase volume ratio of, Vaq/Vor = 20 with significantly uniform narrow 
crystals size distribution (CSD), which can be practically applied as an inhalation 
drug. HPMC appeared as a good surfactant due to the stronger intermolecular 
hydrogen bonds between drug, surfactant and solvent that affecting the formation of 
different molecular clusters in the supersaturated solution.  The monohydrate PRX 
microcrystals were confirmed by Raman spectroscopy, DSC, optical images and 
SEM. A semi-batch membrane dispersion system presented a better performance over 
the other designed systems (i.e. bulk mixing, semi-batch, and continuous membrane 
dispersion system) towards the formation of desired polymorphic monohydrate PRX 
microcrystals.   
 
A novel procedure for seeds production was used in combination with temperature 
cycling to grow crystals of a highly agglomerating compound (monohydrate PRX). 
The seeds synthesised by membrane dispersion cell appeared as new, fast and efficient 
method over the other conventional, such as antisolvent addition and polymorphic 
transformation. A uniform and narrow crystal size distribution (CSD) was obtained at 
the end of the batch without having any agglomeration, for the seeds produced by 
micro-engineered membrane dispersion cell compared to the other crystal seed 
synthesise methods (i.e. antisolvent crystallisation and polymorphic transformation). 
The quality of final crystals produced by polymorphic transformation seeds also 
showed significantly improvement, but with much larger size of crystals. 
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CHAPTER 10  
 
CONCLUSIONS AND FUTURE WORK  
10.1 Conclusions 
This PhD research aimed to create an outstanding method/technique for the formation 
of engineered functional pharmaceutical nano/micro particles using two different 
devices (glass capillary microfluidics and a micro-engineered dispersion cell). The 
main approach of this study was to investigate both synthesis/nucleation and the 
production stage involved during the formation of nano/micro particles, respectively. 
The theoretical selection of a “good solvent” and the physico-chemical interaction 
between the solvent-water-polymer successfully elucidated the nature of anti-solvent 
precipitation method for the formation of desired properties of functional 
pharmaceutical nano/micro-engineered particles. The experimental results obtained 
using both the glass capillary microfluidic device and the micro-engineered 
membrane dispersion cell were found to be significantly well correlated with the 
respective Computational Fluid Dynamic (CFD) simulation results applied to observe 
the formation of nanoparticles by taking into account the solubility parameter, 
diffusion and the convection interaction between two miscible liquids used in the anti-
solvent precipitation method. The key conclusions from this research are as follows: 
 
(1) This work is the first computational and experimental study dealing with the 
formation of polylactide (PLA) and poly(-caprolactone) (PCL) nanoparticles 
by nanoprecipitation in a co-flow glass capillary device. The locations at which 
the nanoparticles would form were determined by using the solubility criteria 
of the polymer and the concentration profiles found by numerical modelling. 
(2) A new microfluidic method for the preparation of biodegradable nanoparticles 
was successfully developed based on micromixing/nanoprecipitation in co-flow 
and flow focusing glass capillary devices. The particle size was precisely tuned 
by varying the orifice size of the inner capillary, the flow rate ratio and the total 
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flow rate in the collection capillary which led to the generation of more nuclei 
and smaller sized nanoparticles.  
(3) The optimum formulation parameters involved in the preparation of 
paracetamol encapsulated nanoparticles (PCM-PCL NPs) using the co-flow 
microfluidic device were simulated using a 25-full factorial design for 
simultaneous statistical analysis of different experimental factors; (i) 
concentration of PCL, (ii) orifice size, (iii) flow rate ratios, Qaq/Qor, (iv) 
surfactant concentration and (v) paracetamol content with respect to 
encapsulation efficiency and drug loading percentage. In general, the results 
show that the PCL nanoparticles could be considered as a promising carrier 
system for controlled release in clinical application. 
(4) Paracetamol (PCM)-loaded composite nanoparticles (NPs) composed of a 
biodegradable poly(ᴅ,ʟ-lactide) (PLA) polymer matrix filled with organically 
modified montmorillonite (MMT) nanoparticles were  also successfully 
formulated by anti-solvent nanoprecipitation in a microfluidic co-flow glass 
capillary device. The incorporation of MMT in the polymer was found to have 
significantly improved the drug encapsulation efficiency and drug loading, and 
to have extended the rate of drug release in simulated intestinal fluid (pH 7.4). 
The encapsulation of MMT and PCM in the NPs were well verified using 
transmission electron microscopy (TEM), energy dispersive x-ray spectroscopy 
(EDS), x-ray diffraction (XRD), differential scanning calorimetry (DSC), 
thermogravimetric analysis (TGA) and attenuated total reflection-Fourier 
transform infrared spectroscopy (ATR-FTIR). 
(5) An extended approach for producing biodegradable polymeric drug-carrier 
nanoparticles (NPs) using a micro-engineered membrane dispersion cell was 
successfully defined by the rapid mixing process combined with the 
instantaneously fast diffusion process between two miscible liquids with respect 
to; (i) volume phase ratios, (ii) rotation speed, (iii) transmembrane flux, (iv) 
chemical composition of the two phases, (v) type of membrane and (vi) 
membrane pore size. A well-defined maximum shear stress within a transitional 
radius, associated with an effective inter-diffusion (between aqueous-to-organic 
phases) mixing area of the micro-engineered membrane was also successfully 
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proved by the Computational Fluid Dynamic (CFD) software and the model 
equations.  
(6) An immunosuppressive agent of highly hydrophobic rapamycin (RAPA) drug 
loaded poly(-caprolactone) (PCL) nanoparticles (NPs) were successfully 
synthesised by the anti-solvent nanoprecipitation method combined with using 
a stainless steel (SS) ringed micro-engineered membrane. The incorporation of 
RAPA onto PCL NPs matrices at the optimum process/formulation parameters 
indicated an average particle size of 204.0 ± 1.2 nm, an encapsulation efficiency, 
%E.E., of 98.91 % and drug loading, %D.L., of 28.26 % which is significantly 
suitable for intravascular delivery. The RAPA-loaded PCL NPs capsulation 
PCM in the NPs was confirmed by TEM, XRD, DSC and ATR-FTIR analyses.   
(7) Less than 10 µm sized monohydrate piroxicam (PRX) micro-crystals were 
successfully formed with the application of the anti-solvent precipitation 
method combined with a membrane dispersion cell, which has been utilised in 
the formation of functional engineered nanoparticles. This study is believed to 
be a new insight into the development of an integrated membrane-crystallisation 
system. A robust crystallisation process can be achieved with the presence of 
high purity, and the desirable polymorphic form, crystals size distribution 
(CSD) and number of produced crystals. To reach this goal, micro-crystal seeds 
could be added to a crystallizer before nucleation occurs, providing the surface 
area for crystal growth and nucleation, hence offering the advantage of being 
able to control the onset of crystallisation. 
(8) The optimum experimental parameters (i.e. PRX concentration, type and 
concentration of surfactant and the different volume ratio), the effect of solvent 
removal and data reproducibility were well pronounced during the formation of 
the monohydrate PRX micro-crystals. A detailed comparison was given 
between bulk mixing, semi-batch, the semi-batch membrane system and the 
continuous membrane system applied for the formation of micro-crystals.  
(9) The simulated results that were found remarkably answered the experimental 
results obtained by both type of micro-engineered dispersion devices (i.e. glass 
capillary microfluidic device and micro-engineered membrane dispersion cell) 
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for the formation of functional pharmaceutical engineered nano/micro-particles 
by anti-solvent precipitation method.  
10.2 Future work 
There are several suggestions that can be carried out in the future to develop the 
findings as outlined below: 
 
(1) Functional pharmaceutical nano/micro-particles have progressed into an 
exciting area of research due to their potential in drug delivery systems (DDS). 
Thus, the efficacy of drug or nanofiller (i.e. nanoclay) incorporation into the 
polymer matrix is crucial and should be answered with a real simulated drug 
release mechanism model. In this study, the rate of drug release was investigated 
by mimicking the simulated intestinal fluid (pH 7.4). This idea may ideally 
complete the biochemical communication and is especially useful in developing 
a mathematical drug or model that can simulate real situations. 
(2) The use of a synthetic biodegradable polymer is well pronounced in this study 
for the formation of functional pharmaceutical nanoparticles by 
nanoprecipitation. Natural biodegradable polymers, such as chitin and chitosan, 
are considerably versatile and promising biomaterials, which offer great 
possibilities for chemical modifications, and the formation of a large variety of 
useful derivatives that are commercially available or can be made available via 
graft reactions and ionic interactions. 
(3) The clogging problem that usually occurs during the formation of nanoparticles 
when a smaller size of microfluidic orifice is used can be solved by controlling 
the operating experimental temperature. However, clear attention must be 
drawn to this suggestion as it may increase the solubility of the polymer/drug 
and result in the uncertainty of the functional particles properties (i.e. physico-
chemical properties change/depletion).  
(4) In this study, only two miscible solvents (i.e. water and a hydrophilic organic 
solvent) were applied in the anti-solvent precipitation method, which might 
cause some limitation on the allowable amount of drug or nanofillers that can 
be dissolved inside the organic solvent. Thus, the Hansen solubility interaction 
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between water and a mixture of organic solvents, which has been 
comprehensively discussed in this study, appears as a wise solution. In this way, 
the solubility of the drug or nanofillers in the organic solvent can be improved 
without elevating the temperature, hence enhancing the percentage of drug 
loading and the encapsulation efficiency.          
(5) The effect of membrane fouling must be considered in future investigations, 
especially for the formation of micro-crystals by the anti-solvent precipitation 
method using both the semi-batch membrane dispersion cell and the continuous 
membrane dispersion cell.   
(6) Statistical analysis using the 2k factorial design simulation (i.e. Design of 
experiment (DOE), Design-Expert® Version 7.1.5 software) has been 
investigated only for the glass capillary microfluidic device experiment by 
taking into account two range factorial parameters (i.e. minimum and maximum 
range). Therefore, some extension study may be significantly useful if Central 
Composite Design (CCD) analysis can also be applied. This statistical engine is 
offered in the Design-Expert® Version 7.1.5 software package. Further analysis 
should also be implemented for the micro-engineered membrane dispersion cell.   
(7) The application and formulation of the produced functional nanoparticle system 
can be improvised for antimicrobial drug delivery. Numerous antimicrobial 
drugs (e.g. penicillin, enzyme, etc.) have been prescribed to kill or inhibit the 
growth of microbes such as bacteria, fungi and viruses. These drugs are difficult 
to administer because of their low water-solubility, cytotoxicity to healthy 
tissues, and rapid degradation and clearance in the blood stream. Their 
antimicrobial activities against intracellular microbes are also severely limited 
by their poor membrane transport capability. Extensive studies have 
demonstrated that nanoparticles, such as liposomes, polymeric nanoparticles, 
solid lipid nanoparticles and dendrimers, are able to overcome these issues and 
facilitate antimicrobial delivery to microbial infection sites.  
(8) Potential drug-release triggers by different release medium pH values should 
also be investigated for the functional pharmaceutical engineered particles 
produced by both the glass capillary microfluidic device and the micro-
engineered membrane dispersion cell.  
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(9) A different module of the continuous membrane dispersion system (e.g. a cross-
flow membrane, an azimuthally oscillating membrane and etc.) can be applied 
to compare and validate the membrane continuous cell that has been applied in 
this study for the formation of microcrystals.     
(10) Extensive attention should be given to the allowable additives composition (e.g. 
surfactant, polymer, co-solvent) applied in the crystallisation process. These 
compositions might predominantly inhibit the crystallisation process, which 
would then result in major difficulties in the crystal control strategy (i.e. 
supersaturation control, slow cooling, direct nucleation control (DNC), 
temperature cycling strategy, etc.).    
 
Future research will contribute to the further understanding of the drug delivery 
potential system and the possible strategy for enhancing the efficacy of functional 
pharmaceutical engineered nano/micro-particles. Progression should also be focused 
on the formation of micro/nano-crystals as monodispersed size-tunable seeds that can 
be applied in the crystallisation system.   
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APPENDIX 
 
S1. Geometry of the cell and membrane 
 
 
 
Figure S1. (a) A schematic view of the dispersion cell with a paddle stirrer used in 
this work ( a =24 mm, b =12.6 mm, T =36.7 mm, 
mD =33 mm, and D =29.2 mm); 
(b) A schematic view of the active region on the whole nickel and ringed stainless 
steel membrane (
2r =13 mm, 1r =9 mm). The grey areas denote active regions on the 
membrane surface through which the organic phase was injected, the dark area is an 
O-ring and the white regions are non-porous metal; (c) Pore morphology; (d) Laser 
drilling and electroforming of nickel and stainless steel membranes.  
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S.2 Effect on membrane cleaning and number of pores 
 
 
Figure S2. Optical micrographs of the membrane surface before and after cleaning: 
(a) 40-μm Ni membrane; (b) 20-μm Ni membrane; (c) 10-μm nickel membrane; (d) 
10-μm SS membrane. 
 
The total number of pores for a hexagonal pore array and whole Ni membrane is given 
by: 
3
2
2L
A
N mp                                                                                                              (S1)                        
where L  is the pore spacing (200 m), 42 /DA mm   is the effective cross-sectional 
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area of the membrane, and 
mD  is the effective membrane diameter (total diameter 
excluding O-ring). For the nickel membrane used in this work, pN  = 24,690.  
 
The total number of pores for a square pore array and ringed SS membrane is given 
by: 
2
2
1
2
2
L
)rr(
N R,p



                                                                                                 (S2)  
where 
2r  and 1r  are the outer and inner radius of the active region. For the stainless 
steel membrane used in this work, R,pN  = 6,912.    
 
S3. Numerical modelling 
 
 
Figure S3. A 3-D model geometry of the cell developed using the CFD package 
ANSYS FLUENT 14.5. 
S3.1. Governing equations 
RNG k-ε model 
 
The RNG model was developed using Re-Normalisation Group (RNG) methods to 
renormalise the Navier-Stokes equations, to account for the effects of smaller scales 
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of motion (Yakhot et al., 1992). The turbulence kinetic energy, k and its rate of 
dissipation, ε were obtained from the following transport equations: 
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In these equations, kG  represents the generation of turbulence kinetic energy due to 
the mean velocity gradients, calculated as:  
i
j
jik
x
u
uuG


                                                                                                     (S5) 
where k  and   are the inverse effective Prandtl numbers for k and ε, respectively, 
kS  and S  are the source terms, and 4211 .C   and 68.12 C  are model constants. 
The main difference between the RNG and standard k-ε models lies in the additional 
term 
R in Eq. (S4), given by:  
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where  /Sk , 3840 . , 0120.  and 08450.C  . 
 
Mixture Multiphase model 
 
The mixture model is a simplified multi-phase model (Manninen et al., 1996). It can 
be used to model multi-phase flows where the phases move at different velocities, but 
assume local equilibrium over short spatial length scales. It can also be used to model 
multiphase flows with very strong coupling and phases moving at the same velocity.  
The continuity equation for the mixture is: 
0).()( 


mmm V
t

                                                                                             (S7) 
where mV

 is the mass-averaged velocity: 
m
n
l lll
m
V
V

  1


                                                                                                   (S8)  
and m  is the mixture density: 
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where n  is the number of phases and l  is the volume fraction of phase l . By 
assuming the individual momentum equations for all the phases, the momentum 
equation for the mixture can be obtained as: 
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where F

 is a body force, and m  is the viscosity of the mixture: 

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ldrV ,

 is the drift velocity for secondary phase l : 
mlldr VVV
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Cavitation model 
 
The cavitation model proposed by Singhal et al. (2002) is used here, where the cavities 
are formed in the vicinity of the rotating blades by pressure drop. The transport 
equation for the vapour mass fraction is expressed as: 
cevvvv RRfVff
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where   is the diffusion coefficient, vV

 is the velocity vector of the vapour phase, vf  
is the vapour mass fraction, and eR  and cR  are the source terms which account for 
vapour generation and condensation rates, respectively. Singhal et al. [3] defined these 
phase change rates, based on the generalised Rayleigh-Plesset equation as: 
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where   is the surface tension of the lubricant and chV  is the characteristic velocity 
associated with the local relative velocity between the liquid and vapour phases. In 
these models it is assumed that the bubble pressure, p  equates the saturation (vapour) 
pressure, satp  at a given temperature which is the case if one assumes that no dissolved 
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gases are present. In addition, eC  and cC  are empirical constants which are 
considered to be 0.02 and 0.01 according to Singhal et al. (2002).  
 
S4. Analytical equations for shear stress at the membrane surface in stirred cell 
 
The shear stress at the membrane surface is a function of the radial distance r  from 
the centre of the membrane (Nagata, 1975): 
For transrr       
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The transitional radius transr  is the radial distance from the centre of the membrane at 
which the shear stress has the maximum value: 
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where D  is the stirrer diameter, T  is the cell diameter, b  is the blade height, bn  is 
the number of blades, n/DRe  22  is the rotating Reynolds number,  and   
are the density and viscosity of the continuous phase, respectively, and   is the 
angular velocity in rad s-1. 
The boundary layer thickness is given by: 
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The average shear stress at the membrane surface for the whole membrane can be 
derived by integrating the local shear stress from r = 0 to r = 2/Dm  using Eqs. (S16) 
and (S17): 
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The average shear stress for a ringed membrane with 
21 rrr trans   is: 
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The maximum shear stress 
max  can be calculated from Eq. (S16) or (S17): 
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